Fluoropyrimidine derivatives as retinoic acid nuclear receptor (ROR) modulators for the treatment of inflammatory, metabolic, oncological, or autoimmune diseases

Abstract

Active compounds against nuclear receptors, pharmaceutical compositions containing the compounds, and the use of the compounds in therapy are described.

Description

COMPOUNDS ACTIVE AGAINST NUCLEAR RECEPTORS Cross reference to related applications This application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 62 / 951 221, filed December 20, 2019, and U.S. Provisional Patent Application No. 62 / 064 502 , filed on August 12, 2020, the disclosures of which are incorporated herein by reference in their entirety. Field The aspects and embodiments described herein relate to compounds active against nuclear receptors, pharmaceutical compositions comprising the compounds and methods of treating inflammatory, metabolic, oncological and autoimmune diseases or disorders using the compounds. Background Nuclear receptors are a family of transcription factors that participate in the regulation of physiological functions such as cell differentiation, embryonic development, and organ physiology. Nuclear receptors have also been identified as important pathological regulators in diseases such as cancer, diabetes, and autoimmune disorders. Some examples of nuclear receptors include retinoic acid receptor-related orphan nuclear receptors (ROR). RORs contain four main domains: an N-terminal A / B domain, a DNA-binding domain, a hinge domain, and a ligand-binding domain. Binding of ligands to the ligand-binding domain is believed to cause conformational changes in the domain that result in actions at downstream sites. There are different isoforms and these isoforms differ only in their N-terminal A / B domain (Jetten, 2009, Nuclear Receptor Signaling). RORs consist of three members, namely ROR alpha (RORa or RORa), ROR beta (ROR3 or RORb) and ROR gamma (RORy or RORc). RORa is expressed in many tissues such as Purkinje cells of the cerebellum, liver, thymus, skeletal muscle, skin, lung, adipose tissue and kidney. RORa regulates neuronal cell development, bone metabolism and arteriosclerosis (Jetten, 2009, Nuclear Receptor Signaling). Additionally, RORa plays a role in immune responses such as regulating interleukin (IL) 17A expression in T helper (Th) 17 cells and regulatory T cell (Treg) function (Castro PLOS 2017; Malhotra 2018). RORpzexhibits a pattern of restricted expression that is limited to certain regions of the brain (cerebral cortex, thalamus, hypothalamus, and pineal gland) as well as the retina (Jetten, 2009, Nuclear Receptor Signaling). RORpz has been linked to epilepsy and, along with RORa, also to bipolar disease (Rudolf 2016; Lai 2015). RORy has a broad expression pattern and has been the most recently discovered of the three members. To date, two different protein isoforms have been recorded: RORyl and RORy2 (RORy2 is also known as RORyt). Typically, RORy is used to describe RORyl and / or RORyt. RORyl is expressed in many tissues and is mainly expressed in the kidneys, liver and skeletal muscle. In contrast, RORyt expression is restricted to some cell types of the immune system and to lymphoid organs such as the thymus and secondary lymphoid tissues (Hirose 1994; Jetten, 2009, Nuclear Receptor Signaling). RORyt has been identified as a key regulator of Th17 cell differentiation and IL-17 production by γδ T cells, Th17 cells, cytotoxic T cells (Te)17, and innate lymphoid cells type 3 (ILC3) (Gaffen 2014). Th17 cells are a subset of T helper cells that preferentially produce the cytokines IL-17A, IL-17F, IL-21, and IL-22 (Castro PLOS 2017). T cells lacking RORyt could not differentiate into Th17 cells even under Th17-polarizing culture conditions, while overexpression of RORyt in untreated CD4+ T cells was sufficient to accelerate the expression of Th17-related chemokines and cytokines (Gaffen 2014). , Nat Rev Immunol; Yang 2014, Trend Pharmacol Sel). IL-23 is a vital checkpoint in the generation, maintenance and activation of pathogenic Th17 lymphocytes. In response to IL23 signals, RORyt cooperates with a network of transcription factors (STAT3, IRF4 and BATF) to initiate the complete differentiation program of Th17 lymphocytes (Gaffen 2014, Nat Rev Immunol). Th17 lymphocytes and the IL-17 immune response have been shown to be associated with the pathology of many human autoimmune and inflammatory disorders. Therapeutic strategies targeting the IL-23—IL-17 axis are being developed in many autoimmune diseases and some of them have already been shown to provide clinical efficacy in certain diseases (Patel 2015; Krueger2018 Exp Dermatol). Therefore, there is evidence that RORa, RORp, and RORy play a role in the pathogenesis of many diseases. It would be desirable to provide compounds that modulate the activity of RORa and / or RORy for use in the treatment of inflammatory, metabolic and autoimmune diseases. Documents WO2016020288 and WO2016020295 describe compounds that modulate the activity of RORgamma receptors. However, there remains a need for potent RORgamma modulators with improved physicochemical properties. Compendium In one aspect, compounds of Formula (I) are provided herein. EITHER H F R3 a stereoisomer of these, or a pharmaceutically acceptable salt of the compound or stereoisomer, where: Yi, Y2 and Y3 are independently N or CRs; R is selected from the group consisting of hydrogen, C1-6 alkyl and C1.4 hydroxyalkyl; Roa and Roo are independently selected from the group consisting of hydrogen, Cm alkyl, Cm hydroxyalkyl, Cm haloalkyl, CN, substituted or unsubstituted heteroalicyclyl and substituted or unsubstituted heteroaryl; Ría and Rw are independently selected from the group consisting of hydrogen, hydroxyl, halogen, amino, Ch alkyl, C« hydroxyalkyl and Cm haloalkyl; R2 is selected from the group consisting of hydrogen, hydroxyl, amino, cyano, halogen, Cm alkyl, Cm haloalkyl, C1-4 hydroxyalkyl, C(=O)OH, C(=O)NH2, C(=O)O-( Cm alkyl and substituted or unsubstituted heteroaryl; R3 is selected from the group consisting of Cm alkyl, C2-4 alkenyl, Cm haloalkyl, Cm hydroxyalkyl, C1.6 hydroxyhaloalkyl, (C-i-4 alkylene)-(Cm alkoxy), substituted or unsubstituted C3-7 cycloalkyl and C3-cycloalkenyl. 7 substituted or not substituted; R4 and R5 are each independently hydrogen or Cm alkyl, or R4 and Rs are considered together with the carbon atom to which they are attached to form a C3-4 cycloalkyl; Rs is selected from the group consisting of hydrogen, CN, halogen, C1.4 alkyl, Cm hydroxyalkyl, C1-6 hydroxyhaloalkyl, Cm haloalkyl, Cm alkoxy, Cm haloalkoxy and substituted or unsubstituted heteroaryl; R? is selected from the group consisting of hydrogen, hydroxyl, CN, halogen, Ci-4 alkyl, C1-4 haloalkyl, C-m hydroxyalkyl, Cu alkoxy, C1.4 haloalkoxy and substituted or unsubstituted heteroaryl; each Rs is independently selected from the group consisting of hydrogen, hydroxyl, CN, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy and substituted or unsubstituted heteroaryl; and provided that R7 is hydrogen and each Rs present is hydrogen, then Re will be selected from the group consisting of CN, halogen, C1-4 alkyl, C1-4 haloalkyl, C1.4 hydroxyalkyl, Ci-e hydroxyhaloalkyl, C« alkoxy, haloalkoxy C1.4 and substituted or unsubstituted heteroaryl; and when substituted, a heteroalicyclyl will be substituted with 1 to 3 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, hydroxy C1-4 alkyl, hydroxyhalo C1-6 alkyl, hydroxy, C1.4 alkoxy and halogen; and when substituted, a heteroaryl will be substituted with 1 to 3 substituents independently selected from the group consisting of Cm alkyl, C1.4 hydroxyalkyl, C2.4 alkenyl, C2-4 alkynyl, hydroxy, C1.4 alkoxy, cyano, halogen, Cm haloalkyl, Ci4 haloalkoxy and Ci-e hydroxyhaloalkyl; and when substituted, a cycloalkyl or cycloalkenyl will be substituted with 1 to 3 substituents independently selected from the group consisting of Cm alkyl and halogen. In one aspect, provided herein are pharmaceutical compositions comprising a compound of Formula (I) or a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereoisomer of Formula (I) and at least one pharmaceutically acceptable excipient. In one aspect, provided herein are compounds of Formula (I) or a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereoisomer of Formula (I), or pharmaceutical compositions thereof for use in the treatment and / or the prevention of a disease or disorder or a symptom thereof that is selected from the group consisting of asthma, acne, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, celiac disease and food allergy, atopic dermatitis, lichen planus, cystic fibrosis, pulmonary allograft rejection, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ichthyosis, bullous diseases, hidradenitis suppurativa, steatosis , steatohepatitis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), lupus erythematosus, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune eye disease, ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (Eli ), irritable bowel syndrome (IBS), Sjógren's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, myasthenia gravis, Guillain-Barre syndrome, Graves' disease, scleritis, obesity, obesity-induced insulin resistance , type II diabetes and cancer. Furthermore, favorable features of various embodiments are defined in the dependent claims and within the following detailed description. Detailed description of preferred embodiments Definitions Unless otherwise defined, all technical and scientific terms used herein have the same meaning as customarily interpreted by one skilled in the art. All patents, applications, published applications and other publications referenced herein are incorporated by reference in their entirety. In the event that there are a plurality of definitions for a term herein, those found in this section shall prevail unless otherwise indicated. As used herein, any “R” group(s) such as, but not limited to, R, Roa, Rob, Ría, Rw, R2, R3, R4, Rs , Re, R7, Rs, Rg and R10, represent substituents that can be attached to the indicated atom. Examples of R groups include, but are not limited to, hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and heteroalicyclyl. If two “R” groups are covalently bonded to the same or adjacent atoms, then they may be “taken together” or “combined” as defined herein to form a cycloalkyl, aryl, heteroaryl, or heteroalicyclyl group. For example, without limitation, if Ray Rb of an NRaRb group is indicated as being “taken together” or “combined,” this means that they are covalently bonded to each other at their terminal atoms to form a ring that includes the nitrogen: / Ra—Nf \ Rb As the skilled person will readily recognize, any group given and disclosed herein may comprise one or more additional hydrogens in addition to that provided by a group R, which is hydrogen, attached to the group. Whenever a group is described as “substituted or unsubstituted”, if substituted, the substituent(s) (which may be present one or more times such as 1, 2, 3 or 4 times) are independently selected from alkyl, alkenyl , alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio , cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, Nsulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, hydroxyalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino, including mono amino groups - and di substituted and protected derivatives of these. When a substituent in a group is considered to be “substituted,” the substituent itself is substituted with one or more of the indicated substituents. When the referenced substituent is substituted, this means that one or more hydrogen atoms in the referenced substituent may be replaced by one or more groups individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl C -amido, Namido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, hydroxyalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino, including mono- and disubstituted amino groups, and protected derivatives thereof . The protective groups that can form the protected derivatives of the above substituents are known to those skilled in the art and can be consulted in the references of Greene and Wuts, Protective Groups in Organic Synthesis, 3rdEd., John Wiley & Sons, New York, NY, 1999, which are incorporated herein by reference in their entirety. As used herein, "Cma Cn", "Cm-Cn" or "Cm.¿ where "m" and "n" are integers, refers to the number of carbon atoms in the relevant group. That is, the group can contain from “m” to “n”, inclusive, carbon atoms. Therefore, for example, a “Ci to Ce alkyl” group refers to all alkyl groups having 1 to 6 carbons, i.e., CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2CH2- , CH3CH2CH(CH3)-, CH3CH(CH)3CH2-, CH3CH(CH)3CH2- and (CH3)3C-. If neither “m” nor “n” is designated with respect to a group, the broader range described in these definitions should be assumed. As used herein, “alkyl” refers to a straight or branched hydrocarbon chain group that is fully saturated (no double or triple bonds). The alkyl group may have from 1 to 20 carbon atoms (wherever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20” to 20 carbon atoms” means that the alkyl group can be constituted by 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to 20 carbon atoms, inclusive, although the present definition also covers the case of term “alkyl” in which no numerical range is designated). The alkyl group may also be a medium-sized alkyl having 1 to 10 carbon atoms such as “Οι-β”. The alkyl group could also be a lower alkyl having 1 to 4 carbon atoms. The alkyl group of the compounds may be designated as “C1-C4 alkyl”, “C14 alkyl” or similar designations. By way of example only, “C1-C4 alkyl” or “C1-4 alkyl” indicates that there are one to four carbon atoms in the alkyl chain, that is, the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and t-butyl. Common alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like. When substituted, the substituent group(s) are one or more groups individually and independently selected from alkenyl, alkynyl, cycloalkyl, including, but not limited to, cyclopropyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, including, but not limited to, methoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, including, but not limited to, fluoro, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, hydroxyalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino, including mono- and disubstituted amino groups , and protected derivatives thereof. As used herein, "alkenyl" refers to an alkyl group containing in the straight or branched hydrocarbon chain one or more double bonds. If more than one double bond is present, the double bonds may be conjugated or unconjugated. The alkenyl group may have from 2 to 20 carbon atoms (wherever it appears herein, a numerical range such as "2 to 20" refers to each integer in the given range; e.g., "2 to 20 carbon atoms” means that the alkenyl group can be constituted by 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, etc., up to 20 carbon atoms, inclusive, although the present definition also covers the case of term “alkenyl” in which no numerical range is designated). When substituted, the substituent group(s) are one or more groups individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, mercapto, alkylthio, cyano, halogen, nitro, haloalkyl, hydroxyalkyl, haloalkoxy and amino, including mono- and disubstituted amino groups, and protected derivatives thereof. As used herein, "alkynyl" refers to an alkyl group containing in the straight or branched hydrocarbon chain one or more triple bonds. The alkynyl group may have from 2 to 20 carbon atoms (wherever it appears herein, a numerical range such as "2 to 20" refers to each integer in the given range; e.g., "2 to 20 carbon atoms” means that the alkynyl group can be constituted by 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, etc., up to 20 carbon atoms, inclusive, although the present definition also covers the case of term “alkynyl” in which no numerical range is designated). An alkynyl group may be substituted or unsubstituted. When substituted, the substituent(s) may be selected from the same groups described above with respect to substitution of the alkenyl group. As used herein, "hetera" may be attached to a group and refers to one or more carbon atoms and the associated hydrogen atom(s) in the attached group having been independently replaced by the same or different heteroatoms. selected from nitrogen, oxygen, phosphorus and sulfur. As used herein, "heteroalkyl", alone or combined with another term, refers to a linear or branched alkyl group consisting of the aforementioned number of carbon atoms, where one or more carbon atoms, such as 1,2, 3 or 4 carbon atoms, and the associated hydrogen atom(s) have been independently replaced by the same or different heteroatoms selected from nitrogen, oxygen and sulfur. The carbon atom(s) being replaced can be found in the middle or at the end of the alkyl group. Some examples of heteroalkyl include C1-6 heteroalkyl where one or more of the carbon atoms have been replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; Examples are -S-alkyl, -O-alkyl, -NH-alkyl, alkylene-O-alkyl, etc. A heteroalkyl may be substituted. As used herein, "aryl" refers to a carbocyclic ring (all carbon) or two or more fused rings (rings sharing two adjacent carbon atoms) that have a fully delocalized pi electron system. In some embodiments described herein, the aryl group is a Cmo aryl, which may be substituted or unsubstituted. Some examples of aryl groups include, but are not limited to, benzene, naphthalene, and azulene. An aryl group may be substituted. When substituted, the hydrogen atoms are replaced by one or more substituent groups which are one or more groups independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl) alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, hydroxyalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino, including mono- and disubstituted amino groups, and protected derivatives thereof. When substituted, substituents on an aryl group can form a non-aromatic ring fused to the aryl group, which includes a cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl. As used herein, "heteroaryl" refers to a monocyclic or multicyclic aromatic ring system (a ring system with a fully delocalized pi electron system), in which at least one of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including, but not limited to, nitrogen, oxygen and sulfur. In some embodiments described herein, heteroaryl includes, but is not limited to, Ce-ium heteroaryl, where one to four carbon atoms are replaced by one to four heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. Some examples of monocyclic "heteroaryl" include, but are not limited to, furan, thiophene, phthalazine, pyrrole, oxazole, oxadiazole, including, but not limited to, 1,2,4oxadiazole and 1,3,4-oxadiazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, including, but not limited to, 1,2,4-triazole and 1,2,3-triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, tetrazole and triazine. Some examples of multicyclic "heteroaryl" include, but are not limited to, quinoline, isoquinoline, quinazoline, quinoxaline, indole, purines, benzofuran, benzothiophene, benzopyranones (e.g., coumarin, chromone, and isocoumarin). A heteroaryl may be substituted. When substituted, the hydrogen atoms are replaced by one or more substituent groups which are one or more groups independently selected from alkyl, including, but not limited to, methyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, hydroxyalkyl, including, but not limited to, 2-hydroxyethyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino, including mono- and disubstituted amino groups, and protected derivatives thereof. When substituted, substituents on a heteroaryl group can form a non-aromatic ring fused to the aryl group, including a cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl. An "aralkyl" or "arylalkyl" is an aryl group connected, as a substituent, through an alkylene group. The alkylene group and the aryl of an aralkyl may be substituted. Some examples include, but are not limited to, benzyl, substituted benzyl, 2-phenylethyl, 3-phenylpropyl and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group. A "heteroaralkyl" or "heteroarylalkyl" is a heteroaryl group connected, as a substituent, through an alkylene group. The alkylene group and the heteroaryl of a heteroaralkyl may be substituted. Some examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, pyrazolylalkyl and imidazolylalkyl, and their substituted as well as benzofused analogues. In some cases, the alkylene group is a lower alkylene group. An “alkylene” is a straight-chain connecting group, which forms bonds to connect molecular fragments through their terminal carbon atoms. Alkylene can have from 1 to 20 carbon atoms. The alkylene may also be a medium-sized alkylene having 1 to 10 carbon atoms such as "Ci-e". The alkylene could also be a lower alkylene having 1 to 4 carbon atoms. The alkylene may be designated as “C1-C4 alkylene,” “C1Z alkylene,” or similar designations. Some non-limiting examples include methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), and butylene ((CH2)4-) groups. In the case of methylene, the two connected fragments connect to the same carbon atom. A lower alkylene group may be substituted. As used herein, "heteroalkylene", alone or combined with another term, refers to an alkylene group consisting of the aforementioned number of carbon atoms, in which one or more of the carbon atoms, such as such as 1,2, 3 or 4 carbon atoms, are independently replaced by equal or different heteroatoms selected from oxygen, sulfur and nitrogen. Some examples of heteroalkylene include, but are not limited to, -CH2-O-, -CH2-CH2-O-, -CH2-CH2-CH2-O-, -CH2-NH-, -CH2-CH2-NH-, -CH2 -CH2-CH2NH-, -CH2-CH2- NH-CH2-, -O-CH2-CH2-O-CH2-CH2-O-, -O-CH2-CH2-O-CH2-CH2- and the like. As used herein, "alkylidene" refers to a divalent group, such as =CR'R, that is bonded to a carbon of another group, forming a double bond. Alkylidene groups include, but are not limited to, methylidene (=CH2) and ethylidene (=CHCH3). As used herein, "arylalkylidene" refers to an alkylidene group wherein R' or R is an aryl group. An alkylidene group may be substituted. As used herein, “alkoxy” refers to the group -OR where R is an alkyl, e.g. e.g., methoxy, ethoxy, n-propoxy, cyclopropoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, secbutoxy, tert-butoxy, amoxi, tert-amoxy and the like. An alkoxy may be substituted. As used herein, “alkylthio” refers to the formula -SR where R is an alkyl defined as above, e.g. e.g., methylmercapto, ethylmercapto, npropylmercapto, 1-methylethylmercapto (isopropylmercapto), n-butylmercapto, isobutylmercapto, secbutylmercapto, tert-butylmercapto and the like. An alkylthio may be substituted. As used herein, “aryloxy” and “arylthio” refer to RO- and RS-, where R is an aryl as defined above, e.g. e.g., phenoxy, naphthalenyloxy, azulenyloxy, anthracenyloxy, naphthalenylthio, phenylthio and the like. An aryloxy and an arylthio may both be substituted. As used herein, "alkenyloxy" refers to the formula -OR where R is an alkenyl as defined above, e.g. e.g., vinyloxy, propenyloxy, n-butenyloxy, isobutenyloxy, sec-pentenyloxy, tert-pentenyloxy and the like. The alkenyloxy may be substituted. As used herein, "acyl" refers to a hydrogen, alkyl, alkenyl, alkynyl or aryl connected, as a substituent, through a carbonite group. Some examples include formyl, acetyl, propanoyl, benzoyl, and acryl. An acyl may be substituted. As used herein, "cycloalkyl" refers to a fully saturated mono- or multicyclic hydrocarbon ring system (without double bonds). When it is composed of two or more rings, the rings may be joined together in a fused manner, ΜΛ / a / ZUZZ / UU 1 bridged or spiranically connected. Cycloalkyl groups can range from C3 to C10, such as from C3 to Ce. A cycloalkyl group can be substituted or unsubstituted. Common cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. If substituted, the substituent(s) may be independently selected from an alkyl, including, but not limited to, methyl, or a halogen, including, but not limited to, fluoro, or may be selected from those set forth above with respect to substitution. of an alkyl group unless otherwise indicated. When substituted, substituents on a cycloalkyl group can form an aromatic ring fused to the cycloalkyl group, which includes an aryl and a heteroaryl. As used herein, "cycloalkenyl" refers to a cycloalkyl group that contains one or more double bonds in the ring although, if there are more than one, they cannot form a fully delocalized pi electron system in the ring ( If not, the group would be an “aryl,” as defined herein). When composed of two or more rings, the rings may be connected to each other in a fused, bridged, or spiranically connected manner. Cycloalkenyl groups may vary from C3 to C10, such as from C3 to Cs or from C5 to C10. For example, C3-8 cycloalkenyl includes C4-8 cycloalkenyl, C5-8 cycloalkenyl or Ce-e cycloalkenyl. A cycloalkenyl group may be substituted or unsubstituted. When substituted, the substituent(s) may be an alkyl or may be selected from the groups described above with respect to substitution of the alkyl group unless otherwise indicated. When substituted, substituents on a cycloalkenyl group can form an aromatic ring fused to the cycloalkenyl group, which includes an aryl and a heteroaryl. As used herein, "cycloalkynyl" refers to a cycloalkyl group containing one or more triple bonds in the ring. When composed of two or more rings, the rings may be joined together in a fused, bridged, or spiranically connected manner. Cycloalkynyl groups can vary from Ce to C12. A cycloalkynyl group may be substituted or unsubstituted. When substituted, the substituent(s) may be an alkyl or may be selected from the groups described above with respect to substitution of the alkyl group unless otherwise indicated. When substituted, substituents on a cycloalkynyl group can form an aromatic ring fused to the cycloalkynyl group, which includes an aryl and a heteroaryl. As used herein, "heteroalicyclic" or "heteroalicyclyl" refers to a 3- to 18-membered ring consisting of carbon atoms and one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. The heteroalicyclic or heteroalicyclyl groups can range from C2 to C10, in some embodiments they can range from C2 to C9 and in other embodiments they can range from C2 to Ce. In some embodiments, MA / a / ZUZZ / UU l o» 1 the “heteroalicyclic” or “heteroalicyclyl” group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can be joined together in a fused manner, with bridges or connected spiranically; and the nitrogen, carbon and sulfur atoms in the “heteroalicyclic” or “heteroalicyclyl” group may be oxidized; the nitrogen may be quaternized; and the rings may also contain one or more double bonds, as long as they do not form a completely delocalized pi electron system throughout all the rings, examples are 2 / - / -benzo[¿>][1,4]oxazin- 3(4 / - / )-one, 3,4-dihydroquinolin-2(1 / 7)-one, 1,2,3,4tetrahydroquinoline, 3,4-dihydro-2 / 7-benzo[b][1, 4]oxazine, 2,3-dihydrobenzo[cf]oxazole, 2,3-dihydro1 / - / -benzo[cf]m¡dazole, indoline and 1,3-dihydro-2 / 7-benzo[cf] midazol-2-one and benzo[c / ]oxazol-2(3 / 7)one. The heteroalicyclyl groups may be substituted or unsubstituted. When substituted, the substituent(s) may be one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo , alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, C-amido, N-amido, S-sulfonamido, N-sulfonamido, isocyanate, thiocyanate, isothiocyanate, nitro, silyl, haloalkyl, hydroxyalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino, including mono- and disubstituted amino groups, and protected derivatives thereof. Some examples of such "heteroalicyclic" or "heteroalicyclyl" groups include, but are not limited to, azepinyl, dioxolanyl, imidazolinyl, morpholinyl, oxetanyl, oxiranyl, piperidinyl ΛΖ-oxide, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, 4-piperidonyl, pyrazolidinyl, 2 -oxopyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide and thiamorpholinylsulfone. When substituted, substituents on a heteroalicyclyl group can form an aromatic ring fused to the heteroalicyclyl group, which includes an aryl and a heteroaryl. A “(cycloalkyl)alkyl” is a cycloalkyl group connected, as a substituent, by an alkylene group. The alkylene and cycloalkyl of a (cycloalkyl)alkyl may be substituted. Some examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl and the like. In some cases, the alkylene group is a lower alkylene group. A “(cycloalkenyl)alkyl” is a cycloalkenyl group connected, as a substituent, by an alkylene group. The alkylene and cycloalkenyl of a (cycloalkenyl)alkyl may be substituted. In some cases, the alkylene group is a lower alkylene group. A “(cycloalkynyl)alkyl” is a cycloalkynyl group connected, as a substituent, by an alkylene group. The alkylene and cycloalkynyl of a (cycloalkynyl)alkyl may be substituted. In some cases, the alkylene group is a lower alkylene group. As used herein, "halo" or "halogen" refers to F (fluoro), CI (chloro), Br (bromo) or I (iodine). As used herein, "haloalkyl" refers to an alkyl group in which one or more of the hydrogen atoms are replaced by halogen. Such groups include, but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1-difluoroethyl, 2-fluoroethyl, 1-chloro-2-fluoromethyl and 2-fluoroisobutyl. A haloalkyl may be substituted or unsubstituted and some embodiments relate to a medium-sized haloalkyl having 1 to 10 carbon atoms such as a C1-6 haloalkyl. As used herein, "haloalkoxy" refers to an RO- group wherein R is a haloalkyl group. Such groups include, but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy and 1-chloro-2-fluoromethoxy, 2-fluoroisobutoxy. A haloalkoxy may be substituted. As used herein, the term “hydroxyalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a hydroxyl group. Such groups include, but are not limited to, hydroxymethyl, hydroxyethyl, including, but not limited to, 2-hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl and hydroxyhexyl. A hydroxyalkyl group may be substituted or unsubstituted and some embodiments relate to a medium-sized hydroxyalkyl having 1 to 10 carbon atoms such as a Ci-e hydroxyalkyl; when substituted, the substituents may be one or more groups independently selected from the group consisting of halogen, including, but not limited to, fluoro, and haloalkyl, including, but not limited to, trifluoromethyl; Such substituted “hydroxyalkyl” groups include, but are not limited to, 1,1,1,3,3,3-hexafluoro-2hydroxypropan-2-yl and 1,1-difluoro-2-hydroxyethyl. An "O-carboxy" group refers to a group "RC(=O)O-" in which R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl or (heteroalicyclyl)alkyl, as defined herein. An Ocarboxy may be substituted. A “C-carbox¡” group refers to a “-C(=O)OR” group in which R may be the same as that defined with respect to O-carbox¡. A C-carboxy may be substituted. A “tñhalomethanesulfonyl” group refers to a “X3CSO2-” group in which X is a halogen. A dashed bond, ξξζζξ, represents optional unsaturation between the atoms forming the bond. This bond can be unsaturated (e.g., C=C, C=N, C=O) or saturated (e.g., C-C, C-N, C-O). When a dashed bond is present in a ring system, it may be part of an aromatic ring system. As used herein, a linear bold or dashed (non-wedged) bond, — or......, refers to the relative stereochemistry that includes all possible stereoisomers at that position. As used herein, and unless otherwise indicated, a wedge bond (bold, dashed or otherwise), —, -= or refers to the absolute stereochemistry relative to the particular stereoisomer as used herein. represents in that position. A “nitro” group refers to a “-NO2” group. A “cyano” group refers to a “-CN” group. A “cyanate” group refers to a “-OCN” group. An “isocyanate” group refers to a “-NCO” group. A “thiocyanate” group refers to a “-SCN” group. A “carbonyl” group refers to a “-C(=O)-” group. A “thiocarbonyl” group refers to a “-C(=S)-” group. An “oxo” group refers to an “=O” group. A “hydroxy” group or “hydroxyl” group refers to an “-OH” group. An “isothiocyanate” group refers to a “-NCS” group. A “suIfinílo” group refers to a “-S(=O)-R” group in which R can be the same as that defined with respect to O-carboxí. A sulfinyl may be substituted. A "sulfonyl" group refers to a "SO2R" group in which R may be the same as defined with respect to O-carboxy. A sulfonyl may be substituted. An "S-sulfonamido" group refers to a "-SO2NRaRb" group in which Ra and Rb can be, independently of each other, the same as those defined with respect to the R group that has been defined for O-carbox! , or they can be combined to form a ring system selected from the group consisting of substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted heteroalicyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. An S-sulfonamide may be substituted. An “N-sulfonamido” group refers to a “RSO2N(Ra)-” group in which R and Ra can be, independently of each other, the same as those defined with respect to the group R that has been defined for O -carbox! An N-sulfonamide may be substituted. A "trihalomethanesulfonamido" group refers to a group "X3CSO2N(R)-" with A trihalomethanesulfonamide may be substituted. A "C-amido" group refers to a "-C(=O)NRaRb" group in which Ra and Rb can be, independently of each other, the same as those defined with respect to the R group that has been defined for O-carboxy, or they may be combined to form a ring system selected from the group consisting of substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C3-8 cycloalkynyl, substituted C3-8 cycloalkenyl or unsubstituted, substituted or unsubstituted heteroalicyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. A C-amido may be substituted. An “N-amido” group refers to a “RC(=O)NRa- group in which R and Ra can be, independently of each other, the same as those defined with respect to the R group that has been defined for O-carboxy. An N-amido may be substituted. An "ester" refers to a group "-C(=O)OR" in which R may be the same as that defined with respect to O-carboxy. An ester may be substituted. A lower alkoxyalkyl refers to an alkoxy group connected through a lower alkylene group. A lower alkoxyalkyl may be substituted. An “amine” or “amino” group refers to “RNH2” (a primary amine), “R2NH” (a secondary amine), “R3N” (a tertiary amine). An amino group may be substituted. A lower aminoalkyl refers to an amino group connected through a lower alkylene group. A lower aminoalkyl may be substituted. Any monosubstituted or unsubstituted amino group in a compound herein can be converted to an amide, any hydroxyl group can be converted to an ester, and any carboxyl group can be converted to an amide or an ester using techniques well known to those skilled in the art. the technique (refer, for example, to Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999). As used herein, the abbreviations for any protecting groups, amino acids and other compounds are in accordance, unless otherwise indicated, with their common use, recognized abbreviations or the IUPAC Commission on Biochemical Nomenclature. IUB (see Biochem. 11:942-944 (1972)). List of abbreviations DMF dimethylformamide DMSO dimethyl sulfoxide MeOH methanol EtOH ethanol THF tetrahydrofuran DCM dichloromethane, methylene chloride DCE 1,2-dichloroethane LRMS low resolution mass spectrometry HPLC high performance liquid chromatography HPLC prep. preparative high-performance liquid chromatography h hour 16 min minutes EA ethyl acetate EDC-HCI 3-((ethylimino)methyleneamino)-A / ,A / -dimethylpropan-1- chloride aminio ινΐΛ / a / zuzz / uu fom DIEA diisopropylethylamine TEA triethylamine TFA trifluoroacetic acid HCI hydrochloric acid, hydrogen chloride HOBt 1-hydroxybenzotriazole hydrate HOAt 1-hydroxy-7-azabenzotriazole HATU 1-[bis(dimethylamino)methylen 3-oxide hexafluorophosphate]-1 / - / -1,2,3- triazolo[4,5-¿>]pyridinium DMAP 4-(dimethylamino)pinna DAST (diethylamino)sulfur trifluoride DIAD diisopropyl azodicarboxylate DMP Dess-Martin periodinane, 1,1,1-tris(acetyloxy)-1,1-dihydro- 1,2- benziodoxol-3-(1 / - / )-one TBAF tetrabutylammonium fluoride trihydrate TBDMSCI tert-butyldimethylsilyl chloride MsCI methanesulfonyl chloride SNA aromatic nucleophilic substitution nBuLi n-butyllithium ¡Pr isopropyl Boc tert-butyloxycarbonyl CC flash tn flash column chromatography overnight at room temperature ac. aqueous ND not determined Cbz carboxybenzyl Hex hexane Hept heptane DEA diethylamine PE petroleum ether DAD diode beam detector TOF time of flight IPA isopropanol Pg enantiomerically enriched protecting group It is understood that, in any compound described herein that has one or more chiral centers, if the absolute stereochemistry is not expressly stated, then each center may independently have an R configuration or an S configuration or a mixture thereof. Therefore, the compounds provided herein may be enantiomerically pure or may be stereoisomeric mixtures. Furthermore, the compounds provided herein may be non-racemic mixtures. Furthermore, it is understood that, in any compound that has one or more double bonds that generate geometric isomers that can be defined as E or Z, each double bond may independently be E or Z or a mixture of these. Similarly, it is also intended to include all tautomeric forms. As used herein, the term “rae” refers to “racemic,” “racemato,” etc., as interpreted by one skilled in the art. For example, a racemate comprises a mixture of enantiomers of a chiral molecule in equivalent amounts. Typically, a racemate does not exhibit optical activity. As used herein, the term "rei" refers to the relative, but not absolute, configuration of a stereogenic center with respect to any other stereogenic center within the same compound, as interpreted by one skilled in the art. As used herein, “tautomer” and “tautomeric” refer to alternative forms of a compound described herein that differ in the position of a proton. Some non-limiting examples include keto-enolic and enamino-iminic tautomers, or tautomeric forms of heteroaryl groups containing a ring atom bonded to both an -NH- ring moiety and an =N- ring moiety such as pyrazoles, imidazoles. , benzimidazoles, triazoles and tetrazoles. It is understood that there may be isotopes present in the compounds described herein. Each chemical element as represented in the structure of a compound can include any isotope of that element. For example, in a compound described herein, a hydrogen atom may be any isotope of hydrogen, including, but not limited to, hydrogen-1 (protium) and hydrogen-2 (deuterium). Therefore, reference herein to a compound encompasses all possible isotopic forms unless the context clearly indicates otherwise. As used herein, reference to an element, whether by description or chemical structure, encompasses all isotopes of that element unless otherwise described. As an example, it is understood that the term “hydrogen” or “H” ΜΛ / a / zuzz / uu / ου i in a chemical structure, as used herein, encompasses, for example, not only 1H, but also deuterium (2H), tritium (3H) and mixtures of these unless indicate otherwise by using a specific isotope. Other specific non-limiting examples of elements for which isotopes are encompassed include carbon, phosphorus, iodine and fluorine. As used herein, a “pharmaceutically acceptable salt” refers to a salt of a compound that does not modify the biological activity or properties of the compound. Pharmaceutical salts can be obtained by reacting a compound described herein with an acid or a base. Salts formed with a base include, but are not limited to, an ammonium salt (NHA); alkali metal salts such as, but not limited to, sodium or potassium; alkaline earth metal salts such as, but not limited to, calcium or magnesium; salts of organic bases such as, but not limited to, dicyclohexylamine, piperidine, piperazine, methylpiperazine AZ-methyl-D-glucamine, dimethylamine, ethylenediamine, tris(hydroxymethyl)methylamine; and salts with the amino group of amino acids such as, but not limited to, arginine and lysine. Useful acid-based salts include, but are not limited to, acetates, adipates, aspartates, ascorbates, benzoates, butyrates, caparate, caproate, caprylate, camsylates, citrates, decanoates, formates, fumarates, gluconates, glutarate, glycolates, hexanoates, laurates, lactates, maleates, nitrates, oleates, oxalates, octanoates, propanoates, palmitates, phosphates, sebacates, succinates, stearates, sulfates, sulfonates, such as methanesulfonates, ethanesulfonates, p-toluenesulfonates, salicylates, tartrates and tosylates. Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more molecules of solvent or water, or from 1 to about 100, or from 1 to about 10, or from 1 to about 2, 3 or 4 molecules of solvent or water. . As used herein, a "prodrug" refers to a compound that may not be pharmaceutically active but is converted to an active drug upon administration in vivo. The prodrug can be designed to alter the metabolic stability or transport characteristics of a drug, to mask side effects or toxicity, to improve the taste of a drug, or to alter other characteristics or properties of a drug. Prodrugs are often useful because they may be easier to administer than the original drug. They may, for example, be bioavailable by oral administration while the parent drug is not. The prodrug may also have better solubility than the active parent drug in pharmaceutical compositions. A non-limiting example of a prodrug would be a compound described herein that is administered as an ester (the “prodrug”) to facilitate absorption across a cell membrane where water solubility is detrimental to mobility. but which is then metabolically hydrolyzed to obtain a carboxylic acid (the active entity) once inside the cell where water solubility is beneficial. Another example of a prodrug would be a short peptide (polyamino acid) linked to an acidic group where the peptide is metabolized in vivo to release the active parent compound. Taking into account knowledge of pharmacodynamic processes and drug metabolism in vivo, once a pharmaceutically active compound is known, those skilled in the art can design prodrugs of the compound (refer, e.g., Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392). As used herein, “modulating” the activity of a receptor means either activating it, that is, increasing its cellular function relative to the basal level that is measured in the particular environment in which it is found, or deactivating it, that is , reduce its cellular function below the basal level measured in the environment in which it is found and / or render it unable to carry out its cellular function at all, even in the presence of its natural binding partner. A natural binding partner is an endogenous molecule that is an agonist for the receptor. An “agonist” is defined as a compound that increases the basal activity of a receptor (i.e., receptor-mediated signal transduction). As used herein, a “partial agonist” refers to a compound that has affinity for a receptor but, unlike an agonist, when bound to the receptor elicits only a fractional degree of the pharmacological response normally associated with the receptor. , even if the compound occupies a large number of receptors. An “inverse agonist” is defined as a compound that reduces or suppresses the basal activity of a receptor, such that the compound is not technically an antagonist but, instead, is an agonist with negative intrinsic activity. As used herein, an "antagonist" refers to a compound that binds to a receptor to form a complex that does not result in any response, as if the receptor were not occupied. An antagonist attenuates the action of an agonist at a receptor. An antagonist can bind reversibly or irreversibly, and effectively eliminates the activity of the receptor permanently or at least until the antagonist is metabolized or dissociates or is otherwise eliminated by a physical or biological process. As used herein, a “subject” refers to an animal that is the object of treatment, observation or experimentation. An “animal” includes cold- and warm-blooded vertebrates and invertebrates such as birds, fish, crustaceans, reptiles and, in particular, mammals. A “mammal” includes, but is not limited to, mice; rats; rabbits; Guinea pigs; dogs; cats; sheep; goats; cows; horses; primates such as monkeys, chimpanzees and apes and, in particular, humans. As used herein, a “patient” refers to a subject who is being treated by a medical professional such as a medical doctor or a veterinary doctor to attempt to cure, or at least ameliorate the effects of, a disease. or disorder or to prevent the disease or disorder from appearing in the first place. As used herein, a "carrier" refers to a compound that facilitates the incorporation of a compound into cells or tissues. For example, but not limited to, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the uptake of many organic compounds into cells or tissues of a subject. As used herein, a "diluent" refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be necessary or desirable from a pharmaceutical point of view. For example, a diluent can be used to increase the volume of a potent drug whose mass is too small for manufacture or administration. It can also be a liquid to dissolve a drug to be administered by injection, ingestion or inhalation. A common form of diluent in the art is a buffered aqueous solution such as, but not limited to, a phosphate-buffered saline solution that mimics the composition of human blood. As used herein, an "excipient" refers to an inert substance that is added to a pharmaceutical composition to provide, but is not limited to, volume, consistency, stability, binding capacity, lubrication, disintegrating capacity, etc. to the composition. A “diluent” is a type of excipient. A "receptor" is intended to include any molecule present within or on the surface of a cell that can affect cellular physiology when inhibited or stimulated with a ligand. Typically, a receptor comprises an extracellular domain with ligand-binding properties, a transmembrane domain that anchors the receptor to the cell membrane, and a cytoplasmic domain that generates a cellular signal in response to ligand binding (“signal transduction”). ). A receptor also includes any intracellular molecule that, in response to ligation, generates a signal. A receptor also includes any molecule that has the characteristic structure of a receptor, but does not have any identifiable ligand. Furthermore, a receptor includes a truncated, modified, mutated receptor or any molecule comprising partial or all sequences of a receptor. A “ligand” is intended to include any substance that interacts with a receptor. “Selective” or “selectivity” is defined as the ability of a compound to generate a desired response from a particular type, subtype, class or subclass of receptor while generating a minor or small response from other types of receptors. receivers. The term “selective” or “selectivity” as applied to one or more particular subtypes of a compound means the ability of a compound to increase the activity of the subtypes while causing a minor, small, or no increase in the activity of other subtypes. . ΜΛ / a / ZUZZ / UU 14» 1 As used herein, "coadministration" of pharmacologically active compounds refers to the delivery of two or more different chemical entities, either in vivo or in vitro. Coadministration refers to the simultaneous delivery of different agents; to the simultaneous delivery of a mixture of agents; as well as the supply of one agent followed by the supply of a second agent or additional agents. It is usually intended that the agents that are co-managed act jointly with each other. The term "an effective amount", as used herein, means an amount of an active compound or pharmaceutical agent that exerts the biological or medical response in a tissue, system, animal or human being that a researcher, veterinarian or veterinarian is seeking. , medical doctor or other physician, which includes the relief or palliation of the symptoms of the disease being treated. When used herein, “prevent / prevents” should not be construed to mean that a condition and / or disease never recurs following the use of a compound or pharmaceutical composition in accordance with the embodiments described herein for achieve prevention. Furthermore, the term should also not be interpreted to mean that a condition does not appear, at least to some degree, after such use to prevent said condition. Instead, “prevent / prevents” is intended to mean that the condition to be prevented, if it occurs despite such use, will be less serious than without such use. Compounds In one embodiment, the present disclosure relates to a compound of Formula (I) i ου i EITHER H F R3 (|)jun stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereoisomer, where Υι, Y2 and Y are independently N or CRs; R is selected from the group consisting of hydrogen, Cm alkyl and C1.4 hydroxyalkyl; Roa and Rob are independently selected from the group consisting of hydrogen, C14 alkyl, C1.4 hydroxyalkyl, Cm haloalkyl, CN, substituted or unsubstituted heteroalicyclyl and substituted or unsubstituted heteroaryl; R-ia and Rib are independently selected from the group consisting of hydrogen, hydroxyl, halogen, amino, Cm alkyl, Cm hydroxyalkyl and Cm haloalkyl; R2 is selected from the group consisting of hydrogen, hydroxyl, amino, cyano, halogen, C1.4 alkyl, C1.4 haloalkyl, C1.4 hydroxyalkyl, C(-O)OH, C(-O)NH2, C(-O )O-(Cm alkyl) and substituted or unsubstituted heteroaryl; Rs is selected from the group consisting of Cm alkyl, C2-4 alkenyl, C-m haloalkyl, C-m hydroxyalkyl, Cie hydroxyhaloalkyl, (Ci-4 alkylene)-(Cm alkoxy), substituted or unsubstituted C3-7 cycloalkyl and substituted C3-7 cycloalkenyl or not replaced; R4 and Rs are each independently hydrogen or Cm alkyl, or R4 and Rj are considered together with the carbon atom to which they are attached to form a C3-4 cycloalkyl; Re is selected from the group consisting of hydrogen, CN, halogen, Cm alkyl, Cm hydroxyalkyl, Cm hydroxyhaloalkyl, Cm haloalkyl, Cm alkoxy, Cm haloalkoxy and substituted or unsubstituted heteroaryl; R7 is selected from the group consisting of hydrogen, hydroxyl, CN, halogen, Cm alkyl, Cm haloalkyl, Cm hydroxyalkyl, Cm alkoxy, Cm haloalkoxy and substituted or unsubstituted heteroaryl; each Rs is independently selected from the group consisting of hydrogen, hydroxyl, CN, halogen, Cm alkyl, Cm haloalkyl, Cm alkoxy, Cm haloalkoxy and substituted or unsubstituted heteroaryl; and provided that R7 is hydrogen and each Rs present is hydrogen, then Re will be selected from the group consisting of CN, halogen, Cm alkyl, Cm haloalkyl, Cm hydroxyalkyl, Cm hydroxyhaloalkyl, Cm alkoxy, Cm haloalkoxy and substituted or unsubstituted heteroaryl; and when substituted, a heteroalicyclyl will be substituted with 1 to 3 substituents independently selected from the group consisting of Cm alkyl, Cm haloalkyl, Cm hydroxyalkyl, Cm hydroxyhaloalkyl, hydroxy, Cm alkoxy and halogen; and when substituted, a heteroaryl will be substituted with 1 to 3 substituents independently selected from the group consisting of Cm alkyl, Cm hydroxyalkyl, C2-4 alkenyl, C2-4 alkynyl, hydroxy, Cm alkoxy, cyano, halogen, Cm haloalkyl, haloalkoxy Ci4 and hydroxyhaloalkyl Ci-e; and ινΐΛ / a / zuzz / uu / ου 1 when substituted, a cycloalkyl or cycloalkenyl will be substituted with 1 to 3 substituents independently selected from the group consisting of C1.4 alkyl and halogen. In some embodiments described herein, Res hydrogen. In some embodiments described herein, Re is selected from the group consisting of hydrogen, CN, halogen, C1-4 haloalkyl, Cu haloalkoxy, C1-4 hydroxyalkyl, C-i-e hydroxyhaloalkyl; 5-membered heteroaryl and 5-membered heteroaryl substituted with 1 or 2 substituents independently selected from methyl or hydroxyethyl, and as long as R7 is hydrogen and each Rs present is hydrogen, then Re cannot be hydrogen. In other embodiments, Re is selected from the group consisting of hydrogen, CN, chloro, CF3, CHF2, CCH3F2, OCF3 and OCHF2, OCH2F, C(CF3)2OH, CF2CH2OH, pyrazolyl and pyrazolyl substituted with 1 substituent selected from methyl or 2- hydroxyethyl, and provided that R? be hydrogen and every Rs present is hydrogen, then Re cannot be hydrogen. In other embodiments, Re is selected from the group consisting of hydrogen, CF3, CCH3F2, OCHF2, C(CF3)2OH, pyrazolyl and methylpyrazolyl, and as long as R7 is hydrogen and each Rs present is hydrogen, then Re cannot be hydrogen. In other embodiments, Re is selected from the group consisting of CF3, C(CF3)2OH, 1-methyl-1 / - / -pyrazol-4-yl and 1 / - / -pyrazol-1-lium. In other embodiments, Re is CF3. In some embodiments described herein, R7 is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, CH3, OCH3, CF3, CHF2, OCF3 and OCHF2. In other embodiments, R7 is hydrogen or fluoro. In some embodiments described herein, Y1, Y2, and Y3 are each CH. In some embodiments, Y1 is N and Y2 and Y3 are each CH. In some embodiments, Y2 is N and Y1 and Y3 are each CH. In some embodiments, Y3 is N and Y1 and Y2 are each CH. In some embodiments, Y3 is CH- and Y1 and Y2 are each N. In some embodiments described herein, Y1 and Y2 are each CH-, and Y3 are CRs where Rs is selected from the group consisting of hydrogen, hydroxyl, methyl, OCH3, fluoro, chloro and CF3. In some embodiments described herein, Rs is hydrogen or fluoro. In some embodiments described herein, Y2 is N and Y1 and Y3 are independently CH. In some embodiments, Y3isNeYi and Y2are each independently CH. In some embodiments described herein, Re is hydrogen, at least one of Y2o Y3es CRs, and Rs is selected from the group consisting of CN, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy and C1 haloalkoxy .4 . In some embodiments, Re is hydrogen and Y2 is C(OCF3). iviA / a / zuzz / uu ι ου 1 In some embodiments described herein, R4 and Rs are independently hydrogen or methyl. In some embodiments, R4 and R5 are considered together with the carbon atom to which they are attached to form a cyclopropyl. In some embodiments described herein, R4 is hydrogen or methyl, and R5 is hydrogen. In some embodiments described herein, R4 and Rs are each hydrogen. In some embodiments described herein, R3 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, CH2CH2F, CH2CH2OCH3, cyclopropyl-CH2-, cyclopropyl, methylcyclopropyl, cyclobutyl and fluorocyclobutyl. In some embodiments, R3 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, nbutyl, isobutyl, tert-butyl, cyclopropyl, 1-methylcyclopropyl, cyclobutyl and 3-fluorocyclobutyl. In some embodiments, R3 is selected from the group consisting of methyl, ethyl, isopropyl, cyclopropyl, 1-methylcyclopropyl, cyclobutyl, (1R,3S)-3-fluorocyclobutyl and (1S,3R)-3fluorocyclobutyl. In some embodiments, R3 is selected from the group consisting of methyl, ethyl and cyclopropyl. In some embodiments, R3 is ethyl. In some embodiments, R3 is cyclopropyl. In some embodiments described herein, R2 is selected from the group consisting of hydrogen, hydroxyl, amino, CN, halogen, methyl, ethyl, CH2OH, CH2CH2OH, C(=O)O(C1.2 alkyl), C(=O )NH2, and substituted or unsubstituted 5-membered heteroaryl. In some embodiments, R2 is selected from the group consisting of hydrogen, hydroxyl, CN, fluoro, methyl, CH2OH, C(=O)OCH3, C(=O)NH2, oxadiazolyl and triazolyl. In some embodiments, R2 is selected from the group consisting of hydrogen, hydroxyl, CN, methyl, CH2OH, C(=O)OCH3, C(=O)NH2, 1,2,4-oxadiazol-3-yl, 1,3 ,4-oxadiazol-2-yl, 1 / 7-1,2,4-triazol-3yl and 1 / 7-1,2,3-triazol-5-yl. In some embodiments, R2 is selected from the group consisting of hydrogen, CN, methyl, CH2OH and hydroxyl. In some embodiments, R2 is hydrogen or hydroxyl. In some embodiments, R2 is hydrogen. In some embodiments, R2 is hydroxyl. In some embodiments described herein, Ria is selected from the group consisting of hydrogen, hydroxyl, fluoro and CF3, and Rw is selected from the group consisting of hydrogen, fluoro and methyl. In some embodiments described herein, Ria is selected from the group consisting of hydroxyl, fluoro and CF3, and Ribse is selected from the group consisting of hydrogen, fluoro and methyl. In some embodiments described herein, Ria is hydroxyl or fluoro. In some embodiments, Ria is hydroxyl. In some embodiments described herein, Rib is hydrogen. In some embodiments, Rw is methyl. MA / a / ZUZZ / UU 1 In some embodiments described herein, at least one of Ria, R-ib and R2 is not hydrogen. In some embodiments described herein, Ría is selected from the group consisting of hydrogen, hydroxyl and fluoro; Ru is selected from the group consisting of hydrogen, fluoro and methyl; and R2 is selected from the group consisting of hydrogen, hydroxyl, methyl, CN, CH2OH and CH2CH2OH. In some embodiments, Riase selects from the group consisting of hydroxyl and hydrogen. In some embodiments, R-ib is hydrogen and R2 is selected from the group consisting of hydrogen, hydroxyl, CH2OH and CH2CH2OH, provided that either Ria is hydroxyl or R2 is selected from the group consisting of hydroxyl, CH2OH and CH2CH2OH. In some embodiments described herein, Roa is selected from the group consisting of hydrogen, methyl, CH2OH, CH2CH2OH, CH2F and CHF2; and Rob is selected from the group consisting of hydrogen, C1.4 alkyl, hydroxy Ci^alkyl and C1.4 haloalkyl. In some embodiments described herein, Roa is selected from the group consisting of hydrogen, methyl, CH2OH and CH2CH2OH. In some embodiments, Roa is hydrogen. In some embodiments, Rob is hydrogen. In some embodiments, a compound having a structure of Formula (II) or Formula (III) is provided herein: iviA / a / ¿u¿¿ / uu 1 or» 1 a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereoisomer, where R-ia is fluoro or hydroxyl, Rw is hydrogen or fluoro, R2 is hydrogen or hydroxyl, Re is CF3, Y2e Y3 are independently N or CRs, and Rs is hydrogen or fluoro. In some embodiments, Y2 and Y3 are each CH, or Y2 is CH and Y3 is CF. In some embodiments, Ria is hydroxyl and Rib is hydrogen. In some embodiments, R2 is hydrogen. In some embodiments, R2 is hydroxyl. In some embodiments described herein, Roa is selected from the group consisting of hydrogen, methyl, CH2OH and CH2CH2OH; Roo is selected from the group consisting of hydrogen and methyl; Riase selects from the group consisting of hydrogen, hydroxyl, fluoro and CF3; Rib is selected from the group consisting of hydrogen, fluoro and methyl; R2 is selected from the group consisting of hydrogen, hydroxyl, amino, CN, fluoro, methyl, CH2-OH, C(=O)-NH2, C(=O)O-CH3, 1,2,4-oxadiazol-3-yl , 1,3,4-oxadiazol-2-yl, 1 / 7-midazol-2-yl, 1 / 7-1,2,3-triazol-5yl, 1 / 7-1,2,4-triazol- 3-yl and 4-methyl-4 / 7-1,2,4-triazol-3-yl; R is selected from the group consisting of hydrogen and CH2OH; R3 is selected from the group consisting of methyl, ethyl, isopropyl, isobutyl, CH2CH2F, CH2CH2OCH3, cyclopropyl-CH2-, cyclopropyl, 1-methylcyclopropyl, cyclobutyl and 3-fluorocyclobutyl; R4 is hydrogen or methyl; R5 is hydrogen; Re is selected from the group consisting of hydrogen, chloro, CN, CF3, CHF2, CCH3F2, OCH3, OCF3, OCH2F, OCHF2, C(CF3)2OH, CF2CH2OH, 1 / 7-pyrazol-1 -yl, 1-methyl-1 / 7-pyrazol-4-yl and 1-(2-hydroxyethyl)-1 / 7-pyrazol-4-yl; R? is hydrogen or chlorine; Y1, Y2e Y3 are each CH; or Y1 is CH, Y2 is CH and Y3 is selected from the group consisting of N, C(F), C(OCH3), C(CH3), C(CI) and C(CF3); or Y1 is CH, Y2 is selected from the group consisting ofN, C(CN), C(1 / 7-1,2,4-triazol-1-yl), C(OCF3), C(OCH3), C(F) , C(OCHF2) and C(CI), and Y3es CH; or Y1 is CH, Y2 is C(CI) and Y3 is C(CI); or Y1 is C(CH3), Y2 is CH and Y3 is C(CH3); or ΥΊis C(CH3), Y2 is C(CH3) and Y3is CH; or ΥΊis C(CF3), Y2is C(CF3) and Y3 is CH; or Y1 is C(CI), Y2 is C(CI) and Y3 is CH ; o Y1 is N, Y2 is N and Y3 is CH. In some cases, when R7 is H and Y1, Y2e Y3 are CH, Re is selected from the group consisting of chlorine, CN, CF3, C(CH3)F2, OCF3, OCH2F, OCHF2, C(CF3)2OH, CF2CH2OH, 1 / - / -pyrazol-1-yl, 1-methyl1 / - / -pyrazol-4-yl and 1- (2-hydroxyethyl)-1 / - / -pyrazol-4-yl. In some embodiments described herein, Roa is selected from the group consisting of hydrogen, methyl, CH2OH and CH2CH2OH; Rob is hydrogen or methyl; Ría is selected from the group consisting of hydrogen, hydroxyl, CF3 and fluoro; Rib is selected from the group consisting of hydrogen, fluoro and methyl; R2 is selected from the group consisting of hydrogen, hydroxyl, CN, CH2OH, methyl, CO2Me, CONH2, 1,2,4-oxadiazol-3-yl, 1,3,4oxadiazol-2-yl, 1 / - / -1,2 ,3-triazol-5-yl and 1 / - / -1,2,4-triazol-3-yl; R is hydrogen; R3 is selected from the group consisting of methyl, ethyl, isopropyl, cyclopropyl-CHz-, cyclopropyl, 1-methylcyclopropyl, cyclobutyl, (1R,3S)-3-fluorocyclobutyl and (1S,3R)-3-fluorocyclobutyl; R4 is hydrogen; R5 is hydrogen; Re is selected from the group consisting of hydrogen, CF3, CF2CH3, OCHF2, C(CF3)2OH, 1 / - / -pyrazol-1-yl and 1-methyl-1 / - / -pyrazol-4-yl; R7 is hydrogen; Y1, Y2e Y3are each CH; or Y1 is CH, Y2 is CH and Y3 is C(F); or Y1 is CH, Y2 is C(OCF3) or C(OCH3) and Y3 is CH; or Y1 is CH, Y2 is CH and Y3 is N; or Y1 is CH, Y2 is N and Y3 is CH; or Y1 is N, Y2 is N and Y3 is CH. In some cases, when R7 is H and Y·,, Y2e Y3 are each CH, Re is selected from the group consisting of CF3, CF2CH3, OCHF2, C(CF3)2OH, 1 / - / -pyrazol-1 -yl and 1 -methyl-1Hpyrazol-4-yl. In some embodiments, Roa is selected from the group consisting of hydrogen, methyl and CH2OH; Rob is hydrogen or methyl; Ría is selected from the group consisting of hydrogen, hydroxyl and fluoro; Rib is selected from the group consisting of hydrogen, fluoro and methyl; R2 is selected from the group consisting of hydrogen, hydroxyl, CN, CH2OH, methyl, 1,2,4-oxadiazol3-yl, 1,3,4-oxadiazol-2-yl and 1 / - / -1,2,3- triazol-5-yl; R is hydrogen; R3 is ethyl or cyclopropyl; R4 is hydrogen; R5 is hydrogen; Re is selected from the group consisting of hydrogen, CF3, CF2CH3, OCHF2iC(CF3)2OH, 1 / - / -pyrazol-1 -yl and 1-methyl-1 H-pyrazol-4-yl; R7 is hydrogen; Y-ι, Y2e Y3are each CH; or Y1 is CH, Y2 is CH and Y3 is C(F); or Y1 is CH, Y2 is C(OCF3) and Y3 is CH. In some cases, when R7 is H and Y1, Y2 and Y3 are each CH, Re is selected from the group consisting of CF3, CF2CH3, OCHF2, C(CF3)2OH, 1 / - / -pyrazol-1-yl and 1 -methyl- 1 / - / -pyrazol-4yl. In some embodiments described herein, Roa is selected from the group consisting of CN, substituted or unsubstituted heteroalicyclyl, and substituted or unsubstituted heteroaryl; and Rob is hydrogen or Cu alkyl. In some embodiments, Roa is substituted or unsubstituted heteroaryl. In some embodiments, Roa is substituted or unsubstituted pyridinyl. In some embodiments described herein, Roo is hydrogen. In one embodiment described herein, the compound, stereoisomer or salt of Formula (I) is selected from the group consisting of: A7-1 rac-2-((3R,4R)-4-(((6-(C¡clopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4yl)amino) methyl)-3-hydroxypiper¡din-1-yl)acetamide, A7-1-1 re / -2-((3R,4R)-4-(((6-(Cyclopropíl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín -4yl)amino)met¡l)-3-hydroxypiper¡din-1-¡l)acetam¡de, eluted 1.erysomer, A7-1-2 re / -2-((3R,4R)-4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl )-3-hydroxypiperídin-1-yl)acetamide, 2nd eluted isomer, A7-2 2-(4-(((6-(cycloprop¡l(2-methyl-4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim¡n-4 l)amino)met¡l)p¡perid¡n-1-yl)acetam¡de, A7-3-1 re / -(R)-2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-¡l)methyl)amino) -5-fluoropírim¡din-4¡l)amino)methyl)-3,3-difluoropiper¡din-1-yl)acetamide, eluted 1.erysomer, A7-3-2 re / -(R)-2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-¡l)methyl)amino) -5-fluorop¡r¡m¡din-4¡l)amino)methyl)-3,3-difluoropiperidin-1-¡l)acetam¡de, 2nd eluted isomer, A7-4-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5fluorop¡r¡ m¡din-4-yl)amino)methyl)-3-fluorop¡perídin-1-l)acetamide, eluted 1.eryisomer, A7-4-2 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-¡l)) met¡l)amino)-5fluoropyrimid¡n-4-yl)amino)met¡l)-3-fluorop¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, A7-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)amino )methyl)-3-fluoropíperidín-1-yl)acetamíde, eluted 1.erysomer, A7-5-2 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r ¡m¡d¡n-4yl)amino)methyl)-3-fluorop¡perídin-1-¡l)acetamide, 2nd eluted isomer, A7-6-1 re / -(R)-2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyram ¡d¡n-4¡l)amino)methyl)-3,3-difluorop¡perid¡n-1-yl)acetamide, eluted 1.eryisomer, A7-6-2 re / -(R)-2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim ¡d¡n-4¡l)amino)met¡l)-3,3-difluoropiperidin-1-¡l)acetam¡de, 2nd eluted isomer, Α7-7-1 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3(trifluoromethyl)piperidin- 1-yl)acetamide, eluted 1.erysomer, A7-7-2 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3( trifluoromethyl)peridín-1-l)acetamide, 2nd eluted isomer, A7-7-3 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3(trifluoromet l)piper¡din-1-¡l)acetam¡de, 3.eluted erysomer, A7-7-4 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)rriethyl )-3(trifluoromethyl)piperidin-1-yl)acetamide, 4th eluted isomer, A7-8 1-(2-Amino-2-oxoethyl)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín4- methyl l)amino)methyl)p¡peridín-4-carboxylate, A7-9 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-4 -hydroxy¡piper¡din-1-¡l)acetam¡de, A7-10 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-l)amino)methyl)-4hydrox piperidin-1-yl)acetamide, A7-11 2-(4-(((6-(cycloprop¡l((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-4 -hydroxy¡piper¡din-1-¡l)acetam¡de, A7-14 rac-2-((3R,4R)-4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridiri-2-yl)methyl)arryno)-5fluorop¡r¡midín -4-yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, A7-14-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyr¡d¡n-2-¡ l)methyl)amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetamide, eluted 1.erysomer, A7-14-2 re / -2-((3R,4R)-4-(((6-(cyclopropíl((5-(trifluoromethyl)pyridín-2-yl)methyl )amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetamide, 2nd eluted isomer, A7-15 rac-2-((3R,4R)-4-(((6-(cyclobutyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5fluoropyrim¡din-4-¡l)amino) met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, ινΐΛ / a / zuzz / uu / ου i Α7-15-1 re / -2-((3R,4R)-4-(((6-(cyclobutyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5fluoropirimidin-4- il)amino)methyl)-3-hydroxypiperidin-1-íl)acetamide, eluted 1.erysomer, A7-15-2 re / -2-((3R,4R)-4-(((6-(cyclobutyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5fluoropyrim¡din-4-¡l )amino)methyl)-3-hydroxy¡p¡perídin-1-l)acetam¡de, 2nd eluted isomer, A7-16 rac-2-((3R,4R)-4-(((6-(cyclobutyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3 -hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-16-1 re / -2-((3R,4R)-4-(((6-(cyclobutíl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyr ¡m¡d¡n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, eluted 1.erysomer, A7-16-2 re / -2-((3R,4R)-4-(((6-(cyclobutyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyramidine -4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2nd eluted isomer, A7-17 rac-2-((3R,4R)-4-(((6-(cycloprop¡l((2-(trifluoromethyl)p¡nm¡d¡n-5-¡l)methyl)am ¡no)-5fluoropyrim¡din-4-yl)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-17-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((2-(trifluoromethyl)pyrimidin-5-yl)methyl)amino)-5fluorop r¡midin-4-yl)amino)methyl)-3-hydroxyp¡perídin-1-¡l)acetamide, eluted 1.eryisomer, A7-17-2 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((2-(trifluoromethyl)p¡r¡m¡d¡n-5 -¡l)met¡l)amino)-5fluoropy¡m¡m¡n-4-¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡ gives, eluted 2nd isomer, A7-18 rac-2-((3R,4R)-4-(((6-(cyclobutyl((2-(trifluoromethyl)pyrimidin-5-yl)methyl)amino)-5fluorop¡r¡m¡din -4-yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, A7-18-1 re / -2-((3R,4R)-4-(((6-(cyclobutíl((2-(trifluoromethyl)pyrimidín-5-íl)) meth¡l)amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetamide, eluted 1.eryisomer, A7-18-2 re / -2-((3R,4R)-4-(((6-(cyclobut¡l((2-(trifluoromethyl)pyrim¡din-5-¡ l)methyl)amino)-5fluorop¡r¡m¡din-4-yl)amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetamide, 2nd eluted isomer, A7-19 rac-2-((3R,4R)-4-(((5-fluoro-6-(isopropyl(4-(trifluoromethyl)benzyl)amino)pyrimidin-4¡l)amino)met ¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, ινΐΛ / a / zuzz / uu ι ου i Α7-19-1 re / -2-((3R,4R)-4-(((5-fluoro-6-(isopropyl(4-(trifluoromethyl)benzyl)amino)pyrimidin-4yl)amino) methyl)-3-hydroxypiperídin-1-yl)acetamide, eluted 1.erysomer, A7-19-2 re / -2-((3R,4R)-4-(((5-fluoro-6-(¡sopropyl(4-(tnfluoromethyl)benzyl)amino)pyrimidín -4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, A7-20 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyrimidin-4¡l)amino)met ¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-20-1 re / -2-((3R,4R)A-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyrimid ¡n-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, eluted 1.eryisomer, A7-20-2 re / -2-((3R,4R)4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyramida ¡n-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2nd eluted isomer, A7-21 rac-2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rímidin-4¡l)amino) met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-21-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4 ¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, eluted 1.erysomer, A7-21-2 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin -4¡l)amino)methyl)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2nd eluted isomer, A7-22 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡din-4-yl) amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, A7-22-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluoropyrimid ¡n-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2nd eluted isomer, A7-22-2 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluorop¡r ¡m¡d¡n-4-yl)amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetamide, eluted erysomer, A7-23 ΜΛ / a / zuzz / uu i ου i rac-2-((3R,4R)-4-(((6-(cyclobutyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)- 5fluoropirimidin-4-yl)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-23-1 re / -2-((3R,4R)-4-(((6-(cyclobutíl((6-(trifluoromethyl)pyridin-3-íl)methyl)amino)-5fluoropyrimid ¡n-4-¡l)amino)methyl)-3-hydroxy¡p¡peridin-1-yl)acetam¡de, eluted 1.eryisomer, A7-23-2 re / -2-((3R,4R)-4-(((6-(cyclobutyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5fluoropirimidin- 4-yl)amino)methyl)-3-hydroxypiperidín-1-íl)acetamide, 2nd eluted isomer, A7-24 rac-2-((3R,4R)-4-(((6-(cyclobutyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5fluoropyrim¡din-4-¡ l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-24-1 re / -2-((3R,4R)-4-(((6-(cyclobutyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5fluorop¡ r¡m¡din-4-yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, eluted 1.eryisomer, A7-24-2 re / -2-((3R,4R)-4-(((6-(cyclobutíl((5-(trifluoromethyl)pyridin-2-¡l)methyl)) amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2nd eluted isomer, A7-25 rac-2-((3R,4R)-4-(((6-(cyclopropyl((6-(difluoromethyl)pyridin-3-yl)methyl)amino)-5fluorop¡r¡m¡d¡n -4-yl)am¡no)met¡l)-3-hydroxy¡p¡perid¡n-1-¡l)acetamide, A7-25-1 re / -2-((3R,4R)4-(((6-(cycloprop¡l((6-(difluoromethyl)pyridín-3-¡l )methyl)amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetamide, eluted 1.erysomer, A7-26 rac-2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín- 4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, A7-26-1 re / -2-((3R,4R)4-((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim d¡n-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, A7-26-2 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5 -fluorop¡r¡m¡d¡n-4¡l)amino)methyl)-3-hydroxy¡p¡peridin-1-¡l)acetam¡de, eluted 1.eryisomer, A7-27 rac-2-((3R,4R)-4-(((6-(ethyl((5-(trifluoromethyl)pyridin-2-¡l)methyl)amino)-5-fluoropyrimidin- 4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-27-1 2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, eluted 1.erysomer, A7-27-2 re / -2-((3R,4R)-4-(((6-(ethyl((5-(tnfluoromethyl)pyridin-2-yl)methyl)amino)-5- fluoropyr¡m¡d¡n-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2nd eluted isomer, A7-28 rac-2-((3R,4R)-4-(((6-(cyclopropyl((6-(trifluoromethyl)pyrdin-3-¡l)metal) )amino)-5fluoropirimidin-4-yl)amino)methyl)-3-hydroxypiperidin-1-íl)acetamide, A7-28-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((6-(trifluoromethyl)pyr¡d¡n-3-¡ l)methyl)amino)-5fluoropyrimid¡n-44l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetamide, eluted 1.erysomer, A7-28-2 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((6-(trifluoromethyl)pyridín-34l)methyl )amino)-5fluorop¡r¡midin-4-yl)amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetamide, 2nd eluted isomer, A7-29 rac-2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)pindin-3-¡l)methyl)amino )-5fluoropyrimidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-29-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)pyr¡din-3-¡ l)met¡l)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetamide , 1.eluted erysomer, A7-29-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)pyr¡din-3-¡l)) met¡l)amino)-5fluoropyrimid¡n-4-¡l)amino)met¡l)-3-hydroxy¡p¡perid¡n-1-¡l)acetam¡de, 2nd isomer eluted, A7-30 rac-2-((3R,4R)-4-(((5-fluoro-6-((2-fluoroethyl)(4-(trifluoromethyl)benzyl)amino)pyramidal ¡n-4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, A7-31 rac-2-((3R,4R)-4-(((5-fluoro-6-(((1R,3S)-3-fluorocyclobutyl)(4(trifluoromethyl)benzyl)am) no)pyrimidin-4-¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-32 rac-2-((3R,4R)-4-(((5-fluoro-6-(((1S,3R)-3-fluorocyclobutyl)(4(trifluoromethyl)benzyl) am¡no)pyrám¡d¡n-4-¡l)am¡no)methyl)-3-hydroxy¡p¡períd¡n-1-yl)acetam¡de, A7-33 2-(4-(((6-(cycloprop¡l(1-(5-(trifluoromethyl)pyr¡din-2-yl)ethyl)amino)-5-fluoropyrimidin-4¡l) am¡no)met¡l)p¡perídin-1-yl)acetamide, A7-34 ΜΛ / a / ZUZZ / UU 14» 1 2-(4-(((6-(cyclopropyl(1 -(4-(tnfluoromethyl)phen¡l)ethyl)amino)-5-fluorop¡rímidín-4yl)amino)methyl) piperidin-1-yl)acetamide, A7-35 2-(4-(((6-(c¡cIoprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)p¡ perid¡n-1-yl)acetam¡de, A7-36 2-(4-(((6-((3-cyanobenzyl)(cyclopropyl)amino)-5-fluoropyrimidin-4-íl)amino)methyl)piperidin1-íl)acetamide, A7-38 2-(4-(( (6-((3-( 1H-1,2,4-triazol-1 -¡l)benzyl)(cycloprop¡l)amino)-5-fluoropyrám¡ d¡n-4¡l)am¡no)met¡l)p¡per¡d¡n-1-yl)acetamide, A7-39 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4¡l)amino)methyl)piperid¡n -1-yl)acetamide, A7-40 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benzyl)amino)-5-fluoropyr¡m¡d¡ n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-41 rac-2-((3R,4R)-4-(((5-fluoro-6-((1-methylcyclopropyl)(4(tnfluoromethyl)benzyl)amino)pyramidal n-4-yl)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-42 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy)-2-fluoroiObenzyl)amino)-5fluoropyrimidín-4-íl) am¡no)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-43 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(difluoromethoxy)benzyl)amino)-5-fluorop¡r¡m¡d¡n- 4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, A7-44 1-(2-amino-2-oxoethyl)-4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡r¡ mid¡n4-¡l)amino)met¡l)p¡perídin-4-carboxamide, A7-45 2-(4-(((6-(cycloprop¡l((6-(tnfluoromethyl)pyridin-3-yl)methyl)amino)-5-fluorop¡nm¡din-4¡ l)amino)met¡l)-4-(hydroxy¡met¡l)p¡perid¡n-1-¡l)acetam¡de, A7-46 2-(4-(((6-((4-chloro-2,5-dimethylbenzyl)(cyclopropyl)amino)-5-fluoropyrámidin-4¡l)amino)methyl)p¡ perid¡n-1-yl)acetam¡de, A7-47 iviA / a / zuzz / uu / ου i 2-(4-(((6-(cyclopropyl(2,5-dimethylbenzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)piperidin-1-yl)acetamide, A7-49 rac-2-((3R,4S)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din-4yl) amino)met¡l)-3-hydroxypiper¡din-1-¡l)acetam¡de, A7-50 2-(4-cyano-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)piperidin-1-l) acetamide, A7-51 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)arnino)methyl)-4(hydroxymethyl) p¡perídin-1-yl)acetam¡de, A7-52 2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino) methyl)-4-(hydroxy¡methyl)p¡peridin-1-yl)acetamide, A7-53 2-(4-(((6-((4-chloro-3,5-dimet¡lbenzyl)(cycloprop¡l)amino)-5-fluoiOpyrimidin-4¡l)amino)met¡ l)p¡períd¡n-1-¡l)acetam¡de, A7-54 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2yl)benzyl) )arníno)-5-fluoropyrimídin-4-í)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, A7-54-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡ l)benzyl)amino)-5-fluoropyrimídin-4-l)amino)methyl)-3-hydroxyl)peridin-1-yl)acetamide, 1 ®risomer eluted, A7-54-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡ l)benzyl)amino)-5-fluoropírimídin-4-yl)amino)methyl)-3-hydroxypiperidin-1-íl)acetamide, 2nd eluted isomer, A7-55 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropinm¡din -4yl)amino)methyl)-3-hydroxy¡piperidin-1 -yl)-2-methylpropanamide, enantiomerically enriched, A7-56 rac-2-((3R,4R)-4-(((6-(cyclopropyl(3-(trifluoromethoxy)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl) -3-hydroxypiper¡din-1-yl)acetamide, A7-57 ινΐΛ / a / zuzz / uu ι ου i re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5 -fluorop¡r¡m¡din-4yl)amino)methyl)-3-hydroxypiper¡din-1 -yl)-2-methylpropanamide, enantiomerically enriched, A7-58 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(3-methoxy-4-(trifluoromethyl)benzyl)amino)-5fluoropyrimidín-4- il)amino)methyl)-3-hydroxy¡p¡peridin-1-yl)acetamide, A7-60 rac-2-((3R,4R)-4-(((5-fluoro-6-((methyl-d3)(4-(trifluoromethyl)benzyl)amino)pyrimidin-4yl)am ¡no)methyl)-3-hydroxyp¡peridin-1-yl)acetamide, A7-61 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-methoxy-4-(trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4- ¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-64 2-(4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4¡l)amino)methyl)piperidin-1 -l)-3-hydroxypropanamide, A7-65 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡d¡ n-4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)-3-hydroxy¡propanamide, A7-66-1 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimid ¡n-4¡l)am¡no)met¡l)-3-hydroxy¡p¡perídin-1-¡l)-3-hydroxy¡propanamide or re / -(R)-2 -((3S,4S)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3-hydrox p¡perídin-1-yl)-3-hydroxy¡propanamide, eluted major erysomer, A7-66-2 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l )amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)-3-hydroxy¡propanamide or re / -(R)-2-((3S,4S )-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidin-4¡l)amino)methyl)-3-hydroxy¡p¡períd ¡n-1-yl)-3-hydroxy¡propanamide, eluted major isomer, A7-67 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl )-3-hydroxy¡p¡peridin-1 -yl)-4-hydroxy¡butanamide, enantiomerically enriched, A7-68 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4hydroxypiper d¡n-1-¡l)-3-hydroxypropanamide, A7-69 ινΐΛ / a / zuzz / uu / ου i re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino) -5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide-2,2-c / 2, enantiomerically enriched, A7-70 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4-yl)amino)methyl)- 4(hydroxymethyl)piperidin-1-yl)-3-hydroxypropanamide, A7-72 rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-methyl-1 / - / -pyrazol-4-yl)benzyl)amino)-5 -fluoropyrimidin-4yl)amino)methyl)-3-hydroxypyrimidin-1-yl)acetamide, A7-73 rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-(2-hydroxyethyl))-1 / - / -pyrazol-4-¡l)benc ¡l)amino)-5fluoropyrim¡din-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-74 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1-methyl-1 / - / -pyrazol-4-yl)benzyl)amino)-5fluorop¡r ¡m¡din-4-yl)am¡no)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, A7-75 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / - / -pyrazol-4-! )benzyl)amino)-5fluoropyrimidín-4-íl)amino)methyl)-3-hydroxy¡piperidín-1-yl)acetamíde, A7-76 rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4-(1 / - / -pyrazol-1-yl)benzyl)amino)-5fluorop ¡r¡m¡d¡n-4-yl)am¡no)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetamide, A7-77 rac-2-((3R,4R)-4-(((6-((4-(1 / - / -P¡razol-1-¡l)benzyl)(ethyl)amino)- 5-fluoropyrimidin-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetamide, A7-78 rac-2-((3R,4R)-4-(((6-((4-cyanobenzyl)(ethyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl )-3hydroxy¡piperidin-1-yl)acetamide, A7-79 rac-2-((3R,4R)-4-(((6-((4-(1,1-difluoro-2-hydroxyethyl)benzyl)(ethyl)amino )-5-fluorop¡r¡m¡d¡n4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-80 2-(4-(((6-(Cíclopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-íl)amino)methyl)-4(1H-1 ,2,4-tnazol-3-¡l)p¡pendin-1-yl)acetam¡de, A7-81 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín-4-yl)amino)methyl)-4(1, 2,4-oxadiazol-3-l)pyridin-1-yl)acetamide, A7-82 iviA / a / zuzz / uu i ου i 2-(4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(1, 3,4-oxadiazol-2-yl)piperidin-1-yl)acetamide, A7-83 2-(4-(((6-(Cíclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(4-methyl-4 / 7-1,2,4-tr¡azol-3-yl)piperidin-1-¡l)acetamide, A7-84 2-(4-(((6-(Cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)met¡l)- 4(1 / 7-ímidazol-2-yl)píperidin-1-íl)acetamide, A7-85 2-(4-(((6-(C¡cloprop¡l(4-(tnfluoromet¡l)benzyl)amino)-5-fluorop¡rímid¡n-4-¡l)amino) met¡l)-4(1 / 7-1,2,3-tr¡azol-5-¡l)p¡peridín-1-yl)acetamide, A7-86 rac-2-((3R,4R)-4-(((6-((4-(1 / 7-pyrazol-1-¡l)benzyl)(cyclopropyl)amino)-5-fluoropyrimidín -4¡l)amino)methyl)-3-hydroxyp¡perídin-1-yl)acetam¡de, A7-87 2-(4-(1-((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim¡din-4-¡l)amino) -2hydroxyethyl)piperidin-1 -yl)acetamide, B4-1-1-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin -4yl)amino)methyl)-3-hydroxy-3-methylpiperidin-1-yl)acetamide, 1 eluted erysomer, B4-1-1-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop rim¡din-4¡l)amino)met¡l)-3-hydroxy¡-3-met¡lpiperidín-1-¡l)acetam¡de, 2nd eluted isomer, B4-1-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)am ¡no)met¡l)-3-hydroxy¡-3-met¡lpiper¡din-1-¡l)acetam¡de, 1 .erysomer eluted, B4-1-2-2 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop rim¡din-4¡l)amino)met¡l)-3-hydroxy¡-3-met¡lpiperidín-1-¡l)acetam¡de, 2nd eluted isomer, B4-2-1-1 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-l)amino)methyl)-3h Droxy-4-met¡lp¡perídin-1-¡l)acetamide, 1 .eluted erysomer, B4-2-1-2 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxyl-4 -met¡lp¡perídin-1-yl)acetamide, 2nd eluted isomer, C4-1-1 iviA / a / zuzz / uu fom 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy-4-(hydroxymethyl)piperid ¡n-1-yl)acetam¡de, eluted 1.eryisomer, C4-1-2 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4-yl)amino)methyl)- 3hydroxy¡-4-(hydroxymethyl)piper¡din-1-¡l)acetam¡de, 2nd eluted isomer, C4-2-1 2-(4-(((6-((3,5-bis(tnfluoromethyl)benzyl)(ethyl)amino)-5-fluoropyrim¡din-4-yl)amino)methyl)-3hydroxy -4-(hydroxymethyl)piper¡din-1-yl)acetam¡de, eluted 1.erysomer, D5-1-1-1 re / -2-((3R,4R)4-(((6-(ethyl(4-(trifluorornetyl)benzyl)amino)-5-fluorop¡r¡midin-4¡l) am¡no)methyl)-3,4-d¡hydroxypiperid¡n-1-¡l)acetamide, eluted 1.eryisomer, D5-1-1-2 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4 ¡l)amino)methyl)-3,4-d¡hydroxy¡p¡perídin-1 -yl)acetamide, 2nd eluted isomer, D5-1-2-1 re / -2-((3R,4S)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropirimidin-4 ¡l)amino)met¡l)-3,4-d¡hydroxypiperid¡n-1-¡l)acetam¡de, eluted 1.eryisomer, D5-1-2-2 re / -2-((3R,4S)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrámidin-4¡l)am ¡non)methyl)-3,4-d¡hydroxy¡piper¡din-1-yl)acetam¡de, 2nd eluted isomer, D5-2-1-1 re / -2-((3R,4R)4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5- fluorop¡rim¡din-4¡l)amino)methyl)-3,4-d¡hydroxypiperid¡n-1-¡l)acetam¡de, eluted 1.erysomer, D5-2-1-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)am ¡no)methyl)-3,4-d¡hydroxy¡piper¡din-1-¡l)acetamide, 2nd eluted isomer, D5-2-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop ¡rim¡din-4¡l)amino)met¡l)-3,4-d¡hydroxypiperidin-1-¡l)acetam¡de, eluted 1.erysomer, D5-2-2-2 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5 -fluoropyrám¡d¡n-4¡l)amino)methyl)-3,4-d¡hydroxypiperid¡n-1-¡l)acetam¡de, 2nd eluted isomer, D5-3-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l )amino)methyl)-3,4-d¡hydroxy¡piper¡din-1-¡l)acetamide, eluted 1.eryisomer, D5-3-1-2 ΜΛ / a / ZUZZ / UU i re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino )-5-fluoropyrimidin-4yl)amino)methyl)-3,4-dihydroxy¡p¡peridin-1-yl)acetamide, 2nd eluted isomer, D5-3-2-1 re / -2-( (3R,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl) -3,4-dihydroxypyperidin-1-yl)acetamide, eluted 1.erysomer, D5-3-2-2 re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluorometal)benzyl)am) no)-5-fluoropírímidín-4yl)amino)methyl)-3,4-dihydroxyípiperidin-1-yl)acetamíde, eluted isomer, D5-4 re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy¡propan-2- il)benz¡l)am¡no)-5fluoropyrim¡n-4-¡l)am¡no)methyl)-3,4-d¡hydroxy¡p¡perid¡n-1-¡l) acetamide, enantiomerically enriched, D5-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazole-4-íl )benzyl)amino)-5fluoropyrimidin-4-l)amino)methyl)-3,4-dihydroxípíperidín-1-yl)acetamide, major isomer, D5-5-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / - / -pyrazol-4-yl )benzyl)amino)-5fluoropyrim¡din-4-¡l)amino)methyl)-3,4-dihydroxy¡p¡perid¡n-1-¡l)acetam¡de , minor isomer, D5-6 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡l) benz¡l)amino)-5-fluorop¡rim¡n-4-yl)amino)met¡l)-3,4-dihydroxy¡p¡perid¡n-1-¡l)acetam¡de , enantiomerically enriched, D5-9 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-¡l)benzyl)amino )-5fluorop¡rim¡din-4-¡l)amino)met¡l)-3,4-di¡hydroxy¡p¡perídin-1-¡l)acetam¡de , enantiomerically enriched, D5-10 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluorobenzyl)amino)-5-fluoropyrimidin-4iI)amino) methyl)-3,4-dihydroxypiperidin-1 -yl)acetamide, enantiomerically enriched, E6-1 2-(4-Amino-4-(((6-(cyclopropyl(4-(trifluoromethyl)benc ¡l)amino)-5-fluorop¡rim¡n-4¡l)amino)met¡l)p¡períd¡n-1-yl)acetamide, F2-1 rac-2-( (3R,4R)-4-(((5-fluoro-6-(methyl(2-methylbenzyl)amino)primidin-4-yl)amino)met l)-3hydroxy¡piper¡n-1-¡l)acetamide, iviA / a / zuzz / uu / ου i F2-2 rac-2-((3R,4R)-4-(((6-((2,6-dichlorobenzyl)(methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiper din-1-yl)acetamide, F2-3 rac-2-((3R,4R)-4-(((6-((2,3-dichlorobenzyl)(methyl)amino)-5-fluoropyrimidin-4¡l)amino )methyl)-3-hydroxy¡piper¡din-1-yl)acetamide, F2-4 rac-2-((3R,4R)-4-(((6-((2,6-dichlorobenzyl)(ethyl)amino)-5-fluoropyrim¡din-4-yl)amino )met¡l)3-hydroxypiper¡din-1-¡l)acetam¡de, F2-5 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(1-(o-tolyl)ethyl)amino)pyrmidin -4-yl)amino)methyl)-3hydroxylpiperidin-1-l)acetamide, F2-6 rac-2-((3R,4R)-4-(((6-((1-(2-chlorophenyl)ethyl)(methyl)amino)-5-fluorOp¡r¡mid¡ n-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, F2-7 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy)benzyl)amino)pyrimidin-4yl) am¡no)methyl)-3-hydroxypiper¡din-1-¡l)acetam¡de, F2-8 rac-2-((3R,4R)-4-(((6-((3-cyanobenzyl)(methyl)amino)-5-fluoropyrimidin-4-¡l)amino) methyl)-3hydroxy¡piperidin-1-yl)acetamide, F2-9 rac-2-((3R,4R)-4-(((5-fluoro-6-(¡sobut¡l(4-(trifluoromethyl)benzyl)amino)pyrim¡ d¡n-4¡l)amino)met¡l)-3-hydroxypiper¡d¡n-1-¡l)acetam¡de, F2-10 rac-2-((3R,4R)-4-(((6-((cyclopropylmethyl)(2-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin4-l )amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, F2-11 rac-2-((3R,4R)-4-(((6-((4-cyanobenzyl)(¡sobut¡l)amino)-5-fluoropyrim¡din-4-¡l )amino)methyl)3-hydroxypiperidin-1-yl)acetamide, F2-12 rac-2-((3R,4R)-4-(((6-((4-chloro-3-fluorobenzyl)(methyl)amino)-5-fluoropyramida ¡n-4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, F2-13 rac-2-((3R,4R)-4-(((6-((4-(difluoromethoxy)benzyl)(methyl)amino)-5-fluoropharm d¡n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, ινΐΛ / a / zuzz / uu ι ου ί F2-14 rac-2-((3R,4R)-4-(((6-((4-(difluoromethoxy¡)-3-methoxybenzyl)(methyl)amino)-5-fluorop¡rimid¡ n4-yl)amino)methyl)-3-hydroxypiperídin-1-yl)acetamide, F2-15 rac-2-((3R,4R)-4-(((6-((4-chlorobenzyl)(isopropyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3-hydroxy¡ piperidin-1-yl)acetamide, F2-16 rac-2-((3R,4R)-4-(((5-fluoro-6-((2-methoxyethyl)(4-(trifluoromethyl)benzyl)amino)pyrimidin-4 ¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, F2-17 rac2-((3R,4R)-4-(((6-((2,4-dichlorobenzyl)(isobutyl)amino)-5-fluorop¡rímidin-4¡l)amino )methyl)-3-hydroxy¡piperidin-1-¡l)acetam¡de, F2-18 rac-2-((3R,4R)-4-(((6-((4-cyanobenzyl)(methyl)amino)-5-fluorop¡r¡m¡d¡n -4-¡l)amino)met¡l)-3h¡droxy¡piperidin-1-yl)acetam¡de, F2-19 rac-2-((3R,4R)-4-(((5-fluoro-6-(((6-methoxypind¡n-3-¡l)methyl)(methyl)am¡ no)pir¡m¡din-4yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetam¡de, F2-20 rac-2-((3R,4R)-4-(((6-((3-(difluoromethoxy)benzyl)(methyl)amino)-5-fluorop¡rímidín-4¡l) am¡no)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, F2-21 rac-2-((3R,4R)-4-(((6-((3,5-dichlorobenzyl)(methyl)amino)-5-fluoropyrimidin-4¡l)amino )met¡l)-3-hydroxypiper¡din-1-¡l)acetam¡de, F2-22 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethoxy)benzyl)amino)pyrimidin-4¡l)amino)methyl)- 3-hydroxypiperidin-1-yl)acetamide, F2-23 rac-2-((3R,4R)-4-(((6-((3-chlorobenzyl)(isopropyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)- 3-hydroxypiperídin-1-yl)acetamide. In some cases, the compound, stereoisomer or salt having a structure of Formula (I) is selected from the group consisting of: 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-l)amino)methyl) -3hydroxy¡piperidin-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(2-methyl-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrymidin-4 ¡l)amino)met¡l)p¡perídin-1-yl)acetamide, ινΐΛ / a / zuzz / uu / ου i 2-(4-(((6-(cyclopropíl((5-(trifluoromethyl)pyridín-2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3 ,3-difluoropíperidin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-fluoropiper¡din -1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3fluoropiperidin- 1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidín-4-yl)amino)methyl)3,3-d fluoropiperidin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(tnfluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-¡l)amino)met¡ l)-3(trifluoromethyl)piper¡din-1-yl)acetam¡de, 1-(2-amino-2-oxoethyl)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyral) methyl m¡din4-yl)amino)methyl)p¡perid¡n-4-carboxylate, 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyr¡din-2-yl)methyl)amino)-5-fluoropyrimidín-4¡l)amino) methyl)-4-hydroxy¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-4hydroxypiperidin-1 -yl)acetamide, 2-(4-(((6-(cycloprop¡l((6-(tnfluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-4 -hydroxy¡piper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l((5-(tnfluoromethyl)pyridin-2-¡l)methyl)amino)-5-fluoropyrámidín-4 ¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2-(4-(((6-(cyclobut¡l(4-(difluoromethoxy¡)-2-fluorobenzyl)amino)-5-fluoiOp¡rimidin-4¡l)amino)methyl)-3- hydrox¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(cyclobut¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡r¡m¡din-4-yl)amino)met ¡l)-3hydroxy¡p¡perid¡n-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l((2-(tnfluoromethyl)pyrim¡din-5-¡l)methyl)amino)-5-fluorop¡rim¡d ¡n-4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, 2-(4-(((6-(cyclobutyl((2-(trifluoromethyl)pyrimidin-5-yl)methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3-hydroxy¡p per¡d¡n-1-yl)acetam¡de, 2-(4-(((5-fluoro-6-(isopropyl(4-(tnfluoromethyl)benzyl)amino)pyrimidin-4-yl)amino)methyl)-3hydrox piperidin-1-l)acetamide, 2-(4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyrmidin-4-yl)amino)met l)-3hydroxypiperidín-1-l)acetamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-¡l) amino)methyl)-3hydroxy¡piperidin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoiOpyrimidín-4¡l )amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, ινΐΛ / a / zuzz / uu ι ου ί 2-(4-(((6-(cyclobutíl((6-(trifluoromethyl)pyridín-3-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiperidin -1-yl)acetamide, 2-(4-(((6-(cyclobutyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiper¡din-1 -il)acetamída, 2-(4-(((6-(cycloprop¡l((6-(difluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrim¡din-4¡l) amino)methyl)-3-hydroxylpiperidin-1-yl)acetamide, 2-(4-(((6-(ethyl(2-fluoro-4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)methyl )3-hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-(ethyl((5-(trifluoromethyl)pyridin-2-l)methyl)amino)-5-fluoropyrim ¡din-4-¡l)am¡no)met¡l)3-hydroxypiper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cyclopropyl((6-(tnfluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrimidin- 4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)pyridín-3-yl)methyl)amino)-5-fluoropyrimidín- 4¡l)amino)methyl)-3-hydroxyp¡perídin-1-yl)acetam¡de, 2-((((5-fluoro-6-((2-fluoroethyl)(4-(trifluoromethyl)benzyl)amino)pyrimidin-4-yl)amino) methyl)-3hydroxypiperidin-1 -yl)acetamide, 2-(4-(((5-fluoro-6-((3-fluoroc¡clobut¡l)(4-(trifluoromethyl)benzyl)amino)pyrimidín-4yl)amino) met¡l)-3-hydroxypiper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l(1-(5-(trifluoromethyl)pyridín-2-yl)ethyl)amino)-5-fluoropyrim¡d¡ n-4yl)amino)methyl)piperidin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(1-(4-(trifluoromethyl)phen¡l)ethyl)amino)-5-fluorop¡rimidin-4¡l) am¡no)methyl)p¡perídin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl) p¡perídin-1-yl)acetam¡de, 2-(4-(((6-((3-cyanobenzyl)(cycloprop¡l)amino)-5-fluorop¡r¡m¡din-4-yl)amino)methyl)p¡perid¡n1- il)acetamide, 2-(4-(((6-((3-( 1H-1,2,4-triazol-1 -yl )benzyl )(cyclopropyl )ami no)-5-fl uoropy rimidi n-4¡l)am ¡no)methyl)piper¡din-1-yl)acetam¡de, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4yl)amino)methyl)piperidin-1 -il)acetamída, 2-(4-(((6-(cycloprop¡l(4-(1,1-difluoroethyl)benzyl)amino)-5-fluoropyrim¡din-4-yl)amino)methyl)3 -hydroxy¡piper¡din-1-¡l)acetam¡de, 2-(4-(((5-fluoro-6-((1-met¡lc¡cloprop¡l)(4-(trifluoromethyl)benzyl)amino)pyramid¡ n-4yl)amino)methyl)-3-hydroxypiperídin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(difluoromethox¡)-2-fluorobenzyl)amino)-5-fluoropyrám¡d¡n-4¡l )amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, MA / a / ZUZZ / UU i 2-(4-(((6-(cycloprop¡l(4-(difluoromethoxy)benzyl)amino)-5-fluoropyrámidín-4-yl)amino)methyl)3-hydroxypiperidin -1-yl)acetamide, 1-(2-amino-2-oxoethyl)-4-(((6-(cyclopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin4-yl)amino)methyl)píperídin- 4-carboxamide, 2-(4-(((6-(cycloprop¡l((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyr¡midin- 4¡l)amino)methyl)-4-(hydroxy¡methyl)piperidín-1-¡l)acetamide, 2-(4-(((6-((4-chloro-2,5-dimethylbenzyl)(cyclopropyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)piperidin- 1-l)acetamide, 2-(4-(((6-(cycloprop¡l(2,5-dimethylbenzyl)amino)-541uorop¡rim¡din-4¡l)amino)methyl)piper¡ d¡n-1-yl)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-44l)amino)met¡l)- 3hydroxy¡piperidín-1-¡l)acetamide, 2-(4-cyano-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)piperidín -1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-44l)amino)met¡l)- 4(hydroxymethyl)p¡perídin-1-¡l)acetamide, 2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-4 -(hydroxymethyl)piperídin-14l)acetamide, 2-(4-(((6-((4-chloro-3,5-dimethylbenzyl)(cyclopropyl)amino)-5-fluoiOp¡rimidin-4yl)amino)methyl)piperidin- 1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)amino)-5fluoropirimidin-4-¡ l)amino)methyl)-3-hydroxy¡p¡perídin-1-l)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3hydroxy¡p¡perídin-1-¡l)-2-methylpropanamide, 2-(4-(((6-(cycloprop¡l(3-(trifluoromethoxy)benzyl)amino)-5-fluoropyrim¡din-4-¡l)amino)methyl)3-hydroxypiperidin- 1-yl)acetamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-44l)amino)methyl)-3hydroxylpiperidin-1-l )-2-methylpropanamide, 2-(4-(((6-(cycloprop¡l(3-methoxy¡-4-(tnfluoromethyl)benzyl)amino)-5-fluoropyriin¡din-4yl)amino)methyl) -3-hydroxypiperidin-1-yl)acetamide, 2-(4-(((5-fluoro-6-((methyl-d3)(4-(trifluoromethyl)benzyl)amino)pyrimidín-4-¡l)amino)methyl)-3h¡ droxi¡p¡pend¡n-1-yl)acetam¡de, 2-(4-(((6-(cycloprop¡l(2-methoxy¡-4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡riin¡din-4yl) amino)methyl)-3-hydroxypiperídin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidin-4¡l)amino)met l)pyridin-1-yl)-3-hydroxypropanamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)-3 -hydroxypropanamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy¡piperidin-1-yl)-3-hydrox propanamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrmidin-4-yl)amino)methyl )-3hydroxy¡piperid¡n-1-¡l)-4-hydroxy¡butanamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidín-4-yl)amino)methyl)-4hydroxy¡piperidin- 1-yl)-3-hydroxypropanamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-3hydroxy¡pipenden- 1-¡l)acetamide-2,2-d2, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-4(hydroxymethyl)p¡perídin-1-¡l)-3-hydroxy¡propanamide, 2-(4-(((6-(ethyl(4-( 1 -methyl-1 H-pyrazol-4-¡l)benzyl)amino)-5-fluorop¡r¡m¡din-4-yl )amino)methyl)3-hydroxylpiperidin-1-l)acetamide, 2-(4-(((6-(ethyl(4-(1-(2-hydroxyethyl)-1 / 7-pyrazol-4-yl)benzyl)amino)-5-fluoropyrimidin -4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(cyclopropyl(4-(1-methyl-1 / 7-pyrazol-4-¡l)benzyl)amino)-5-fluoropyrimidín- 4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazol-4-yl)benzyl)amino)-5-fluoropyrimid ¡n-4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-l)benzyl)amino)-5-fluoropyrimidiri-4) l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-((4-(1 / - / -pyrazol-1-¡l)benzyl)(ethyl)amino)-5-fluorop¡r¡mid ¡n-4-yl)amino)met¡l)-3hydroxy¡piper¡din-1-¡l)acetam¡de, 2-(4-(((6-((4-cyanobenzyl)(ethyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy¡piperidín-1-¡l)acetam¡ gives, 2-(4-(((6-((4-(1,1-difluoro-2-hydroxyethyl)benzyl)(ethyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3-h¡ droxi¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)met ¡l)-4(1 / 7-1,2,4-tr¡azol-3-yl)p¡per¡din-1 -yl)acetamide, 2-(4-(((6-(C¡clopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4-¡l)amino)methyl)-4(1 ,2,4-oxad¡azol-3-¡l)piper¡din-1-¡l)acetam¡de, 2-(4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-yl)amino)methyl)-4(1, 3,4-oxadiazol-2-yl)piperidin-1-yl)acetamide, 2-(4-(((6-(C¡cloprop¡l(4-(tnfluoromet¡l)benzyl)amino)-5-fluorop¡rímid¡n-4-¡l)amino) met¡l)-4(4-met¡l-4 / 7-1,2,4-tr¡azol-3-¡l)piper¡din-1-¡l)acetamide, iviA / a / zuzz / uu Yo 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín-4-yl)amino)methyl)-4(1H- im¡dazol-2-yl)p¡peridin-1-¡l)acetamide, 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-4(1 / 7- 1,2,3-triazol-5-yl)píperidín-1 -yl)acetamide, 2-(4-(((6-((4-(1 / 7-pyrazol-1-yl)benzyl)(cyclopropyl)amino)-5-fluoropyrimidin-4íl)amino )methyl)-3-hydroxy¡piper¡din-1-yl)acetamide, 2-(4-(1-((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropiridin-4-yl)amino)-2hydroxyethyl)piperidin- 1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(tnfluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-¡l)amino)met¡ l)-3hydroxy¡-3-met¡lp¡perídin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3hydroxy-4-met¡lp¡perídin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rym¡d¡n-4-yl)amino)methyl)-3hydroxy- 4-(hydroxymethyl)piperidín-1-yl)acetamide, 2-(4-(((6-((3,5-bis(tnfluoromethyl)benzyl)(ethyl)amino)-5-fluorop¡rim¡din-4-yl)amino)met¡ l)-3h¡droxy-4-(hydroxy¡met¡l)p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrymidin-4-yl)amino)methyl )-3,4dihydroxypiperid¡n-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)3,4-dih droxypiperidin-1-yl)acetamide, 2-(4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino )methyl)3,4-d¡hydroxypiperidín-1-¡l)acetamide, 2-(4-(((6-(ethyl(4-(1 Λ1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)amino)-5fluoropyrámidín- 4-l)amino)methyl)-3,4-dihydroxylpiperidin-1-l)acetamide, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazol-4-l)benzyl)amino)-5-fluoropyrimidin- 4yl)amino)methyl)-3,4-dihydroxy¡p¡peridin-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)amino)-5fluoropyrimidin-4 -l)amino)methyl)-3,4-dihydrox¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-yl)benzyl)amino)-5-fluoropyrimide ¡n-4yl)amino)methyl)-3,4-dihydroxypiperidin-1-yl)acetamide, 2-((3R,4R)-4-(((6-(cyclopropyl(2-fluorobenzyl)amino)-5-fluoropyrimidin-4-l)amino)methyl )3,4-d¡hydroxy¡p¡perídin-1-¡l)acetamide, 2-(4-Am¡no-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d ¡n-4yl)amino)methyl)piperidin-1-¡l)acetamide, 2-(4-(((5-fluoro-6-(methyl(2-methylbenzyl)amino)pyrimidin-4-l)amino)methyl)-3hydroxy ¡piperid¡n-1-¡l)acetam¡da, ινΐΛ / a / zuzz / uu / ου i 2-(4-(((6-((2,6-dichlorobenzyl)(methyl)amino)-5-fluoropyrimidin-4-l)amino)methyl)-3hydroxy piperidin-1-yl)acetamide, 2-(4-(((6-((2,3-dichlorobenzyl)(methyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-((2,6-dichlorobenzyl)(ethyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy¡piperidin-1-¡l)acetam¡ gives, 2-(4-(((5-fluoro-6-(methyl(1-(o-tolyl)ethyl)amino)pyrimidin-4-yl)amino)methyl)-3 -hydroxypiper¡d¡n1-¡l)acetamide, 2-(4-(((6-((1-(2-chlorophen¡l)ethyl)(methyl)amino)-5-fluorop¡r¡m¡d¡n-4-¡ l)amino)methyl)-3hydroxylpiperidin-1-l)acetamide, 2-(4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy)benzyl)amino)pyrimidin-4-l)amino)methyl)- 3hydroxy¡piperidín-1-¡l)acetamide, 2-(4-(((6-((3-cyanobenzyl)(methyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxypiperidin-1 -yl)acetamide, 2-(4-(((5-fluoro-6-(isobutyl(4-(trifluoromethyl)benzyl)amino)pyrimidin-4-l)amino)methyl)- 3hydroxypiperidin-1 -yl)acetamide, 2-(4-(((6-((cyclopropylmethyl)(2-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)- 3-hydroxypiper¡din-1-yl)acetamide, 2-(4-(((6-((4-cyanobenzyl)(isobutyl)amino)-5-fluoropyridinidin-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-((4-chloro-3-fluorobenzyl)(methyl)amino)-5-fluorop¡rim¡din-4-¡l)amino)methyl)- 3hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-((4-(difluoromethoxy¡)benz¡l)(met¡l)amino)-5-fluorop¡r¡m¡d¡n-4-¡l )amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-((4-(difluoromethoxy)-3-methoxybenzyl)(methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3-hydrox p¡perídin-1-¡l)acetam¡da, 2-(4-(((6-((4-chlorobenzyl)(¡sopropyl)amino)-5-fluoropyrimidin-4-¡l)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((5-fluoro-6-((2-methoxyethyl)(4-(trifluoromethyl)benzyl)amino)primidin-4-l )amino)methyl)3-hydroxypipendin-1-l)acetamide, 2-(4-(((6-((2,4-dichlorobenzyl)(¡sobut¡l)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino )methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-((4-cyanobenzyl)(methyl)amino)-5-fluoroprímídin-4-yl)amino)methyl)-3hydroxypiperidin-1 -yl)acetamide, 2-(4-(((5-fluoro-6-(((6-methoxy¡p¡r¡d¡n-3-¡l)met¡l)(met¡l)amino)p¡r midín-4-l)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, ΜΛ / a / zuzz / uu / oy i 2-(4-(((6-((3-(difluoromethoxy)benzyl)(methyl)amino)-5-fluoropyrimidin-4-l)amino)methyl)-3hydroxypiperidin-1-yl)acetamide , 2-(4-(((6-((3,5-dichlorobenzyl)(methyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((5-fluoro-6-(methyl(4-(trifluoromethoxy)benzyl)amino)pyrimidin-4-íl)amino)methyl)-3hydroxypiperidin-1 -yl)acetamide and 2-(4-(((6-((3-chlorobenzyl)(isopropyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide. In some cases, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: A7-1 rac-2-((3R,4R)-4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyr¡m¡d¡ n-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-l)acetam¡de, A7-1-1 re / -2-((3R,4R)-4-(((6-(C¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidine -4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-2 2-(4-(((6-(cyclopropyl(2-methyl-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4 l)amino)met¡l)p¡perid¡n-1-yl)acetam¡de, A7-3-1 re / -(R)-2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino )-5-fluoropinm¡din-4¡l)amino)methyl)-3,3-d¡fluoropiperidin-1-¡l)acetam¡de, A7-4-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyr¡din-2-yl)methyl )amino)-5fluoropyrim¡din-4-¡l)amino)methyl)-3-fluorop¡perídin-1-¡l)acetam¡de, A7-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l )amino)methyl)-3-fluorop¡perídin-1-yl)acetam¡de, A7-6-1 re / -(R)-2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4 l)amino)methyl)-3,3-difluoropiperidin-1-l)acetamide, A7-7-1 2-(4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡nmidin-4-¡l)amino)methyl)-3 (trifluoromethyl)piperidin-1-yl)acetamide, A7-8 ινΐΛ / a / zuzz / uu ι ου ί -(2-Amino-2-oxoethyl)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín4 methyl -yl)amino)methyl)piperidine-4-carboxylate, A7-9 2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-4-hydrox piperdin-1-yl)acetamide, A7-10 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-l)amino)methyl) -4hydroxy-piperidin-1-yl)acetamide, A7-11 2-(4-(((6-(cycloprop¡l((6-(tnfluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrámidín- 4¡l)amino)methyl)-4-hydroxy¡piperidin-1-¡l)acetam¡de, A7-14 rac-2-((3R,4R)-4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridín-2-¡l)methyl )amino)-5fluoropyrámidin-4-yl)amino)methyl)-3-hydroxypiperídin-1-íl)acetamide, A7-14-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridín-2-¡l)) methyl)amino)-5fluoropyrimid¡n-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-15 rac-2-((3R,4R)-4-(((6-(cyclobutyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5fluoropyr¡m¡d¡n-4-yl)am ¡no)methyl)-3-hydroxy¡piper¡din-1-yl)acetamide, A7-15-1 re / -2-((3R,4R)-4-(((6-(cyclobutíl(4-(difluoromethoxy)-2-fluoroiObenzyl)amino)- 5fluoropyrimidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-16 rac-2-((3R,4R)-4-(((6-(cyclobutyl(4-(trifluoromethyl)benzyl)amino)-5-fluoiOpyrimidin-4¡l)amino)methyl)-3-h droxypperidin-1-l)acetamide, A7-16-1 re / -2-((3R,4R)4-((6-(cyclobutyl(4-(trifluoromethyl)benzyl)amino)-5-fluoiOpyrimidin-4¡ l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-17 rac-2-((3R,4R)-4-(((6-(cycloprop¡l((2-(trifluoromethyl)p¡nmidín-5-yl)methyl) am¡no)-5fluoropyrim¡din-4-¡l)am¡no)met¡l)-3-hydroxy¡p¡períd¡n-1-¡l)acetam¡de, A7-17-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((2-(trifluoromethyl)pyrimidin-5-yl)methyl)amino)-5fluoromethyl d¡n-4-¡l)amino)met¡l)-3-hydroxy¡p¡per¡d¡n-1-¡l)acetam¡de, A7-18 5-¡l)methyl)amino)-5fluorop¡rimidin-4-yl)amino)methyl)-3-hydroxypiperidin-1-¡l)acetamide, A7-18-1 re / -2-((3R,4R)-4-(((6-(cyclobutíl((2-(trifluoromethyl)pyrimidín-5-yl)methyl) )amino)-5fluoropyrimidín-4-íl)amino)methyl)-3-hydroxy¡píperidin-1-yl)acetamáde, A7-19 rac-2-((3R,4R)-4-(((5-fluoro-6-(isopropyl(4-(trifluoromethyl)benzyl)amino)pyrimidin-4yl)amino )methyl)-3-hydroxypyridin-1-yl)acetamide, A7-19-1 re / -2-((3R,4R)-4-(((5-fluoro-6-(¡soprop¡l(4-(trifluoromethyl)benzyl)amino )pyr¡m¡d¡n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-20 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyrimidin-4¡l)amino)methyl)- 3-hydroxypiperidin-1-yl)acetamide, A7-20-1 re / -2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyrimidin- 4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-21 rac-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4yl)amino) met¡l)-3-hydroxypiper¡din-1-¡l)acetamide, A7-21-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroiOp¡r¡midin-4 ¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-22 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluorop¡rimidin-4-¡l )amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-22-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(trifluororriethyl)benzyl)amino)-5fluoropyrimidine -4-¡l)am¡no)methyl)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, A7-23 rac-2-((3R,4R)-4-(((6-(cyclobutyl((6-(trifluoromethyl)pind¡n-3-¡l)methyl)amino)-5fluoropinm¡ d¡n-4-¡l)am¡no)met¡l)-3-hydroxyp¡per¡d¡n-1-¡l)acetam¡de, A7-23-1 re / -2-((3R,4R)-4-(((6-(cyclobutyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5fluorop¡ rim¡d¡n-4-¡l)amino)met¡l)-3-hydroxy¡p¡per¡d¡n-1-¡l)acetam¡de, A7-24 ινΐΛ / a / zuzz / uu i ουι rac-2-((3R,4R)-4-(((6-(cyclobutyl((5-(trifluoromethyl)pyridin-2 -l)methyl)amino)-5fluoropirimidin-4-yl)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-24-1 re / -2-((3R,4R)-4-(((6-(cyclobutíl((5-(trifluoromethyl)pyridin-2-íl)methyl)amino)-5fluoropyrimid ¡n-4-¡l)am¡no)methyl)-3-hydroxy¡p¡peridin-1-yl)acetam¡de, A7-25 rac-2-((3R,4R)-4-(((6-(cyclopropyl((6-(difluoromethyl)pyridin-3-yl)methyl)amino)-5fluoropirimidin-4 -yl)amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetamide, A7-25-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((6-(difluoromethyl)pyrid¡n-3-¡l)) methyl)amino)-5fluoropyrim¡din-4-yl)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetamide, A7-26 rac-2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyriiTi¡din- 4¡l)amino)methyl)-3-hydroxyp¡perídin-1-yl)acetam¡de, A7-26-1 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r ¡m¡d¡n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-27 rac-2-((3R,4R)-4-(((6-(ethyl((5-(trifluoromethyl)pyridin-2-¡l)methyl)amino)- 5-fluorop¡r¡m¡din-4yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, A7-27-1 re / -2-((3R,4R)-4-(((6-(ethyl((5-(tnfluoromethyl)pyridin-2-yl)methyl)amino )-5-fluoropyrám¡dín-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-28 rac-2-((3R,4R)-4-(((6-(cycloprop¡l((6-(trifluoromethyl)pyr¡din-3-yl)methyl)amino)-5fluorop rimidin-4-l)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-28-1 re / -2-((3R4R)-4-(((6-(cycloprop¡l((6-(trifluoromethyl)pyridín-3-¡l)methyl)) amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-29 rac-2-((3R,4R)-4-(((6-(cyclopropH((6-(1,1-difluoroethyl)pind¡n-3-¡l)methyl )am¡no)-5fluoropy¡m¡d¡n-4-¡l)am¡no)met¡l)-3-hydroxy¡p¡períd¡n-1-¡l)acetam¡de , A7-29-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)pyridin-3-yl)methyl)amino )-5fluorop¡rim¡din-4-¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-30 ινΐΛ / a / zuzz / uu / ου i rac-2-((3R,4R)-4-(((5-fluoro-6-((2-fluoroethyl)(4-(tnfluoromethyl)benzyl )amino)pyrimidín-4yl)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, A7-31 rac-2-((3R,4R)-4-(((5-fluoro-6-(((1R,3S)-3-fluorocyclobutíl)(4(trifluoromethyl)benzyl) amino)pyrámidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-32 rac-2-((3R,4R)-4-(((5-fluoro-6-(((1S,3R)-3-fluorocyclobutyl)(4(trifluoromethyl)benzyl)amino)p¡ nmidin-4-yl)amino)methyl)-3-hydroxypiperidin-1-íl)acetamide, A7-33 2-(4-(((6-(cycloprop¡l(1-(5-(tnfluoromethyl)pyrid¡n-2-¡l)ethyl)amino)-5-fluoropyr ¡m¡d¡n-4¡l)am¡no)met¡l)p¡perid¡n-1-yl)acetam¡de, A7-34 2-(4-(((6-(cycloprop¡l(1-(4-(trifluoromethyl)phen¡l)ethyl)amino)-5-fluorop¡rymidin-4¡l)amino) methyl)piperidn-1-yl)acetamide, A7-35 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl) p¡per¡d¡n-1-¡l)acetam¡de, A7-36 2-(4-(((6-((3-cyanobenzyl)(cycloprop¡l)amino)-5-fluorop¡r¡m¡din-4-yl)am¡no)methyl)p¡perid¡ n1-yl)acetamide, A7-38 2-(4-(((6-((3-(1 / 7-1,2,4-triazol-1 -¡l)benzyl)(cyclopropyl)amino)-5-fluoropyrimidin- 4¡l)amino)met¡l)p¡perdin-1-yl)acetam¡de, A7-39 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)piperidin-1-yl)acetamide , A7-40 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benzyl)amino)-5-fluoropyrámidín- 4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-41 rac-2-((3R,4R)-4-(((5-fluoro-6-((1-methylcyclopropyl)(4(trifluoromethyl)benzyl)amino)p¡ r¡m¡d¡n-4-¡l)am¡no)met¡l)-3-hydroxy¡p¡per¡d¡n-1-¡l)acetam¡de, A7-42 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy)-2-fluorObenzyl)amino)-5fluorop¡rim¡din-4-¡l) amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-43 ΜΛ / a / ZUZZ / UU i rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy¡)benzyl)amino)-5-fluoropyrimidin- 4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, A7-44 1-(2-amino-2-oxoethyl)-4-(((6-(cyclopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrymidin4-yl) amino)methyl)peridine-4-carboxamide, A7-45 2-(4-(((6-(cyclopropyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl) -4-(hydroxyrnet¡l)piperidin-1-yl)acetamide, A7-46 2-(4-(((6-((4-chloro-2,5-dimet¡lbenzyl)(cycloprop¡l)amino)-5-fluorop¡rímidin-4¡l)am¡ non)met¡l)p¡perid¡n-1-yl)acetam¡de, A7-47 2-(4-(((6-(cycloprop¡l(2,5-dimethylbenzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)piperidín- 1-yl)acetamide, A7-49 rac-2-((3R,4S)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín- 4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-50 2-(4-cyano-4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)piperidin-1 -il)acetamída, A7-51 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-4(hydroxymethyl)piper¡din-1-yl)acetamide, A7-52 2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4yl) amino)methyl)-4-(hydroxymethyl)piperidin-1-yl)acetamide, A7-53 2-(4-(((6-((4-chloro-3,5-dimethylbenzyl)(cyclopropyl)amino)-5-fluoropyry¡midin-4¡l)amino)met¡ l)perid¡n-1-l)acetam¡de, A7-54 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡l)benc ¡l)am¡no)-5-fluorop¡rim¡n-4-¡l)am¡no)met¡l)-3-hydroxy¡p¡pendin-1-¡l)acetam¡de , A7-54-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡ l)benz¡l)arn¡no)-5-fluoropyrim¡din-4-¡l)amino)methyl)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-55 ινΐΛ / a / zuzz / uu / ου i re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5 -fluoropirimidin-4yl)amino)methyl)-3-hydroxypiperidin-1-yl)-2-methylpropanamide, A7-56 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(3-(trifluoromethoxy)benzyl)amino)-5-fluoroiOpyrim¡d¡n- 4yl)amino)met¡l)-3-hydroxypiper¡din-1-¡l)acetam¡de, A7-57 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino )methyl)-3-hydroxypyridin-1-yl)-2-methylpropanamide, A7-58 rac-2-((3R,4R)-4-(((6-(cyclopropíl(3-methoxy-4-(trifluoromethyl)benzyl)amino)-5fluoropyrimídin- 4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-60 rac-2-((3R,4R)-4-(((5-fluoro-6-((methyl-d3)(4-(trifluoromethyl)benzyl)amino)pyrimidine -4¡l)amino)methyl)-3-hydroxyp¡perídin-1-yl)acetam¡de, A7-61 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(2-methoxy-4-(trifluoromethyl)benzyl)amino)-5fluoropyrimidín-4-¡l )amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-64 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)piperidin-1-yl)-3- hydroxypropanamide, A7-65 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din- 4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)-3-hydroxy¡propanamide, A7-66-1 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin -4yl)amino)methyl)-3-hydroxypiperidin-1-yl)-3-hydroxypropanamide or re / -(R)-2-((3S,4S)-4-(((6-(ethyl (4-(trifluoromethyl)benzyl)amino)-5-fluoiOp¡rimidin-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)-3-h droxypropanamide, A7-67 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4¡l)amino )met¡l)-3-hydroxy¡p¡perídin-1-¡l)-4-hydroxy¡butanamide, A7-68 2-(4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡nmid¡n-4-¡l)amino)methyl) -4hydroxy-piperidin-1-yl)-3-hydroxypropanamide, A7-69 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4yl)amino )methyl)-3-hydroxypiperídin-1 -yl)acetamide-2,2-c / 2, A7-70 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4-yl)amino)methyl)- 4(hydroxymethyl)piperidin-1-yl)-3-hydroxypropanamide, A7-72 rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-methyl-1H-pyrazol-4-yl)benzyl)amino)-5-fluoropyrimidin-4yl) amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, A7-73 rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-(2-hydroxyethyl))-1 / - / -pyrazol- 4-yl)benzyl)amino)-5fluoropyrimídin-4-íl)amino)methyl)-3-hydroxy¡píperídin-1-yl)acetamide, A7-74 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(1-methyl-1H-pyrazol-4-yl)benzyl)amino)-5fluorop¡ r¡m¡din-4-yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, A7-75 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1H-pyrazol-4-¡l)benz) l)amino)-5fluoropyrimidín-4-l)amino)methyl)-3-hydroxylpiperidin-1-yl)acetamide, A7-76 rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4-(1H-pyrazol-1-yl)benzyl)amino)-5fluorop¡r¡ m¡d¡n-4-yl)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, A7-77 rac-2-((3R,4R)-4-(((6-((4-(1H-Pyrazol-1-Il)benzyl)(ethyl)amino)-5-fluoropyrimidine -4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-78 rac-2-((3R,4R)-4-(((6-((4-cyanobenzyl)(ethyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl )-3hydroxy¡piperidin-1-yl)acetamide, A7-79 rac-2-((3R,4R)-4-(((6-((4-(1,1-difluoro-2-hydroxyethyl)benzyl)(ethyl)am ¡no)-5-fluorop¡rímid¡n4-¡l)amino)methyl)-3-hydroxyp¡perídin-1-¡l)acetam¡de, A7-80 2-(4-(((6-(Cíclopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropírimidin-4-íl)amino)methyl)-4(1H -1,2,4-tr¡azol-3-¡l)p¡perídin-1 -yl)acetamide, A7-81 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín-4-yl)amino)methyl)-4( 1,2,4-oxadiazol-3-l)pyridin-1-yl)acetamide, A7-82 ινΐΛ / a / zuzz / uu ι ου ί 2-(4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(1, 3,4-oxadiazol-2-yl)piperidin-1-yl)acetamide, A7-83 2-(4-(((6-(C¡clopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(4-methyl-4 / 7-1,2,4-tr¡azol-3-yl)piperidin-1-¡l)acetamide, A7-84 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl)-4( 1H-imídazol-2-yl)píperidin-1-íl)acetamide, A7-85 2-(4-(((6-(C¡cloprop¡l(4-(tnfluoromet¡l)benzyl)amino)-5-fluorop¡rímid¡n-4-¡l)amino) met¡l)-4(1 / 7-1,2,3-tr¡azol-5-¡l)p¡peridín-1-yl)acetamide, A7-86 rac-2-((3R,4R)-4-(((6-((4-(1 H-pyrazol-1-¡l)benzyl)(cyclopropyl)amino)-5-fluorop¡r¡ mid¡n-4¡l)am¡no)methyl)-3-hydroxyp¡per¡din-1-yl)acetam¡de, A7-87 2-(4-(1-((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim¡din-4-¡l)amino) -2hydroxyethyl)piperidin-1 -yl)acetamide, B4-1-1-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin -4yl)amino)methyl)-3-hydroxy-3-methylpiperidin-1-yl)acetamide, B4-1-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)beiic¡l)amino)-5-fluorop¡rim ¡d¡n-4¡l)am¡no)met¡l)-3-hydroxy¡-3-met¡lpiperid¡n-1-¡l)acetam¡de, B4-2-1-1 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-3hydroxy¡-4 -methylpiperidin-1-yl)acetamide, C4-1-1 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3h¡droxy-4-(hydroxy¡met¡l)p¡perídin-1-yl)acetam¡de, C4-2-1 2-(4-(((6-((3,5-bis(trifluoromethyl)benzyl)(ethyl)amino)-5-fluoropyrimidin-4-yl)amino)met l)-3h¡droxy-4-(h¡drox¡met¡l)p¡perídin-1-¡l)acetam¡de, D5-1-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4 l)amino)methyl)-3,4-d¡hydroxy¡p¡perídin-1-l)acetamide, D5-1-2-1 iviA / a / zuzz / uu ι ουι re / -2-((3R,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl) )amino)-5-fluoropirimidin-4yl)amino)methyl)-3,4-dihydroxy¡píperidin-1-yl)acetamide, D5-2-1-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim ¡d¡n-4yl)am¡no)met¡l)-3,4-di¡hydroxyp¡peridin-1-¡l)acetamide, D5-2-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino )methyl)-3,4-dihydroxy¡p¡peridin-1-yl)acetamide, D5-3-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5 -fluorop¡r¡m¡d¡n-4¡l)amino)met¡l)-3,4-d¡hydroxyp¡pendin-1-¡l)acetamide, D5-3-2-1 re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim ¡din-4¡l)am¡no)methyl)-3,4-dihydroxy¡p¡períd¡n-1 -yl)acetamide, D5-4 re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) benzyl)amino)-5fluoropyrimidin-4-l)amino)methyl)-3,4-dihydroxípíperidín-1-yl)acetamide, D5-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / - / -pyrazole-4-¡ l)benzyl)amino)-5fluorop¡r¡m¡din-4-yl)amino)methyl)-3,4-dihydroxypiper¡din-1-¡l)acetamide, D5-6 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡l) benzyl)amino)-5-fluoropyrimídin-4-l)amino)methyl)-3,4-dihydroxípíperídin-1-l)acetamide, D5-9 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 / - / -pyrazol-1-¡l)benzyl)amino) -5fluoropirimidin-4-l)amino)methyl)-3,4-dihydroxypiperidin-1-yl)acetamide, D5-10 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluorobenzyl)amino)-5-fluorop¡r¡m¡din-4¡l)amino) methyl)-3,4-dihydroxypiperidin-1-l)acetamide, E6-1 2-(4-Am¡no-4-(((6-(c¡clopropH(4-(trifluorometH)benz¡l)amino)-5-fluoiOpinm¡d¡n-4¡l)amino)met ¡l)p¡perídin-1-¡l)acetamide, F2-1 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(2-methylbenzyl)amino)pyrimidin-4-yl)amino)methyl)-3h droxypiperidin-1-l)acetamide, F2-2 ΜΛ / a / ZUZZ / UU 14» 1 rac-2-((3R,4R)-4-(((6-((2,6-dichlorobenzyl)(methyl)amino)-5-fluoropyrám¡ d¡n-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, F2-3 rac-2-((3R,4R)-4-(((6-((2,3-dichlorobenzyl)(methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3- hydroxypiperidin-1-l)acetamide, F2-4 rac-2-((3R,4R)-4-(((6-((2,6-dichlorobenzyl)(ethyl)amino)-5-fluoropyrámidín-4 -yl)amino)methyl)3-hydroxypiperidin-1-yl)acetamide, F2-5 rac-2-((3R,4R)-4-(((5-fluoro-6-(met¡l(1-(o-tol¡l)et¡l)amino)p¡r¡m ¡din-4-yl)am¡no)met¡l)-3h¡droxy¡piperid¡n-1-¡l)acetam¡de, F2-6 rac-2-((3R,4R)-4-(((6-((1-(2-chlorophenyl)ethyl)(methyl)amino)-5-fluorop¡rymidin-4¡ l)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, F2-7 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy¡)benzyl)amino)pyrimidin-4¡l) amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, F2-8 rac-2-((3R,4R)-4-(((6-((3-cyanobenzyl)(methyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)- 3hydroxy¡piper¡din-1-yl)acetamide, F2-9 rac-2-((3R,4R)-4-(((5-fluoro-6-(¡sobut¡l(4-(trifluoromethyl)benzyl)amino)pyrimid¡ n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, F2-10 rac-2-((3R,4R)-4-(((6-((cycloprop¡lmethyl)(2-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡ midin4-yl)amino)methyl)-3-hydroxypiperídin-1-yl)acetamide, F2-11 rac-2-((3R,4R)-4-(((6-((4-cyanobenzyl)(¡sobut¡l)amino)-5-fluorop¡rim¡din-4-yl) am¡no)methyl)3-hydroxypiper¡din-1-¡l)acetamide, F2-12 rac-2-((3R,4R)-4-(((6-((4-chloro-3-fluorobenzyl)(methyl)amino)-5-fluoropinmidin-4¡l )amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, F2-13 rac-2-((3R,4R)-4-(((6-((4-(difluoromethoxy)benzyl)(methyl)amino)-5-fluoropyrámidín-4¡l) am¡no)methyl)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, F2-14 ινΐΛ / a / zuzz / uu / ου i rac-2-((3R,4R)-4-(((6-((4-(difluoromethoxy¡)-3-methoxybenzyl)(methyl )amino)-5-fluorop¡r¡m¡d¡n4-yl)amino)methyl)-3-hydroxyp¡perídin-1-yl)acetamide, F2-15 rac-2-((3R,4R)-4-(((6-((4-chlorobenzyl)(isopropyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3- hydroxypiperidin-1-l)acetamide, F2-16 rac-2-((3R,4R)-4-(((5-fluoro-6-((2-methoxyethyl)(4-(tnfluoromethyl)benzyl)amino )pyrimidin-4yl)amino)methyl)-3-hydroxypyridin-1-yl)acetamide, F2-17 rac2-((3R,4R)-4-(((6-((2,4-dichlorobenzyl)(isobutyl)amino)-5-fluorop¡rímidín-4¡l )amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, F2-18 rac-2-((3R,4R)-4-(((6-((4-cyanobenzyl)(methyl)amino)-5-fluoropyrimidín-4-yl)amino)met ¡l)-3hydroxypiperidin-1 -yl)acetamide, F2-19 rac-2-((3R,4R)-4-(((5-fluoro-6-(((6-methoxy¡pyridín-3-yl)methyl)(methyl )am¡no)p¡r¡m¡d¡n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, F2-20 rac-2-((3R,4R)-4-(((6-((3-(difluoromethoxy)benzyl)(methyl)amino)-5-fluoropyrámidín- 4yl)amino)methyl)-3-hydroxypiperídin-1-íl)acetamide, F2-21 rac-2-((3R,4R)-4-(((6-((3,5-dichlorobenzyl)(methyl)amino)-5-fluoropyrim¡din-4¡l)amino)met ¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, F2-22 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethoxy)benzyl)amino)pyrimidin-4yl)amino)methyl) -3-hydroxypiper¡din-1-yl)acetamide, F2-23 rac-2-((3R,4R)-4-(((6-((3-chlorobenzyl)(¡sopropyl)amino)-5-fluoropyrim¡din-4¡l)amino)met¡ l)-3-hydroxy¡piper¡din-1-l)acetam¡de. In another preferred embodiment described herein, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: A7-1-1 re / -2-((3R,4R)-4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl )-3-hydroxy¡piper¡din-1-¡l)acetam¡de, eluted 1.eryisomer, A7-1-2 iviA / a / zuzz / uu i ου i re / -2-((3R,4R)-4-(((6-(C¡clopropyl(4-(trifluoromethyl)benzyl)) amino)-5-fluoropirimidin-4yl)amino)methyl)-3-hydroxypiperídin-1-yl)acetamide, 2nd eluted isomer, A7-3-1 re / -(R)-2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-¡l)methyl)amino)-5 -fluorop¡r¡m¡din-4¡l)arn¡no)methyl)-3,3-difluorop¡perid¡n-1-¡l)acetamide, 1.eluted erysomer, A7-3-2 re / -(R)-2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimide) n-4yl)amino)methyl)-3,3-difluoropiperidin-1-yl)acetamide, 2nd eluted isomer, A7-4-1 re / -2-((3R,4R)4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-¡l)methyl)amino)-5fluoropyrimidín- 4-¡l)amino)methyl)-3-fluorop¡perídin-1-¡l)acetam¡de, eluted 1.erysomer, A7-4-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5fluorop¡ r¡m¡din-4-yl)amino)methyl)-3-fluoropiper¡din-1-¡l)acetamide, 2nd eluted isomer, A7-5-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r ¡m¡d¡n-4yl)amino)methyl)-3-fluorop¡per¡din-1-¡l)acetamide, eluted 1.eryisomer, A7-5-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)amino )met¡l)-3-fluorop¡perid¡n-1-¡l)acetam¡de, 2nd eluted isomer, A7-6-1 re / -(R)-2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4 l)amino)methyl)-3,3-difluoropiperidin-1-l)acetamide, eluted 1.eryisomer, A7-6-2 re / -(R)-2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl )-3,3-difluorop¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, A7-7-1 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3(trifluoromethyl)piper¡din-1-¡l)acetamide, eluted 1.erysomer, A7-7-2 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-l)amino)methyl)-3 (trifluoromethyl)piper¡din-1-¡l)acetam¡de, 2nd eluted isomer, A7-7-3 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3(trifluoromet l)piper¡din-1-yl)acetam¡de, eluted 3.®risomer, A7-7-4 iviA / a / zuzz / uu fom 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3(trifluoromethyl)piperidin-1- il)acetamide, eluted 4th isomer, A7-8 1-(2-Am¡no-2-oxoethyl)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡midin4- methyl yl)amino)methyl)peridin-4-carboxylate, A7-9 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-l)methyl)amino)-5 -fluorop¡r¡m¡din-4yl)amino)methyl)-4-hydroxypiper¡din-1-yl)acetamide, A7-10 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-¡l)amino) met¡l)-4h¡droxy¡piperid¡n-1-¡l)acetam¡de, A7-14-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino )-5fluorop¡r¡midín-4-yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, eluted 1.eryisomer, A7-14-2 re / -2-((3R,4R)4-(((6-(cycloprop¡l((5-(trifluoromethyl))pyrdin-2-¡l )methyl)amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2nd eluted isomer, A7-15-1 re / -2-((3R,4R)-4-(((6-(cyclobutyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5fluorop¡r¡m¡d¡n- 4-yl)amino)methyl)-3-hydroxylpíperidin-1-l)acetamide, eluted 1.eryisomer, A7-15-2 re / -2-((3R,4R)-4-(((6-(cyclobutíl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5fluoropyrimidín- 4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, A7-16-1 re / -2-((3R,4R)-4-(((6-(cyclobutyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín-4¡l)amino )met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, eluted 1.erysomer, A7-16-2 re / -2-((3R,4R)4-(((6-(cyclobutyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidin-4¡ l)amino)methyl)-3-hydroxy¡p¡perídin-1-l)acetam¡de, 2nd eluted isomer, A7-17-1 re / -2-((3R,4R)4-(((6-(cycloprop¡l((2-(trifluoromethyl)p¡nmidín-5-yl)methyl) am¡no)-5fluoropyrim¡din-4-¡l)am¡no)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, eluted 1.eryisomer, A7-17-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl((2-(trifluoromethyl)pyrimidin-5-yl)methyl)amino)-5fluorop rim¡din-4-¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, 2nd eluted isomer, A7-19-1 )amino)pyrimidin-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, eluted 1.erysomer, A7-19-2 re / -2-((3R,4R)-4-(((5-fluoro-6-(¡soprop¡l(4-(trifluoromethyl)benzyl)amino )pyrám¡din-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2nd eluted isomer, A7-20-1 re / -2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyri m¡din-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, eluted 1.erysomer, A7-20-2 re / -2-((3R,4R)A-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyrimidin-4¡l )amino)methyl)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2nd eluted isomer, A7-21-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4¡l )amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, eluted 1.erysomer, A7-21-2 re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4¡l )amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, A7-22-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d ¡n-4-yl)amino)methyl)-3-hydroxy¡p¡peridín-1-¡l)acetamide, 2nd eluted isomer, A7-22-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluoropyrimid ¡n-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, eluted 1.eryisomer, A7-26-1 re / -2-((3R,4R)A-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l) amino)methyl)-3-hydroxy¡p¡perídin-1-l)acetam¡de, 2nd eluted isomer, A7-26-2 re / -2-((3R,4R)4-((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim d¡n-4¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, eluted 1.eryisomer, A7-28-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((6-(trifluoromethyl)pindin-3-¡l)methyl)amino) -5fluoropyrim¡din-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetamide, eluted 1.erysomer, A7-28-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5fluoropyrim) d¡n-4-¡l)amino)met¡l)-3-hydroxy¡p¡períd¡n-1-¡l)acetam¡de, 2nd eluted isomer, A7-29-1 MA / a / ZUZZ / UU i re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)pyridín-3-íl) )methyl)amino)-5fluoropirimidin-4-yl)amino)methyl)-3-hydroxypiperidin-1-íl)acetamide, eluted 1.eryisomer, A7-29-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)pyr¡din-3-¡l)) met¡l)amino)-5fluoropyrimid¡n-4-¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2. ° eluted isomer, A7-31 rac-2-((3R,4R)-4-(((5-fluoro-6-(((1R,3S)-3-fluorocyclobutyl)(4(trifluoromethyl)benzyl)amino)p¡ r¡midin-4-yl)amino)rnet¡l)-3-hydroxypiperidin-1-¡l)acetamide, A7-32 rac-2-((3R,4R)-4-(((5-fluoro-6-(((1S,3R)-3-fluorocyclobutyl)(4(trifluoromethyl)benzyl)am) no)pyrimid¡n-4-¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-39 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4¡l)amino)methyl)piperidin -1-¡l)acetam¡da, A7-40 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benzyl)amino)-5-fluoropyr¡m¡d¡ n-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-l)acetam¡de, A7-41 rac-2-((3R,4R)-4-(((5-fluoro-6-((1-methylcyclopropyl)(4(trifluoromethyl)benzyl)amino)p¡ r¡m¡d¡n-4-yl)am¡no)met¡l)-3-hydroxyp¡per¡d¡n-1-¡l)acetamide, A7-42 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5fluoropyrimidín-4-íl) am¡no)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-43 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3 -hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-44 1-(2-amino-2-oxoethyl)-4-((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop r¡m¡d¡n4-¡l)amino)methyl)p¡períd¡n-4-carboxamide, A7-45 2-(4-(((6-(cyclopropyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5-fluorop¡r¡m¡d¡ n-4¡l)amino)methyl)-4-(hydroxy¡methyl)p¡peridín-1-¡l)acetamide, A7-50 2-(4-cyano-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din-4¡l)amino)methyl )pyridin-1-yl)acetamide, A7-51 ινΐΛ / a / zuzz / uu / ου i 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(hydroxymethyl)piperidin-1- il)acetamide, A7-52 2-(4-(((6-(c¡cIoprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-4 -(hydroxymet¡l)piperid¡n-14l)acetam¡de, A7-54-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2yl) benz¡l)amino)-5-fluorop¡r¡midin-4-yl)amino)methyl)-3-hydroxypiperidin-1-¡l)acetamide, 1 .eluted erysomer, A7-54-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,34nexafluoro-2-hydroxy¡propan-2¡ l)benz¡l)amino)-5-fluorop¡rim¡din-44l)amino)met¡l)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2. ° eluted isomer, A7-55 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4¡l enantiomerically enriched A7-56 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(3-(trifluoromethoxy¡)benzyl)amino)-5-fluoropinm¡d¡n-4¡l )amino)met¡l)-3-hydroxy¡piper¡din-14l)acetam¡de, A7-57 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡din -4iI)amino)methyl)-3-hydroxypiperidin-14l)-2-methylpropanamide, enantiomerically enriched, A7-58 rac-2-((3R,4R)-4-((6-(cyclopropyl(3-methoxy-4-(trifluoromethyl)benzyl)amino)-5fluoropyrim d¡n-4-¡l)am¡no)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-60 rac-2-((3R,4R)-4-(((5-fluoro-6-((methyl-d3)(4-(trifluoromethyl)benzyl)amino)pyrimidin-4 ¡l)amino)methyl)-3-hydroxy¡p¡perídin-14l)acetam¡de, A7-65 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡nm¡d¡ n-4¡l)amino)methyl)-3-hydroxypiperidin-1-¡l)-3-hydroxypropanamide, A7-66-1 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino) -5-fluorop¡r¡m¡din-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)-3-hydroxypropanamide or re / -(R)-2-((3S, 4S)-4-(((6-(ethyl(4(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-¡l)amino )met¡l)-3-hydroxyp¡peridín-1-¡l)-3hydroxypropanamide, eluted major erysomer, A7-66-2 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)am ¡no)methyl)-3-hydroxypiper¡din-1-yl)-3-hydroxypropanamide or re / -(R)-2-((3S,4S)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)am¡ no)methyl)-3-hydroxy¡p¡perídin-1-¡l)-3-hydroxy¡propanamide, eluted major isomer, A7-67 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡midin-4¡l)amino)met ¡)-3-hydroxy¡piper¡din-1 -yl)-4-hydroxy¡butanamide, enantiomerically enriched, A7-68 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)methyl)- 4hydroxy¡piper¡din-1-yl)-3-hydroxy¡propanamide, A7-69 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim¡d ¡n-4iI)amino)methyl)-3-hydroxypiperidin-1 -yl)acetamide-2,2-c / 2, enantiomerically enriched, A7-70 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(hydroxymethyl) l)p¡períd¡n-1-¡l)-3-hydroxy¡propanamide, A7-72 rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-methyl-1H-pyrazol-4-yl)benzyl)amino)-5- fluorop¡r¡m¡d¡n-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-74 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1-methyl-1H-pyrazol-4-¡l)benzyl)amino)-5fluorop¡rim¡d ¡n-4-¡l)am¡no)met¡l)-3-hydroxy¡piper¡d¡n-1-¡l)acetam¡de, A7-75 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1H-pyrazol-4-¡l)benzyl)) am¡no)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-76 rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4-(1H-pyrazol-1-¡l)benzyl)amino) -5fluoropyrim¡din-4-¡l)amino)methyl)-3-hydroxy¡piper¡din-1-yl)acetam¡de, A7-80 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din-4-yl)amino)methyl)-4(1 / 7-1,2,4-tr¡azol-3-¡l)p¡perid¡n-1-yl)acetam¡de, A7-81 iviA / a / zuzz / uu ι ουι 2-(4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(1, 2,4-oxadiazol-3-yl)piperidin-1-yl)acetamide, A7-82 2-(4-(((6-(Cíclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(1,3,4- oxadiazol-2-íl)píperidin-1-yl)acetamide, A7-85 2-(4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(1 / 7-1, 2,3-triazol-5-yl)piperidin-1-yl)acetamide, A7-86 rac-2-((3R,4R)-4-(((6-((4-(1 / 7-pyrazol-1-¡l)benzyl)(cycloprop¡l)amino)-5 -fluoropyrimidín-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, B4-1-1-1 re / -2-((3R,4R)4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim) d¡n-4¡l)amino)methyl)-3-hydroxy¡-3-methyl¡lp¡peridin-1-yl)acetamide, eluted 1 eryisomer, B4-1-1-2 re / -2-((3R,4R)4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡ r¡m¡d¡n-4¡l)amino)methyl)-3-hydrox¡-3-met¡lpiperid¡n-1-¡l)acetamide, 2nd eluted isomer, B4-1-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino )met¡l)-3-hydroxy¡-3-met¡lpiper¡din-1-¡l)acetam¡de, 1 .eluted erysomer, B4-1-2-2 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5 -fluorop¡rim¡din-4¡l)amino)met¡l)-3-hydroxy¡-3-met¡lpiperid¡n-1-¡l)acetam¡de, 2nd isomer eluted, B4-2-1-1 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy-4-methylpiperidin-1- il)acetamide, 1 .eluted erysomer, B4-2-1-2 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3hydroxy¡-4-met¡lp¡perídin-1-¡l)acetamide, 2nd eluted isomer, C4-1-1 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-l)amino)methyl) -3h¡drox¡-4-(h¡drox¡met¡l)piper¡din-1-¡l)acetamide, eluted 1.eryisomer, C4-1-2 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy-4- (hydroxy¡methyl)p¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, D5-1-1-1 ινΐΛ / a / zuzz / uu / ου i re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benz) l)amino)-5-fluorop¡r¡midin-4yl)amino)methyl)-3,4-dihydroxy¡p¡peridin-1-yl)acetamide, eluted 1.erysomer, D5-1-1-2 re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrámidin-4¡l)am ¡no)methyl)-3,4-d¡hydroxyp¡per¡din-1-¡l)acetamide, 2nd eluted isomer, D5-1-2-1 re / -2-((3R,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4yl )amino)methyl)-3,4-dihydroxy¡p¡peridin-1-yl)acetamide, eluted 1.erysomer, D5-1-2-2 re / -2-((3R,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4¡l )amino)methyl)-3,4-d¡hydroxypiperidin-1-¡l)acetamide, 2nd eluted isomer, D5-2-1-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimide ¡n-4¡l)amino)methyl)-3,4-d¡hydroxypiper¡din-1 -yl)acetamide, eluted 1.eryisomer, D5-2-1-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyr ¡m¡d¡n-4¡l)am¡no)met¡l)-3,4-d¡hydroxyp¡peridin-1-¡l)acetam¡de, 2nd eluted isomer, D5-2-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)am ¡no)methyl)-3-hydroxy¡p¡perídin-1-l)acetam¡de, eluted 1.erysomer, D5-2-2-2 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5 -fluorop¡rim¡din-4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, D5-3-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4 l)amino)methyl)-3,4-d¡hydroxy¡p¡perídin-1-l)acetamide, eluted 1.eryisomer, D5-3-1-2 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5 -fluoropyrim¡din-4¡l)amino)methyl)-3,4-d¡hydroxypiperidin-1-¡l)acetam¡de, 2nd eluted isomer, D5-3-2-1 re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino) -5-fluorop¡r¡m¡din-4¡l)amino)met¡l)-3,4-d¡hydroxypiper¡din-1-¡l)acetam¡de, eluted 1.eryisomer, D5-3-2-2 re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l )amino)methyl)-3,4-d¡hydroxy¡p¡perídin-1-¡l)acetamide, 2nd eluted isomer, D5-4 re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) benzyl)amino)-5fluoropirimidin-4-yl)amino)methyl)-3,4-dihydroxypiper¡din-1-yl)acetamide, enantiomerically enriched, D5-5-1 re / -2-( (3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benzyl)amino)-5fluoropyrim¡d¡ n-4-¡l)am¡no)methyl)-3,4-di¡hydroxy¡p¡perid¡n-1-¡l)acetam¡de, major isomer, D5-5-2 re / - 2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1H-pyrazol-4-¡l)benzyl)amino)-5fluorop¡rim¡d¡ n-4-¡l)am¡no)met¡l)-3,4-dih¡droxy¡p¡per¡din-1-¡l)acetam¡de, minor isomer, D5-6 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡l) benzyl)amino)-5-fluoropyrim¡din-4-¡l)amino)methyl)-3,4-d¡hydroxy¡p¡peridín-1-¡l)acetam¡ da, enantiomerically enriched, D5-9 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1H-pyrazol-1-¡l)benzyl)amino)-5fluoropyrimidin- 4-¡l)amino)methyl)-3,4-d¡hydroxy¡p¡peridín-1-yl)acetam¡de, enantiomerically enriched, F2-7 rac-2-((3R, 4R)-4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy)benzyl)amino)pyrimidin-4¡l)amino)methyl)-3-hydroxy¡p¡perídin -1-¡l)acetam¡de. In some cases, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: A7-1-1 re / -2-((3R,4R)-4-(((6-(C¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r ¡m¡d¡n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-3-1 re / -(R)-2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)- 5-fluoropyrim¡din-4¡l)amino)methyl)-3,3-d¡fluoropiperidin-1-yl)acetam¡de, A7-4-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyr¡d¡n-2-¡ l)met¡l)amino)-5fluoropyrim¡din-4-¡l)amino)methyl)-3-fluorop¡perídin-1-yl)acetam¡de, A7-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4yl)amino)methyl )-3-fluoropiper¡din-1-yl)acetamide, A7-6-1 ΜΛ / a / zuzz / uu / oy i re / -(R)-2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡ m¡d¡n-4yl)amino)methyl)-3,3-difluorop¡peridin-1-yl)acetamide, A7-7-1 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4-yl)amino)methyl)- 3(trifluoromethyl)piper¡din-1-yl)acetam¡de, A7-8 1-(2-Amino-2-oxoethyl)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín4-l methyl)amino)methyl)piperidine-4-carboxylate, A7-9 2-(4-(((6-(cycloprop¡l((5-(tnfluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyr¡m¡d¡ n-4¡l)amino)met¡l)-4-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-10 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-¡l) amino)methyl)-4hydroxypiperidin-1 -yl)acetamide, A7-14-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyr¡d¡n-2-yl) )methyl)amino)-5fluoropyrimid¡n-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-15-1 re / -2-((3R,4R)-4-(((6-(cyclobut¡l(4-(difluorOmethoxy)-2-fluorobenzyl)amino)-5fluorop¡r¡ m¡d¡n-4-yl)am¡no)met¡l)-3-hydroxy¡piper¡d¡n-1-¡l)acetamide, A7-16-1 re / -2-((3R,4R)4-(((6-(cyclobutíl(4-(trifluoromethyl)benzyl)amino)-5- fluoiOpyr¡m¡d¡n-4¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-17-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((2-(trifluoromethyl)pyrimidin-5-yl)methyl)amino)-5fluorop rim¡d¡n-4-¡l)am¡no)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, A7-19-1 re / -2-((3R,4R)-4-(((5-fluoro-6-(isoprop¡l(4-(tnfluoromethyl)benzyl)amino)pyrimidin- 4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, A7-20-1 re / -2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyri) m¡d¡n-4¡l)amino)methyl)-3-hydroxy¡p¡peridin-1-¡l)acetam¡de, A7-21-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4¡l )amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-22-1 ινΐΛ / a / zuzz / uu i ουι re / -2-((3R,4R)4-(((6-(cyclopropyl(2-fluoro-4-(trifluoromethyl)benzyl) amino)-5fluoropirimidin-4-yl)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-26-1 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin -4yl)amino)met¡l)-3-hydroxypiper¡din-1-¡l)acetam¡de, A7-28-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5fluorop¡ rimidin-4-yl)amino)methyl)-3-hydroxypiperidín-1-íl)acetamide, A7-29-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)p¡r¡din-3-¡l)) methyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3-hydroxylpiperidin-1-yl)acetamide, A7-31 rac-2-((3R,4R)-4-(((5-fluoro-6-(((1R,3S)-3-fluorocyclobutyl)(4(trifluoromethyl)benzyl)am) no)p¡r¡m¡d¡n-4-yl)am¡no)rnetyl)-3-h¡diOxypiper¡d¡n-1-¡l)acetamide, A7-32 rac-2-((3R,4R)-4-(((5-fluoro-6-(((1S,3R)-3-fluorocyclobutyl)(4(trifluoromethyl)benzyl)amino) pyrimidin-4-l)amino)methyl)-3-hydroxylpiperidin-1-l)acetamide, A7-39 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)piperidin-1-yl)acetamide, A7-40 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡ n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-41 rac-2-((3R,4R)-4-(((5-fluoro-6-((1-methylcyclopropyl)(4(trifluoromethyl)benzyl)amino)pyrimidin-4-¡l)amino )met¡l)-3-hydroxy¡piperidin-1-¡l)acetamide, A7-42 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(difluoromethoxy)-2-fluoroiObenzyl)amino)-5fluoropyrimidín-4-¡l) am¡no)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-43 rac-2-((3R,4R)-4-(((6-(cyclopropH(4-(difluoromethoxy¡)benzyl)amino)-5-fluoiOp¡nm¡d¡n-4 ¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡de, A7-44 1-(2-amino-2-oxoethyl)-4-(((6-(cyclopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin4-íl)amino)methyl)p períd¡n-4-carboxamide, A7-45 ινΐΛ / a / zuzz / uu / ου i 2-(4-(((6-(cyclopropyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl) -4-(hydroxymethyl)piperidin-1-yl)acetamide, A7-50 2-(4-cyano-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din-4yl)amino)methyl )pyridin-1-yl)acetamide, A7-51 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidín-4-yl)amino)methyl)-4(h¡ droxymethyl)piperidin-1-yl)acetamide, A7-52 2-(4-(((6-(cycloprop¡l((5-(tnfluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyr¡m¡d¡ n-4¡l)amino)met¡l)-4-(hydroxy¡met¡l)piperid¡n-1-¡l)acetam¡de, A7-54-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-h¡diOX¡ propan-2¡l)benz¡l)amino)-5-fluorop¡rim¡din-4-yl)amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetam¡de , A7-55 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)beiic¡l)amino)-5-fluorop¡r¡m¡d ¡n-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1-¡l)-2-methylpropanamide, A7-56 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(3-(trifluoromethoxy)benzyl)amino)-5-fluorop¡rymidin-4yl)amino) met¡l)-3-hydroxypiper¡din-1-¡l)acetamide, A7-57 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4¡l )amino)methyl)-3-hydroxy¡piper¡din-1-¡l)-2-methylpropanamide, A7-58 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(3-methoxy-4-(trifluoromethyl)benzyl)amino)-5fluorop¡rimidin-4- l)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-60 rac-2-((3R,4R)-4-(((5-fluoro-6-((methyl-d3)(4-(trifluoromethyl)benzyl)amino)pyrimidine -4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-65 rac-2-((3R,4R)-4-(((6-(cyclopropH(4-(trifluoromethyl)benzyl)amino)-5-fluoiOp¡nmidín-4¡ l)am¡no)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)-3-hydroxy¡propanamide, A7-66-1 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l )amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)-3-hydroxy¡propanamide or ινΐΛ / a / zuzz / uu / ου i re / -(R) -2-((3S,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡din-4yl)am¡ no)methyl)-3-hydroxypiperidin-1-yl)-3-hydroxypropanamide, A7-67 re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl )-3-hydroxypiperídin-1-íl)-4-hydroxybutanamide, A7-68 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidín-4-yl)amino)methyl)-4hydroxy¡piperidin- 1-yl)-3-hydroxypropanamide, A7-69 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d ¡n-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1 -yl)acetamide-2,2-d2, A7-70 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-4( hydroxy¡methyl)piperid¡n-1-¡l)-3-hydroxypropanamide, A7-72 rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-methyl-1H-pyrazol-4-yl)benzyl)amino)- 5-fluorop¡r¡m¡din-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-74 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1-methyl-1 / 7-pyrazol-4-yl)benzyl)amino)- 5fluorop¡r¡m¡din-4-yl)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, A7-75 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazol-4-¡l)benz) l)amino)-5fluoropyrimidin-4-l)amino)methyl)-3-hydroxylpiperidin-1-l)acetamide, A7-76 rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4-(1H-pyrazole-1-¡l)benzyl)amino)-5fluoropirimidine -4-l)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-80 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)met ¡l)-4(1 / 7-1,2,4-triazol-3-yl)p¡peridín-1 -yl)acetamide, A7-81 2-(4-(((6-(Cíclopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropírimidin-4-íl)amino)methyl)-4(1 ,2,4-oxad¡azol-3-¡l)piper¡din-1-¡l)acetam¡de, A7-82 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín-4-yl)amino)methyl)-4( 1,3,4-oxadiazol-2-l)pyridin-1-yl)acetamide, A7-85 iviA / a / zuzz / uu / ου i 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín-4-yl)amino)methyl)-4(1 / 7-1,2,3-triazol-5-yl)piperidin-1-yl)acetamide, A7-86 rac-2-((3R,4R)-4-(((6-((4-(1H-pyrazol-1-yl)benzyl)(cyclopropyl)amino)-5-fluoropyral m¡d¡n-4yl)amino)met¡l)-3-hydroxypiper¡din-1-¡l)acetam¡de, B4-1-1-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl )-3-hydroxy-3-methylpiperidin-1-yl)acetamide, B4-1-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop ¡r¡m¡d¡n-4¡l)am¡no)met¡l)-3-hydroxy¡-3-met¡lpiperid¡n-1-¡l)acetamide, B4-2-1-1 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3hydroxy¡ -4-methylpiperidín-1-yl)acetamide, C4-1-1 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-yl)amrio)metal )-3hydroxy-4-(hydroxy¡met¡l)piper¡din-1-¡l)acetam¡de, D5-1-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroiOp¡rimidin-4yl )amino)methyl)-3,4-dihydroxy¡p¡perídin-1-yl)acetamide, D5-1-2-1 re / -2-((3R,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprímidin -4¡l)amino)met¡l)-3,4-d¡hydroxypiperid¡n-1-¡l)acetamide, D5-2-1-1 re / -2-((3R,4R)-4-(((6-(cyclopropíl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámide ¡n-4yl)amino)methyl)-3,4-dihydroxy¡p¡peridin-1-yl)acetamide, D5-2-2-1 re / -2-((3R,4S)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoiOp rimidín-4¡l)amino)methyl)-3,4-d¡hydroxypiperidin-1-¡l)acetamide, D5-3-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluorop ¡nm¡d¡n-4¡l)am¡no)met¡l)-3,4-di¡hydroxyp¡perídin-1-¡l)acetam¡de, D5-3-2-1 re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l )amino)methyl)-3,4-d¡hydroxy¡p¡perídin-1-¡l)acetamide, D5-4 ινΐΛ / a / zuzz / uu ι ουι re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro -2-hydroxypropan-2-¡l)benzyl)amino)-5fluorop¡rimidin-4-yl)amino)methyl)-3,4-dihydroxypiper¡din-1-yl)acetamide, D5-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / - / -pyrazol-4-yl )benzyl)amino)-5fluoropyrimidín-4-íl)amino)methyl)-3,4-dihydroxy¡piperidín-1-yl)acetamíde, D5-6 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2yl)benzyl) l)amino)-5-fluorop¡r¡midin-4-yl)amino)methyl)-3,4-dihydroxypiperidin-1-¡l)acetamide, D5-9 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 / - / -pyrazol-1-¡l)benzyl)amino) -5fluoropyrim¡din-4-¡l)amino)methyl)-3,4-dihydrox¡p¡peridín-1-yl)acetam¡de, F2-7 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy¡)benzyl)amino)pyrimidin-4¡l)amino)methyl) -3-hydroxy¡p¡perídin-1-yl)acetam¡de. In some cases, the compound, salt or salt of a stereoisomer is selected from the group consisting of: 2-(4-(((6-(C¡clopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡rnid¡n-4-yl)arn¡no)methyl)- 3hydroxypiper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5 -fluoropyrimidin-4yl)amino)methyl)-3,3-difluoropípendin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l((5- (trifluoromethyl)pyridín-2-yl)methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3-fluorop¡perídin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rnidin-4-yl)arn¡no)metal )-3fluoropiperidin-1-íl)acetamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)3,3-difluoroper ¡d¡n-1-¡l)acetamide, 2-(4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4-¡l)amino)methyl) -3(trifluoromethyl)piper¡din-1-¡l)acetamide, 1-(2-amino-2-oxoethyl)-4-((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5- methyl fluoropyr¡m¡d¡n4-¡l)amino)methyl)piper¡d¡n-4-carbox¡late, 2-(4-(((6-(cyclopropyl((5-(tnfluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrymidin-4 l)amino)methyl)-4-hydroxy¡p¡peridin-1-l)acetam¡de, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-l)amino)methyl) -4hydroxy¡piperidin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrnidin-4¡l)amino)methyl)-3 -hydroxy¡piper¡din-1-¡l)acetam¡de, ΜΛ / a / ZUZZ / UU i 2-(4-(((6-(cyclobutyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-(cyclobutyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l((2-(trifluoromethyl)pyrim¡din-5-yl)methyl)amino)-5-fluorop¡r¡ m¡d¡n-4¡l)am¡no)methyl)-3-hydroxy¡piper¡din-1-yl)acetam¡de, 2-(4-(((5-fluoro-6-(isopropyl(4-(trifluoromethyl)benzyl)amino)pyrimidin-4-yl)amino)methyl)-3hydroxy¡piperidin-1-yl acetamide, 2-(4-(((5-fluoro-6-(met¡l(4-(trifluoromet¡l)benzyl)amino)prim¡din-4-¡l)amino )met¡l)-3h¡droxy¡piperid¡n-1-¡l)acetam¡de, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)met ¡l)-3h¡droxy¡piperid¡n-1-¡l)acetamide, 2-(4-(((6-(cycloprop¡l(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3- hydroxyp¡perídin-1-yl)acetam¡de, 2-(4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino )methyl)3-hydroxypiper¡din-1 -yl)acetamide, 2-(4-(((6-(cyclopropyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3 -hydroxypiper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cyclopropyl((6-(1,1-difluoroethyl)pyridín-3-yl)methyl)amino)-5-fluoropyrimidín-4yl)amino no)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, 2-(4-(((5-fluoro-6-(3-fluoroc¡clobut¡l)(4-(trifluoromethyl)benzyl)amino)pyrimidin-4¡l)amino)methyl )-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4¡l)amino)methyl)p perídin-1-yl)acetamída, 2-(4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl )3-hydroxypiperidin-1-yl)acetamide, 2-(4-(((5-fluoro-6-((1-methylcyclopropyl)(4-(trifluoromethyl)benzyl)amino)pyrimidin-4¡l)amino) methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(cyclopropyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)- 3-hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(difluoromethoxy¡)benzyl)amino)-5-fluoropihmidin-4-¡l)amino)methyl)3 -hydroxy¡piper¡din-1-¡l)acetam¡de, 1-(2-amino-2-oxoethyl)-4-((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5- fluorop¡r¡m¡d¡n4-¡l)amino)methyl)piperidine-4-carboxamide, 2-(4-(((6-(cycloprop¡l((6-(tnfluoromet¡l)pyr¡din-3-¡l)met¡l)amino)-5-fluorop¡rim ¡d¡n-4¡l)am¡no)met¡l)-4-(hydroxy¡met¡l)piperid¡n-1-¡l)acetam¡de, ινΐΛ / a / zuzz / uu / ου i 2-(4-cyano-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)piperidin-1-yl)acetamide , 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-4(hydroxymethyl)piperidín- 1-yl)acetamide, 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyr¡midin- 4¡l)amino)methyl)-4-(hydroxy¡methyl)piperidín-1-¡l)acetamide, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)amino)-5fluoropirimidin-4-yl )amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-3hydroxy¡piperidín- 1-1)-2-methylpropanamide, 2-(4-(((6-(cycloprop¡l(3-(trifluoromethox¡)benzyl)amino)-5-fluoropyrim¡din-4-¡l)amino)methyl )3-hydroxypiperidín-1-íl)acetamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4-yl)amino)methyl)-3hydroxy¡piper¡din- 1-yl)-2-methylpropanamide, 2-(4-(((6-(cycloprop¡l(3-methoxy-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)- 3-hydroxy¡piper¡din-1-yl)acetam¡de, 2-(4-(((5-fluoro-6-((methyl-c / 3)(4-(trifluoromethyl)benzyl)amino)pyrimidin-4-yl) am¡no)met¡l)-3hydroxy¡piperid¡n-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-3hydroxy¡piper¡din- 1-yl)-3-hydroxypropanamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-l)amino)methyl)-3hydroxy piperidin-1-l)-3-hydroxypropanamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrmidin-4-yl)amino)methyl )-3hydroxy¡p¡perídin-1-¡l)-4-hydroxybutanamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4hydroxypiperidin- 1-yl)-3-hydroxypropanamide, 2-(4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-¡l)amino)methyl) -3hydroxy¡piperidin-1-yl)acetam¡de-2,2-d2, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-yl)anino)methyl )-4(hydroxymethyl)piperidin-1-yl)-3-hydroxypropanamide, 2-(4-(((6-(ethyl(4-(1-methyl-1 H-pyrazol-4-íl)benzyl)amino)-5-fluoropyrimidin-4-íl)amino) methyl)3-hydroxypiper¡din-1-¡l)acetamide, 2-(4-(((6-(cyclopropyl(4-(1-methyl-1 H-pyrazol-4-¡l)benzyl)amino)-5-fluoiOpyrim¡din-4yl)amino)methyl )-3-hydroxypiperídin-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazol-4-¡l)benzyl)amino)-5-fluoropyramí d¡n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, IVIA / a / ZUZZ / UU 1091 2-(4-(((6-(Cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-yl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)- 3-hydroxypiper¡din-1-yl)acetamide, 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-4(1 / 7- 1,2,4-triazol-3-yl)píperidín-1 -yl)acetamide, 2-(4-(((6-(C¡clopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-¡l)amino)methyl)-4(1 ,2,4-oxadiazol-3-yl)pyridin-1-yl)acetamide, 2-(4-(((6-(C¡cloprop¡l(4-(tnfluoromet¡l)benzyl)amino)-5-fluoropyrámidín-4-¡l)amino) methyl)-4(1,3,4-oxadiazol-2-yl)piperidin-1-yl)acetamide, 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-¡l) am¡no)met¡l)-4(1 / 7-1,2,3-tr¡azol-5-¡l)p¡perid¡n-1-yl)acetam¡de, 2-(4-(((6-((4-(1 / 7-pyrazol-1 -yl)benzyl)(cyclopropyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl )-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3hydroxy¡ -3-methylpiperidín-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3hydroxy¡-4-met¡lp¡perídin-1-yl)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3hydroxy¡-4-(hydroxy¡methyl)piper¡din-1-yl)acetam¡de, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrmidin-4-yl)amino)methyl)- 3,4dihydroxypyridin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)met ¡l)3,4-d¡hydroxypiperidín-1-¡l)acetamide, 2-(4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim¡n-4-yl)amino )met¡l)3,4-dihydroxy¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy¡propan-2-¡l)benzyl)amino)-5fluorop¡ rimidin-4-¡l)amino)met¡l)-3,4-dih¡droxypiper¡n-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazol-4-yl)benzyl)amino) -5-fluoropyrimidín-4¡l)amino)methyl)-3,4-d¡hydroxy¡p¡peridin-1-yl)acetam¡de, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-¡l)benzyl)amino)-5fluoropyrimidin-4- yl)amino)methyl)-3,4-dihydroxypiperidín-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-yl)benzyl)amino)-5-fluoropinmidin -4¡l)am¡no)met¡l)-3,4-dih¡droxyp¡per¡d¡n-1 -yl)acetamide and 2-(4-(((5-fluoro-6-(met¡l(3-(trifluoromethox¡)benzyl)amino)prim¡din-4-¡l)am¡ non)methyl)-3hydroxy¡piperidin-1-yl)acetamide. In some cases, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: ΜΛ / a / ZUZZ / UU 14» 1 Α7-1-1 re / -2-((3R,4R)-4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3- hydroxypiperídin-1-yl)acetamide, eluted 1.erysomer, A7-1-2 re / -2-((3R,4R)-4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl )-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, A7-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4yl)amino)met ¡l)-3-fluorop¡perídin-1-¡l)acetamide, eluted 1.eryisomer, A7-5-2 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r ¡m¡d¡n-4yl)amino)methyl)-3-fluorop¡perídin-1-yl)acetam¡de, 2nd eluted isomer, A7-6-1 re / -(R)-2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡din -4¡l)amino)methyl)-3,3-difluoropiperidin-1-yl)acetam¡de, eluted 1.eryisomer, A7-6-2 re / -(R)-2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin -4¡l)amino)met¡l)-3,3-difluorop¡perid¡n-1-¡l)acetam¡de, 2nd eluted isomer, A7-10 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-l)amino)methyl)-4hydrox piperidin-1-yl)acetamide, A7-21-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4 ¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, eluted 1.eryisomer, A7-21-2 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropharm ¡din-4¡l)amino)methyl)-3-hydroxy¡p¡per¡din-1-yl)acetam¡de, 2nd eluted isomer, A7-22-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluoropyrimid ¡n-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, 2nd eluted isomer, A7-22-2 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluorop¡r ¡m¡d¡n-4-yl)amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetamide, eluted 1.erysomer, A7-26-1 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino )met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2nd eluted isomer, Α7-26-2 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl )-3-hydroxypiperídin-1-yl)acetamide, eluted 1.erysomer, A7-40 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benzyl)amino)-5-fluoropyrimidín-4¡l)amino) met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-43 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3 -hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-50 2-(4-cyano-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din-4¡l )amino)met¡l)p¡perid¡n-1-yl)acetam¡de, A7-51 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-¡l) amino)methyl)-4(hydroxy¡methyl)piperidín-1-¡l)acetamide, A7-54-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡ l)benzyl)amino)-5-fluoropyrim¡din-4-l)amino)methyl)-3-hydroxy¡piper¡din-1-yl)acetamide, 1 ®risomer eluted, A7-54-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,34iexafluoro-2-hydroxypropan-2¡l)) benz¡l)amino)-5-fluorop¡rim¡din-4-yl)amino)methyl)-3-hydroxyp¡perídin-1-¡l)acetamide, 2nd eluted isomer , A7-55 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)amino)methyl )-3-hydroxy¡p¡perídin-1 -yl)-2-methylpropanamide, enantiomerically enriched, A7-56 rac-2-((3R,4R)-4-(((6-(cyclopropíl(3-(trifluoromethoxy)benzyl)amino)-5-fluoropyrimídin- 4¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, A7-57 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl )-3-hydroxy¡peridin-1 -yl)-2-methylpropanamide, enantiomerically enriched, A7-65 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)met¡ l)-3-hydroxy¡piper¡din-1-¡l)-3-hydroxy¡propanamide, A7-69 ινΐΛ / a / zuzz / uu ι ουι re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5- fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiperydin-1-yl)acetamide-2,2-c / 2, enantiomerically enriched, A7-70 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4-yl)amino)methyl)- 4(hydroxymethyl)pipendin-1-yl)-3-hydroxypropanamide, A7-74 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1-methyl-1 / 7-pyrazol-4-yl)benzyl)amino)-5fluoropirimidin- 4-yl)amino)methyl)-3-hydroxypiperidín-1-íl)acetamide, A7-75 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazol-4-¡l)benzyl)) amino)-5fluoropyrim¡din-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-76 rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-yl)benzyl)amino)-5fluorop¡r¡ m¡din-4-yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, A7-81 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrámidín-4-yl)amino)methyl )-4(1,2,4-oxadiazol-3-¡l)p¡per¡din-1-yl)acetamide, A7-82 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(1, 3,4-oxad¡azol-2-yl)piperidin-1-¡l)acetamide, A7-85 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrámidín-4-yl)amino)methyl )-4(1 / 7-1,2,3-triazol-5-yl)p¡perídin-1 -yl)acetamide, A7-86 rac-2-((3R,4R)-4-(((6-((4-(1 / 7-pyrazol-1-yl)benzyl)(cyclopropyl)amino)-5- fluoropinm¡din-4¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, B4-1-1-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5 -fluoropyrim¡din-4¡l)amino)methyl)-3-hydroxy¡-3-methylpiper¡din-1-¡l)acetam¡de, 1, eluted erysomer, B4-1-1-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropinm ¡din-4¡l)amino)methyl)-3-hydroxy¡-3-methylpiper¡din-1-¡l)acetamide, 2nd eluted isomer, B4-2-1-1 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-3hydroxy¡-4-met ¡lp¡períd¡n-1-yl)acetamide, eluted 1.®risomer, B4-2-1-2 MA / a / ZUZZ / UU i 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy-4-methylpiperidin-1- il)acetamide, 2nd eluted isomer, C4-1-1 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4-yl)amino)methyl)- 3hydroxy¡-4-(hydroxy¡methyl)piper¡din-1-yl)acetam¡de, eluted 1.erysomer, C4-1-2 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy- 4-(hydroxymethyl)piper¡din-1-yl)acetam¡de, 2nd eluted isomer, D5-1-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4¡l )amino)methyl)-3,4-d¡hydroxypiperid¡n-1-¡l)acetamide, eluted 1.eryisomer, D5-1-1-2 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4 ¡l)amino)methyl)-3,4-d¡hydroxy¡p¡per¡din-1 -yl)acetamide, 2nd eluted isomer, D5-2-1-1 re / -2-((3R,4R)4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡ r¡m¡d¡n-4¡l)amino)met¡l)-3,4-d¡hydroxypiperid¡n-1-¡l)acetam¡de, eluted 1.erysomer, D5-2-1-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)am ¡non)methyl)-3,4-d¡hydroxy¡p¡perídin-1-yl)acetam¡de, 2nd eluted isomer, D5-2-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5 -fluorop¡rim¡din-4¡l)amino)met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, eluted 1.eryisomer, D5-2-2-2 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)amino )met¡l)-3-hydroxy¡p¡perídin-1-¡l)acetam¡de, 2nd eluted isomer, D5-3-1-1 re / -2-((3R,4R)4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5- fluoropyrim¡din-4¡l)amino)methyl)-3,4-d¡hydroxypiperidin-1-¡l)acetam¡de, eluted 1.erysomer, D5-3-1-2 re / -2-((3R,4R)4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5- fluorop¡r¡m¡d¡n-4¡l)amino)methyl)-3,4-d¡hydroxypiperid¡n-1-¡l)acetam¡de, 2nd eluted isomer, D5-4 re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) benzyl)amino)-5fluorop¡rim¡n-4-¡l)amino)methyl)-3,4-di¡hydroxy¡p¡perídin-1-¡l)acetam¡ da, enantiomerically enriched, D5-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 -methyl-1 / - / -pyrazol-4-yl)benzyl )amino)-5fluorop¡rimidin-4-yl)amino)methyl)-3,4-dihydroxypiper¡din-1-yl)acetamide, major isomer, D5-5-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazole-4- il)benz¡l)am¡no)-5fluoropyrim¡n-4-¡l)am¡no)met¡l)-3,4-d¡hydroxy¡p¡perid¡n-1-¡ l) acetamide, minor isomer, D5-6 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡l) benz¡l)am¡no)-5-fluorop¡rim¡din-4-¡l)am¡no)met¡l)-3,4-dih¡droxy¡p¡períd¡n-1-¡ l)acetamide, enantiomerically enriched, D5-9 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-¡l)benzyl)amino )-5fluorop¡rim¡din-4-¡l)amino)met¡l)-3,4-di¡hydroxy¡piper¡din-1-¡l)acetam¡de, enantiomerically enriched. In some cases, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: A7-1-1 re / -2-((3R,4R)-4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r ¡m¡d¡n-4¡l)am¡no)met¡l)-3-hydroxypiper¡din-14l)acetam¡de, A7-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l)am ¡no)methyl)-3-fluoropiper¡din-14l)acetam¡de, A7-6-1 re / -(R)-2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropymid) ¡n-4¡l)amino)met¡l)-3,3-difluorop¡perid¡n-1-¡l)acetam¡de, A7-10 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-44l)amino)methyl)- 4hydroxy¡p¡peridin-1-¡l)acetam¡de, A7-21-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidin-4¡l )amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-22-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5fluorop¡rimidine -4-yl)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-26-1 iviA / a / zuzz / uu i ουι re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl) )benzyl)amino)-5-fluoropirimidin-4yl)amino)methyl)-3-hydroxypiperídin-1-yl)acetamide, A7-40 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benzyl)amino)-5-fluoropyrimídin-4yl) amino)met¡l)-3-hydroxypiper¡din-1-¡l)acetam¡de, A7-43 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3 -hydroxypyridin-1-yl)acetamide, A7-50 2-(4-cyano-4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidín-4¡l)amino )met¡l)p¡perid¡n-1-yl)acetam¡de, A7-51 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-4( hydroxyl-methyl-piperidin-1-l-acetamide, A7-54-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy¡propan- 2¡l)benzyl)arn¡no)-5-fluoropyrim¡din-4-¡l)amino)methyl)-3-hydroxy¡p¡perídin-1-yl)acetam¡de, A7-55 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din-4yl)am non)methyl)-3-hydroxypiper¡din-1-yl)-2-methylpropanamide, A7-56 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(3-(trifluoromethoxy)benzyl)amino)-5-fluorop¡r¡m¡d¡ n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, A7-57 re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4yl)amino)methyl )-3-hydroxypiper¡din-1-yl)-2-methylpropanamide, A7-65 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡d¡ n-4¡l)am¡no)met¡l)-3-hydroxy¡piper¡din-1-¡l)-3-hydroxy¡propanamide, A7-69 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benchH)amino)-5-fluoiOpinm¡din-4yl)am ¡no)methyl)-3-hydroxy¡p¡perídin-1 -yl)acetamide-2,2-c / 2, A7-70 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(hydroxyl) methyl)pyridin-1-1)-3-hydroxypropanamide, A7-74 -l)benzyl)amino)-5fluoropirimidin-4-yl)amino)methyl)-3-hydroxypiperidin-1-l)acetamide, A7-75 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(1-rnetyl-1 / 7-pyrazol-4-¡l)) benzyl)amino)-5fluoropyrimidin-4-l)amino)methyl)-3-hydroxylpiperidin-1-yl)acetamide, A7-76 rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4-(1H-pyrazol-1-yl)benzyl)amino)-5fluoropirimidin-4- il)amino)methyl)-3-hydroxypiperid¡n-1-¡l)acetamide, A7-81 2-(4-(((6-(C¡cloprop¡l(4-(tnfluoromet¡l)benzyl)amino)-5-fluorop¡rímid¡n-4-¡l)amino) met¡l)-4(1,2,4-oxadiazol-3-¡l)p¡perid¡n-1-yl)acetamide, A7-82 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl)- 4(1,3,4-oxadiazol-2-yl)píperidín-1-íl)acetamide, A7-85 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)met ¡l)-4(1 / 7-1,2,3-tr¡azol-5-yl)p¡peridín-1 -yl)acetamide, A7-86 rac-2-((3R,4R)-4-(((6-((4-(1 / 7-pyrazol-1-yl)benzyl)(cyclopropyl)amino)-5-fluoropyri¡ m¡din-4yl)amino)methyl)-3-hydroxypiper¡din-1-¡l)acetamide, B4-1-1-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim ¡d¡n-4¡l)am¡no)met¡l)-3-hydroxy¡-3-met¡lpiperid¡n-1-¡l)acetam¡de, B4-1-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropíl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámide ¡n-4yl)amino)methyl)-3-hydroxy-3-methylpiperidin-1-yl)acetamide, B4-2-1-1 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3hydroxy¡-4-met¡lp¡perídin-1-yl)acetam¡de, C4-1-1 2-(4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-¡l)amino)methyl) -3h¡droxy-4-(h¡drox¡met¡l)p¡per¡d¡n-1-¡l)acetam¡de, D5-1-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4 l)amino)methyl)-3,4-d¡hydroxy¡p¡perídin-1-l)acetamide, D5-1-2-1 iviA / a / zuzz / uu / ου i re / -2-((3R,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)) amino)-5-fluoropyrimidín-4yl)amino)methyl)-3,4-dihydroxy¡píperidin-1-yl)acetamide, D5-2-1-1 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rim ¡d¡n-4yl)am¡no)met¡l)-3,4-di¡hydroxyp¡peridin-1-¡l)acetamide, D5-2-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino )methyl)-3,4-dihydroxy¡p¡peridin-1-yl)acetamide, D5-3-1-1 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino) -5-fluoropinm¡din-4¡l)amino)methyl)-3,4-d¡hydroxyp¡peridin-1-¡l)acetamide, D5-3-2-1 re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim ¡din-4¡l)amino)methyl)-3,4-d¡hydroxypipendin-1 -yl)acetamide, D5-4 re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy¡propan-2- il)benzyl)amino)-5fluoropyrimidín-4-íl)amino)methyl)-3,4-dihydroxípíperidín-1-yl)acetamide, D5-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / - / -pyrazol-4-yl)benzyl )amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3,4-dihydroxypiper¡d¡n-1-¡l)acetamide, D5-6 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡l) benzyl)amino)-5-fluoropyrimídin-4-l)amino)methyl)-3,4-dihydroxípíperídin-1-l)acetamide, D5-9 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-yl)benzyl)amino)-5fluoropirimidin -4-¡l)amino)methyl)-3,4-dihydroxypiper¡din-1-yl)acetamide and F2-7 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy)benzyl)amino)pyrimidin-4 l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de. In some cases, the compound, stereoisomer or salt of the disclosure is selected from the group consisting of: 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín-4-¡l)amino) met¡l)-3h¡droxy¡piper¡din-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3fluoropiperidin-1-yl) acetamide, iviA / a / zuzz / uu / ου i 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)3,3-difluoropiperidin-1-yl )acetamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4hydroxypiperidin-1-yl) acetamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrmidin-4-yl)amino)methyl )-3h¡droxy¡piperidin-1-¡l)acetam¡de, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypyrimidin- 1-yl)acetamide, 2-(4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4 -l)amino)methyl)3-hydroxypiper¡din-1-l)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(1,1-d¡fluoroethyl)benzyl)amino)-5-fluoropyrim¡din-4-¡l)am¡ no)methyl)3-hydroxypiperidn-1-l)acetamide, 2-(4-(((6-(cycloprop¡l(4-(difluoromethoxy¡)benzyl)amino)-5-fluorop¡rim¡din-4-yl)amino)methyl)3- hydroxyiperidin-1-yl)acetamide, 2-(4-cyano-4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)p per¡d¡n-1-yl)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-4(hydroxymethyl)pipendin-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-¡l)benzyl)amino)-5fluorop¡r¡ m¡d¡n-4-yl)amino)methyl)-3-hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)met ¡l)-3hydroxy¡piperidin-1-yl)-2-methylpropanamide, 2-(4-(((6-(cycloprop¡l(3-(trifluoromethoxy¡)benz¡l)amino)-5-fluorop¡r¡m¡din-4-¡l)amino)rnet ¡l)3-hydroxy¡piper¡din-1-¡l)acetamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)met ¡l)-3hydroxy¡piperidin-1-yl)-2-methylpropanamide, 2-(4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-¡l)amino)methyl) -3hydroxy¡piperidin-1-¡l)-3-hydroxy¡propanamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoroprymidin-4-yl)anino)methyl )-3hydroxypiperidin-1-yl)acetamide-2,2-c / 2, 2-(4-(((6-(cycloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-¡l)amino)methyl) -4(hydroxymet¡l)p¡perídin-1-¡l)-3-hydroxy¡propanamide, 2-(4-(((6-(cyclopropyl(4-(1-methyl-1H-pyrazol-4-l)benzyl)amino)-5-fluoropyri) m¡d¡n-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(2-fluoro-4-(1-methyl-1 / 7-pyrazol-4-¡l)benzyl)amino)- 5-fluoropyrám¡d¡n-4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, iviA / a / zuzz / uu ι ουι 2-(4-(((6-(Cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-yl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)- 3-hydroxypiper¡din-1-yl)acetamide, 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)-4(1,2, 4-oxadiazol-3-yl)pyridin-1-yl)acetamide, 2-(4-(((6-(Cíclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(1,3,4- oxadiazol-2-yl)peridín-1-yl)acetamide, 2-(4-(((6-(Cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl)-4( 1 / 7-1,2,3-triazol-5-yl)piperidin-1-yl)acetamide, 2-(4-(((6-((4-(1 / 7-pyrazole-1-¡l)benzyl)(cyclopropyl)amino)-5-fluorop¡rímidín- 4¡l)amino)met¡l)-3-hydroxy¡piper¡din-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3hydroxy-3-met¡lp¡perídin-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3hydroxy¡ -4-methylpiperidín-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rímidín-4-yl)amino)methyl )-3h¡droxy-4-(hydroxy¡met¡l)p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrymidin-4-yl)amino)methyl )-3,4dihydroxypiperid¡n-1-¡l)acetam¡de, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)3,4-dih droxypiperidin-1-yl)acetamide, 2-(4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl)amino )methyl)3,4-d¡hydroxypiperidín-1-¡l)acetamide, 2-(4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-¡l)benzyl)amino)-5fluoropyrámide¡ n-4-¡l)am¡no)methyl)-3,4-dihydroxy¡piperid¡n-1-¡l)acetam¡de, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / 7-pyrazol-4-l)benzyl)amino)-5-fluoropyrimidin- 4yl)amino)methyl)-3,4-dihydroxy¡p¡peridin-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)amino)-5fluoropyrimidin-4 -l)amino)methyl)-3,4-dihydrox¡p¡perídin-1-yl)acetam¡de, 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1 / 7-pyrazol-1-yl)benzyl)amino)-5-fluoropyrimide ¡n-4iI)amino)methyl)-3,4-dihydroxyp¡peridin-1 -yl)acetamide and 2-(4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy)benzyl)amino)pyrimidin-4-yl)amino)methyl) -3hydroxypiperidin-1-l)acetamide. In one embodiment, the compound has a structure selected from the group consisting of: ΜΛ / a / zuzz / uu / what and ί iviA / a / ¿u¿¿ / uu ι ουι ΜΛ / a / zuzz / uu / what and ί iviA / a / ¿u¿¿ / uu ι ουι ΜΛ / a / zuzz / uu / what and ί iviA / a / ¿u¿¿ / uu ι ουι iviA / a / ¿u¿¿ / uu ι ουι ινΐΛ / a / zuzz / uu ι ουι or a stereoisomer or salt or salt of a stereoisomer thereof. In one embodiment, the compound has a structure selected from the group consisting of: iviA / a / ¿u¿¿ / uu ι ουι 100 ινΐΛ / a / zuzz / uu ι ουι 101 iviA / a / ¿u¿¿ / uu ι ουι 102 ΜΛ / a / zuzz / uu / what and ί iviA / a / ¿u¿¿ / uu ι ουι 104 CFS ινΐΛ / a / zuzz / uu i ουι 105 ΜΛ / a / zuzz / uu / what and ί 106 iviA / a / ¿u¿¿ / uu ι ουι 107 or a stereoisomer or salt or salt of a stereoisomer thereof. In a preferred embodiment, the compound of the invention is: 108 2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡din-4yl)am ¡no)methyl)-3-hydroxy-3-methylpiperidin-1-yl)acetamide. In a preferred embodiment, the compound of the invention is: 2-((3S,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)- 3-hydroxy¡-3-met¡lp¡perídin-1-l)acetam¡de. In a preferred embodiment, the compound of the invention is: 2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxy- 3-methylpiperidin-1-yl)acetamide. In a preferred embodiment, the compound of the invention is: 2-((3S,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidín -4¡l)amino)methyl)-3-hydroxy¡-3-methylpiper¡din-1-¡l)acetamide. In a preferred embodiment, the compound of the invention is: 2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl )amino)methyl)3,4-dihydroxy¡piperidin-1-¡l)acetamide. In a preferred embodiment, the compound of the invention is: 2-((3S,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl )amino)methyl)3,4-dihydroxy¡p¡perídin-1-¡l)acetamide. In a preferred embodiment, the compound of the invention is: 2-((3R,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín-4-yl)amino)methyl)3 ,4-d¡hydroxy¡piper¡din-1-¡l)acetam¡de. In a preferred embodiment, the compound of the invention is: 2-((3S,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4-yl )amino)methyl)3,4-dihydroxy¡p¡perídin-1-¡l)acetamide. In a preferred embodiment, the compound of the invention is: 2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rmide) ¡n-4¡l)am¡no)met¡l)-3,4-di¡hydroxy¡p¡perídin-1-¡l)acetamide. In a preferred embodiment, the compound of the invention is: 2-((3S,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)am ¡no)methyl)-3,4-d¡hydroxypy¡peridin-1-¡l)acetamide. In a preferred embodiment, the compound of the invention is: 2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡nmidín-4¡l)amino )met¡l)-3,4-d¡hydroxypiper¡din-1-¡l)acetam¡de. In a preferred embodiment, the compound of the invention is: 2-((3S,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)met ¡l)-3,4-d¡hydroxy¡p¡perídin-1-¡l)acetamide. ΜΛ / a / zuzz / uu / what and ί 109 In another particular embodiment, the present disclosure relates to compounds of formula (I) or a salt, stereoisomer or salt of a stereoisomer thereof, wherein Roa is selected from the group consisting of -CN, substituted or unsubstituted heteroalicyclyl and substituted heteroaryl or not replaced; and Roo is hydrogen or Cu alkyl. In some preferred embodiments, Roa is substituted or unsubstituted heteroaryl. In other more preferred embodiments, Roa is substituted or unsubstituted pyridinyl. In even more preferred embodiments, Rob is hydrogen. In some embodiments described herein, the compound, stereoisomer or salt has a structure of Formula (IV): where: Roa is a substituted or unsubstituted pyridinyl; Rob is hydrogen; Ria is hydroxyl; Ru is hydrogen; R3 is hydrogen or hydroxyl; R3 is ethyl or cyclopropyl; Re is CF3;e Y3 is CRs, where Rs is hydrogen or fluoro. In some embodiments described herein, Roa is selected from the group consisting of CN, pyridinyl and tetrahydropyranyl; Rob is hydrogen; Ria is hydroxyl; R-ib is hydrogen; R2 is hydrogen or hydroxyl; R is hydrogen; R3 is ethyl or cyclopropyl; R4 is hydrogen; Rs is hydrogen; Re is CF3; R7 is hydrogen; and Y1, Y2 and Y3 are each CH. In some embodiments described herein, Roa is pyridinyl; Rob is hydrogen; R-ia is hydroxyl; Rib is hydrogen; R2 is hydrogen or hydroxyl; R is hydrogen; R3 is ethyl or cyclopropyl; R4 is hydrogen; Rs is hydrogen; Rs is CF3; R7 is hydrogen; and Y1, Y2 and Y3 are each CH. In another embodiment, the present disclosure relates to a compound of Formula (I) or a salt, stereoisomer or salt of a stereoisomer thereof, wherein: Roa is selected from the group consisting of CN, pyridinyl and tetrahydropyranyl; Rob is hydrogen; Riaes hydroxyl; Ribes hydrogen; R2 is hydrogen or hydroxyl; R is hydrogen; R3 is ethyl or cyclopropyl; R4 is hydrogen; Rs is hydrogen; Re is CF3; R7 is hydrogen; and Y1, Y2 and Y3 are each CH. 110 In another more preferred embodiment, the present disclosure relates to a compound of Formula (I) or a salt, stereoisomer or salt of a stereoisomer thereof, where: Roa is pyridinyl; Roo is hydrogen; Ria is hydroxyl; Ribes hydrogen; R2 is hydrogen or hydroxyl; R is hydrogen; R3 is ethyl or cyclopropyl; R4 is hydrogen; R5 is hydrogen; Re is CF3; R7 is hydrogen; and Y1, Y2 and Y3 are each CH. In another embodiment described herein, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: A7-59 rac-2-cyano-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl l)-3-hydroxy¡piper¡din-1-l)acetam¡de, A7-62 rac-2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rímidin-4¡l)am¡ no)met¡l)-3-hydroxy¡piper¡din-1-¡l)-2-(p¡r¡d¡n-4-yl)acetam¡de, A7-63 rac-2-( (3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl) -3-hydroxy¡p¡perídin-1 -yl)-2-(pyridin-4-yl)acetamide, A7-71 rac-2-((3R,4R)-4-(((6- (cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropinm¡n-4¡l)amino)methyl)-3-hydroxypiper¡din- 1-¡l)-2-(tetrahydro-2H-pyran-4-¡l)acetamide, D5-7 re / -2-((3R,4R)-4-(((6-(et ¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡din-4¡l)amino)methyl)-3,4-d¡hydroxy¡p¡peridin-1 - il)-2-(pyridin-4-yl)acetamide, enantiomerically enriched, D5-7-1 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4- (trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3,4-dihydroxy¡p¡peridin-1 -yl)-2-(pyridin-4-yl)acetamide or re / - (R)-2-((3S,4S)-4-(((6(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡ n-4-yl)amino)methyl)-3,4-dihydroxypiperidin-1 -yl)2-(pyridin-4-yl)acetamide, 1, major eluted erysomer, D5- 7-2 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop ¡nm¡d¡n-4yl)amino)methyl)-3,4-dihydroxypiperidin-1 -yl)-2-(pyridin-4-yl)acetam¡de or re / -(R)-2-( (3S,4S)-4-(((6(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyri¡m¡din-4-¡l)amino) methyl)-3,4-di¡hydroxy¡piperidin-1-¡l)2-(pyrídin-4-yl)acetamide, 2nd major isomer eluted, and D5-8 ινΐΛ / a / zuzz / uu foxi 111 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rymidin-4yl)amino )methyl)-3,4-dihydroxypíperidin-1 -yl)-2-(pyridin-4-íl)acetamide, enantiomerically enriched. In some cases, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: A7-59 rac-2-cyano-2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5- fluorop¡rim¡din-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, A7-62 rac-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rímid¡ n-4¡l)am¡no)met¡l)-3-hydroxy¡piper¡din-1-yl)-2-(p¡r¡d¡n-4-yl)acetam¡de, A7-63 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡ m¡d¡n-4yl)amino)methyl)-3-hydroxypiperidin-1 -yl)-2-(pyridín-4-¡l)acetamide, A7-71 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyr¡m¡d¡ n-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1-¡l)-2-(tetrahydro-2 / 7-pyran-4-¡l)acetamide , D5-7 re / -2-((3R4R)4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrámidin-4¡l)amino)methyl) -3,4-d¡hydroxy¡p¡perídin-1-yl)-2-(p¡ndin-4-yl)acetamide, D5-7-1 re / -(R)-2-((3R4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l )amino)methyl)-3,4-d¡hydroxyp¡peridín-1 -yl)-2-(pyridin-4-yl)acetamide, re / -(R)-2-((3S ,4SH-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyri¡m¡d¡n-4¡l)amino)metal )-3,4-di¡hydroxyp¡perídin-1-¡l)-2-(p¡r¡din-4-yl)acetam¡de and D5-8 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino )methyl)-3,4-d¡hydroxy¡p¡peridin-1 -yl)-2-(pyridin-4-yl)acetamide. In some cases, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: 2-cyano-2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3h¡droxypiper¡d¡ n-1-yl)acetamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡rn¡din-4 -¡l)amino)methyl)-3hydroxypiperidin-1 -yl)-2-(pyridín-4-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4- (tnfluoromethyl)benzyl)amino)-5-fluoropirimidin-4-l)amino)methyl)-3hydroxypiperidin-1 -yl)-2-(pyridin-4- il)acetamide, iviA / a / zuzz / uu / ου i 112 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)-2 -(tetrahydro-2 / - / -pyran-4-yl)acetamide, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3,4dihydroxypiperidin-1 -yl)-2-( pyrídin-4-yl)acetamide and 2-(4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡midín- 4-yl)amino)methyl)-3,4-dihydroxy¡piperídin-1-íl)-2(pyridín-4-yl)acetamide. In some cases, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: A7-62 rac-2-((3R,4R)-4-(((6 -(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrámidin-4¡l)amino)methyl)-3-hydroxy¡piperidin-1-¡l)-2-( pyridin-4-yl)acetamide, A7-63 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl )amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiperidin-1 -yl)-2-(pyridín-4-íl)acetamide, D5-7 re / -2-(( 3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3,4- dihydroxypiperidin-1 -yl)-2-(pyridin-4-yl)acetamide, enantiomerically enriched, D5-7-1 re / -(R)-2-((3R,4R)- 4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡nmidin-4¡l)amino)methyl)-3,4-dihydrox p¡peridin-1 -yl)-2-(pyridin-4-yl)acetamide or re / -(R)-2-((3S,4S)-4-(((6(ethyl(4-(trifluoromet l)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3,4-dihydroxypiperidin-1 -yl)2-(pyridin-4-l)acetamide, 1 ,eluted major erysomer, D5-7-2 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5- fluoropyrimidin-4¡l)am¡no)methyl)-3,4-di¡hydrox¡p¡pendin-1-¡l)-2-(p¡r¡din-4-¡l)acetam da or re / -(R)-2-((3S,4S)-4-(((6(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡ r¡m¡d¡n-4-yl)amino)methyl)-3,4-d¡hydroxypiperidin-1 -yl)2-(pyr¡din-4-yl)acetamide, 2. ° eluted major isomer, and D5-8 re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop ¡nmid¡n-4¡l)amino)met¡l)-3,4-di¡hydroxypipenden-1-¡l)-2-(pyr¡din-4-yl)acetam¡de , enantiomerically enriched. In some cases, the compound, salt, stereoisomer or salt of a stereoisomer according to Formula (I) is selected from the group consisting of: A7-62 ινΐΛ / a / zuzz / uu / ου i 113 rac-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡d¡n-4yl) amino)methyl)-3-hydroxypiper¡din-1 -yl)-2-(pyridin-4-¡l)acetamide, A7-63 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidín- 4yl)amino)methyl)-3-hydroxypiperidin-1-l)-2-(pyrdin-4-yl)acetamide, D5-7 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4yl)amino )methyl)-3,4-dihydroxy¡p¡peridin-1-yl)-2-(pyridin-4-yl)acetamide, D5-7-1 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5 -fluoropyrimídin-4yl)amino)methyl)-3,4-dihydroxypiperidin-1 -yl)-2-(pyridin-4-íl)acetamide, re / -(R)-2-((3S, 4S)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3, 4-dihydroxy¡p¡peridin-1-¡l)-2-(p¡r¡din-4-¡l)acetam¡de and D5-8 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropirimidin-4¡l )amino)methyl)-3,4-dihydroxypiperidin-1 -yl)-2-(pyridin-4-yl)acetamide. In some embodiments, whenever a halogen is specified as a substituent, the halogen will be selected from fluoro or chloro. The particular embodiments and descriptions used herein are to illustrate different alternatives of the disclosure and the embodiments may be combined with others. MA / a / ZUZZ / UU i applicable realizations. Specific examples of the compounds are described in the following Table 1. Table 1. Illustrative compounds according to their structure and name. Ex. No. Structure Name A7-1 u_ '—' —<j| ,--\ ZI o=\ z b il)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide 114 A7-1-1 0 JL F\PF h2n η Y·. x HO' ~Y N^ N Y l ¡fluoromethyl)benzyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3hyd roxypi perid i n-1 -yl)acetamide 1st eluted isomer A7-1-2 A7-1-2 re / -2-((3R,4R)-4-(((6-(Cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino )met¡l)-3hid roxipi perid i n-1 -yl)acetamide 2nd eluted isomer A7-2 / —\ H—\ iz \ \=z z Y / ) %z )---- / <ü A7 -2 2-(4-(((6-(cyclopropyl(2-methyl-4- (trifluoromethyl)benzyl)amino)-5- fluorop¡r¡m¡d¡n-4-¡l)am¡ no)met¡l)p¡períd¡n-1yl)acetamide A7-3-1 0 A NH CT 1 ' N' H A A7-3-1 re / -(R)-2-(4-(((6-(cyclopropyl((5- (trifluoromethyl)pyridin-2-!l)met ¡l)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)met¡l)-3,3difluorop¡períd¡n-1-¡l)acetamide 1st eluted isomer A7-3-2 A7-3-2 re / -(R)-2-(4-(((6-(cyclopropyl((5- (trifluoromethyl)pyridin-2-! )methyl)amino)-5fluoropirimidin-4-yl)amino)methyl)-3,3difluoropiperidin-1-yl)acetamide 2nd eluted isomer ινΐΛ / a / zuzz / uu i or yi 115 Α7-4-1 0 ^νη2 cf3 ΐ?? Η 1 Α Α7-4-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((5(trifluoromethyl)pyridin-2-yl)methyl)amino)-5fluoropyrimidin-4- yl)amino)methyl)-3fluoropiperidin-1 -yl)acetamide, 1st eluted isomer Α7-4-2 A7-4-2 re / -2-((3R,4R)-4-(((6-( cyclopropyl((5(trifluoromet¡l)pyr¡d¡n-2-¡l)met¡l)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)methyl )-3fluorop¡peridin-1-¡l)acetam¡de, 2nd eluted isomer Α7-5-1 0 Α f νη2 cf3 ,Ν. Α UJ _ Ο F' γ Ν' Ν Ύ Η F / / \ A7-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino )-5fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3fluoropiper¡din-1-¡l)acetamide 1st eluted isomer Α7-5-2 A7 -5-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluoroprímidín-4-yl )amino)methyl)-3fluoropiperidin-1-íl)acetamide 2nd eluted isomer 116 A7-6-1 0 Á | M-, CF3 f4oJ (J ' Y Ν'- N Y F l u i J N Y' 'N H Í l / \ A7-6-1 re / -(R)-2-(4-(((6-(cyclopropyl(4- ( trifluoromethyl)benzyl)amino)-5fluoropinmidin-4-¡l)amino)methyl)-3,3difluoropiper¡din-1-¡l)acetamide 1st eluted isomer A7- 6-2 A7-6-2 re / -(R)-2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5fluoropyrámidin-4-¡l)amino)met ¡l)-3,3difluoropiperidin-1-¡l)acetam¡de 2nd eluted isomer A7-7-1 0 4'NH: cf3 H F Λ A7-7-1 2-(4-(((6 -(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3(trifluoromethyl)p¡per¡din-1 -yl)acetamide 1st eluted isomer A7-7-2 A7-7-2 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropyrimidín- 4-yl)amino)methyl)-3(trifluoromethyl)piperídin-1-yl)acetamide 2nd eluted isomer A7-7-3 A7-7-3 2-(4-(((6 -(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3(trifluoromethyl)píperídin-1-íl) acetamide 3rd isomer eluted 117 A7-7-4 A7-7-4 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-511uoropyrimidín-4-yl)amino)methyl)- 3(trifluoromethyl)piperidin-1-¡l)acetamide 4th eluted isomer A7-8 Ξ Q O \=Z J Y—z —Z . \o A7-8 1-(2-amino-2-oxoethyl)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5- fluorop¡nm¡d¡n- Methyl 4-¡l)am¡no)methyl)p¡períd¡n-4carboxylate A7-9 í co λ—Z LL / / \\ O \ / --\ t Cr A7-9 2-(4 -(((6-(cyclopropyl((5-(trifluoromethyl)pyridin2-¡l)methyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-4-hydroxy¡piper¡ d¡n-1yl)acetamide A7-10 Ll? f / --- \ z.—<^| f A7-10 2-(4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)methyl) -4hid roxipi perid i n-1 -yl)acetamide iviA / a / ¿u¿¿ / uu / ου ι 118 A7-11 0 γήη2 cf3 G or WJ H τ Λ A7-11 2-(4-(((6-(cycloprop¡l((6-(trifluoromethyl)pyr¡d¡n3-yl)methyl) amino)-5-fluoropyrimidin-4¡l)amino)methyl)-4-hydroxy¡piper¡din-1yl)acetamide A7-14 0 CF3 ώ ά HO' N^N and H T A A7-14 rac-2-(( 3R,4R)-4-(((6-(cyclopropyl((5- (trifluoromet¡l)pyr¡din-2-¡l)methyl)amino)-5- fluoropyr¡midín -4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide A7-14-1 1 f NH2 CF3 J°o 1J U.N HO' Y N 'N r ÚV» f Δ A7 -14-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((5- (trifluoromethyl)pyridin-2-¡l)methyl)amino )-5fluoropirimidin-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide 1st eluted isomer A7-14-2 A7-14-2 re / - 2-((3R,4R)-4-(((6-(cyclopropyl((5(trifluoromethyl)pyridin-2-yl)methyl)amino)-5fluorop¡r¡m¡d¡n-4-yl)am ¡no)methyl)-3hid roxipi perid i n-1 -yl)acetamide 2nd eluted isomer 119 A7-15 0 A f2HC. < νη2 0 / Ν / ¾. kJk ΗΟ' Ν Ν F νζ Ί Α7-15 rac-2-((3R,4R)-4-(((6-(cyclobutyl(4- (difluoromethoxy)-2-fluorobenzyl)amino)-5- fluoropyrimidin-4 -yl)amino)methyl)-3- hid roxipi perid i η-1 -yl)acetamide A7-15-1 0 A f2hc. φ νη2 ο Ν, χ'χΑ ,.Q J Ο- κό τ Ν Ν γ F 1 ΑΑ. xJ 'Ν ^ Ν - Λ A7-15-1 re / -2-((3R,4R)-4-(((6-(cyclobutyl(4(difluoromethoxy)-2-fluorobenzyl)amino)-5fluoropyri¡ m¡d¡n-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide 1st eluted isomer A7-15-2 A7-15-2 re / -2-(( 3R,4R)-4-(((6-(cyclobutyl(4-(difluoromethoxy)-2-fluorobenzyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide 2nd eluted isomer A7-16 el· Γ.----λ \ / —\ Ζ\ \= / ζ— / \ ζ=\ τ 4 Ο=ζ / —\ ζι . 5 Ο no)methyl)-3hid roxipi perid i n-1 -yl)acetamide 120 Α7-16-1 0 A ρ' ΝΗ2 CF?. . Ν. ΑQ. Π ΗΟ''οΐΎ ν' 'ν Ά 1 Α Ί J ν' V ν Η Α7-16-1 re / -2-((3R,4R)-4-(((6-(cyclobutyl(4(trifluoromethyl) benzyl)amino)-5fluoropyrimidin-4-yl)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide 1st eluted isomer Α7-16-2 A7-16-2 re / -2-((3R ,4R)-4-(((6-(cyclobutyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-¡l)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide 2nd eluted isomer Α7-17 φ ο / !» \ ΙΖ '--' Α° -η—7 7 r? [Α—ζ / =2 / Η A7-17 rac-2-((3R,4R)-4-(((6-(cyclopropyl((2(trifluoromet¡l)p¡r¡m¡d¡n- 5-yl)met¡l)amino)-5fluorop¡r¡m¡d¡n-4-¡l)amino)met¡l)-3- hid roxipi perid i n-1 -yl)acetamide Α7- 17-1 0 Λ ρ' ΝΗ2 CF? ,ΝΧ Α r j Ν - Ν II J k A. A J ν γ Ν' Η F 1 / \ A7-17-1 re / -2-((3R,4R)-4-(((6-(cycloprop ¡l((2- (trifluoromet¡l)p¡r¡m¡din-5-yl)met¡l)amino)-5- fluorop¡r¡m¡d¡n-4-¡l)amino)met ¡l)-3- hid roxipi perid i n-1 -yl)acetamide 1st eluted isomer Α7-17-2 A7-17-2 re / -2-((3R,4R)-4-(((6 -(cyclopropyl((2- (trifluoromethyl)pyrimidin-5-yl)methyl)amino)-5-fluoropyrimidin-4-amino)methyl)-3 - hid roxipi perid i n-1 -yl)acetamide 2nd eluted isomer ΜΛ / a / zuzz / uu / ου ι 121 Α7-18 0 |^NH2 CF3 ,Ν. Á < > Ν J JJ HCT N vV,~ '1 A7-18 rac-2-((3R,4R)-4-(((6-(cyclobutyl((2- (trifluoromethyl)pyrimid¡n -5-yl)methyl)amino)-5- fluoropyrimidin-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide Α7-18-1 0 Λ f nh2 cf3 ,N „ Á < ó N J°p1 J k J HO V N^N 'T k X- Jk J N Y N H ó A7-18-1 re / -2-((3R,4R)-4-(((6-(cyclobutyl(( 2(trifluoromethyl)pyrimidin-5-yl)methyl)amino)-5- fluoropyrimidin-4-yl)amino)methyl)-3-hyd roxipi perid i η-1 -yl)acetamide 1st eluted isomer Α7-18-2 A7-18-2 re / -2-((3R,4R)-4-(((6-(cyclobutyl((2(tr ¡fluoromethyl)pyrimidin-5-yl)methyl)amino)-5- fluoropyrimidin-4-yl)amino)methyl)-3-hyd roxipi perid i η -1 -yl)acetamide 2nd eluted isomer Α7-19 ri) / --------V X (\ o X A7-19 rac-2-((3R,4R)-4-(((5 -fluoro-6-(isoprop¡l(4(trifluoromethyl)benzyl)amino)pririm¡din-4yl)amino)methyl)-3-hydroxipi peridin-1yl)acetamide 122 Α7-19-1 0 ^'νη2 cf3 φ F Α7-19-1 re / -2-((3R,4R)-4-(((5-fluoro-6-(isopropyl(4(trifluoromethyl)benzyl)amino )pyrimidin-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1 yl)acetamide 1st eluted isomer Α7-19-2 A7-19-2 re / -2-((3R,4R) -4-(((5-fluoro-6-(isopropyl(4(trifluoromethyl)benzyl)amino)pyrimidin-4!l)amino)methyl)-3- h¡droxy¡piper¡din-1yl)acetamide 2nd eluted isomer Α7-20 0 ^ΝΗ. CF, A I, J¿áiJ II J Η ί I A7-20 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(4(trifluoromethyl)benz) l)amino)pyrám¡n-4yl)amino)met¡l)-3-hydroxy¡piper¡din-1yl)acetamide Α7-20-1 ο Λ νη2 cf3 'Ν' ί° ο11 ] Í J Η O V Ν Ν Η J 1 A7-20-1 re / -2-((3R,4R)-4-(((5-fluoro-6-(methyl(4(trifluoromethyl) benzyl)amino)pinmidin-4l)amino)methyl)-3-hydroxylpiperidin-1yl)acetamide 1st eluted isomer Α7-20-2 A7-20-2 re / -2-((3R,4R)-4-(((5-fluoro-6-(methyl(4(trifluoromethyl)benzyl)amino)pyramidan-4yl )amino)methyl)-3-hydroxypiperidin-1 yl)acetamide 2nd eluted isomer ΜΛ / a / zuzz / uu / ου ι 123 Α7-21 ir / / \ ° \ / —\ / ί °<θ... / ΖΧ ο X Α7-21 rac-2-((3R,4R)-4-(((6-(ethyl(4( trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4-yl)amino)methyl)-3hid roxipi perid i η-14l)acetamide Α7-21-1 Ο Ρ^νη2 cf3 Δ kofiJ A J ΗΟ <^ Ν^Ν Η F k A7 -21-1 re / -2-( (3R,4R)-4-(((6-(et¡ I (4(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4 -yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 1st eluted isomer Α7-21-2 A7-21-2 re / -2-((3R,4R)-4-( ((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-¡l)amino)methyl)-3h¡droxypiperidin-1-yl )acetamide, 2nd eluted isomer Α7-22 0 cf3 Ν. ,Χ I [I HCT^ Ν^Ν T^F Ξ ϊ ¡[ I Η τ Α A7-22 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4 - (trifluoromethyl)benzyl)arn¡no)-5- fluorop¡r¡m¡d¡n-4-¡l)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide iviA / a / ¿u¿¿ / uu ι ουι 124 Α7-22-1 0 f νη2 cf3 Α , (1 HO Y N x ' N Y ' F k ΛΛ J N Y N H λ L______1 A7-22-1 re / -2-((3R,4R)-4-(((6-( cyclopropyl(2-fluoro-4(trifluoromethyl)benzyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3hydroxy¡p¡perídin-1-¡l)acetamide , 2nd eluted isomer Α7-22-2 A7-22-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4(trifluoromethyl)benzyl)amino) -5fluorop¡r¡m¡d¡n-4-¡l)amino)methyl)-3h¡droxy¡p¡per¡din-1-¡l)acetamide, 1st eluted isomer Α7-23 w Z~λ U- / / \\ ° \ \= / z—ó \ z=\ i <\ z Z—ξ O=¿ / --y ΖΞ ^Z \ oS / b X A7-23 rac-2 -((3R,4R)-4-(((6-(cyclobutyl((6(trifluoromethyl)pyridin-3-yl)methyl)amino)-5fluorop¡r¡m¡d¡n-4-¡l)amino )met¡l)-3hyd roxy p i perid i n-1 -yl)acetamide Α7-23-1 O Λ ( NH2 cf3 _N. / -2-((3R,4R)-4-(((6-(cyclobutyl((6- (trifluoromethyl)pyridin-3-!l)methyl)amino)-5 - fluoropyrimidín-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide 1st eluted isomer ινΐΛ / a / zuzz / uu ι ουι 125 A7-23-2 A7-23-2 re / -2-((3R,4R)-4-(((6-(cyclobutyl((6- (trifluoromethyl)pyridin-3-yl)methyl)amino)-5 - fluoropyrimidín-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide 2nd eluted isomer A7-24 0 ^nh2 cf3 0 ... Ó HO N T WJ ró A7-24 rac-2-((3R,4R)-4-(((6-(cyclobutyl((5- (trifluoromethyl)pyridin-2-!l)methyl)amino )-5- fluorop¡r¡m¡d¡n-4-yl)amino)met¡l)-3- hid roxipi perid i n-1 -yl)acetamide A7-24-1 0 Λ nh2 cf3 N . A_ .QiJ Í -N HO' V N 'f l pyri¡din-2-yl)methyl)amino)-5fluorop¡r¡m¡din-4-yl)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide 1st eluted isomer A7- 24-2 A7-24-2 re / -2-((3R,4R)-4-(((6-(cyclobutyl((5- (trifluoromethyl)pyridin-2-yl)methyl)amino)-5- fluoropyrimid ¡n-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide 2nd eluted isomer 126 A7-25 0 |^NH2 chf2 .Ó or H γ Λ A7-25 rac-2-((3R,4R)-4-(((6-(cyclopropyl((6(difluoromethyl)pyridin-3-yl)methyl )amino)-5fluoropyrimidin-4-yl)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide A7-25-1 o .A nh2 chf2 o - o HO'' r Ν' N V L ΑΛ J H J A L___Ϊ A7-25-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6(difluoromethyl)p¡r¡din-3-¡l)methyl)) amino)-5fluoropinm¡d¡n-4-¡l)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide 1st eluted isomer A7-25-2 A7-25-2 re / -2- ((3R,4R)-4-(((6-(cyclopropyl((6(difluoromethyl)pyridin-3-yl)methyl)amino)-5fluoroprymidin -4-¡l)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide 2nd eluted isomer A7-26 ΞΕ O / u \ iz A— / )=o -Π—ς i? / —2 / =\ benzyl)amino)-5fluorop¡r¡m¡din-4-¡l)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide 127 A7-26-1 0 Λ I νη2 cf3 .ν. / k HO' T N^'N Y F l (trifluoromethyl)benzyl)amino)-5- fluoropyrimidín-4-yl)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide 2nd eluted isomer A7-26-2 A7- 26-2 re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4(trifluoromethyl)benzyl)amino)-5fluorop¡nm¡din-4- il)am¡no)met¡l)-3hid roxipi perid i n-1 -yl)acetamide 1st eluted isomer A7-27 0 |^NH2 cf3 ώ or HO' Y^ N^ N Y H F k A7-27 rac- 2-((3R,4R)-4-(((6-(ethyl((5- (trifluoromethyl)pyridin-2-yl)methyl)amino)-5- fluorop¡r¡mid¡n- 4-yl)amino)methyl)-3- hid roxipi perid i n-1 -yl)acetamide A7-27-1 0 A nh2 cf3 / k J?o1lJ / x 1 / N HO' Y Ν' N ''r 1 k i J n'V ν' H F k A7-27-1 re / -2-((3R,4R)-4-(((6-(ethyl((5- (trifluoromethyl))p ¡r¡d¡n-2-¡l)met¡l)amino)-5- fluorop¡r¡m¡d¡n-4-yl)amino)met¡l)-3- hid roxipi perid i n-1 -yl)acetamide 1st eluted isomer A7-27-2 A7-27-2 re / -2-((3R,4R)-4-(((6-(ethyl((5- (trifluoromet) l)pyridín-2-¡l)methyl)amino)-5- fluoropyrimidín-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl )acetamide 2nd eluted isomer ΜΛ / a / zuzz / uu / what and ί 128 A7-28 0 [ / ^NH2 cf3 .5 ... 0 HO N H τ Λ A7-28 rac-2-((3R,4R)-4-(((6-(cyclopropyl((6(trifluoromethyl)pyridin- 3-yl)methyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide A7-28-1 nh2 cf3 A ,.kJ L j HOV Y 'N Y L A Λ J N Y N H F । / \ A7-28-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6(trifluoromethyl)pyridin-3-¡l)methyl )amino)-5fluoropinm¡d¡n-4-¡l)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide 1st eluted isomer A7-28-2 A7-28-2 re / -2 -((3R,4R)-4-(((6-(cyclopropyl((6- (trifluoromethyl)pyridin-3-yl)methyl)amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide 2nd eluted isomer A7-29 0 Anh2 Yf2 .5 , o WJ H τ Λ A7-29 rac-2-((3R,4R)-4-(((6- (cyclopropyl((6-(1,1 difluoroethyl)pyridin-3-yl)methyl)amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide ινΐΛ / a / zuzz / uu foxi 129 A7-29-1 0 A p NH2 CF2 A u . o HO' Ύ l A Λ J Ύ 'Ν' H F i / \ / \ ' s A7-29-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6- (1,1difluoroethyl)pyridin-3-yl)methyl)amino)-511uoropyrimidín-4-yl)amino)methyl)-3- hydroxypi perid i n-1 -yl)acetamide 1st isomer eluted A7 -29-2 A7-29-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1difluoroethyl)p¡r¡d¡n) -3-yl)methyl)amino)-5fluorop¡nm¡din-4-yl)amino)methyl)-3- hid roxipi perid i n-1 -yl)acetamide 2nd eluted isomer A7 -30 o [ANh2 cf3 hoA n^n Ó Ao A7-30 rac-2-((3R,4R)-4-(((5-fluoro-6-((2- fluoroethyl)(4- (trifluoromet ¡l)benz¡l)am¡no)pyrám¡din-4¡l)amino)met¡l)-3-hyd roxypi peridin-1yl)acetamide A7-31 o—A^>-\ zx \^A z»A / Ll- ~Z-=( f <\ Az z \ O=¿ / --y ZI \ <Λ / Ó X A7-31 rac-2-((3R,4R)-4- (((5-fluoro-6-(((1R,3S)-3fluorocyclobutyl)(4- (trifluoromethyl)benzyl)amino)pyrimidin-4¡l)amino)methyl)-3-hydroxipi peridin- 1 il)acetamide MA / a / zuzz / uu / ου ι 130 Α7-32 O—A / —\ / \ \= / ζ~\ X O=¿ / --< ΖΙ \ «) / ο 5-fluoro-6-(((1S,3R)-3fluorocyclobutyl)(4- (trifluoromethyl)benzyl)amino)pyrimidin-4yl)amino)methyl)-3-hydroxy¡piper ¡din-1yl)acetamide Α7-33 0 CF3 Ai Q N^N Q WA H T A A7-33 2-(4-(((6-(cyclopropyl (1 -(5- (trifluoromethyl)pyridin-2-yl)) ethyl)amino)-5- fluorop¡rímidín-4-¡l)amino)met¡l)piper¡d¡n-1yl)acetamide Α7-34 / —\ z^\ IZ '-- / 2=0 \^z z -n—A i? \=z [A^—Z / =\ ?—V y— A7-34 2-(4-(((6-(cyclopropyl (1 -(4- (trifluoromethyl)phen¡l)ethyl) )amino)-5- fluoropyrim¡din-4-¡l)amino)methyl)p¡per¡din-1 yl)acetamide Α7-35 0 [χ / ^ΝΗ2 CF3 H T Á A7-35 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)pyr¡din- 2-¡l)methyl)amino)-5-fluoropyrim¡din -4- ¡l)amino)methyl)p¡perídin-1-yl)acetam¡de 131 Α7-36 0 rA' .. 0 - 0 LaV Η τ Λ Α7-36 2-(4-(((6-((3-cyanobenzyl)(cyclopropyl)amino)5-fluoropyrimidin-4-yl )amino)methyl)piperidin1-¡l)acetamide Α7-38 ζ-ζ ζ 2 \ O=¿ / —\ ζι '—ζ 2—' Α7-38 2-(4-(((6-(( 3-(1Η-1,2,4-triazol-1yl)benzyl)(cyclopropyl)amino)-5fluoropinm¡d¡n-4-¡l)amino)methyl)piper¡d¡n- 1yl)acetamide Α7-39 ο γήη2 cf3 Άγί1 Η τ Α A7-39 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropirimidín -4-¡l)am¡no)methyl)piperidin-1yl)acetamide Α7-40 <Ν r---λ b—A Α—\ / \= / ζ α ι < Ζ οΑ / —< ζι \ ίϋ / Ο n4-yl)amino)methyl)-3-hydroxypiperidin-1yl)acetamide 132 A7-41 0 f~NH2 CF3 ό or HO r N^N γ F A7-41 rac-2-((3R,4R)-4-(((5-fluoro-6-((1methylcyclopropyl)(4- ( trifluoromethyl)benzyl)amino)pyrimidin-4yl)amino)methyl)-3-hydroxy¡p¡perídin-1yl)acetamide A7-42 o • Ó ¿L HO' N^N T^ F n'J:^ H τ Λ A7-42 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4- (difluoromethoxy)-2-fluorobenzyl)amino)- 5fluoropyrámidín-4-¡l)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide A7-43 0 UHC. < nh2 2 0 ώ or HO' N^N V\V H 7 Λ A7-43 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4(difluoromethoxy)benzyl)amino)- 5fluoropirimidin-4-yl)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide A7-44 X O Z Z—. \=O y 'Z— / IZ '-- / ”-^z> / Z l / >—z / —\ A7-44 1-(2-amino-2-oxoethyl)-4-(((6- (cyclopropyl(4(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)piperidine-4carboxamide iviA / a / ¿u¿¿ / uu / ου ι 133 Α7-45 LL / / V Ο \ / --\ γ1 / —\ ζ= Γ~ ι ο=( '—' ζ C4 6-(trifluoromethyl)pyridin3-l)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-4-(hydroxymethyl)piperidin-1 yl)acetamide Α7-46 0 ΗοΝ ^ ? ο Υ Ν Ν Τ Η F Α A7-46 2-(4-(((6-((4-chloro-2,5- dimethylbenzyl)(cyclopropyl)amino)-5 - fluoropinm¡d¡n-4-¡l)amino)methyl)piper¡d¡n-1yl)acetamide Α7-47 ο ο Υ Νχ Ν | Η f Λ A7-47 2-(4-((( 6-(cyclopropyl(2,5- dimethylbenzyl)amino)-5-fluoropyrim¡din-4¡l)amino)methyl)piper¡din-1-¡l)acetamide Α7- 49 0 Η2Ν^η CF3 ώ ,, ό ΗΟ*&ιγ Ν γ^ WJ Η τ Λ A7-49 rac-2-((3R,4S)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)) amino)-5fluoropyrim¡din-4-yl)amino)methyl)-3hydroxypiperidin-1 -yl)acetamide ινΐΛ / a / zuzz / uu ι ουι 134 Α7-50 0 η2ν^ cf3 Ν Ν Η γ Á Α7-50 2-(4-cyano-4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- 11uoropyrimidín-4- il)amino)methyl)piperidin-1 il)acetamide Α7-51 ο CF3 0 . Ó ν Η τ Á A7-51 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5fluoropyrámidín-4-¡l)amino)methyl) -4(hydroxymet¡l)piper¡din-1-yl)acetam¡de Α7-52 Μ Π—^. LL / / Λ ° \ / --\ γΤ1 / —Α— --- / ζ Ο ζ 1 A7-52 2-(4-(((6-(c¡clopropyl((5-(trifluoromethyl)pyridin2-¡ l)methyl)amino)-5-fluoropyrimidín-4¡l)amino)methyl)-4-(hydroxymethyl)piperidín-1yl)acetamide Α7-53 ζ 60 Ζ / --\ )^0 / —ς ζ—' ζζ '— / )=ζ , Γ>—ζ / =\ ¿ / 7 - A7-53 2-(4-(((6-((4-chloro-3,5- dimethylbenzyl)( cycloprop¡l)amino)-5fluoropyrimidín-4-yl)amino)methyl)piperidin-1 yl)acetamide 135 A7-54 0 «A ώ - i HO' N Λ LA A7-54 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4- (1,1,1,3,3 ,3-hexafluoro-2-hydroxypropan-2- ¡l)benzyl)amino)-5-fluoropyrim¡din-4yl)amino)methyl)-3-h¡d roxipi peridin-1yl)acetamide A7-54-1 I F3c H2N > 3 -Y k i J x—, [ HO'' Y Ν 'N i ϊ Ί ^N^Y h ' Δ AA Ó A7-54-1 re / -2-((3R,4R)-4-( ((6-(cyclopropyl(4- (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2- ¡l)benzyl)amino)-5-fluoropyrimidín- 4¡l)amino)methyl)-3-hyd roxypi peridin-1yl)acetamide 1st eluted isomer A7-54-2 A7-54-2 re / -2-((3R,4R)-4-( ((6-(cyclopropyl(4- (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2- ¡l)benzyl)amino)-5-fluoropyrimidín-4¡ l)amino)methyl)-3-hydroxypi peridin-1yl)acetamide 2nd eluted isomer A7-55 Enantiomerically enriched 0 H2N φ— CF3 A HO' Y Ν X'N Ά L zU J Ν γ N H F A / \ A7-55 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluorop¡nm¡d¡ Enantiomerically enriched iviA / a / ¿u¿¿ / uu / ου ι 136 A7-56 λ, Y h2n > y - u HO' Y N γ H τ Λ A7-56 rac-2-((3R,4R)-4-(((6-(cyclopropyl(3(trifluoromethoxy)benzyl) amino)-5fluoropinmid¡n-4-¡l)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide A7-57 Enantiomerically enriched A / η2ν y- cf3 Λ Λ A J / >. í A HO' Y N Y | ú Ϊ | Y ynz H F A A7-57 re / -2-((3R,4R)-4-(((6-(ethyl(4- (trifluoromethyl)benzyl)amino)-5fluorop¡nmidín-4-¡l )amino)methyl)-3hydroxy¡p¡perídin-1-¡l)-2-methylpropanamide Enantiomerically enriched A7-58 0 H2nA cf3 rN> AX .O U HO' Y N N γ H τ Λ A7-58 rac-2-((3R,4R)-4-(((6-(cyclopropyl(3-methoxy¡4-(trifluoromethyl)benzyl)amino)-5fluoropyrimidín-4 -l)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide A7-59 Jí .N H2N^Y^ cf3 rN> Al HO' Υγ N H F A A7-59 rac-2-cyano-2 -((3R,4R)-4-(((6-(ethyl(4(trifluoromethyl)benz¡l)amino)-5fluoropyrám¡d¡n-4-¡l)amino)met¡ l)-3hid roxipi perid i n-1 -yl)acetamide ινΐΛ / a / zuzz / uu i or yi 137 A7-60 0 H2nA cf3 Λ . 0 HO' N Y^ H F d4o D A7-60 rac-2-((3R,4R)-4-(((5-fluoro-6-((methyl-á3)(4(trifluoromethyl)benzyl)am¡ no)pyrimidin-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1yl)acetamide A7-61 O H2N^| CF3 Δ ,.Xi J / HO' N N 0 H T Á A7-61 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(2-methoxy4-(tnfluoromethyl)benzyl)am¡ no)-5fluoropyrám¡d¡n-4-¡l)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide A7-62 O X JL j H2N^V^ CFs φ -. c HO' YY N Y Y^ vyj H F -4-(l)amino)methyl)-3hydroxypiperidin-1 -yl)-2-(pyridin-4yl)acetamide A7-63 „.1Y .. X, or WJ H F Á A7-63 rac-2 -((3R,4R)-4-(((6-(cycloprop¡l(4(trifluoromethyl)benzyl)amino)-5fluoropyrimidín-4-¡l)amino)methyl)-3hydroxypiperidin-1 -yl )-2-(pyridin-4yl)acetamide 138 Α7-64 0 CF3 άα Η τ Α A7-64 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- 11uoropyrimidín-4-yl)amino )methyl)piperidin-1 ¡l)-3-hydroxy¡propanamide Α7-65 0 Η2Ν'^γ^θΗ cf3 Λ ό Η τ Λ A7-65 rac-2-((3R,4R)-4-((( 6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluoropinm¡din-4-¡l)amino)methyl)-3hydroxyp¡penden-1-¡l)-3-hydroxypropanamide Α7 -66-1 0 Η2Ν .:::. 2f OH CF3 .Ν. A AJ í A HO'' Y N^N Y l A A J Ν' Y Ν' H f A A7-66-1 re / -(R)-2-((3R,4R)-4-(((6-(ethyl (4(trifluoromethyl)benzyl)amino)-5fluoropyrim¡din-4-yl)amino)methyl)-3hydroxy¡piperid¡n-1-yl)-3-hydroxy¡propanamide 0 re / -( R)-2-((3S,4S)-4-(((6-(ethyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino )methyl)-3hydroxypyridin-1-yl)-3-hydroxypropanamide 1st major isomer eluted ΜΛ / a / zuzz / uu ι ου i 139 A7-66-2 A7-66-2 re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4(trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4 -¡l)amino)methyl)-3hydroxy¡p¡pend¡n-1-yl)-3-hydroxy¡propanamide 0 re / -(R)-2-((3S,4S )-4-(((6-(ethyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡r¡midín-4-¡l)amino)methyl)-3h¡droxy¡p¡pendin -1-¡l)-3-hydroxy¡propanamide 2nd major eluted isomer. A7-67 nh2 A7-67 A. .OH or γ cf3 re / -2-((3R,4R)-4-(((6-(ethyl(4- Enantiom I (trifluoromethyl)benzyl)amino)- 5- ericament Ao1J ί J HO Y N N Ύ l II A I N' Ά 'n' H Ϊ < fluoropyrimid¡n-4-¡l)am¡no)methyl)-3- and hydroxyp¡perdin-1-¡ l)-4-hydroxy¡butanamide enriched Enantiomerically enriched da A7-68 0 A7-68 H2N>Y^OH cf3 2-(4-((((6-(cyclopropyl(4- A Δ (trifluoromethyl))benc ¡l)amino)-5- and n^n and fluoropyrimád¡n-4-¡l)amino)met¡l)-4- H T Λ hydroxy¡p¡pendin-1-yl)-3- hydroxypropanamide A7-69 o _ D II A7-69 D i A Y nh2 cf3 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4- Enantiom a, JL (trifluoromethyl)benzyl)amino)-5- ericament kJ u fluorop¡nmid¡n-4-¡l)amino)methyl)-3- e HO' N XN 'Ν'' A' 'Ν'' H F * r / \ hydroxyp¡pendin-1-¡l)acetamide-2,2-cy2 enriched Enantiomerically enriched da 140 Α7-70 0 ΗοΝ'^γ^'ΟΗ CF3 ΗΟ Ν Ν Η τ Λ Α7-70 2-(4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5- 11uoropyrimidín-4 -yl)amino)methyl)-4(hydroxy¡methyl)piperidin-1 -yl)-3- hydroxypropanamide Α7-71 0 ι^Ο YN^y^^ CF3 .φ Q ΗΟ' Ν ΜΑ1 Η Τ Λ A7-71 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluoropinm¡din-4-¡l)amino)met ¡l)-3hydroxyp¡peridín-1-¡l)-2-(tetrahydro-2H-pyran4-¡l)acetamide Α7-72 / 0 Ν-Ν Η2Ν^ Υ J L ΗΟ' y^ N^N y^ γ^γ^Ν^ Η F A7-72 rac-2-((3R,4R)-4-(((6-(ethyl(4-(1 -methyl-1 Hp¡razol-4-¡l )benz¡l)amino)-5-fluoropyrám¡d¡n4-¡l)amino)methyl)-3-hydroxypiperid¡n-1yl)acetamide Α7-73 ^ΟΗ Ο Ν-Ν H2N^ and Υ Α Αί AJ ΗΟ' ν ^ν ^ν^τ^ν^ Η F k. A7-73 rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-(2-hydroxyethyl))-1H-pyrazol-4-yl)benzyl )amino)-5fluoropyrimidín-4-íl)amino)methyl)-3- hydroxypiperid i n-1 -yl)acetamide ινΐΛ / a / zuzz / uu ι ου i 141 Α7-74 / 0 Ν-Ν Η2Ν^ Α ώ ό ΗΟ' Ν Η τ Λ Α7-74 rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1-methyl1 / - / -pyrazol-4-yl)benzyl)amino)-5fluoropyrimidin-4-yl)amino)methyl)-3- hid roxipi perid i n-14l)acetamide Α7-75 0 Ν- ΐ / ηΛ V Λ ΑΧ ΗΟ' ψ Ν | F Η τ Λ A7-75 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4(1-methyl-1 / - / -pyrazole-4-¡ l)benz¡l)amino)-5fluorop¡rímidín-4-¡l)amino)methyl)-3- hid roxypi perid i n-1 -yl)acetamide Α7-76 .Λ Q rN> Α -θ / χ CX ΗΟ' Ν -Ν F Η τ Λ A7-76 rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4(1 / 7-pyrazole) -1-yl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-¡l)amino)methyl)-3- hid roxipi perid i n-1 -yl)acetamide Α7-77 „, Λ <? Ο. Q ^bmnJ Η F < A7-77 rac-2-((3R,4R)-4-(((6-((4-(1 H-Pyrazole-1¡l)benzyl)(et¡l) am¡no)-5-fluoropy¡m¡d¡n-4yl)amino)methyl)-3-h¡d roxipi peridin-1yl)acetamide 142 A7-78 nh2 |Aq CN .0 , 0 HO' N N H F A7-78 rac-2-((3R,4R)-4-(((6-((4- c¡anobenzyl)(ethyl)amino)-5 -fluoropyrim¡din-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1yl)acetamide A7-79 0 H2N^\ fV^oh A. HO' γ N Y y H F A7-79 rac-2- ((3R,4R)-4-(((6-((4-(1,1-difluoro-2hydroxyethyl)benzyl)(ethyl)amino)-5fluorop¡r¡midín -4-yl)amino)met¡l)-3- hid roxypi perid i n-1 -yl)acetamide A7-80 0 H^N^^ CF3 yn n y n H T A A7-80 2-(4-(((6 -(Cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropinmidín-4-íl)amino)methyl)-4-(1 / 7-1,2,4triazol-3-yl )piperidin-1 -yl)acetamide A7-81 0 Η,Ν^η CF3 0 A >r N N Y^ A AA J H T A A7-81 2-(4-(((6-(Cyclopropyl(4(trifluoromethyl))benzyl )amino)-5fluorop¡r¡m¡d¡n-4-¡l)amino)met¡l)-4-(1,2,4oxadiazol-3-¡l)piper¡d¡n-1- il)acetamide 143 A7-82 0 CF3 ν-Ν Ν Ν η τλ Α7-82 2-(4-(((6-(Cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropyrimidín-4-yl)amí no)methyl)-4-(1,3,4oxadiazol-2-yl)p¡perídin-1 -yl)acetamide A7-83 0 CF3 .ρΓΛ n-Ν ' / Ál η τλ A7-83 2-( 4-(((6-(Cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-4-(4-methyl- 4 / 7-1,2,4-tr¡azol-3-yl)piperidin-1 -yl)acetamide A7-84 0 H2N^ CF3 1J Ο νΑ>| CN ^VnH N^V^'N Η γ Λ A7-84 2-(4-(((6-(Cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5fluoropyrim¡din-4-yl)am¡ no)methyl)-4-(1 / 7¡midazol-2-yl)piperidin-1-yl)acetamide A7-85 0 lUN'^ CF3 ap η Φ ν; ιι Λ ΛΑ Λ Η 1 Λ A7-85 2-(4-(((6-(Cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropyrimidín-4-yl)amino)methyl )-4-(1 / 7-1,2,3triazol-5-yl)piperidin-1 -yl)acetamide 144 A7-86 1 , Ó ΗΟ Ν AaV Η τ Λ Α7-86 rac-2-((3R,4R)-4-(((6-((4-(1H-pyrazol-1-yl)benzyl)(cyclopropyl )amino)-5- fluoropyrimidin-4-yl)amino)methyl)-3- hid roxipi perid i n-1 -yl)acetamide A7-87 0 Η,Ν^ CFa 0Ó Η τ Λ A7-87 2-(4 -(1 -((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5- fluorop¡r¡m¡din-4-¡l)amino)-2hydroxyethyl)piperidin-1 -yl) acetamide B4-1-1-1 ο\ ιζΖ υο Vz ζ -π—Α) μ / ζ [>—ζ '—y χm B4-1-1-1 re / -2-((3R,4R)-4 -(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡din-4-¡l)amino)methyl)-3-hydroxy¡-3methylpiperidin-1 -yl)acetamide 1st eluted isomer B4-1-1-2 B4-1-1-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4(trlfluoromethyl)benc ¡l)amino)-5fluoropyrim¡din-4-¡l)amino)methyl)-3-hydroxy¡-3methylpiperidín-1-¡l)acetamide 2nd eluted isomer 145 B4-1-2-1 0 Λ C 'nh2 cf· Αχ Y . 5 'J ' Y ΓΥ'Ν Y l ,k Λ J Y Y Ύ H A B4-1-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4(trifluoromethyl )benzyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3-hydroxy-3methylpiperídin-1-íl)acetamide 1st eluted isomer B4-1- 2-2 B4-1-2-2 re / -2-((3R,4S)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluoropínmidín -4-¡l)amino)methyl)-3-hydroxy¡-3methylpiperidin-1-yl)acetamide 2nd eluted isomer B4-2-1-1 o ll '—' ζγ / —\ HX / —H A—' o=\ \ z O I B4-2-1-1 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropyrimidín-4-yl)amino)methyl)-3-hydroxy-4methyllpíperídin-1-íl)acetamide 1st eluted isomer B4-2-1-2 B4-2 -1-2 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropyrimidín-4-íl)amino)methyl)-3 -hydroxy¡-4methylpiper¡din-1-¡l)acetamide 2nd eluted isomer ινΐΛ / a / zuzz / uu foxi 146 C4-1-1 0 η2ν^ cf, H T Λ C4-1-1 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropinm¡n- 4-yl)amino)methyl)-3-hydroxy-4(hydroxymethyl)piperidín-1-yl)acetamide 1st eluted isomer C4-1-2 C4-1-2 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluorop¡nmidín-4-¡l)amino)methyl )-3-hydroxy¡-4(hydroxy¡met¡l)p¡perídin-1-yl)acetam¡de 2nd eluted isomer C4-2-1 0 N F3C^zCF3 IJ IJ Ho'by N^N ΟΗ^Ν'η / ^'Ν^ H F k C4-2-1 2-(4-(((6-((3,5- bis(trifluoromethyl)benzyl)(ethyl)amino )-5fluorop¡r¡m¡din-4-¡l)amino)methyl)-3-hydroxy¡-4(hydroxy¡methyl)piper¡din-1-yl)acetamide 1. er eluted isomer C4-2-2 C4-2-2 2-(4-(((6-((3,5-bis(trifluoromethyl)benzyl)(ethyl)amino)-5fluorop ¡r¡mid¡n-4-¡l)amino)methyl)-3-hydroxy¡-4(hydroxymethyl)piper¡din-1-¡l)acetamide 2nd eluted isomer 147 D5-1-1-1 0 Λ I'· ΊΗ. CFs ,ΝΧ Λ uj η HOV V Ν' Τ ΗΟ'( Λ J J Ν' f 'Ν' Η ί k χ D5-1-1-1 re / -2-((3R,4R)-4-((( 6-(ethyl(4(trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4-yl)amino)methyl)-3,4d¡hydroxy¡p¡perídin-1-¡l)acetamide 1st eluted isomer D5-1-1-2 D5-1-1-2 re / -2-((3R,4R)-4-(((6-(ethyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡r ¡m¡d¡n-4-yl)am¡no)met¡l)-3,4d¡hydroxy¡piper¡din-1-¡l)acetam¡de 2nd eluted isomer D5-1 -2-1 0 Λ ρ νη2 cf3 ,Ν. -4-(((6-(ethyl(4(trifluoromethyl)benzyl)amino)-5fluoroprímidín-4-yl)amino)methyl)-3,4dih droxypiperidn-1-¡l)acetamide, 1st eluted isomer D5-1-2-2 D5-1-2-2 re / -2-((3R,4S)-4-(((6- (ethyl(4(trifluoromethyl)benzyl)amino)-5fluoropyrim¡din-4-yl)amino)methyl)-3,4d¡hydroxy¡piper¡din-1-¡l)acetam¡ gives, eluted 2nd isomer ΜΛ / a / zuzz / uu ι ου i 148 D5-2-1-1 0 A f nh2 cf3 γ / A HO' Y N^X'N y h0A 1 Λ J K γ Y H 1 Λ D5-2-1-1 re / -2-((3R,4R)- 4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluoropyrámidín-4-yl)amino)methyl)-3,4d¡hydroxy¡p¡ períd¡n-1-¡l)acetamide 1st eluted isomer D5-2-1-2 D5-2-1-2 re / -2-((3R,4R)-4-(((6- (cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡nm¡d¡n-4-¡l)amino)methyl)-3,4d¡hydroxypiperidin-1-yl)acetamide 2 .° eluted isomer D5-2-2-1 0 A r nh2 cr rA A J°.4i I - L HO Y NY Y' HO I J! J. I nT Y 'n H F A D5-2-2-1 re / -2-((3R,4S)-4-(((6-(cyclopropíl(4(trifluoromethyl)benzyl)amino)-5fluoropyrimidí n-4-yl)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide 1st eluted isomer D5-2-2-2 D5-2-2-2 re / -2-((3R, 4S)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡ríd¡n-4-yl)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide 2nd eluted isomer 149 D5-3-1-1 ΏΞ O Τ ' A X X \ __ ' / ~ \ i \ / --Z r s 3R,4R)-4-(((6-(ethyl(2-fluoro-4(trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4-yl)amino)methyl)-3,4d ¡hydroxy¡p¡perídin-1-¡l)acetamide 1st eluted isomer D5-3-1-2 D5-3-1-2 re / -2-((3R,4R)- 4-(((6-(ethyl(2-fluoro-4(trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3, 4d¡hydroxy¡piper¡din-1-yl)acetam¡de 2nd eluted isomer D5-3-2-1 X O oz %“Λ IZ X- / ko \=z z -k > ? \ / —z (trifluoromethyl)benzyl)amino)-5- fluorop¡r¡m¡din-4-yl)amino)methyl)-3,4dihydroxypiperidin-1 -yl)acetamide, 1st eluted isomer D5- 3-2-2 D5-3-2-2 re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4(trifluoromethyl)benzyl)amino) -5fluoropyr¡mid¡n-4-yl)amino)methyl)-3,4dihydroxy¡piper¡din-1-yl)acetam¡de, 2nd eluted isomer ΜΛ / a / zuzz / uu / what and ί 150 D5-4 Enantiomerically enriched 0 JA f3cj h2n j J 'Í HO' Y N Ύ A ΗΟγ J n y n H F k. )H YF3 D5-4 re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3hexafluoro-2-hydroxypropan-2¡l )benzyl)amino)-5-fluoropyrimidin-4¡l)amino)methyl)-3,4-d¡hydroxy¡piper¡d¡n-1yl)acetamide Enantiomerically enriched D5-5-1 / 0 N-N A A k H2N' γ y A J / Y í A HO' N N Y F HÓ t 1 A I N Y 'N' H T A D5-5-1 re / -2-((3R,4R)-4-(((6-(cyclopropyl (2-fluoro-4(1-methyl-1H-pyrazol-4-yl)benzyl)amino)-5fluoropínmidín-4-yl)amino)methyl)-3,4d ¡hydroxy¡p¡pendin-1-yl)acetam¡de Major isomer D5-5-2 D5-5-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl( 2-fluoro-4(1-methyl-1H-pyrazole-4-¡l)benzyl)amino)-5fluoropyrim¡din-4-¡l)amino)methyl)-3,4dihydroxy¡p¡per¡ d¡n-1-¡l)acetamide Minor isomer D5-6 Enantiomerically enriched o JL f3c¿ h2n η Y... c HO Y N N HO i Y J H T A )H / CF3 D5-6 re / -2-(( 3R,4R)-4-(((6-(cyclopropyl(4(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2¡l)benzyl)amino)-5-fluoropyrim¡ d¡n-4¡l)am¡no)methyl)-3,4-dih¡droxyp¡pend¡n-1yl)acetamide Enantiomerically enriched 151 D5-7 Enantiomerically enriched ° n CF3 n / L Jy V J HO^X N Y today Ji ϊ 1 ^N'^Y^N'^ H F D5-7 re / -2-((3R,4R)-4- (((6-(ethyl(4(trifluoromethyl)benzyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3,4dihydroxypiperidin-1 -yl)-2-(pyridí n-4yl)acetamide Enantiomerically enriched D5-7-1 0 f^N χΐγι W o2| CF3 XNX A J / Vi J í J HC< X N' Y HOΛ J X J N' Y ^N' H F L ethyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡nmidín-4-¡l)amino)methyl)-3,4dihydroxypiperidin-1-yl)-2-(pyrídin -4yl)acetamide 0 re / -(R)-2-((3S,4S)-4-(((6-(ethyl(4(trifluoromethyl)benzyl)amino)-5fluoropínmidín-4- l)amino)methyl)-3,4dihydroxypiperidin-1 -yl)-2-(pyridin-4yl)acetamide 1st major isomer eluted D5-7-2 D5-7-2 re / -(R)-2-((3R,4RH-(((6-(ethyl(4- (trifluoromethyl)benzyl)amino)-5fluorop¡nmid¡n-4-¡l)amino)methyl )-3,4dihydroxypiperidin-1 -yl)-2-(pyridin-4yl)acetamide 0 re / -(R)-2-((3S,4SH-(((6-(ethyl(4- (trifluoromethyl))benz) l)amino)-5fluorop¡nmidín-4-¡l)amino)methyl)-3,4dihydroxypiperidin-1 -yl)-2-(pindin-4yl)acetamide 2nd major isomer eluted ινΐΛ / a / zuzz / uu ι ουι 152 D5-8 Enantiomerically enriched 0 r-^N aJj H2N CF3 ,N, A HO^X N'^N X HO< l| J | H F A D5-8 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluoropyrimidín-4-¡l)amino) methyl)-3,4dihydroxypiperidin-1 -¡l)-2-(pindin-4yl)acetamide Enantiomerically enriched D5-9 Enantiomerically enriched A h2n η n J°o11J Al HO X N ''N Y 'F Ηθ\ A J J 'N' Y 'N' H F A D5-9 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4(1 / - / -pyrazol-1-yl )benzyl)amino)-5fluoropyrámidín-4-¡l)amino)methyl)-3,4d¡hydroxypiperidín-1-¡l)acetamide, Enantiomerically enriched D5-10 Enantiomerically enriched gives 0 h2nA ,Χ / Y AJ — (A HO 2- fluorobenzyl)amino)-5-fluoropyrim¡din-4¡l)amino)methyl)-3,4-d¡hydroxyp¡perídin-1 il)acetamide, Enantiomerically enriched E6-1 0 H-rAj cf3 0 . Ó hAT ϊ I J H τ Λ E6-1 2-(4-Amino-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluorop¡nm¡d¡n- 4-¡l)amino)met¡l)pipend¡n-1yl)acetamide 153 F2-1 0 ηΑ ΗΟ' γ^ Ν^· Ν Η ί I F2-1 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(2methylbenzyl)amino)pyrimidin- 4yl)amino)methyl)-3-hydroxypiperidin-1 il)acetamide F2-2 0 Λη: ΗΟ' γ^ Νχ Ν γ^ CI 'Ν'^Υ^'ΝΓ Η I F2-2 rac-2-((3R ,4R)-4-(((6-((2,6- dichlorobenzyl)(methyl)amino)-5-fluorop¡r¡m¡din4-¡l)amino)metal) -3-hydroxypiperidín-1yl)acetamide F2-3 Ο Λη: / Νγ / ^Cl ,.Ο OC ΗΟ' γ^ Ν γ^ CI Η ¿ I F2-3 rac-2-((3R,4R)- 4-(((6-((2,3-dichlorobenzyl)(methyl)amino)-5-fluoropirimidin4-l)amino)methyl)-3-hydroxypiperidin -1yl)acetamide F2-4 ο \ ω / ζ=( τ \\ -ζ. ζ \ Ο=ζ / --ν ΖΙ \ οΰ / ο I F2-4 rac-2-((3R,4R)-4 -(((6-((2,6-dichlorobenzyl)(ethyl)amino)-5-fluoropyrimidin4-yl)amino)methyl)-3-hydroxypiperidin-1yl)acetamide 154 F2-5 0 Λη: / χ LA HO' Y N ^'N^Y^N'^ H í I F2-5 rac-2-((3R,4R)-4-(((5-fluoro-6-( methyl(1-(otolyl)ethyl)amino)pyrimidin-4-yl)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide F2-6 X O / S \ —\ IZ '—z I Vz Z - Y \) J / =Z — O F2-6 rac-2-((3R,4R)-4-(((6-((1-(2-chlorophenyl)ethyl)(methyl)amino) -5fluorop¡r¡m¡d¡n-4-yl)am¡no)met¡l)-3hid roxipi perid i n-1 -yl)acetamide F2-7 0 Y n ΥΧ* AJ / x La HO' Y Y N Y ^ H ¿ I F2-7 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(3(trifluoromethoxy¡)benzyl)amino)pyrámidín -4yl)amino)methyl)-3-hyd roxypi peridin-1yl)acetamide F2-8 0 ¿NH, Y YN Y) / X O HO' Y N Y^ n^y^n^ H I F2-8 rac-2-(( 3R,4R)-4-(((6-((3-cyanobenzyl)(methyl)amino)-5-fluoropyrimiden4-yl)amino)methyl)-3 -hydroxypyridin-1 yl)acetamide ινΐΛ / a / zuzz / uu i or yi 155 F2-9 0 CF. ώ .1 or HO' Y^ lY N <NYYJ H V F2-9 rac-2-((3R,4R)-4-(((5-fluoro-6-(isobutyl(4(trifluoromethyl)benzyl)am ¡no)pyrimidin-4¡l)amino)methyl)-3-hydroxy¡piper¡din-1yl)acetamide F2-10 0 YY Ά CX HO' Y^ lY N Y^ CF3 Ή^Υ^γΥ hTY F2- 10 rac-2-((3R,4R)-4-(((6-((cyclopropylmethyl)(2(trifluoromethyl)benzyl)amino)-5fluoropyrim¡din-4-yl)amino)methyl)- 3hid roxipi perid i n-1 -yl)acetamide F2-11 o 4^NH2 CN «X or HO' Y^ N H F2-11 rac-2-((3R,4R)-4-(((6-(( 4cyanobenzyl)(isobutyl)amino)-5fluoropyrimid¡n-4-¡l)amino)methyl)-3hyd roxipi perid i n-1 -yl)acetamide F2-12 o Anh2 ci rNÁ rV HO' Y^ Nx N Y^ H ¿ 1 F2-12 rac-2-((3R,4R)-4-((6-((4-chloro-3- fluorobenzyl)(methyl)amino)-5-fluoropyram¡m¡d¡ n- 4-¡l)amino)methyl)-3-hydroxypiperid¡n-1yl)acetamide 156 F2-13 0 A f2hy ^nh2 2 0 „ A or HO Y^ N H ¿ I F2-13 rac-2-((3R,4R)-4-(((6-((4- (difluoromethoxy)benzyl)( methyl)amino)-5fluoropyrimidín-4-yl)amino)methyl)-3- hydroxypipendin-1 -yl)acetamide F2-14 |AhVHC'O N l oMe O u ί-γΑ H ( I F2-14 rac- 2-((3R,4R)-4-(((6-((4-(difluoromethoxy¡)-3methoxy¡benzyl)(methyl)amino)-5-fluorop¡r¡m¡din4-¡l) amino)methyl)-3-hydroxypiperidin-1yl)acetamide F2-15 0 φ^ΝΗ2 CI Y ... Ó HO Y^ N Y^ WJ H f A\ F2-15 rac-2-((3R,4R)-4 -(((6-((4chlorobenzyl)(isoprop¡l)am¡no)-5fluorop¡r¡m¡d¡n-4-¡l)am¡no)methyl)-3hid roxipi perid i n-1 - il)acetamide F2-16 0 k^NH2 CF3 A or HO' Y N Y H F F2-16 rac-2-((3R,4R)-4-(((5-fluoro-6-((2methoxyethyl)(4- (trifluoromethyl )benzyl)amino)pyrimidin-4yl)amino)methyl)-3-h¡d roxipi peridin-1 yl)acetamide iviA / a / ¿u¿¿ / uu / ου ι 157 F2-17 0 |^ΝΗ2 CI AS A ho' Y n Y ci H F2-17 rac-2-((3R,4R)-4-(((6-((2,4dichlorobenzyl)(isobutyl)amino)- 5fluoropyrimidín-4-yl)amino)methyl)-3hyd roxypi perid i n-1 -yl)acetamide F2-18 0 |Aho cn .0 , or VyJ H í I F2-18 rac-2-((3R, 4R)-4-(((6-((4- cyanobenzyl)(methyl)amino)-5-fluorop¡rymid¡n4-¡l)amino)methyl)-3- hydroxypiper¡din-1yl)acetamide F2-19 0 ^NH2 OMe A or A-yJ H / I F2-19 rac-2-((3R,4R)-4-(((5-fluoro-6-( ((6methoxypyridin-3- ¡l)methyl (methyl)amino)pyr¡midin-4yl)amino)methyl)-3-h¡d roxypi peridin-1 yl)acetamide F2-20 0 Y N YY0CHFz JA / X ( J ho' N 'νΑ^ι / H । F2-20 rac-2-((3R,4R)-4-(((6-((3- (difluoromethoxy)benzyl)(methyl)amino )-5fluoropyrim¡din-4-¡l)amino)methyl)-3hid roxipi perid i n-1 -yl)acetamide ΜΛ / a / zuzz / uu / ου ι 158 F2-21 O A N CI^^.CI U HO' N A^Y^A H ¿ । F2-21 rac-2-((3R,4R)-4-(((6-((3,5-dichlorobenzyl)(methyl)amino)-5-fluoropyrimidin4-yl)amino)methyl)-3- hydroxypiperidin-1 - l)acetamide F2-22 0 OCF3 ώ or HO' N Y^ 'kyj H I F2-22 rac-2-((3R,4R)-4-(((5-fluoro-6-( methyl(4(trifluoromethoxy¡)benzyl)amino)pyr¡m¡d¡n-4yl)amino)methyl)-3-hydroxypiperidin-1 yl)acetamide F2-23 X Q / s \ / —Y z—\ ΙΖ '- / A° Vz z -n—A r? A or F2-23 rac-2-((3R,4R)-4-(((6-((3chlorobenzyl)(isopropyl)amino)-5fluorop¡r¡m¡din-4-yl)amino)methyl )-3hid roxipi perid i n-1 -yl)acetamide In a related aspect, a prodrug of a compound of Formula (I) is provided as described herein. The compounds of the present disclosure are active, e.g. e.g., have a RORy Gal4 < 1000 nM, such as < 500 nM, such as < 100 nM, and have a substantially lower logP (e.g., a reduced logP of 1.5, such as 2.0, such as 2.5 log units ) compared to the compounds described in documents WO2016020288 and WO2016020295. In certain embodiments, LogD and LogP are substantially lower compared to the compounds in WO2016020288 and WO2016020295. Therefore, the compounds described herein have improved lyophilicity with similar potency. Therefore, the compounds described herein may be improved modulators of RORy, e.g. e.g., with an attractive interaction (e.g., higher binding capacity) in the hydrophobic binding sites of the ligand binding domain (LBD) of RORy and a low value of logP and / or a low value of logD. ινΐΛ / a / zuzz / uu / ου i 159 Pharmaceutical compositions In another aspect, the present disclosure relates to a pharmaceutical composition comprising physiologically acceptable surfactants, carriers, diluents, excipients, softening agents, suspending agents, film-forming substances and coating assistants, or a combination thereof; and a compound as described herein, e.g. e.g., a compound of Formula (I), (II), (III) and (IV) as described herein, or a salt, stereoisomer or salt of a stereoisomer thereof. The compound of Formula (I), (II), (III) and (IV) included in the pharmaceutical composition may also be any compound of the preferred embodiments described above. In another aspect, the present disclosure relates to a pharmaceutical composition comprising physiologically acceptable surfactants, carriers, diluents, excipients, softening agents, suspending agents, film-forming substances and coating assistants, or a combination thereof; and a compound of any of Formulas (I), (II) or (III) as described herein. Acceptable carriers or diluents, as well as other additives that are to be combined with one or more compounds of Formula (I), (II), (III) and (IV) as described herein to provide a pharmaceutical composition for therapeutic use are well known in the pharmaceutical field and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990), which is incorporated herein by reference in its entirety. . In the pharmaceutical composition, preservatives, stabilizers, colorants, sweeteners, fragrances, flavoring agents, flavor masking agents and the like may be provided. For example, sodium benzoate, ascorbic acid and p-hydroxybenzoic acid esters can be added as preservatives. Additionally, antioxidants and suspending agents can be used. In various embodiments, alcohols, esters, sulfated aliphatic alcohols and the like may be used as surfactants; Sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium aluminate and metasilicate, synthetic aluminum silicate, calcium carbonate, sodium hydrogen carbonate, calcium hydrogen phosphate, can be used as excipients. calcium carboxymethylcellulose and the like; magnesium stearate, talc, hardened oil and the like can be used as softening agents; coconut oil, olive oil, sesame oil, peanut oil, soybean oil can be used as suspending agents or lubricants; cellulose acetate and phthalate as a derivative of a carbohydrate such as cellulose or sugar, or a methyl acetate-methacrylate copolymer as a polyvinyl derivative can be used as suspending agents; and plasticizers such as phthalate-type asters and the like can be used as suspending agents. The term "pharmaceutical composition" refers to a mixture of a compound described herein with other chemical components such as diluents or carriers. The 160 pharmaceutical composition facilitates the administration of the compound to an organism. In the art there are multiple techniques for administering a compound including, but not limited to, oral, injection, aerosol, parenteral and topical administration. Pharmaceutical compositions can also be obtained by reacting the compounds with organic or inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Similarly, pharmaceutical compositions can also be obtained by reacting the compounds with organic or inorganic bases such as ammonia, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide and the like. The term “carrier” defines a chemical compound that facilitates the incorporation of a compound into cells or tissues. For example, and without limitation, dimethyl sulfoxide (DMSO) is a commonly used carrier since it facilitates the uptake of many organic compounds in the cells or tissues of an organism. The term “diluent” defines chemical compounds diluted in water that will dissolve the compound of interest while stabilizing the biologically active form of the compound. In the art, salts dissolved in buffered solutions are used as diluents. A commonly used buffer solution is phosphate-buffered saline, as it mimics the saline conditions of human blood. Because buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound. The term “physiologically acceptable” defines a carrier or diluent that does not modify the biological activity or properties of the compound. The pharmaceutical compositions described herein can be administered to a human patient per se or in pharmaceutical compositions in which they are mixed with other active ingredients, such as in a combination therapy, or carriers or one or more suitable excipients. Techniques for the formulation and administration of the compounds of the present application can be found in “Remington's Pharmaceutical Sciences”, Mack Publishing Co., Easton, PA, 18th edition, 1990. Suitable routes of administration may include, for example, oral, rectal, transmucosal, topical or intestinal administration; parenteral delivery, which includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal or intraocular injections. The compounds may also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, patches. 161 transdermal (including electrotransport) and the like, for pulsed, timed and / or prolonged administration with a predetermined rate. The pharmaceutical compositions can be prepared in a manner known per se, e.g. e.g., through conventional processes of mixing, dissolving, granulation, drageing, levigating, emulsification, encapsulation, trapping or tableting. Pharmaceutical compositions for use as described herein may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate the processing of the active compounds into pharmaceutically usable preparations. The appropriate formulation depends on the chosen route of administration. Any of the techniques, carriers and excipients known in the art may be used appropriately and as interpreted in the art, e.g. e.g., at Remington's Pharmaceutical Sciences, which has been mentioned above. Injectable products can be prepared in conventional forms, whether liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid before injection, or as emulsions. Some suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine ​​hydrochloride and the like. Furthermore, if desired, the injectable pharmaceutical compositions may contain minor amounts of non-toxic auxiliary substances such as wetting agents, pH buffering agents and the like. Some physiologically compatible buffers include, but are not limited to, Hanks' solution, Ringer's solution, or physiological saline buffer. If desired, absorption enhancing preparations (eg liposomes) can be used. For transmucosal administration, suitable penetrating agents to penetrate the barrier can be used in the formulation. Pharmaceutical formulations for parenteral administration, e.g. For example, by bolus injection or continuous infusion, they include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds can be prepared as suitable oily injection suspensions. Suitable lipophilic carriers or solvents include fatty oils such as sesame oil or other organic oils such as soybean, grapefruit or almond oil, or esters of synthetic fatty acids such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension such as sodium carboxymethylcellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to make possible the preparation of highly concentrated solutions. The iviA / a / ¿u¿¿ / uu i ουι 162 formulations for injection can be presented in a unit dosage form, e.g. e.g., in blisters or multi-dose containers, with an added preservative. The compositions may take forms such as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending agents, stabilizers and / or dispersants. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. e.g., sterile pyrogen-free water, before use. For oral administration, the compounds can be easily formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers allow the compounds described herein to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral intake by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by combining the active compounds with a solid excipient, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Some suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulose preparations such as, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and / or polyvinyl pyrroleidone (PVP). If desired, disintegrating agents such as cross-linked polyvinylpyrrolidone, agar or alginic acid or a salt thereof such as sodium alginate may be added. The tablet cores are provided with suitable coatings. For this purpose, concentrated sugar solutions can be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol and / or titanium dioxide, enamel solutions and suitable organic solvents or mixtures of solvents. Dyes or pigments can be added to the coatings of dragees or tablets for identification or to characterize different dose combinations of the active compounds. For this purpose, concentrated sugar solutions can be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol and / or titanium dioxide, enamel solutions and suitable organic solvents or mixtures of solvents. Dyes or pigments can be added to the coatings of dragees or tablets for identification or to characterize different dose combinations of the active compounds. Pharmaceutical preparations that can be used orally include hard capsules made of gelatin, as well as soft sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The hard capsules may contain the ingredients iviA / a / zuzz / uu fóxi 163 active ingredients mixed with a filler such as lactose, binders such as starches and / or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids such as fatty oils, liquid paraffin or liquid polyethylene glycols. Additionally, stabilizers can be added. All formulations for oral administration must be in dosages appropriate for such administration. For buccal administration, the compositions may take the form of tablets or dragees that are formulated in a conventional manner. For administration by inhalation, the compounds for use as described herein are conveniently supplied in the form of an aerosol spray presentation from pressurized containers or a nebulizer, with the use of a suitable propellant, e.g. e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a measured amount. Capsules and cartridges of e.g. For example, gelatin, for use in an inhaler or insufflator may be formulated to contain a powder mixture of the compound and a suitable powder base such as lactose or starch. Also described herein are several pharmaceutical compositions well known in the pharmaceutical art for uses including infraocular, intranasal and intraauricular delivery. Penetrating agents suitable for these uses are generally known in the art. Topical ophthalmic compositions can be formulated as a solution in buffered water at a pH of 5.0 to 8.0. Other ingredients that may be desirable for use in ophthalmic preparations include preservatives (such as benzalkonium chloride, stabilized oxychlor complex, which is marketed as Punte™, or stabilized chlorine dioxide), cosolvents (such as polysorbate 20, 60 and 80, Pluronic® F-68, F-84 and P103, cyclodextrin or Solutol) and viscosity enhancing agents (such as polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose or hydroxypropylcellulose). The compounds described herein may also be used in an infraocular implant as described in US Patent 7,931,909, which is incorporated herein by reference. Pharmaceutical compositions for infraocular delivery include aqueous ophthalmic solutions of the active compounds in water-soluble form, such as eye drops, or in gellan gum (Shedden et al., Clin. Ther., 23(3):44050 (2001)) or hydrogels ( Mayer et al., Ophthalmologica, 210(2):101-3 (1996)); ophthalmic ointments, ophthalmic suspensions such as microparticles, small polymeric particles containing the drug and suspended in a liquid carrier medium (Joshi, A., J. Ocu!. Pharmacol., 10(1):29-45 (1994) ), fat-soluble formulations (Alm etal., Prog. Clin. ΜΛ / a / zuzz / uu / what and ί 164 Biol. Res., 312:447-58 (1989)) and microspheres (Mordenti, Toxico! Sci., 52(1):101-6 (1999)); and eye grafts. All references mentioned above are incorporated herein by reference in their entirety. Such pharmaceutical formulations suitable for intraocular delivery are in most cases and preferably formulated to be sterile, isotonic and buffered for stability and comfort. Pharmaceutical compositions for intranasal delivery may also include drops and sprays which are typically prepared to stimulate nasal secretions in various ways to ensure maintenance of normal ciliary action. As described in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990), which is incorporated herein by reference in its entirety, and as is well known to those skilled in the art, the formulations Suitable are in most cases and preferably isotonic, are lightly buffered to maintain a pH of 5.5 to 6.5 and in most cases and preferably include suitable antimicrobial preservatives and pharmacological stabilizers. Pharmaceutical formulations for intra-auricular delivery include suspensions and ointments for topical application to the ear. Common solvents for such auricular formulations include glycerin and water. The compounds described herein can also be formulated in rectal compositions such as suppositories or retention enemas, e.g. e.g., containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described above, the compounds can also be formulated as a depot preparation. Such long-acting formulations can be administered by implant (for example, subcutaneously or intramuscularly) or by intramuscular injection. Therefore, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins or as poorly soluble derivatives, for example, as a poorly soluble salt. For hydrophobic compounds, a suitable pharmaceutical carrier may be a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer and an aqueous phase. A common cosolvent system used is the VPD cosolvent system, which is a solution of 3% w / v benzyl alcohol, 8% w / v nonpolar surfactant Polysorbate 80™, and 65% w / v polyethylene glycol. 300, completing the volume in absolute ethanol. Obviously, the proportions of a cosolvent system can vary considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the cosolvent components may vary: for example, other low-toxicity nonpolar surfactants may be used instead of POLYSORBATE 80™; the size of the polyethylene glycol fraction may vary; other polymers 165 biocompatibles can replace polyethylene glycol, e.g. e.g., polyvinylpyrrolidone; and other sugars or polysaccharides can replace dextrose. Alternatively, other delivery systems can be employed for hydrophobic pharmaceutical compounds. Liposomes and emulsions are well-known examples of carriers or delivery vehicles for hydrophobic drugs. Certain organic solvents such as dimethyl sulfoxide can also be used. Additionally, the compounds can be delivered using a sustained release system such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained release materials have been established and are well known to those skilled in the art. Depending on their chemical nature, sustained-release capsules can release the compounds for a few weeks and up to more than 100 days. Depending on the chemical nature and biological stability of the therapeutic reagent, additional strategies can be employed for protein stabilization. Agents designed to be administered intracellularly can be administered using techniques well known to those skilled in the art. For example, such agents can be encapsulated in liposomes. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are protected from the external microenvironment and, because liposomes fuse with cell membranes, are simultaneously efficiently delivered into the cell cytoplasm. The liposome can be coated with a tissue-specific antibody. The liposomes will be directed towards the desired organ and will be selectively captured by it. Alternatively, low molecular weight hydrophobic organic molecules can be administered directly intracellularly. Additional therapeutic or diagnostic agents may be incorporated into the pharmaceutical compositions. Alternatively or additionally, the pharmaceutical compositions may be combined with other compositions containing other therapeutic or diagnostic agents. Combinations The compounds described herein may also be combined with other compounds active in the treatment and / or prevention of inflammatory, metabolic, oncological and autoimmune diseases or disorders, or a symptom thereof. The combinations provided herein comprise the compounds described herein and one or more additional active substances such as: a) Corticosteroids such as prednisone, methylprednisolone or beta-methasone; 166 b) Immunosuppressants such as cyclosporine, tacrolimus methotrexate, hydroxyurea, mycophenolate mofetil, mycophenolic acid, sulfasalazine, 6-thioguanine or azathioprine; c) Esters of fumaric acid such as dimethyl fumarate; d) Dihydroorotate dehydrogenase (DHODH) inhibitors such as leflunomide; e) Retinoids such as acitretin or isotretinoin; f) Anti-inflammatories such as apremilast, crisaborole, celecoxib, diclofenac, aceclofenac, aspirin or naproxen; g) JAK inhibitors such as tofacitinib, baricitinib, upadacitinib, ruxolitinib or delgocitinib; h) Antibiotics such as gentamicin; i) Anticancer agents such as lenalidomide, pomalidomide, pembrolizumab, nivolumab, daratumumab, bortezomib, carfilzomib, ixazomib, bendamustine or ventoclast; j) T cell blockers such as alefacept or efalizumab; k) Tumor necrosis factor alpha (TNF-alpha) blockers such as etanercept, adalimumab, infliximab, golimumab, certolizumab pegol; I) Interleukin 12 / 23 blockers such as ustekinumab; m) IL-23 blockers such as tristenkizumab, guselkumab or tildrakizumab; n) Anti-IL4 / IL13 antagonist such as dupilumab, lebrikizumab or tralokinumab; o) IL-1β blockers such as canakinumab; p) IL-alpha blockers such as bermekimab; q) CD6 blockers such as itolizumab; r) IL-36R blockers such as BI-655130 or bimekizumab; s) IL-6 antagonist such as tocilizumab; t) Calcineurin inhibitors such as pimecrolimus, tacrolimus or cyclosporine; u) Phototherapy agents commonly used in phototherapy such as psoralen, methoxypsoralen or 5-methoxypsoralen + UVA (PUVA) or UVB treatment (with or without tar); v) Fixed combinations of corticosteroids and vitamin D derivatives; w) Fixed combinations of corticosteroids and retinoids; x) Corticosteroid tapes e y) one or more agents selected from the group consisting of BMS986165, PF06700841, PF-06826647, piclidenosone, tepilamide fumarate, LYC-30937, LEO-32731, Bl ινΐΛ / a / zuzz / uu / ου i 167 730357, PRCL-02, LNP-1955, GSK-2982772, CBP-307, KD-025, MP-1032, petesicatib, JTE451, Hemay-005, SM-04755, EDP-1815, BI-730460, SFA-002 ER , JNJ-3534, SAR-441169, BOS-172767, SCD-044, ABBV-157, BAY-1834845, AUR-101, R-835, PBF-1650, RTA-1701, AZD-0284, mirikizumab, CD20 antagonist , salicylic acid, coal tar, Mical-1, DUR928, AM-001, BMX-010, TA-102, SNA-125, brepocitinib tosylate, pegcantratinib, ESR-114, NP-000888, SM-04755, BOS- 475, SB-414, LEO-134310, CBS-3595, PF-06763809, XCUR-17 and BTX-1308. The active compounds in the combination, that is, the compounds described herein, and the other optional active compounds can be administered together in the same pharmaceutical composition or in different compositions intended for separate, simultaneous, concomitant or sequential administration by means of same route or through a different route. Applications The compounds or pharmaceutical compositions disclosed herein as described above can be used to modulate the activity of an orphan receptor related to retinoic acid receptors (ROR) such as a RORa, RORp and / or RORy receptor. RORy modulators have been reviewed by B. Fauber and S. Magnuson in J. Med. Chem., February 6, 2014, and by Pandya et al. in J. Med. Chem. 2018, 61.24, 10976-10995, which are incorporated herein by reference in their entirety. Some examples of RORy receptors are RORyl and RORyt receptors. Compounds or pharmaceutical compositions as described above may also exhibit selective modulation of a particular ROR receptor with respect to a different ROR receptor. For example, according to some embodiments described herein, some compounds or pharmaceutical compositions modulate the activity of a RORy receptor to a greater extent than the activity of RORa and / or RORp receptors. The compounds or pharmaceutical compositions described herein can also be used to modulate the activity of cells that produce IL-17A in a RORyt-dependent manner, for example, γδΤ cells, Th17 cells, Tc17 cells and ILC3 cells. The compounds or pharmaceutical compositions described herein can also be used to inhibit the function of RORyt upon stimulation of IL-23, which in turn exerts a negative effect on the differentiation and expansion of pathogenic Tc17 and Th17 cells. Some publications that provide useful background information are Arthritis & Rheumatism, 2014, 66, 579-588; Curr Top Microbial Immun, 2014, 378, 171-182; Drug Disc. Today, May 2014; Nature Rev. Drug Disc. 2012, 11,763-776 and Nature Rev. Drug Disc., 2014, 13, 197-216, all of which are incorporated herein by reference in their entirety. 168 The pharmaceutical compounds or compositions as described herein and above may also be used in therapy or may be used to treat inflammatory, metabolic, oncological and autoimmune diseases or disorders, or a symptom thereof. Some examples of such diseases or disorders are inflammatory, metabolic, oncological and autoimmune diseases or disorders mediated or affected by IL-17A and / or RORy. The role of RORy in the pathogenesis of autoimmune or inflammatory diseases has been described in Immunity 2007, 26(5), 643-654; Nat. Rev. Immunol. 2006, 6, 205-217; J. Immunol. 2009, 183, 7169-7177; Brain Pathol. 2004, 14, 164-174; Brain 2007, 130, 1089-1104; and Nat Rev. Immunol. 2008, 8, 183-192, all of which are incorporated herein by reference in their entirety. Some more specific examples of diseases or disorders, or a symptom of these, include asthma, acne, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, celiac disease and food allergy, atopic dermatitis, lichen planus, cystic fibrosis, pulmonary allograft rejection, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ichthyosis, bullous diseases, hidradenitis suppurativa, steatosis, steatohepatitis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), lupus erythematosus, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune eye disease, ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (ILD), syndrome irritable bowel syndrome (SIL), Sjógren's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, myasthenia gravis, Guillain-Barre syndrome, Graves' disease, scleritis, obesity, obesity-induced insulin resistance, diabetes type II and cancer. More preferably, the diseases or disorders, or a symptom thereof, include acne, atopic dermatitis, lichen planus, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ichthyosis, bullous diseases, hidradenitis suppurativa , ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (Eli) and lupus erythematosus. An example of a symptom is a physical or mental characteristic that is considered to indicate a disease condition, particularly such a characteristic that is obvious to the patient, e.g. For example, treating or preventing a symptom is not considered to modify the disease but rather to prevent or alleviate one or more symptoms commonly experienced in connection with that disease. More specifically, compounds or pharmaceutical compositions that have an antagonistic or inverse agonist effect on RORy can be used to reduce levels of ΜΛ / a / zuzz / uu / ου i 169 IL-17A and / or other gene products, such as interleukin and cytokines, regulated by RORy. This may occur, for example, in subjects suffering from, for example, asthma, acne, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, celiac disease. and food allergy, atopic dermatitis, lichen planus, cystic fibrosis, pulmonary allograft rejection, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, osteoarthritis, ichthyosis, bullous diseases, hidradenitis suppurativa, ankylosing spondylitis, psoriasis, psoriatic arthritis, steatosis, steatohepatitis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), lupus erythematosus, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune eye disease, ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (ILD) , irritable bowel syndrome (IBS), Sjógren's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, myasthenia gravis, Guillain-Barre syndrome, Graves' disease, scleritis, obesity, obesity-induced insulin resistance and type II diabetes. On the contrary, compounds or pharmaceutical compositions that have an agonist effect on RORy can be used to increase IL-17A levels. Increasing IL-17A levels may be particularly useful in immunosuppressive conditions or to enhance the immune system response, for example, during infections and cancer. The compounds described herein can be used in the preparation of a medicament for the treatment and / or prevention of inflammatory, metabolic, oncological and autoimmune diseases or disorders, or a symptom thereof. Administration methods The pharmaceutical compounds or compositions may be administered to the patient by any suitable means. Some non-limiting examples of methods of administration include, but are not limited to, (a) administration via oral routes, wherein said administration includes administration in a capsule, tablet, granule, spray, syrup or other such forms; (b) administration through non-oral routes such as rectal, vaginal, intraurethral, ​​infraocular, intranasal or intraauricular, where said administration includes administration as an aqueous suspension, an oil preparation or the like, or as a drip, spray, suppository , ointment, ointment or similar; (c) administration by injection, subcutaneous, intraperitoneal, intravenous, intramuscular, intradermal, intraorbital, intracapsular, intraspinal, sternum or the like, including delivery with an infusion pump; (d) local administration such as by injection directly into the renal or cardiac area, e.g. e.g., through a depot implant, through an intratumoral injection or through an injection into the intralymphatic nodes; (e) topical administration; So 170 as well as (f) administration to ex vivo cells followed by insertion of said cells into the patient; as deemed appropriate by those skilled in the art to bring the compound described herein into contact with living tissue. Pharmaceutical compositions suitable for administration include compositions in which the active ingredients are contained in an amount effective to achieve their desired objective. The therapeutically effective amount of the compounds described herein required as a dose will depend on the route of administration, the type of animal, which includes a mammal, e.g. e.g., a human being, what is being treated and the physical characteristics of the specific animal under consideration. The dosage can be tailored to achieve a desired effect, but will depend on factors such as weight, diet, concurrent medication, and other factors that will be recognized by experts in the field of medicine. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or improve the symptoms of a disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is within the purview of those skilled in the art, especially in light of the detailed disclosure provided herein. As will be very obvious to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending on the age, weight and species of mammal being treated, the particular compounds used and the specific use for which these compounds are used. Determination of effective dosage levels, which correspond to the dosage levels necessary to achieve the desired result, can be carried out by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are started at lower dosage levels and the dosage level is increased until the desired effect is achieved. Alternatively, acceptable in vitro studies may be used to establish useful doses and routes of administration of the compositions identified by the methods herein using established pharmacological methods. In non-human animal studies, applications of potential products are started at higher dosage levels and the dosage is reduced until the desired effect is no longer achieved or adverse side effects disappear. Dosages can vary widely, depending on the desired effects and the therapeutic indication. Typically, dosages may be between about 10 micrograms / kg and 100 mg / kg body weight, preferably between about 100 micrograms / kg and 10 mg / kg body weight. Alternatively, dosages can be 171 base and calculate based on the surface area of ​​the patient, as interpreted by those skilled in the art. The exact formulation, route of administration and dosage for the pharmaceutical compositions described herein can be selected by the physician based on the patient's condition, (refer, e.g., to Fingí etal. 1975, in The Pharmacological Basis of Therapeutics, which is incorporated herein by reference in its entirety, with particular reference to Chapter 1, page 1). Typically, the dosage range of the composition administered to the patient may be about 0.5 to 1000 mg / kg of the patient's body weight. The dosage may be a single dosage or may be a series of two or more, administered over the course of one or more days, as needed by the patient. In cases where human dosages for the compounds have been established for at least some condition, those same dosages, or dosages between about 0.1% and 500%, more preferably between about 25% and 250%, can be used. % of established human dosage. When no human dosage has been established, as will be the case for newly discovered pharmaceutical compounds, a suitable human dosage can be inferred from the ED50 or ID50 values, or other suitable values ​​derived from in vivo or in vitro studies, which They are qualified by toxicity studies and efficacy studies in animals. It should be noted that the responsible physician will know how and when to determine, interrupt or adjust administration due to toxicity or organ dysfunction. On the other hand, the responsible doctor will also know how to adjust the treatment with higher doses if the clinical response is not adequate (excluding toxicity). The magnitude of a dose administered in the management of the disorder of interest will vary depending on the severity of the condition to be treated and the route of administration. The severity of the condition, for example, can be assessed, in part, using standard prognostic assessment methods. Additionally, the dosage and perhaps dosing frequency will also vary according to the age, body weight, and response of the individual patient. In veterinary medicine, a program comparable to that discussed above can be used. Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations can be made regarding dosage. The daily dosage regimen for an adult human patient may be, for example, an oral dose between 0.1 mg and 2000 mg of each active ingredient, preferably between 1 mg and 500 mg, e.g. e.g., from 5 to 200 mg. The concentration of an eye drop can be between 0.005 and 5 percent. In one embodiment, an eye drop may vary between 0.01 and 1 percent, or between 0.01 and 0.3 percent in another embodiment. In other embodiments, an intravenous, subcutaneous or intramuscular dose of each ingredient is used. 172 active of between 0.01 mg and 100 mg, preferably between 0.1 mg and 60 mg, p. e.g., from 1 to 40 mg. In cases of administration of a pharmaceutically acceptable salt, dosages can be calculated in free base form. In some embodiments, the composition is administered 1 to 4 times a day. Alternatively, the compositions described herein may be administered by continuous intravenous infusion, preferably with a dose of each active ingredient of up to 1000 mg per day. As those skilled in the art will understand, in certain situations it may be necessary to administer the compounds described herein in amounts that exceed, or even greatly exceed, the frequency or preferred dosage range mentioned above in order to effectively treat and aggressive infections or particularly aggressive diseases. In some embodiments, the compounds will be administered over a period of continuous therapy, for example, for a week or more, or for months or years. The amount and interval of dosages can be individually adjusted to provide tissue or plasma levels of the active moiety that are sufficient to maintain the modulatory effects, or a minimum effective concentration (MEC). The CME will vary for each compound but can be estimated from in vitro data. The dosages necessary to achieve CME will depend on individual characteristics and the route of administration. Despite this, HPLC assays or biological assays can be used to determine plasma concentrations. Dosing intervals can also be determined using the CME value. The compositions should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably 30-90% and most preferably 50-90%. In cases of local or ex vivo administration or selective uptake, it may happen that the effective local concentration of the drug does not correlate with the plasma concentration. The amount of composition administered may depend on the subject being treated, the weight of the subject, the severity of the affliction, the mode of administration, and the judgment of the prescribing physician. The compounds described herein can be evaluated for efficacy and toxicity using known methods. For example, the toxicology of a particular compound, or a subset of compounds, sharing certain chemical moieties, can be established by determining the in vitro toxicity against a cell line such as a mammalian and preferably a human cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically in humans. Alternatively, the toxicity of particular compounds in an animal model, such as mice, rats, rabbits or monkeys, can be determined using methods 173 known. The efficacy of a particular compound can be established using various recognized methods such as in vitro methods, animal models or human clinical trials. There are recognized in vitro models for almost every class of condition, including, but not limited to, cancer, cardiovascular disease, and various immune dysfunctions. Similarly, acceptable animal models can be used to establish the efficacy of chemicals to treat such conditions. When selecting a model to determine efficacy, the expert can be guided by the state of the art to choose a suitable model, dose, route of administration and regimen. Obviously, human clinical trials can also be used to determine the effectiveness of a compound in humans. The compositions may be presented, if desired, in a container or dispensing device that may contain one or more unit dosage forms containing the active ingredient. The packaging may comprise, for example, a plastic or metal foil such as a blister pack. The container or dispensing device may be accompanied by instructions for administration. The container or device may also be accompanied by a note associated with the container in a form prescribed by a government agency regulating the manufacture, use or sale of pharmaceutical products, where such note reflects the agency's approval of the form of the drug for veterinary or human administration. Such a note may be, for example, the U.S. Food and Drug Administration-approved label for prescription drugs or the approved product package insert. Compositions comprising a compound described herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in a suitable container, and labeled for the treatment of an indicated condition. General clarifications As described above with reference to specific illustrative embodiments, they are not intended to be limited to the specific form set forth herein. It should be appreciated that any combination of the above-mentioned embodiments is within the scope of the disclosure. Furthermore, the disclosure is limited only by the appended claims and other embodiments other than the specific ones above are equally possible within the scope of these appended claims. In the claims, the expression “comprises / understands” does not exclude the presence of other species or steps. Furthermore, although individual features may be included in different claims, these may possibly be combined favorably and inclusion in different claims does not imply that a combination of features is not possible and / or favorable. Furthermore, references in the singular do not exclude a plurality. The terms “a”, “first”, “second”, etc. they do not exclude a plurality. The expressions “at 174 minus one” or “one or more” refer to 1 or a number greater than 1 such as 1,2,3, 4, 5, 6, 7, 8, 9, or 10. Wherever a chemical name or structure is given, it has been generated by conventional means or by means of suitable software. Compound names were generated with ChemDraw Professional, version 17.1.0.105 (19). In the present disclosure, in the drawings of the structures, the labels “o 1”, “o 2”, “& 1” or “& 2” on each stereogenic center specify the “stereochemical group” to which the center belongs. In the case of “o” groups, the meaning is a structure representing a stereoisomer having either the “stereochemical group” as drawn ((R,S), for example) or the stereoisomer in which the stereogenic centers of the group have the opposite configuration (S, R). In the case of “&” groups, & in combination with the given number (e.g., & 1) indicates a mixture of the labeled asymmetrically substituted atoms. When the numbering groups several asymmetrically substituted atoms together, it shows their configuration relative to each other. If displayed as (R,S) the opposite configuration (S,R) is also present for the specified clustered group. In the present disclosure, the symbol ” specifies that it is enantiomerically enriched. Any compound or intermediate synthesized in an enantiomerically enriched manner and where no chiral separation has been carried out is identified with “”. experimental part The following examples are merely examples and should not be construed in any way to limit the scope of the disclosure. Instead, disclosure is limited only by the accompanying claims. General chemical procedures General clarifications Unless otherwise indicated, starting materials were obtained from commercial suppliers such as (but not limited to) AbBchem, ABCR, Alfa Aesar, Anaspec, Anichem, Apollo Scientific, ASDI-Inter, Asiba Pharmatech, Astetech, ArkPharm, Bachem, Chem-lmpex, ChemCollect, Chembridge, Combi-Blocks, Enamine, FCH, Fluka, Fluorochem, Frontier Scientific, HDH Pharma, InFarmatik, InterBioScreen, Life Chemicals, Manchester organics, Matrix, MercaChem, NetChem, Oakwood Chemical, PepTech , Pharmcore, PrincetonBio, Sigma-Aldrich, TRC, Tyger Scientific, and Ukrorgsyn, and were used without further purification. Solvents such as DMF, DMSO and DCM, etc. They were used directly or anhydrized with molecular sieves. 175 Equipment NMR 1H NMR spectra were recorded on the following instruments: Bruker Avance 300 spectrometer (at 300 MHz), Bruker Avance III 400 spectrometer (at 400 MHz), Bruker Avance Neo (400 MHz), Bruker Avance III 600 (at 600 MHz), VNMR spectrometer (at 400 MHz) using the solvents CD3OD, CDCI3 or DMSO-cfe. Chemical shifts are indicated in ppm (δ) using the residual solvent as an internal standard; CDCh: 7.26 ppm; CD3OD: 3.31 ppm; DMSO-cfe: 2.50 ppm. Coupling constants (J) are indicated in Hz. Analytical U / HPLC For analytical U / HPLC, the following equipment was used: Waters Acquity system equipped with Acquity BEH C18 (1.7pm, 2.1 x 50 mm) with a linear gradient of a binary solvent system using a flow rate of 0.5 mL / min and DAD at room temperature, combined with type MS detection SQD I. Agilent Infinity l / ll -TOF6230B / CLND Antek 8060 equipped with Acquity BEH C18 (1.7pm, 2.1 x 50 mm) with a linear gradient of a binary solvent system using a flow rate of 0.75 mL / min combined with DAD. Agilent 1200-1260 Infinity series equipped with Waters , combined with MS detection (Agilent). Shimadzu Nexera equipped with Waters MS (Shimadzu). Waters Acquity system using Acquity BEH C18 (1.7pm, 2.1 x 50 mm) with a linear gradient of a binary solvent system using a flow rate of 0.65 mL / min and DAD at room temperature, combined with a Waters detection spectrometer of MS. Preparative HPLC For prep. HPLC, the following equipment was used: Waters Acquity system featuring Supelco DISCOVERY C18 (5 pm, 25 cm x 21.2 mm), with a linear gradient of a binary solvent system using a flow rate of 45 mL / min and UV detection at 254 nm, combined with detection of MS on a Waters Micromass ZQ single quadrupole mass spectrometer. Shimadzu Nexera , combined with MS detection on a Shimadzu LCMS-2020. 176 Waters Masslynx system using a Waters XBridge C18 column (5 pm, 19 combined with MS detection (Waters). Gilson GX-281 TRILUTION fitted with a Phenomenex Gemini NX-C18 column (5 pm, 21.2 x 150 mm) with a linear gradient of a binary solvent system using a flow rate of 15 mL / min and UV detection at 214 nm or 254 nm, combined with MS detection (Waters). The following linear gradients have been used: HCO2H - (H2O / CH3CN / HCO2H (from 100 / 0 / 0.1% to 0 / 100 / 0.1%)) NH4OAc - (H2O / CH3CN / NH4OAc (100 / 0 / 0.02% to 0 / 100 / 0.02%)) TFA - (H2O / CH3CN / TFA (from 100 / 0 / 0.1% to 0 / 100 / 0.1%)) NH4HCO3-(H2O / CH3CN / NH4HCO3(from 100 / 0 / 0.1% to 0 / 100 / 0.1%)) NH4OH - (H2O / CH3CN / NH4OH (100 / 0 / 0.1% to 0 / 100 / 0.1%)) HCO2 NH4- (H2O / 50% MeOH + 50% CH3CN / HCO2H / NH3 (95 / 5 / 0.05% / 0.01% to 5 / 95 / 0.05% / 0.01%)) Flash QC was carried out in most cases on Isolera® automated systems. CC flash and TLC prep. were carried out using SÍO2, if not mentioned otherwise. Despite this, C18 columns have also been used (using a gradient of water-acetonitrile / MeOH (1:1), with or without 0.1% v / v of ammonium formate in both phases, from 0% to a 100% acetonitrile / MeOH (1:1)). Analytical chiral chromatography It was carried out in a Waters UPC2 system coupled to a DAD detector with a Waters QDa type MS detector, equipped with a chiral column with a gradient elution using a flow rate of 1 mL / min. The chiral columns available were CHIRALPAK (3 pm, 4.6 x 100 mm) IA, IB, IC and ID and Trefoil AMY1 (2.5 pm, 2.1 x 150 mm). The following linear gradients have been used for the analytical UPC2: CO2 / MeOH / DEA (from 99 / 1 / 0.2% to 60 / 40 / 0.2%)) CO2 / EtOH / DEA (from 99 / 1 / 0.2% to 60 / 40 / 0.2%) CO2 / IPA / DEA (from 99 / 1 / 0.2% to 60 / 40 / 0.2%) Preparative chiral chromatography Before chiral separation, compounds were purified by standard methods described previously using appropriate solvents. Preparative chiral separations were carried out on a Gilson system (306, GX-281 trilution, 156-UV / Vis, Waters 3100 MSD) or a Waters SFC-80 system, fitted with a chiral column with the specified solvents using rates of flow between 10-50 mL / min (only 50 g / min for SCF) and detection at 214 or 230 nm. chiral columns 177 available were Reprosil AMS (5 pm, 20 mm x 250 mm), Lux C2 (5 pm, 21.2 mm x 250 mm), Lux C4 (5 pm, 21.2 mm x 250 mm), Chiralpak® IA, IB, IC column , ID, IF or IG (5 pm, 20 mm x 250 mm) or Chiralcel® OJ-H or OD-H. The exact elution and column conditions used for each compound are described in the experimental part. Synthetic methods The compounds described herein can be synthesized by one of the following general methods: General Method A, General Method 2A, General Method 3A, General Method 4A, General Method 5A, General Method 6A, General Method B, General Method C, Method General 1D, General Method 2D, General Method 2D', General Method 3D, General Method E and General Method F. General Method A - Synthesis from Boc-protected piperidines ΜΛ / a / zuzz / uu 1 and 1 Boc i EITHER The secondary amine A1 was reacted with A2 (at room temperature or slightly above, 30 °C) together with a suitable base (such as DIEA, TEA or K2CO3) at rt. After the reaction was completed, intermediate A3 was treated and purified by chromatography (flash CC or HPLC) or used as crude oil. Subsequently, the intermediate A3, a base (such as DIEA, TEA or CS2CO3) and the primary amine A4 were dissolved in a solvent (such as DMSO or mixtures of DMSO-H2O, H2O, H2O-EtOH) and the temperature was increased to 70- 100 °C tn or until the reaction was completed. Treatment and purification then provided intermediate A5, which was subjected to deprotection. The intermediate formed after deprotection of boc A6 was used directly 178 in most cases, as the corresponding piperidinium salt (HCI or TFA), on alkylation with 2-bromoacetamides A8 and a suitable base such as DIEA, Na2CO3 0 K2CO3 at rt or heating up to 100°C. The A7 products were first purified by standard chromatographic methods. In cases where the A7 products were a mixture of stereoisomers, these were often (but not always) subjected to chiral resolution (chromatography) to obtain the individual stereoisomers as final products. All compounds in Table A were synthesized using this methodology, ranging from 2 pmol to ca. 1 mole scale. Example A7-1 Synthesis of rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4-yl)amino)methyl)-3-hydroxypiperidin-1- il)acetamide A7-1 and chiral separation into A7-1-1 andA7-1-2 ινΐΛ / a / zuzz / uu 1 jsh A7-1 ή A7-1-1 A7-1-2 a) DIEA, DMSO, ta, tn. b) DIEA, DMSO, 80 °C, tn. c) i) HCl, dioxane, 60 min. i) DIEA, 2bromoacetamide. d) Chiral chromatography. Scheme A7-1 Synthesis of rac-2-((3R,4 / ?)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4-yl)amino)methyl)-3-hydroxypiperidin- 1-l)acetamide, A7-1 / V-Cyclopropyl-5,6-difluoro- / V-(4-(trifluoromethyl)benzyl)pyrimidín-4-amine, A3-1 iviA / a / zuzz / uu foxi To anhydrous DMSO (7 mL), A2-1 (375 mg, 2.8 mmol), A1-1 (737 mg, 3.1 mmol), and DEA (1.5 mL) were added and the reaction was stirred for tn. The reaction mixture was then poured onto aq LiCl. (40 mL, 5%) and extracted three times with EA. The combined EA phase was then washed twice with aq. LiCl. (5%) and once with brine, and subsequently dried (Na2SO4). Its filtration, followed by concentration under reduced pressure, provided a crude oil, which was subsequently purified by flash CC (EA:Hept) to provide A3-1 (832 mg). LCMS: MS cal.: 329; Experimental MS: 330 ([M+1 ]+). tert rac-(3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxypiperidine-1-carboxylate -butyl, A5-1 Compound A3-1 (828 mg, 2.5 mmol) was dissolved in anhydrous DMSO (8 mL) followed by A4-1 (750 mg, 3.26 mmol) and DEA (2.2 mL). The reaction mixture was heated to 80 °C for tn. The reaction mixture was cooled and then poured onto aq LiCl. (40 mL, 5%) and extracted three times with EA. The combined EA phase was then washed twice with aq. LiCl. (5%) and brine, and then dried (Na2SO4). Filtration, followed by concentration under reduced pressure, gave a crude oil, which was then purified by flash CC (EA:Hept) to give A5-1 (1.28 g). LCMS: MS caled.: 539; Experimental MS: 540 ([M+1 ]+). rac-2-((3R,4R)-4-(((6-(Cíclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin4-yl)amino)methyl)-3-hydroxypiperidin-1- il)acetamide, A7-1 180 iviA / a / zuzz / uu foxi Compound A5-1 (1.27 g, 2.35 mmol) was added to HCl in dioxane (2 M, 10 mL), stirred at room temperature for 60 min, and subsequently concentrated under reduced pressure. The resulting residue was dissolved in a solution of DIEA (3.3 mL) in DCM (30 mL) in an ice bath. Subsequently, 2-bromoacetamide (0.39 g, 2.8 mmol) was added and the reaction was allowed to reach rt and then stirred for tn. The reaction was concentrated under reduced pressure. Subsequently, aq. NaHCOa (sat.) was added to the resulting dense suspension and then the resulting mixture was extracted three times with EA. The combined EA phase was washed with brine, dried (Na2SO4), filtered, concentrated and purified, CC flash (MeOHOCM), to provide A7-1 (1.0 g, 2.0 mmol, 71% in 4 steps). re / -2-((3R,4R)-4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin4-yl)amino)methyl)-3-hydroxypiperidin-1-yl )acetamide, A7-1-1 and A7-1-2 Compound A7-1 (0.95 g) was then subjected to chiral chromatography, to provide the optically pure compounds: A7-1-1 (380 mg) as the eluted 1.erysomer and A7-1-2 (365 mg) as the eluted 2nd isomer. General Method A was used to prepare the following numbers of examples using the indicated starting materials (Table A). Table A: 181 Α1 A4 A7 Α1-2 CF3 ex HIT Λ A / -(2-methyl-4- (trifluoromethyl)benzyl)cyc lopropanamine A4-2 Boc 0 nh2 tert-butyl 4-(aminomethyl)piperídine1-carboxylate A7-2 0 [A CF, 9xk H T A 2-(4-(((6-(cyclopropyl(2-methyl-4(trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4- l)amino) methyl)piperídin-1-yl)acetamide A1-3 cf3 Á HN A A / -((5- (trifluoromethyl)pyridin-2yl)methyl)cyclopropanamine A4-3 Boc A nh2 4-(aminomethyl) -3,3difluoropiperidin-1 - fert-butyl carboxylate A7-3-1 0 A < 'NH cr N -A AO Q / Y Νx N । F l k A J 'ν' y n' H F A re / -(R)-2-(4-(((6-(cyclopropyl((5(trifluoromethyl)pyridín-24l)methyl)amino)5- fluoropirimidin-4-l)amino)methyl)-3,3difluoropiperidin-1-l)acetamide 1,er eluted isomer A1-3 A4-3 A7-3-2 re / -(R)-2 -(4-(((6-(cyclopropyl((5-(tnfluoromethyl)pyrid¡n-24l)methyl)amino)5-fluorop¡r¡m¡d¡n-4-¡l)amino )methyl)-3,3difluoropiperidin-1 -yl)acetamide 2nd eluted isomer 182 Α1-3 Α4-4 A7-4-1 Boc A 0 Á F'Y 'nh2 cf. r Ί íj Ί ήη2 rac-(3R,4R)-4- .TiJ U. ^-N F' Ν T (aminomethyl)-3- í. K IL- J fluoropiperidin-1 - 'ν' t H । I fert-butyl carboxylate f A. re / -2-((3R,4R)-4-(((6-(cyclopropyl((5(trifluoromethyl)pyridín-2-yl)methyl)) amino)5-fluoropyrimidín-4-yl)amino)methyl)-3fluoropiperidin-1-íl)acetamide, 1st eluted isomer Α1-3 A4-4 A7-4-2 re / -2-((3R ,4R)-4-(((6-(cyclopropyl((5(trifluoromet¡l)pyrid¡n-2-¡l)methyl)amino)5-fluorop¡rim¡n- 4-¡l)amino)methyl)-3fluoropiperidin-1-¡l)acetamide, 2nd eluted isomer ΜΛ / a / zuzz / uu / ου ι 183 Α1-1 Α4-4 Α7-5-1 cf3 0 ΗIV Λ Λ / -(4- (trifluoromethyl)benzyl)cyc lopropanamine 0 Λ r ΝΗ C-. kj. 5 :ι F-γ Ν^Ν J 'Ν' Υ Ν' Η △ re / -2-((3R,4R)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl) amino)-5fluoropírmádin-4-yl)amino)methyl)-3fluoropiperidin-1 -yl)acetamide 1st eluted isomer Α1-1 Α4-4 A7-5-2 re / -2-(( 3R,4R)-4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluoropírim¡n-4-yl)amino)methyl)-3fluoropiperidin -1-¡l)acetamide 2nd eluted isomer 184 A1-1 A4-3 A7-6-1 0 A A NH; CFj A f Ί < Ύ f-LJ - 5 J F l A I J N γ Ν' A re / -(R)-2-(4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino) -5fluoropirimidin-4-yl)amino)methyl)-3,3difluoropiperidin-1-l)acetamide 1st eluted isomer A1-1 A4-3 A7-6-2 re / -(R) -2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5fluoropyrimidin-4-yl)amino)methyl)-3,3difluoropiper ¡n-1-yl)acetamide 2nd eluted isomer 185 Α1-1 Α4-5 Boc A? nh2 tert-butyl 4-(aminomethyl)-3(trifluoromethyl)piperid¡n1-carboxylate A7-7-1 0 ^^nh2 cf3 Aí1 H T A 2-(4-((((6-(cyclopropyl(4-(trifluoromethyl)) benzyl)amino)-5fluoroprymidin-4-yl)amino)methyl)-3(trifluoromethyl)piperidin-1-l)acetamide 1st isomer eluate Α1-1 A4-5 A7-7-2 2-(4-(((6-(cyclopropyl(4(trifluoromethyl)benzyl)amino)-5fluoropyrim¡din-4-yl)amino) methyl)-3- (trifluoromethyl)piperidin-1 -yl)acetamide 2nd eluted isomer Α1-1 A4-5 A7-7-3 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5fluorop¡r¡m¡d¡n-4-yl)amino)methyl)-3(trifluoromethyl)p¡perid¡n-1-yl )acetamide 3rd eluted isomer Α1-1 A4-5 A7-7-4 2-(4-(((6-(cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5fluoropyrimídine -4-yl)amino)methyl)-3(trifluoromethyl)píperídin-1-yl)acetamide 4th eluted isomer ινΐΛ / a / zuzz / uu ι ουι 186 A7-8 Y 5 II N^N MeOY^^ -N^T^N ' F Λ 1 -(2-amino-2-oxoethyl)-4-(((6- (cyclopropyl(4- (trifluoromethyl)benzyl)amino)-5- fluoropyrimidin-4- ¡ methyl l)amino)methyl)piperidin-4-carboxylate Α1-3 cf3 ΗΝ Λ Λ / -((5- (trifluoromethyl)pyridin-2yl)methyl)cyclopropanamine A4-7 Boc ήη2 4-(aminomethyl)-4hydroxypiperidin- 1 - tert-butyl carboxylate A7-9 O r nh2 cf3 Φ Φ H F Λ 2-(4-(((6-(cyclopropyl((5- (tnfluoromethyl)pyrid¡n-2-¡l))met¡ l)amino)5-fluoropínmidín-4-í)amino)methyl)-4hydroxypiperidín-1-íl)acetamide ινΐΛ / a / zuzz / uu ι ουι 187 A1-1 A4-7 A7 -10 c 2-C (trif fluc hid 0 NH2 cf3 or H T A 4-(((6-(cyclopropyl(4luoromethyl)benzyl)amino)-5)roprím¡d ¡n-4-yl)amino)methyl)-4roxyp¡per¡din-1-¡l)acetamide > \\ V ΤΊ \-2 w A4-7 A7-11 O CF3 .N, A HN A W-( (6- (trifluoromethyl)pyridin-3- l)amino)5-fluoropiridin-4-l)amino)methyl)-4hydroxypiperidin-1-yl)acetamide ΜΛ / a / zuzz / uu / what and ί 188 Α1-5 0 A4-8 Boc A7-12 ηνΛ Λγ Μ ΉΗ2 0 0 A^NH2 HN^i I F I í T ΗΙΨ 4-(aminomethyl)-4- N^N A k J Α 7- fluoropiperidin-1 tert-carboxylate butyl ^N^Y^N^ H F A ((cycloprop¡lamino)methyl 2-(4-(((6-(cyclopropyl((3-oxo-3,4- )-2 / - / - dihydro-2 / - / -benzo[b][1,4]oxaz¡n-7- benzo[b][1,4]oxazin- yl)methyl)amino)-5-fluoropyrim¡din-4- 3 (4H)-one yl)amino)methyl)-4-fluoropiperidin-1yl)acetamide Α1-6 A4-8 A7-13 \ Ρ ν-Α σ O A \ J ( nh2 n-\ ΗΝ^ Α 6- ((cyclopropylam ¡no)methyl 2-G A U ΓΥ N Y^ I L Ϊ J N^Y^N H F A l-(((6-(cyclopropyl((3-methyl-2-oxo- )-3- methi lbenzo[d]oxazol- 2(3H )-one 2,3-dihydrobenzo[c / ]oxazol-6yl)methyl)amino)-5-fluoropyrimidin-4yl)amino)methyl)-4-fluoropiperidin-1yl)acetamide 189 A1-3 A4-1 Boc ή ΗΟ' γ ήη2 rac-(3R,4R)-4(aminomethyl)-3hydroxypiperidine-1 fert-butyl carboxylate A7-14 0 CF3 ώ or ΗΟ' N I [ H γ Λ rac-2 -((3R,4R)-4-(((6-(cyclopropyl((5(trifluoromethyl)pyridin-2-l)methyl)amino)5-fluoromethyl d¡n-4-yl)am¡no)met¡l)-3hydroxypiperid¡n-1-¡l)acetamide A1-3 A4-1 A7-14-1 0 Y^nh2 cf3 / N yK k1iJ ho' ν ν γ H T △ re / -2-((3R,4R)-4-(((6-(cyclopropyl((5(trifluoromethyl)pyridn-2-¡l)methyl)amino) 5-fluoropyrim¡din-4-yl)amino)methyl)-3hydroxy¡p¡perídin-1-yl)acetamide 1,er eluted isomer 190 Α1-3 A4-1 A7-14-2 re / -2-((3R,4R)-4-(((6-(cyclopropyl((5(trifluoromethyl)pyridín-2-yl)methyl)) amino)5-fluorop¡r¡midín-4-yl)amino)methyl)-3hydroxy¡p¡perídin-1-¡l)acetamide 2nd eluted isomer Α1-7 ρ2Η0 .0 A4-1 A7-15 O e And f2hc. <nh2 0 ανί A HlY y) Ar HO' N y F H cyclobutyl(4-amine (difluoromethoxy)-2-fluorobenzyl)amino)5-fluorop¡r¡m¡d¡n-4-¡l)amino)methyl)-3hydroxypiperidin-1-¡l) acetamide 191 Α1-7 Α4-1 Α7-15-1 0 A F2HC. ¿nh2 0 n YiJ Y A HO' Ν Ν Y^ F i 7 ) Ν^γΝ H re / -2-((3R,4R)-4-(((6-(cyclobutyl(4- (difluoromethoxy))-2- fluorobenzyl)amino)5-fluoropyrimid¡n-4-yl)amino)methyl)-3hydroxy¡p¡perídin-1-yl)acetam¡de 1,er eluted isomer Α1-7 Α...

Claims

1. A compound according to Formula (I): ινΐΛ / a / zuzz / uu 1 ou ί a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereoisomer, wherein: Yi, Y2 and Y3 are independently N or CRs; R is selected from the group consisting of hydrogen, Cm alkyl and C1,4 hydroxyalkyl; Roa and Rob are independently selected from the group consisting of hydrogen, C1,4 alkyl, Ci-4 hydroxyalkyl, Cm haloalkyl, CN, substituted or unsubstituted heteroalicylicyl and substituted or unsubstituted heteroaryl; Ría and R-ib are independently selected from the group consisting of hydrogen, hydroxyl, halogen, amino, Cm alkyl, Cm hydroxyalkyl and C1-4 haloalkyl; R2 is selected from the group consisting of hydrogen, hydroxyl, amino, cyano, halogen, C14 alkyl, Ci-4 haloalkyl, C1.4 hydroxyalkyl, C(=O)OH, C(=O)NH2, C(=O)O-(Cu alkyl) and substituted or unsubstituted heteroaryl; R3 is selected from the group consisting of Cm alkyl, C2 alkenyl.4, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-6 hydroxyhaloalkyl, (C1-4 alkyl)-(C1-4 alkoxy), substituted or unsubstituted C3-7 cycloalkyl and substituted or unsubstituted C3-7 cycloalkenyl; R4 and Rs are each independently hydrogen or C1-4 alkyl, or R4 and Rs are considered together with the carbon atom to which they are attached to form a C1-4 cycloalkyl; 367 Rs is selected from the group consisting of hydrogen, CN, halogen, C1-4 alkyl, C1-4 hydroxyalkyl, C1-6 hydroxyhaloalkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy.4 and substituted or unsubstituted heteroaryl; R7 is selected from the group consisting of hydrogen, hydroxyl, CN, halogen, C-4 alkyl, Cm haloalkyl, Cm hydroxyalkyl, Cm alkoxy, Cm haloalkoxy, and substituted or unsubstituted heteroaryl; each Re is selected independently from the group consisting of hydrogen, hydroxyl, CN, halogen, C1-4 alkyl, Cm haloalkyl, Cm alkoxy, Cm haloalkoxy, and substituted or unsubstituted heteroaryl; and provided that R7 is hydrogen and each Rs present is hydrogen, then Re shall be selected from the group consisting of CN, halogen, Cm alkyl, Ci-4 haloalkyl, Cm hydroxyalkyl, Cm hydroxyhaloalkyl, Cu alkoxy, Cu haloalkoxy, and substituted or unsubstituted heteroaryl; and when substituted, a heteroalicylicyl will be substituted with 1 to 3 substituents selected independently of the group consisting of alkyl Cm, haloalkyl Ci.4, Ci-4 hydroxyalkyl, C1-6 hydroxyhaloalkyl, hydroxy, Cm alkoxy and halogen; and when substituted, a heteroaryl shall be substituted with 1 to 3 substituents selected independently from the group consisting of Cm alkyl, Cm hydroxyalkyl, C24 alkenyl, C2-4 alkynyl, hydroxy, Cm alkoxy, cyano, halogen, Cm haloalkyl, C14 haloalkoxy and Cm hydroxyhaloalkyl; and when substituted, a cycloalkyl or cycloalkenyl shall be substituted with 1 to 3 substituents selected independently from the group consisting of C1.4 alkyl and halogen.

2. The compound, stereoisomer or salt according to claim 1, where R is hydrogen.

3. The compound, stereoisomer, or salt according to claim 1 or 2, wherein Rs is selected from the group consisting of hydrogen, CN, halogen, Cm haloalkyl, C1-4 haloalkoxy, Cm hydroxyalkyl, Cm hydroxyhaloalkyl; 5-membered heteroaryl and 5-membered heteroaryl substituted with 1 or 2 substituents independently selected from methyl or hydroxymethyl, and provided that R7 is hydrogen and each Rs present is hydrogen, then Rs cannot be hydrogen.

4. The compound, stereoisomer, or salt according to any one of claims 1-3, wherein Rs is selected from the group consisting of hydrogen, CN, chlorine, CF3, CHF2, CCH3F2, OCF3 and OCHF2, OCH2F, C(CF3)2OH, CF2CH2OH, pyrazolyl, and pyrazolyl substituted with one substituent selected from methyl or 2-hydroxyethyl, and provided that R7 is hydrogen and each Rs present is hydrogen, then Re cannot be hydrogen. 368 5. The compound, stereoisomer, or salt according to any one of claims 1-4, wherein Re is selected from the group consisting of hydrogen, CF3, CCH3F2, OCHF2, C(CF3)2OH, pyrazolyl, and methylpyrazolyl, and provided that Rz is hydrogen and each Rs present is hydrogen, then Re cannot be hydrogen.

6. The compound, stereoisomer or salt according to any of claims 1-5, wherein Re is selected from the group consisting of CF3, C(CF3)2OH, 1-methyl1H-pyrazol-4-yl and 1 / - / -pyrazol-1-yl.

7. The compound, stereoisomer or salt according to any of claims 1-6, where Re is CF3.

8. The compound, stereoisomer or salt according to any of claims 1-7, wherein Rz is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, CH3, OCH3, CF3, CHF2, OCF3 and OCHF2.

9. The compound, stereoisomer or salt according to any of claims 1-8, wherein Rz is hydrogen or fluoro.

10. The compound, stereoisomer or salt according to any of claims 1-9, wherein: Y1, Y2 and Y3 are each CH; or Y1 is N and Y2 and Y3 are each CH; or Y2 is N and Y1 and Y3 are each CH; or Y3 is N and Y1 and Y2 are each CH; or Y3 is CH- and Y1 and Y2 are each N.

11. The compound, stereoisomer or salt according to any of claims 1-9, wherein: Y1 and Y2 are each CH-, and Y3 is CRs where Rs is selected from the group consisting of hydrogen, hydroxyl, methyl, OCH3, fluoro, chlorine and CF3.

12. The compound, stereoisomer or salt according to claim 11, wherein Rs is hydrogen or fluoro.

13. The compound, stereoisomer or salt according to any of claims 1-10, wherein: Y2 is N and Y1 and Y3 are independently CH; or Y3 is N and Y1 and Y2 are independently each CH.

14. The compound, stereoisomer or salt according to any of claims 1-5 and 8-13, wherein Re is hydrogen, at least one of Y2 or Yses CRs, and Rs is selected from the group consisting of CN, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy and C1-4 haloalkoxy.

15. The compound, stereoisomer, or salt according to claim 14, wherein Re is hydrogen and Y2 is C(OCF3). ινΐΛ / a / zuzz / uu / ου 1 369 16. The compound, stereoisomer or salt according to any of claims 1-15, wherein FU and Rs are independently hydrogen or methyl, or R4 and Rs are considered together with the carbon atom to which they are attached to form a cyclopropyl.

17. The compound, stereoisomer or salt according to any of claims 1-16, wherein R4 is hydrogen or methyl and R5 is hydrogen.

18. The compound, stereoisomer or salt according to any of claims 1-17, wherein R4 and Rs are each hydrogen.

19. The compound, stereoisomer or salt according to any of claims 1-18, wherein R3 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, CH2CH2F, CH2CH2OCH3, cyclopropyl-CH2-, cyclopropyl, methylcyclopropyl, cyclobutyl and fluorocyclobutyl.

20. The compound, stereoisomer or salt according to any of claims 1-19, wherein R3 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, 1-methylcyclopropyl, cyclobutyl and 3-fluorocyclobutyl.

21. The compound, stereoisomer or salt according to any of claims 1-20, wherein R3 is selected from the group consisting of methyl, ethyl, isopropyl, cyclopropyl, 1-methylcyclopropyl, cyclobutyl, (1R,3S)-3-fluorocyclobutyl and (1S,3R)-3-fluorocyclobutyl.

22. The compound, stereoisomer or salt according to any of claims 1-21, wherein R3 is selected from the group consisting of methyl, ethyl and cyclopropyl.

23. The compound, stereoisomer or salt according to any of claims 1-22, wherein R3 is ethyl.

24. The compound, stereoisomer or salt according to any of claims 1-22, wherein R3 is cyclopropyl.

25. The compound, stereoisomer or salt according to any of claims 1-24, wherein R2 is selected from the group consisting of hydrogen, hydroxyl, amino, CN, halogen, methyl, ethyl, CH2OH, CH2CH2OH, C(=O)O(C1.2 alkyl), C(=O)NH2, and substituted or unsubstituted 5-membered heteroaryl.

26. The compound, stereoisomer or salt according to any of claims 1-25, wherein R2 is selected from the group consisting of hydrogen, hydroxyl, CN, fluoro, methyl, CH2OH, C(=O)OCH3, C(=O)NH2, oxadiazolyl and triazolyl.

27. The compound, stereoisomer or salt according to any of claims 1-26, wherein R2 is selected from the group consisting of hydrogen, hydroxyl, 370 CN, methyl, CH2OH, C(=O)OCH3, C(=O)NH2, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, 1H1,2,4-triazol-3-yl and 1 / - / -1,2,3-triazol-5-yl.

28. The compound, stereoisomer, or salt according to any of claims 1-27, wherein R2 is selected from the group consisting of hydrogen, CN, methyl, CH2OH, and hydroxyl.

29. The compound, stereoisomer or salt according to any of claims 1-28, wherein R2 is hydrogen or hydroxyl.

30. The compound, stereoisomer or salt according to any of claims 1-29, wherein R2 is hydrogen.

31. The compound, stereoisomer or salt according to any of claims 1-29, wherein R2 is hydroxyl.

32. The compound, stereoisomer or salt according to any of claims 1-31, wherein Ría is selected from the group consisting of hydrogen, hydroxyl, fluoro and CF3, and R-ib is selected from the group consisting of hydrogen, fluoro and methyl.

33. The compound, stereoisomer or salt according to any of claims 1-32, wherein R-ia is selected from the group consisting of hydroxyl, fluoro and CF3, and Rw is selected from the group consisting of hydrogen, fluoro and methyl.

34. The compound, stereoisomer, or salt of claims 1-33, wherein Ria is hydroxyl or fluoro, according to any of the 35. The compound, stereoisomer of claims 1-34, wherein Ria is hydroxyl.

36. The compound, stereoisomer of claims 1-35, where Rib is hydrogen.

37. The compound, stereoisomer of claims 1-35, wherein Rib is methyl.

38. The compound, stereoisomer of salt salt salt salt of of of of according to according to according to according to according to with with any any any any any of of of of the the the the claims 1-37, wherein at least one of Ria, Rib and R2 is not hydrogen.

39. The compound, stereoisomer or salt according to claims 1-38, wherein R-iase is selected from the group consisting of hydrogen, hydroxyl and fluoro; Rwse is selected from the group consisting of hydrogen, fluoro and methyl; and R2 is selected from the group consisting of hydrogen, hydroxyl, methyl, CN, CH2OH and CH2CH2OH.

40. The compound, stereoisomer, or salt according to claim 39, wherein Ria is selected from the group consisting of hydroxyl and hydrogen; R-ib is hydrogen, and R2 is selected from the group consisting of hydrogen, hydroxyl, CH2OH, and CH2CH2OH, provided that either Ria is hydroxyl or R2 is selected from the group consisting of hydroxyl, CH2OH, and CH2CH2OH. 371 41. The compound, stereoisomer or salt according to claims 1-40, wherein Roa is selected from the group consisting of hydrogen, methyl, CH2OH, CH2CH2OH CH2F and CHF2; and Rob is selected from the group consisting of hydrogen, Cu alkyl, C1.4 hydroxyalkyl and Ci-4 haloalkyl.

42. The compound, stereoisomer or salt according to any of claims 1-41, wherein Roa is selected from the group consisting of hydrogen, methyl, CH2OH and CH2CH2OH.

43. The compound, stereoisomer or salt according to claim 42, wherein Roa is hydrogen.

44. The compound, stereoisomer or salt according to claim 42 or claim 43, wherein Rob is hydrogen.

45. The compound, stereoisomer or salt according to claim 1, having a structure of Formula (II) or Formula (III): oo where: R-ia is fluoro or hydroxyl; Ru is hydrogen or fluoro; 372 R2 is hydrogen or hydroxyl; Rs is CF3; Y2 and Y3 are independently N or CRs; and Rs is hydrogen or fluoro.

46. ​​The compound, stereoisomer or salt according to claim 45, wherein Y2 and Y3 are each CH, or Y2 is CH and Y3 is CF.

47. The compound, stereoisomer or salt according to claim 45 or 46, wherein Ría is hydroxyl and Rib is hydrogen.

48. The compound, stereoisomer or salt according to any of claims 45-47, wherein R2 is hydrogen.

49. The compound, stereoisomer or salt according to any of claims 45-47, wherein R2 is hydroxyl.

50. The compound, stereoisomer or salt according to claim 1, wherein: Roa is selected from the group consisting of hydrogen, methyl, CH2OH and CH2CH2OH; Rob is selected from the group consisting of hydrogen and methyl; Ría is selected from the group consisting of hydrogen, hydroxyl, fluoro and CF3; Ru is selected from the group consisting of hydrogen, fluoro and methyl; R2 is selected from the group consisting of hydrogen, hydroxyl, amino, CN, fluoro, methyl, CH2-OH, C(=O)-NH2, C(=O)O-CH3i 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, 1 / 7-imidazol-2-yl, 1 / 7-1,2,3-triazol-5-yl, 1 / 7-1,2,4-triazol-3-yl and 4-methyl-4 / 7-1,2,4-triazol-3-yl; R is selected from the group consisting of hydrogen and CH2OH; R3 is selected from the group consisting of methyl, ethyl, isopropyl, isobutyl, CH2CH2F, CH2CH2OCH3, cyclopropyl-CH2-, cyclopropyl, 1-methylcyclopropyl, cyclobutyl and 3-fluorocyclobutyl; R4 is hydrogen or methyl; Rs is hydrogen;Re is selected from the group consisting of hydrogen, chlorine, CN, CF3, CHF2, CCH3F2, OCH3, OCF3, OCH2F, OCHF2, C(CF3)2OH, CF2CH2OH, 1 / 7-pyrazol-1-yl, 1-methyl-1H-pyrazol-4-yl and 1-(2-hydroxyethyl)-1 / 7-pyrazole-4-¡lo; R7 is hydrogen or chlorine; Y 1, Y2 and Y3 are each CH; o Y 1 is CH, Y2 is CH and Y3 is selected from the group consisting of N, C(F), C(OCH3), C(CH3), C(CI) and C(CF3); o Y 1 is CH, Y2 is selected from the group consisting of N, C(CN), C(1 / 7-1,2,4-tr¡azol-1-yl), C(OCF3), C(OCH3), C(F), C(OCHF2) and C(CI), and Y3 is CH; or Y1 is CH, Y2 is C(CI) and Y3 is C(CI); o Y1 is C(CH3), Y2 is CH and Y3 is C(CH3); or Y1 is C(CH3), Y2 is C(CH3) and Y3 is CH; o ινΐΛ / a / zuzz / uu / ου 1 373 Yi is C(CF3), Y2 is C(CF3) and Y3 is CH; o Yi is C(CI), Y2 is C(CI) and Y3 is CH ; o Yi is N, Y2 is N and Y3 is CH.; 51. The compound, stereoisomer, or salt according to claim 1 or 50, wherein: Roa is selected from the group consisting of hydrogen, methyl, CH2OH, and CH2CH2OH; Rob is hydrogen or methyl; R-ia is selected from the group consisting of hydrogen, hydroxyl, CF3, and fluoro; Ru is selected from the group consisting of hydrogen, fluoro, and methyl; R2 is selected from the group consisting of hydrogen, hydroxyl, CN, CH2OH, methyl, CO2Me, CONH2, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, 1 / 7-1,2,3-triazol-5-yl, and 1 / 7-1,2,4-triazol-3-yl; R is hydrogen; R3 is selected from the group consisting of methyl, ethyl, isopropyl, cyclopropyl-CH2-, cyclopropyl, 1-methylcyclopropyl, cyclobutyl, (1R,3S)-3-fluorocyclobutyl and (1S,3R)-3-fluorocyclobutyl; R4 is hydrogen; Rs is hydrogen; Re is selected from the group consisting of hydrogen, CF3, CF2CH3, OCHF2, C(CF3)2OH, 1 / 7-pyrazol-1-yl and 1-methyl-1 / 7-pyrazol-4-yl; R? is hydrogen; Y-1, Y2 and Y3 are each CH; or Y1 is CH, Y2 is CH and Y3 is C(F);or Y1 is CH, Y2 is C(OCF3) or C(OCH3) and Y3 is CH; or Yi is CH, Y2 is CH and Y3 is N; or Yi is CH, Y2 is N and Y3 is CH; or Yi is N, Y2 is N and Y3 is CH.; 52. The compound, stereoisomer, or salt according to any one of claims 1 and 50-51, wherein: Roa is selected from the group consisting of hydrogen, methyl, and CH2OH; Rob is hydrogen or methyl; Ría is selected from the group consisting of hydrogen, hydroxyl, and fluoro; Ru is selected from the group consisting of hydrogen, fluoro, and methyl; R2 is selected from the group consisting of hydrogen, hydroxyl, CN, CH2OH, methyl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, and 1 / 7-1,2,3-triazol-5-yl; R is hydrogen; R3 is ethyl or cyclopropyl; R4 is hydrogen; Rs is hydrogen; Re is selected from the group consisting of hydrogen, CF3, CF2CH3, OCHF2, C(CF3)2OH, 1 / - / -pyrazol-1-yl and 1-methyl-1 / - / -pyrazol-4-yl; R7 is hydrogen; Yi, Y2 and Y3 are each CH; or Y1 is CH, Y2 is CH and Y3 is C(F); o Y1 is CH, Y2 is C(OCF3) and Y3 is CH.

53. The compound, stereoisomer or salt of claim 1, selected from the group consisting of: rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(tr¡fluoromet¡l)benc¡l)am¡no)-5-fluorop¡hm¡d¡n-4¡l)amino)met¡l)-3-h¡drox¡piperdino-l) re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyrim¡d¡n-4¡l)am¡no)methyl)-3-h¡drox¡p¡per¡din-1-acetate, 2-(4-(((6-(c¡cloprop¡l(2-methyl-4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrimidine-4yl)am¡no)met¡l)p¡perid¡n-1-yl)acetam¡da, re / -(R)-2-(4-(((6-(cyclopropyl((5-(trifluorometh¡l)pyridin-2-yl)methyl)amino)-5-fluoropyr¡m¡dyn-4¡l)am¡no)meth¡l)-3,3-d¡fluorop¡peridin-1-tam¡l), re / -2-((3R,4R)-4-(((6-(cycloprop¡l((5-(tr¡fluorometh¡l)p¡ndin-2-¡l)methyl)a mino)-5fluorop¡rim¡d¡n-4-¡l)am¡no)meth¡l)-3-fluorop¡per¡d¡n-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluorometh¡l)benzyl)amino)-5-fluorop¡rimidin-4¡l)amino)meth¡l)-3-fluoro¡per¡d¡n-1-¡l)acetam¡da,re / -(R)-2-(4-(((6-(cyclopropyl(4-(trifluorometh¡l)benzyl)amino)-5-fluoropyrimidine-4¡l)am¡no)meth¡l)-3,3-d¡fluoropiperid¡n-1-¡l)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoro¡rmid¡n-4-yl)am¡no)met¡l)-3(tr¡fluoromethl)piper¡n-1-ace, 1-(2-amino-2-oxoet¡l)-4-(((6-(c¡cloppro¡l(4-(tr¡fluoromethyl)benz¡l)am¡no)-5-fluorop¡r¡m¡n4-¡l)amino)meth¡l)piper¡d¡n-methoxyl, 2-(4-(((6-(c¡cloprop¡l((5-(trifluoromethyl)pyrid¡n-2-yl)methyl)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)-4-h¡drox¡p¡per¡din-1-¡l)acetam 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromethl)benzyl)amno)-5-fluorophrimidine-4-¡l)am¡no)meth¡l)-4h¡drox¡piper¡din-1-l)acetate, 2-(4-(((6-(c¡cloprop¡l((6-(tr¡fluorometh¡l)p¡rdin-3-¡l)met¡l)am¡no)-5-fluorop¡r¡m¡d¡n-4¡l)am¡n)methyl)-4-hydroxy-dip-a-percep. rac-2-((3R,4R)-4-(((6-(cycloprop¡l((5-(tr¡fluoromethyl)pyridine-2-¡l)met¡l)a mino)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3-hydrox¡p¡per¡d¡n-1-l)acetamide,iviA / a / zuzz / uu / ου 1,375 re / -2-((3R,4R)Y(((6-(ciclopropil((5-(trifluoromet¡l)piridin-2-il)metil)amino)-5fluorop¡r¡midin-4-il)amino)met¡l)-3-hidroxipiper¡d¡n-1-¡l)acetamida, rac-2-((3R,4R)-4-(((6-(ciclobut¡l(4-(d¡fluorometoxi)-2-fluorobenc¡l)am¡no)-5fluoropirimid¡n-4-¡l)am¡no)met¡l)-3-h¡drox¡p¡per¡din-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((6-(cyclobutyl(4-(d-fluorometox)-2-fluorobencil)amino)-5fluoropyrimidine-4-il)amino)methyl)-3-hydroxiperidin-1-il)acetamada, rac-2-((3R,4R)-4-(((6-(cyclobutyl(4-(trifluorometil)bencil)amino)-5-fluoropyrimidine-4-il)amino)methyl)-3-hydroxiperidin-1-il)acetamada, re / -2-((3R,4R)-4-(((6-(c¡clobutil(4-(tr¡fluoromethyl)bencil)amino)-5-fluoropyrimidine-4¡l)amino)methyl)-3-hydroxpiperidin-1-il)acetamada, rac-2-((3R,4R)-4-(((6-(ciclopropyl((2-(tr¡fluoromethyl)penmidine-5-¡l)methyl)amino)-5fluoropyrimidine-4-¡l)amino)methyl)-3-hydroxpiperidin-1-il)acetamada, re / -2-((3R,4R)-4-(((6-(cyclopropyl((2-(trifluoromethyl)pyrimidine-5-il)methyl)amino)-5fluoroperimidine-4-il)amino)methyl)-3-hydroxipiridine-1-il)acetamida, rac-2-((3R,4R)-4-(((6-(cyclobutyl((2-(trifluoromethyl)pyrimidine-5-il)methyl)amino)-5fluoroperimidine-4-il)methyl)methyl)methyl)-3-hydroxipiridine-1-il)acetamida, re / -2-((3R,4R)-4-(((6-(cyclobutyl((2-(trifluoromethyl)pyrimidine-5-il)methyl)amino)-5fluoropyrimidine-4-il)amino)methyl)-3-hydroxipeperidine-1-il)acetamada, rac-2-((3R,4R)-4-(((5-fluoro-6-(sopropyl(4-(trifluoromethyl)bencel)amino)pyrimidine-4-il)amino)methyl)-3-hydroxipeperidine-1-il)acetamada, re / -2-((3R,4R)-4-(((5-fluoro-6-(isopropil(4-(tnfluorometil)bencil)am¡no)pirimidin-4¡l)amino)met¡l)-3-h¡drox¡p¡per¡din-1-¡l)acetam¡da, rac-2-((3R,4R)-4-(((5-fluoro-6-(met¡l(4-(trifluorometil)benc¡l)am¡no)pirim¡d¡n-4¡l)am¡no)metil)-3-h¡drox¡piper¡din-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((5-fluoro-6-(metil(4-(trifluoromet¡l)benc¡l)amino)p¡rimid¡n-4il)am¡no)metil)-3-h¡droxipiperidin-1-il)acetamida, rac-2-((3R,4R)-4-(((6-(et¡l(4-(trifluoromethyl)bench¡l)amino)-5-fluorop¡r¡m¡n-4¡l)amno)methyl)-3-hydroxyp¡p¡perdin-1-yl)acetate, re / -2-((3R,4R)-4-(((6-(ethyl(4-(tr¡fluorometh¡l)benzyl)amino)-5-fluorop¡rmidine-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1-¡l)acetaminophen, rac-2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(tr¡fluoromethyl)benzyl)amino)-5fluoropyrimidine-4-¡l)amino)methyl)-3-hydroxy¡p¡peridin-1-yl)acetam¡da re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(trifluoromethyl)benzyl)am¡no)-5fluorop¡r¡m¡din-4-yl)amino)met¡l)-3-hydroxypiper¡d¡n-1-tamide,) rac-2-((3R,4R)-4-(((6-(cyclobutyl((6-(tr¡fluoromethyl)pyridin-3-¡l)met¡l)am¡no)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3-h¡drox¡p-dino-percep. 376 re / -2-((3R,4R)-4-(((6-(cyclobutyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amirium)-5fluorop¡r¡midin-4-yl)amino)met¡l)-3-hydroxypiper¡n-1-tamida) rac-2-((3R,4R)-4-(((6-(cyclobut¡l((5-(tr¡fluoromethyl)pyrid¡n-2-¡l)met¡l)am no)-5fluoropyrimidine-4-l)am¡no)methl)-3-hydrox¡p¡per¡din-1-¡l)acetamide,re / -2-((3R,4R)-4-(((6-(cyclopropyl((5-(trifluoromethyl)pendin-2-1)methyl)amino)-5fluoropyrimidine-4-1)amino)methyl)-3-hydroxiperidin-1-1)acetamida, rac-2-((3R,4R)-4-(((6-(cyclopropyl((6-(difluoromethyl)pyrimidine-3-1)methyl)amino)-5fluoropyrimidine-4-1)amino)methyl)-3-hydroxiperidin-1-1)acetamida, re / -2-((3R,4R)-4-(((6-(c¡clopropil((6-(d¡fluoromet¡l)piridin-3-¡l)metil)am¡no)-5fluorop¡rimidin-4-¡l)am¡no)met¡l)-3-hidrox¡p¡per¡d¡n-1-¡l)acetam¡da, rac-2-((3R,4R)-4-(((6-(etil(2-fluoro-4-(tr¡fluoromet¡l)benc¡l)am¡no)-5-fluorop¡rim¡d¡n-4il)am¡no)metil)-3-h¡droxipiper¡din-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((6-(etil(2-fluoro-4-(trifluorometil)benc¡l)am¡no)-5-fluoiOpir¡m¡d¡n-4il)amino)metil)-3-hidroxipiper¡din-1-il)acetamida, rac-2-((3R,4R)-4-(((6-(etil((5-(trifluorometil)peridin-2-¡l)metil)amino)-5-fluoropirimidin-4il)amino)met¡l)-3-h¡droxipiper¡din-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((6-(ethyl((5-(tr¡fluoromethyl)pyridin-2-yl)meth¡l)amino)-5-fluorop¡r¡m¡m¡n-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1-acetate) rac-2-((3R,4R)-4-(((6-(cycloprop¡l((6-(trifluoromethyl)p¡nd¡n-3-¡l)methyl)amino)-5fluorop¡rimidin-4-¡l)am¡no)meth¡l)-3-hydroxypiper-ace, re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(tr¡fluorometh¡l)pyridine-3-¡l)methyl)a mino)-5fluorop¡r¡r¡m¡n-4-¡l)amino)meth¡l)-3-hydrox¡p¡per¡d¡n-1-l)acetamide, rac-2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-d¡fluoroet¡l)p¡r¡d¡n-3-¡l)methyl) am¡no)-5fluoropyrim¡d¡n-4-¡l)amino)methyl)-3-hydrox¡p¡per¡din-1-yl)acetate, re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1-difluoroet¡l)p¡nd¡n-3-yl)met¡l)amirium)-5fluoropyrimidine-4-¡l)amino)meth¡l)-3-hydroxyp¡p¡ppyridine-1,ace) rac-2-((3R,4R)-4-(((5-fluoro-6-((2-fluoroethyl)(4-(tr¡fluoromethyl)benc¡l)am¡no)pyr¡midin-4¡l)am¡no)methyl)-3-hydroxyp¡p¡per¡din-1-ace, rac-2-((3R,4R)-4-(((5-fluoro-6-(((1R,3S)-3-fluorocyclobutyl)(4(trifluoromethl)bencl)amno)p¡rimid¡n-4-¡l)am¡no)methl)-3-hydrox¡p¡per¡d¡n-1-l)acetamide, rac-2-((3R,4R)-4-((((5-fluoro-6-(((1S,3R)-3-fluorocyclobut¡l)(4(trifluoromethyl)benc¡l)amino)p¡rimidin-4-¡l)amino)meth¡l)-3-hydroxy¡piperidine-1-ace) 2-(4-(((6-(cyclopropyl(1 -(5-(trifluoromethyl)pyr¡dine-2-yl)ethyl)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)piperidin-1-yl)acetam¡da, 2-(4-(((6-(c¡cloppro¡l(1-(4-(trifluorometh¡l)phen¡l)ethyl)amino)-5-fluorophrmidine-4¡l)am¡no)met¡l)p¡per¡d¡n-1-yl)acetamide, 377 2-(4-(((6-(c¡cloprop¡l((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)piperidin-1-¡l)acetam¡da, 2-(4-(((6-((3-cyanobenzyl)(cyclopropyl)am¡no)-5-fluorop¡r¡m¡m¡n-4-¡l)am¡no)met¡l)p¡per¡d¡n1-¡l)acetamide, 2-(4-((3-((-())- 1H-1,2,4-triazole-1 -¡l)benzyl)(cycloprop¡l)amno)-5-fluoropyr¡md¡n-4yl)am¡no)met¡l)p¡perdin-1-yl)acetam,2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)annino)-5-fluoropyrimid¡n-4¡l)am¡no)methyl)piper¡n-1-yl)acetam¡da, rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benc¡l)am¡no)-5-fluoropyrimid¡n-4¡l)amino)methyl)-3-h¡drox¡piper¡din-1-yl)acetamin, rac-2-((3R,4R)-4-((((5-fluoro-6-((1-methylcyclopropyl)(4(trifluorometh¡l)benc¡l)amino)p¡rimid¡n-4-¡l)amino)meth¡l)-3-h¡drox¡p¡per¡din-1-ace) rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy)-2-fluorObenzyl)amino)-5fluorop¡rimidin-4-yl)amino)met¡l)-3-hydroxypiperidin-1-yl)acetamide, rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(difluoromethoxy)benzyl)amino)-5-fluoropyrimidine-4yl)amino)met¡l)-3-h¡droxypiper¡din-1-¡l)acetam¡da, 1-(2-am¡no-2-oxoet¡l)-4-(((6-(c¡clopropyl(4-(tr¡fluorometh¡l)benzyl)am¡no)-5-fluoropyr¡midin4-yl)amino)met¡l)p¡per¡n-4-carboxam¡, 2-(4-(((6-(c¡cloprop¡l((6-(trifluorometh¡l)pyridin-3-yl)methl)amno)-5-fluoropyrim¡d¡n-4¡l)am¡no)methyl)-4-(hydroxymethl)piperidine-1-amine) 2-(4-(((6-((4-chloro-2,5-dimethylbenzyl)(cyclopropyl)amino)-5-fluorop¡r¡mdin-4¡l)am¡no)methl)p¡perid¡n-1-¡l)acetamin, 2-(4-(((6-(cycloprop¡l(2,5-d¡met¡lbenc¡l)amino)-5-fluorop¡rim¡m¡n-4¡l)am¡no)met¡l)piper¡d¡n-1-yl)acetamine, rac-2-((3R,4S)-4-(((6-(cycloprop¡l(4-(tr¡fluoromethyl)benc¡l)amno)-5-fluorop¡r¡m¡d¡n-4yl)am¡no)methyl)-3-h¡droxypiperidin-1-yltamida,) 2-(4-cyano-4-(((6-(c¡cloprop¡l(4-(trifluoromethl)benc¡l)amino)-5-fluoropyr¡m¡m¡din-4¡l)am¡no)methyl)piperid¡n-1-¡l)acetamin, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoro¡rmid¡n-4-yl)am¡rium)met¡l)-4(hydroxymethyl)piper¡d¡n-1-yl)acetamide, 2-(4-(((6-(c¡cloprop¡l((5-(tnfluoromethl)pyridine-2-¡l)methl)amno)-5-fluorop¡r¡mid¡n-4yl)am¡no)methyl)-4-(h¡droxymethl)-a-pice) 2-(4-(((6-((4-chloro-3,5-dimethylbenzyl)(cycloprop¡l)amino)-5-fluoiOpyr¡midine-4¡l)am¡no)methyl)piperid¡n-1-yl)acetam¡da, rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropane-2¡l)benc¡l)amino)-5-fluoropyrim¡dine-4-¡l)am¡no)methyl)-3-hydroxy¡p¡per¡d¡n-1-yl)acetamide, 378 re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropane-2¡l)b enc¡l)amino)-5-fluorop¡rim¡din-4-yl)amino)met¡l)-3-hydroxypiperidin-1-l)acetamide, re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fluoiOp¡rim¡m¡n-4¡l)am¡no)methyl)-3-h¡drox¡piperdino-1-promethane-2-l) rac-2-((3R,4R)-4-(((6-(c¡cloprop¡l(3-(tr¡fluoromethoxy¡)benc¡l)am¡no)-5-fluoroph¡r¡m¡d¡n-4yl)am¡no)methl)-3-hperidine-acetamida) re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoiOp¡r¡rmidin-4¡l)am¡no)met¡l)-3-hydroxy¡p¡p¡per¡din-1-¡l)-2-am¡l, rac-2-((3R,4R)-4-(((6-(c¡cloprop¡l(3-methoxy¡-4-(trifluoromet¡l)benc¡l)am¡ no)-5fluorop¡rimidin-4-¡l)am¡no)meth¡l)-3-hydroxyp¡p¡per¡d¡n-1-¡l)acetate, rac-2-((3R,4R)-4-(((5-fluoro-6-((met¡l-d3)(4-(trifluorometh¡l)benzyl)am¡no)p¡r¡m¡d¡n-4yl)amino)met¡l)-3-h¡droxypiper¡din-1-acetate,rac-2-((3R,4R)-4-(((6-(cycloprop¡l(2-methoxy-4-(trifluoromet¡l)benc¡l)amino)-5fluoro¡rimidin-4-yl)amino)met¡l)-3-hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benc¡l)amino)-5-fluoropyrimidine-4yl)am¡no)met¡l)p¡per¡d¡n-1-yl)-3-hydroxypropanamide, rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyrim¡d¡n-4¡l)am¡no)met¡l)-3-h¡drox¡piperidin-1-¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡-hydro-propane, re / -(R)-2-((3R,4R)-4-(((6-(et¡l(4-(tnfluoromet¡l)benc¡l)am¡no)-5-fluoropyrimidine-4¡l)am¡no)methyl)-3-hydroxyp¡per¡din-1-yl)-3-hydroxyp¡pa re / -(R)-2-((3S,4S)-4-(((6-(ethyl(4-(trifluorometh¡l)benzyl)amino)-5-fluoropyr¡m¡din-4¡l)am¡no)meth¡l)-3-hydroxy¡p¡per¡din-1-¡l)-3-h re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)am¡no)-5-fluorop¡r¡r¡mid¡n-4¡l)am¡no)met¡l)-3-hydroxypiper¡din-1-¡l)-hydroxy-4-h 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoro¡rmid¡n-4-yl)am¡no)rriet¡l)-4hydroxypiperidin-1-¡l)-3-hydroxypropanam,re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrimidine-4¡l)amino)methyl)-3-h¡drox¡p¡per¡din-1 -yl)acetamide-2,2-c / 2 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorophr¡rmid¡n-4-yl)am¡rium)met¡l)-4(hydroxymethyl)p¡per¡d¡n-1-yl)-3-hp, rac-2-((3R,4R)-4-(((6-(et¡l(4-(1-methyl-1H-p¡razol-4-¡l)benc¡l)amino)-5-fluorop¡r¡m¡d¡n-4yl)am¡no)methyl)-3-h¡droxypita-per-amyl) rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-(2-hidiOxyethyl))-1 / - / -pyrazol-4-yl)benc¡l)amino)-5fluorop¡r¡m¡din-4-yl)amino)meth¡l)-3-hydroxypyrl-acetyl) rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(1-meth¡l-1 / - / -pyrazol-4-¡l)benzyl)amino)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3-h¡drox¡p¡p-ad¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡-l) ινΐΛ / a / zuzz / uu and ουι 379 rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 -methyl-1 H-pyrazole-4-¡l)benzyl)amino)-5fluorop¡rmidine-4-yl)am¡no)methl)-3-hydroxypiperid¡n-1-¡l)acetamide, rac-2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 / - / -pyrazol-1-¡l)benc¡l)amino)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3-h¡drox¡p¡per¡d¡n-l)a) rac-2-((3R,4R)-4-(((6-((4-(1H-p¡razol-1-¡l)benc¡l)(et¡l)amno)-5-fluorop¡rim¡m¡n-4¡l)amino)meth¡l)-3-h¡drox¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡l) rac-2-((3R,4R)-4-(((6-((4-cyanobenzyl)(ethyl)amino)-5-fluoropyr¡midin-4-yl)amino)methyl)-3hydroxypiperidin-1 -yl)acetamide, rac-2-((3R,4R)-4-(((6-((4-(1,1-d¡fluoro-2-h¡drox¡ethyl)benc¡l)(et¡l)amine o)-5-fluorop¡r¡r¡md¡n4-¡l)amino)meth¡l)-3-hydrox¡p¡perdin-1-¡l)acetate, 2-(4-(((6-(C¡clopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluoro¡r¡mid¡n-4-yl)am¡no)met¡l)-4(1H-1,2,4-triazol-3-¡l)piperidin-1 -ylthamida,) 2-(4-(((6-(Cycloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyrim¡n-4-yl)amino)methyl)-4(1,2,4-oxadiazol-3-yl)piperidin-1-yl)acetamide, 2-(4-(((6-(Cycloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyrim¡n-4-yl)amino)methyl)-4(1,3,4-oxadiazol-2-l)p¡perid¡n-1-yl thamida)2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyrimid¡n-4-yl)amino)methyl)-4(4-methyl-4H-1,2,4-tr¡azol-3-¡l)piper-acetate-1) 2-(4-(((6-(C¡clopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡r¡mid¡n-4-yl)am¡no)met¡l)-4(1 / - / -¡m¡dazol-2-¡l)p¡m¡dazol-2-¡l)p¡d¡n-1-acetamida) 2-(4-(((6-(Cycloprop¡l(4-(tnfluoromet¡l)benc¡l)amino)-5-fluoropyr¡md¡n-4-¡l)amino)methyl)-4(1H-1,2,3-tr¡azol-5-¡l)piper¡l) rac-2-((3R,4R)-4-(((6-((4-(1H-p¡razol-1-¡l)benzyl)(c¡cloprop¡l)amino) -5-fluorop¡r¡m¡d¡n-4¡l)amino)methl)-3-hydrox¡piper¡din-1-¡l)acetate, 2-(4-(1-((6-(c¡cloprop¡l(4-(tr¡fluoromethl)benc¡l)amino)-5-fluoropyrim¡din-4-¡l)am¡no)-2h¡drox¡ethyl)piper¡d¡n-1-tamidal, re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rimidin-4¡l)am¡no)methyl)-3-h¡drox¡-3-methylpiperidin-1-yl)acetam¡da,da re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(tr¡fluoromethyl)beiic¡l)am¡no)-5-fl uorop¡rim¡d¡n-4¡l)am¡no)met¡l)-3-hydrox¡-3-met¡lpiperid¡n-1-¡l)acetam¡da,2-(4-(((6-(c¡cloprop¡l(4-(tnfluoromethl)benzyl)amino)-5-fluororimid¡n-4-l)am¡no)methl)-3hydroxy-4-methlp¡per¡din-1-yl)acetamin, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡n-4-yl)amino)methyl)-3hydroxy¡-4-(hydroxymet¡l)p¡per¡din-1 -yl)acetamide, 2-(4-(((6-((3,5-b¡s(tnfluoromethyl)benc¡l)(et¡l)amino)-5-fluorop¡r¡m¡n-4-yl)amino)meth¡l)-3h¡droxy-4-(hydroxymeth¡l)p¡n-p¡n-1, iviA / a / zuzz / uu fom 380 re / -2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoiOp¡r¡midin-4¡l)am¡no)methyl)-3,4-d¡h¡x¡p¡p¡p¡amidine-1, re / -2-((3R,4S)-4-(((6-(ethyl(4-(trifluorometh¡l)benzyl)amino)-5-fluorop¡rmidine-4¡l)am¡no)meth¡l)-3,4-d¡h¡diOxip¡peridin-1-¡acetamide, re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(tr¡fluoromet¡l)benc¡l)amino)-5-fluoiOp¡r¡m¡d¡n-4yl)am¡no)met¡l)-3,4-d¡perihydroxyp¡tamida-1-ace) re / -2-((3R,4S)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benc¡l)amino)-5-fluoiOpirim¡d¡n-4¡l)am¡no)meth¡l)-3,4-d¡h¡drox¡p¡p¡din-perhydra-1, re / -2-((3R,4R)-4-(((6-(et¡l(2-fluoro-4-(tr¡fluoromethyl)benc¡l)amino)-5-fluoropyrim¡n-4¡l)am¡no)methyl)-3,4-d¡h¡drox¡p¡peridin-1-yl)acetamida, re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(tr¡fluoromethyl)benc¡l)amino)-5-fluorop¡r¡m¡d¡n-4yl)am¡no)meth¡l)-3,4-d¡h¡peridoxyp-acetamida) re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropane-2-yl)benzyl)amino)-5fluorop¡rimidin-4-yl)amino)met¡l)-3,4-dihydroxypiper-tamida) re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1-methyl-1 / - / -pyrazol-4-yl)benzyl) amino)-5fluorop¡rimid¡n-4-¡l)am¡no)methyl)-3,4-d¡h¡drox¡piper¡n-1-yl)acetam¡da, re / -2-((3R,4R)-4-(((6-(cyclopr°pil(4-(1,1,1,3,3,3-hexafluoiO-2-hydroxyprc)pan-2¡l)ben cyl)arn¡no)-5-fluoropyr¡mdin-4-l)am¡no)methyl)-3,4-dihydrox¡p¡per¡n-1-l)acetamide, re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 / - / -pyrazol-1-¡l)benc¡l)amine o)-5fluorop¡rimidin-4-¡l)am¡no)meth¡l)-3,4-dih¡drox¡p¡per¡d¡n-1-yl)acetamide, re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluorobenzyl)amyrium)-5-fluoropyr¡m¡m¡din-4¡l)am¡no)met¡l)-3,4-d¡h¡drox¡p¡per¡dyn-1-¡l)acetate, 2-(4-Am¡no-4-(((6-(c¡cloprop¡l(4-(tr¡fluoromet¡l)benc¡l)am¡no)-5-fluoromethl)m¡n-4¡l)am¡no)methl)piper¡n-1-acetate, rac-2-((3R,4R)-4-(((5-fluoro-6-(met¡l(2-met¡lbenzyl)am¡no)p¡r¡m¡din-4-yl)am¡no)meth¡l)-3hydroxypiperidin-1-yl)acetate, rac-2-((3R,4R)-4-(((6-((2,6-dichlorobenzyl)(methyl)amino)-5-fluoropyr¡m¡d¡n-4¡l)am¡no)methyl)-3-hydroxy¡p¡per¡din-1-yl)acetamin, rac-2-((3R,4R)-4-(((6-((2,3-dichlorobenzyl)(methyl)amino)-5-fluoiOpyr¡m¡din-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1-¡l)acetam¡da, rac-2-((3R,4R)-4-(((6-((2,6-d¡chlorobenzyl)(et¡l)am¡no)-5-fluoropyrimidine-4-¡l)am¡no)meth¡l)3-hydroxypiperid¡n-1-¡l)acetannida, rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(1-(o4ol¡l)ethyl)amino)pyrimidine-4-yl)amino)methyl)-3hydroxypiperidin-1 -yl)acetamide, rac-2-((3R,4R)-4-(((6-((1-(2-chlorophenyl)et¡l)(meth¡l)amino)-5-fluoiOp¡rmidin-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1-acet),ινΐΛ / a / zuzz / uu / ου i 381 rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy)benzyl)amino)pyrimidine-4¡l)amino)methyl)-3-hydroxy¡p-1¡¡¡-a dince rac-2-((3R,4R)-4-(((6-((3-cyanobenc¡l)(meth¡l)amino)-5-fluorop¡r¡mid¡n-4-yl)am¡no)meth¡l)-3hydroxypiperidin-1 -yl)acetamide, rac-2-((3R,4R)-4-(((5-fluoro-6-(¡subut¡l(4-(tr¡fluorometh¡l)benc¡l)amino)pyr¡m¡d¡n-4yl)am¡no)met¡l)-3-h¡droxypiperidine-1-tamida,) rac-2-((3R,4R)-4-(((6-((cycloprop¡lmethyl)(2-(tr¡fluoromet¡l)benzyl)am¡no)-5-fluoropyrimidin4-¡l)am¡no)met¡l)-3-h¡droxip¡per¡d-n-1-ace, rac-2-((3R,4R)-4-(((6-((4-cyanobenc¡l)(¡subut¡l)amino)-5-fluorop¡rim¡dine-4-yl)am¡no)met¡l)3-hydroxypipehd¡n-1-¡l)acetam¡da, rac-2-((3R,4R)-4-(((6-((4-chloro-3-fluorobenc¡l)(meth¡l)am¡no)-5-fluoropyrimid¡n-4yl)amino)meth¡l)-3-h¡droxypiper¡din-1-¡l)acetam rac-2-((3R,4R)-4-(((6-((4-(d¡fluoromethoxy)benzyl)(methyl)am¡no)-5-fluoropyr¡m¡d¡n-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, rac-2-((3R,2)4R)-4-(((6-((4-(difluoromethoxy)-3-methoxybenzyl)(methyl)am¡no)-5-fluorop¡rimidin4-yl)am¡no)methyl)-3-h¡droxip¡per¡din-1-¡l)acetamide, rac-2-((3R,4R)-4-(((6-((4-chlorobenc¡l)(isopropyl)amino)-5-fluoropyrimidine-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1-¡l)acetam¡da, rac-2-((3R,4R)-4-((((5-fluoro-6-((2-methoxyet¡l)(4-(trifluorometh¡l)benc¡l)amino)p¡r¡m¡d¡n-4¡l)am¡no)methyl)-3-hydroxyp¡peridin-1-a) rac-2-((3R,4R)-4-(((6-((2,4-dichlorobenc¡l)(isobut¡l)amino)-5-fluorop¡r¡m¡m¡n-4¡l)amino)met¡l)-3-h¡drox¡p¡per¡din-1-l) rac-2-((3R,4R)-4-(((6-((4-c¡anobenc¡l)(meth¡l)amino)-5-fluorop¡r¡rmid¡n-4-¡l)am¡no)meth¡l)-3hydroxypiperidin-1 -yl)acetamide, rac-2-((3R,4R)-4-(((5-fluoro-6-(((6-methoxyp¡r¡r¡d¡n-3-¡l)meth¡l)(methyl)am¡no)p¡r¡m¡d¡n-4yl)am¡no)methyl)-3-hydroxypiperda-1-acetal rac-2-((3R,4R)-4-(((6-((3-(d¡fluoromethoxy)benzyl)(methyl)amino)-5-fluoropyrimid¡n-4¡l)am¡no)methyl)-3-hydroxy¡p¡p¡per¡din-1-yl)acetam¡da, rac-2-((3R,4R)-4-(((6-((3,5-dichlorobenc¡l)(methyl)amino)-5-fluoropyrim¡din-4¡l)am¡no)methl)-3-hydroxyp¡per¡dyn-1-¡l)acetate, rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethoxy¡)benzyl)amino)p¡hm¡d¡n-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1 -yl)acetamide y rac-2-((3R,4R)-4-(((6-((3-chlorobenzyl)(isopropyl)amino)-5-fluoropyrim¡din-4¡l)amno)methyl)-3-hydroxyp¡per¡din-1-yl)acetam¡da., 54. The compound, stereoisomer or salt of claim 1, selected from the group consisting of: 382 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benc¡l)amino)-5-fluoropyrimidine-4¡l)amino)methyl)-3-h¡drox¡p¡peridin-1-yl)acetam¡da, 2-(4-(((6-(cycloprop¡l(2-meth¡l-4-(tr¡fluoromethyl)benz¡l)amno)-5-fluoropyrim¡d¡n-4yl)amino)met¡l)p¡peridin-1-yl)acetate, 2-(4-(((6-(c¡cloprop¡l((5-(tnfluoromethyl)p¡r¡n-2-¡l)met¡l)am¡no)-5-fluorop¡r¡mid¡n-4yl)amino)meth¡l)-3,3-difluoropi-pertane-1,l) 2-(4-(((6-(cyclopropyl((5-(tr¡fluoromethyl)p¡rdin-2-yl)met¡l)amino)-5-fluoropyr¡m¡m¡din-4yl)am¡no)methyl)-3-fluoropiper¡d¡n-14l)acetam 2-(4-(((6-(c¡clopropyl(4-(trifluorometh¡l)benzyl)amino)-5-fluoropyr¡m¡din-4yl)amino)meth¡l)-3-fluoropiperidine-14l)acetam¡da, 2-(4-(((6-(c¡cloprop¡l(4-(tnfluoromet¡l)benc¡l)amno)-5-fluoropyrimidine-4yl)amino)methl)-3,3-difluoropiper¡n-1-¡l)acetate,2-(4-(((6-(c¡clopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimid¡n-4yl)amino)methyl)-3-(trifluoromethyl)piperidin-1-yl)acetamide, 1-(2-amino-2-oxoet¡l)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5fluoropyr¡m¡m¡n-4-¡l)amino)methyl)p¡per¡d¡n-4-methyl carboxylate, 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)p¡r¡din-2-yl)meth¡l)amino)-5-fluoropyr¡m¡m¡n-4yl)amino)met¡l)-4-h¡droxyp¡peridin-1-acetamida), 2-(4-(((6-(c¡cloprop¡l(4-(tnfluoromethl)benc¡l)amno)-5-fluoroOpyr¡n-4yl)am¡no)meth¡l)-4-h¡drox¡p¡per¡dyne-1-acetamida, 2-(4-(((6-(cycloprop¡l((6-(trifluoromethl)p¡r¡din-3-yl)meth¡l)amino)-5-fluoropyrimidine-4¡l)am¡no)meth¡l)-4-h¡drox¡piper¡n-1-acetate, 2-(4-(((6-(c¡cloprop¡l((5-(tr¡fluorometh¡l)p¡rdyn-2-¡l)meth¡l)amno)- 5-fluorop¡r¡m¡n-4yl)amino)methl)-3-hydroxypiper¡n-1-l)acetamide, 2-(4-(((6-(c¡clobut¡l(4-(d¡fluoromethoxy)-2-fluorobenc¡l)am¡no)-5-fluorop¡r¡m¡m¡n-4yl)am¡no)meth¡l)-3-h¡drox¡piper¡n-acetate,2-(4-(((6-(c¡clobut¡l(4-(tr¡fluoromethyl)benc¡l)amno)-5-fluorop¡rim¡d¡n-4-¡l)amino)methyl)3-h¡droxypiperidin-1-¡l)acetamide, 2-(4-(((6-(c¡cloprop¡l((2-(tr¡fluoromethl)p¡rmidine-5-¡l)methl)amno) -5-fluorop¡r¡m¡d¡n-4yl)amino)methl)-3-hydrox¡piperid¡n-1-¡l)acetamin, 2-(4-(((6-(c¡clobut¡l((2-(tnfluorometh¡l)pyr¡m¡d¡n-5-¡l)met¡l)amino)-5-fluoropyr¡m¡d¡n-4yl)amino)meth¡l)-3-h¡drox¡pyl-acetate, 1) 2-(4-(((5-fluoro-6-(isoprop¡l(4-(tnfluoromethyl)benc¡l)amino)p¡rim¡dyn-44l)am¡no)met¡l)3-hydroxypiperidin-1-yl)acetam¡da, 2-(4-(((5-fluoro-6-(methyl(4-(tr¡fluorometh¡l)benzyl)am¡no)p¡r¡m¡n-44l)amino)met¡l)-3h¡droxypiper¡din-1-¡l)acetamide, 383 2-(4-(((6-(ethyl(4-(tr¡fluoromet¡l)benzyl)am¡no)-5-fluoropyrimidine-4-¡l)amino)methyl)-3h¡droxypiperidin-1-yl)acetamide, 2-(4-(((6-(c¡cloprop¡l(2-fluoro-4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fluoropyrim¡d¡n-4yl)amino)met¡l)-3-h¡drox¡piperidine-1-¡l)acetamidal,2-(4-(((6-(cyclobutyl((6-(tr¡fluoromethyl)pyridine-3-¡l)met¡l)amino)-5-fluorophr¡mid¡n-4yl)amino)met¡l)-3-hydroxyp¡peridin-1-tamida), 2-(4-(((6-(cyclobut¡l((5-(trifluoromethyl)pyr¡d¡n-2-yl)met¡l)amino)-5-fluoropyrim¡d¡n-4yl)am¡no)methyl)-3-h¡drox¡piper¡n-1-tamida,) 2-(4-(((6-(c¡clopropyl((6-(difluorometh¡l)p¡r¡din-3-yl)met¡l)am¡no)-5-fluoiOpirim¡d¡n-4yl)amino)meth¡l)-3-h¡drox¡pperidin-1-l) 2-(4-(((6-(et¡l(2-fluoro-4-(tnfluoromethyl)benzyl)amino)-5-fluorophrmidine-4yl)amino)methl)-3-h¡droxip¡perid¡n-1-¡l)acetamide, 2-(4-(((6-(ethyl((5-(trifluorometh¡l)pyridin-2-¡l)methyl)am¡no)-5-fluorop¡rimidin-4yl)amino)methyl)-3-hydroxy¡p¡peridin-1-yl)acetamide, 2-(4-(((6-(cyclopropyl((6-(trifluoromethyl)p¡r¡din-3-yl)met¡l)amino)-5-fluoropyrimidine-4yl)amino)met¡l)-3-h¡drox¡piperid¡n-1-¡l)acetamide, 2-(4-(((6-(cyclopropyl((6-(1,1 -difluoroethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrimidine-4yl)amino)met¡l)-3-h¡droxypiperid¡n-1-¡l)acetamide,2-((((5-fluoro-6-((2-fluoroet¡l)(4-(tr¡fluoromethyl)benc¡l)am¡no)pyrimidine-4yl)amino)met¡l)-3-h¡drox¡piperidine-1-¡l)acetamide, 2-(4-(((5-fluoro-6-((3-fluorocyclobut¡l)(4-(trifluoromethyl)benc¡l)am¡no)pyrimidine-4¡l)am¡no)met¡l)-3-h¡drox¡piper¡d¡n-1-l)acetaminophen, 2-(4-(((6-(c¡cloprop¡l(1-(5-(tnfluoromethyl)pyridine-2-¡l)et¡l)am¡no)-5-fluoropyr¡m¡d¡n-4yl)amino)methyl)p¡peridin-1-yl)acetate, 2-(4-(((6-(cyclopropyl(1-(4-(tr¡fluoromethyl)phenyl)et¡l)amno)-5-fluoropyrim¡d¡n-4yl)amino)methyl)p¡peridin-1-yl)acetam¡da, 2-(4-(((6-(cycloprop¡l((5-(trifluoromethyl)p¡r¡din-2-¡l)met¡l)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)piper¡d¡n-1-¡l)acetamide, 2-(4-(((6-((3-cyanobenzyl)(c¡cloprop¡l)amino)-5-fluorop¡r¡m¡n-4yl)amino)methyl)p¡peridin-1-yl)acetate, 2-(4-(((6-((3-(1 / 7-1,2,4-tnazol-1-1-¡l)benc¡l)(c¡cloprop¡l)amno)-5-fluoropyr¡m¡d¡n-4yl)amino)met¡l)p¡peridin-1-yl)ace, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrmidine-4¡l)am¡no)methyl)piperid¡n-1-¡l)acetamide,2-(4-(((6-(cyclopropyl(4-(1,1-difluoroet¡l)benzyl)amino)-5-fluoiOp¡r¡midine-4yl)amino)meth¡l)-3-h¡drox¡piperidine-1-¡l)acetamide, iviA / a / zz / 34 υ iu 2-(4-(((5-fluoro-6-((1-methylcyclopropyl)(4-(trifluoromethyl)benzyl)amino)pyrimidine-4¡l)amino)methyl)-3-h¡drox¡p¡peridin-1-yl)acetam¡da, 2-(4-(((6-(c¡cloprop¡l(4-(difluoromethoxy)-2-fluorobenc¡l)amino)-5-fluoropyr¡m¡d¡n-4yl)amino)met¡l)-3-h¡drox¡p¡peridin-1-¡l)acetamidal, 2-(4-(((6-(c¡cloprop¡l(4-(difluoromethoxy)benc¡l)am¡no)-5-fluorop¡rim¡d¡n-4yl)amino)met¡l)-3-hydroxyp¡peridin-1-¡l)acetamide, 1-(2-amino-2-oxoet¡l)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5fluorop¡nm¡din-4-¡l)amino)met¡l)piperidine-4-carboxam¡da, 2-(4-(((6-(c¡clopropyl((6-(trifluorometh¡l)p¡r¡n-3-yl)met¡l)am¡no)-5-fluoropyrim¡d¡n-4yl)amino)methyl)-4-(h¡drox¡methyl)piper-acetate, 2-(4-(((6-((4-chloro-2,5-d¡meth¡lbenc¡l)(cycloprop¡l)am¡no)-5-fluoropyrim¡n-4yl)amino)met¡l)p¡peridin-1-yl)acetam¡da, 2-(4-(6-(2,5-d¡met¡lbenc¡l)(cycloprop¡l)amno)5-d¡met¡lbenzyl)amino)-5-fluoropyrimidine-4yl)amino)methyl)piperidine-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyr¡m¡din-4yl)amino)met¡l)-3-h¡drox¡piperid¡n-1-¡l)acetamide, 2-(4-cyano-4-(((6-(cycloprop¡l(4-(trifluoromethyl)beiic¡l)amno)-5-fluoropyrim¡n-4yl)amino)methyl)p¡per¡din-1-yl)acetam¡da, 2-(4-(((6-(c¡cloprop¡l(4-(tnfluoromet¡l)benzyl)am¡no)-5-fluoroOpir¡midine-4yl)amino)methyl)-4-(hydrox¡methyl)piper¡din-1-¡l)acetamide, 2-(4-(((6-(cycloprop¡l((5-(trifluorometh¡l)p¡r¡din-2-yl)meth¡l)amino)-5-fluoropyrimidine-4¡l)am¡no)meth¡l)-4-(h¡drox¡met¡l)p¡d¡n-1, 2-(4-(((6-((4-chloro-3,5-d¡met¡lbenc¡l)(cycloprop¡l)am¡no)-5-fluoropyrimid¡n-4yl)amino)methyl)p¡peridin-1-yl)acetam¡da, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-h¡drox¡propan-2-yl)benzyl)am¡no)-5fluoropyrim¡d¡n-4-yl)amino)methyl)-3-h¡droxypiper-1-amino)2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benc¡l)amino)-5-fluoropyr¡mid¡n-4¡l)amno)methyl)-3-h¡drox¡p¡peridin-1-yl)-2-met¡lpropanamide, 2-(4-(((6-(c¡cloprop¡l(3-(trifluoromethoxy¡)benzyl)am¡no)-5-fluorophrmidine-4yl)amino)met¡l)-3-h¡drox¡p¡perid¡n-1-¡l)acetamide, 2-(4-(((6-(ethyl(4-(trifluoromethl)benzyl)amno)-5-fluorop¡r¡m¡n-4-¡l)am¡no)methl)-3h¡droxypiper¡din-1-yl)-2-methylpropanam,da 2-(4-(((6-(cycloprop¡l(3-methoxy-4-(trifluoromethyl)benc¡l)amino)-5-fluoropyrimidine-4¡l)amno)methyl)-3-h¡drox¡piper¡din-1-¡l)acetamide, 2-(4-(((5-fluoro-6-((methyl-d3)(4-(tr¡fluoromethyl)benc¡l)amino)p¡r¡m¡din-4-yl)am¡no)met¡l)3-hydroxypiper¡d¡n-1-¡l)acetamide, ι / Λ / ΐ / ΐ / ΐ ου i 385 2-(4-(((6-(cycloprop¡l(2-methoxy-4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din-4¡l)amino)methyl)-3-h¡drox¡p¡peridin-1-yl)acetamin¡da 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyr¡midin-4yl)amino)methyl)p¡peridin-1-yl)-3-h¡drox¡propanam¡da,2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromethyl)benc¡l)amno)-5-fluoropyrmidine-4yl)amino)methl)-3-hydroxyp¡peridin-1-¡l)-3-hydroxypropanam, 2-(4-(((6-(ethyl(4-(tr¡fluorometh¡l)benzyl)amno)-5-fluoropyrimidine-4-¡l)amino)methyl)-3h¡drox¡p¡peridin-1-¡l)-3-hydroxypropanamda, 2-(4-(((6-(et¡l(4-(tr¡fluorometh¡l)benc¡l)am¡no)-5-fluorophnm¡n-4-yl)amino)met¡l)-3h¡droxypiper¡d¡n-1-¡l)-4-hydroxybuty, 2-(4-(((6-(c¡cloprop¡l(4-(tnfluorometh¡l)benc¡l)amno)-5-fluoropyrimidine-4yl)amino)methl)-4-h¡droxyp¡perid¡n-1-¡l)-3-hydroxypropane, 2-(4-(((6-(cyclopropyl(4-(tnfluoromethyl)benzyl)amino)-5-fluoropyrimidine-4yl)amino)methyl)-3-hydrox¡p¡peridin-1-¡l)acetamide-2,2-d2, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡din-4yl)amino)met¡l)-4-(hydroxymethyl)p¡per¡d¡n-1-yl)-3-hydroxypropanam, 2-(4-(((6-(ethyl(4-(1-methyl-1H-p¡razol-4-yl)benc¡l)amno)-5-fluoiOp¡rimidin-4yl)amino)met¡l)-3-h¡droxypiperid¡n-1-¡l)acetamide,2-(4-(((6-(et¡l(4-(1-(2-hydroxy¡et¡l)-1 / - / -pyrazol-4-yl)benc¡l)am¡no)-5-fluorop¡r¡mid¡n-4yl)amino)met¡l)-3-hydrox¡¡¡¡¡¡¡¡¡amida) 2-(4-(((6-(cycloprop¡l(4-(1-methyl-1H-p¡razol-4-¡l)benzyl)am¡no)-5-fluoiOpyrimidine-4¡l)am¡no)met¡l)-3-h¡drox¡piper¡n-l)acetate, 2-(4-(((6-(cycloprop¡l(2-fluoro-4-(1-methyl-1 / - / -p¡razol-4-¡l)benzyl)amine o)-5fluorop¡r¡m¡n-4-¡l)amino)meth¡l)-3-hydrox¡p¡perid¡n-1-¡l)acetate, 2-(4-(((6-(c¡cloppro¡l(2-fluoro-4-(1 / - / -pyrazol-1-yl)benc¡l)amino)-5-fluorop¡r¡m¡d¡n-4yl)amino)met¡l)-3-hydroxy¡p¡peridin-1-tamida, 2-(4-(((6-((4-(1 H-pyrazol-1-yl)benzyl)(ethyl)am¡no)-5-fluoropyrimid¡n-4-¡l)amino)methyl)-3h¡droxypiperidin-1-yl)acetam¡da, 2-(4-(((6-((4-cyanobenzyl)(et¡l)am¡no)-5-fluoropyrim¡d¡n-4-¡l)am¡no)methyl)-3h¡droxipiper¡d¡n-1-¡l)acetamide, 2-(4-(((4-1-(1) -difluoro-2-hydrox¡ethyl)benc¡l)(et¡l)amno)-5-fluorop¡rm¡n-4yl)amino)methl)-3-hydrox¡p¡peridin-1-yl)acetamide,2-(4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡rmidine-4yl)amino)methyl)-4-(1 Λ7-1,2,4-tr¡azol-3-yl)piper¡din-1 -yl)acetamide, 2-(4-(((6-(C¡cloppro¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluorophrmidine-4yl)amino)methyl)-4-(1,2,4-oxadiazol-3-¡l)p¡perdin-1-a / a / a / a / a i ¿yi 386 2-(4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidine-4¡l)amino)methyl)-4-(1,3,4-oxadiazol-2-yl)piper¡din-1-yl)acetamide, 2-(4-(((6-(C¡clopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡r¡m¡din-4yl)amino)methyl)-4-(4-met¡l-4 / - / -1,2,4-triazol-3-yl)piperidin-1-tamyl) 2-(4-(((6-(C¡cloprop¡l(4-(tnfluoronet¡l)benc¡l)amno)-5-fluoropyr¡m¡din-4yl)amino)methyl)-4-(1 / - / -inn¡dazol-2-¡l)p¡din-1-1-a) 2-(4-(((6-(Cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyr¡m¡din-4yl)amino)methyl)-4-(1 / - / -1,2,3-tr¡azol-5-yl)p¡peridin-1-yl)acetamide,2-(4-(((6-((4-(1 / - / -pyrazol-1 -yl)benzyl)(cyclopropyl)amino)-5-fluoro¡r¡midine-4yl)amino)meth¡l)-3-h¡drox¡p¡peridin-1-yl)acetate, 2-(4-(1-((6-(c¡chlopropyl(4-(tr¡fluoromet¡l)benc¡l)amno)-5-fluorophrimidine-4-¡l)amno)-2hydroxyet¡l)piper¡d¡n-1 -yl)acetamida, 2-(4-(((6-(cyclopropyl(4-(tr¡fluoromethyl)benzyl)amino)-5-fluoropyrinidine-4yl)amino)methyl)-3-hydrox¡-3-methylpiperidin-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡din-4yl)amino)met¡l)-3-h¡drox¡-4-met¡lp¡per¡d¡n-1-yl)acetamide, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benc¡l)amino)-5-fluoropyr¡midin-4yl)amino)met¡l)-3-h¡droxy-4-(hydroxymet¡l)p¡perid¡n-1-yl)acetam 2-(4-(((6-((3,5-b¡s(trifluorometh¡l)benzyl)(ethyl)amino)-5-fluoropyrimidine-4-¡l)am¡no)methyl)3-hydroxy-4-(h¡drox¡methyl)piperidin-1-yl)acetamide, 2-(4-(((6-(ethyl(4-(tr¡fluoromethyl)benzyl)amno)-5-fluoropyrimid¡n-4-¡l)am¡no)methyl)-3,4d¡h¡drox¡piper¡n-1-¡l)acetaminophen,2-(4-(((6-(c¡cloprop¡l(4-(tnfluoromet¡l)benzyl)am¡no)-5-fluoropyr¡mid¡n-4yl)amino)meth¡l)-3,4-dihydroxypiper¡n-1-¡l)acetamide, 2-(4-(((6-(et¡l(2-fluoro-4-(tnfluorometh¡l)benzyl)amino)-5-fluoro¡rmidine-4yl)amino)met¡l)-3,4-dihydroxypiperid¡n-1-yl)acetane, 2-(4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-h¡h¡droxypropan-2-yl)benzyl)amino)-5fluoropyrim¡din-4-¡l)am¡no)methyl)-3,4-d¡h¡drox¡p¡pyridine-1, 2-(4-(((6-(cycloprop¡l(2-fluoro-4-(1-met¡l-1 / - / -pyrazol-4-¡l)benc¡l)amino) -5fluoropyr¡m¡n-4-¡l)am¡no)methyl)-3,4-d¡h¡drox¡piperidin-1-¡l)acetane, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy¡propane-2-¡l)benc¡l)amino)-5fluoropyrim¡d¡n-4-yl)amino)methyl)-3,4-droxyperidine-1-acetamida) 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1 / - / -pyrazol-1-yl)benc¡l)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)-3,4-d¡h¡drox¡p¡peridin-1-yl)acetamide, 2-((3R,4R)-4-(((6-(cyclopropyl(2-fluorobenc¡l)amino)-5-fluorop¡rmidine-4yl)amino)meth¡l)-3,4-d¡h¡drox¡piperid¡n-1-l)acetaminophenινΐΛ / a / zuzz / uu / ου i 387 2-(4-Amino-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim¡din-4¡l)amino)methyl)piperid¡n-1-acetamide, 2-(4-(((5-fluoro-6-(methyl(2-met¡lbenc¡l)am¡no)pyrim¡n-4-yl)am¡no)meth¡l)-3h¡droxypiperid¡n-1-¡l)acetamide, 2-(4-(((6-((2,6-d¡chlorobenc¡l)(meth¡l)amino)-5-fluorop¡r¡m¡n-4-¡l)amino)meth¡l)-3h¡droxypiperid¡n-1-yl)acetannide, 2-(4-(((6-((2,3-d¡chlorobenc¡l)(methyl)amino)-5-fluorop¡rmidine-4-¡l)amino)met¡l)-3hydroxypiperidine-1 -yl)acetamide, 2-(4-(((6-((2,6-dichlorobenzyl)(ethyl)amno)-5-fluoropyr¡m¡n-4-¡l)am¡no)methyl)-3h¡droxypiperid¡n-1-¡l)acetamide, 2-(4-(((5-fluoro-6-(met¡l(1-(o-tol)et¡l)am¡no)p¡r¡m¡n-4-¡l)amino)met¡l)-3h¡droxipiper¡n-1-l)acetannida, 2-(4-(((6-((1-(2-chlorophenyl)et¡l)(methyl)am¡no)-5-fluorop¡rmidine-4-¡l)amino)methyl)-3hydroxypiperidin-1 -yl)acetamide, 2-(4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy¡)benzyl)amino)pyrimid¡n-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide,2-(4-(((6-((3-cyanobenzyl)(met¡l)amino)-5-fluorop¡r¡m¡n-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((5-fluoro-6-(isobut¡l(4-(tr¡fluoromethl)benc¡l)am¡no)p¡r¡mid¡n-4-yl)am¡no)meth¡l)-3hydroxypiperidin-1 -¡l)acetamide, 2-(4-(((6-((cyclopropylmethyl)(2-(trifluoromethyl)benzyl)amino)-5-fluoropyr¡midine-4¡l)am¡no)met¡l)-3-h¡drox¡p¡per¡dyn-1-¡l)acetamide, 2-(4-(((6-((4-cyanobenzyl)(isobutyl)amino)-5-fluoropyrimidine-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-((4-chloro-3-fluorobenc¡l)(methyl)amino)-5-fluorop¡r¡mid¡n-4-yl)amno)meth¡l)-3hydroxypiperidin-1-yl)acetamide, 2-(4-(((6-((4-(difluoromethoxy)benzyl)(met¡l)amno)-5-fluoropyrim¡n-4-¡l)amino)methyl)3-h¡droxypiperidin-1-¡l)acetamide, 2-(4-(((6-((4-(d¡fluoromethoxy¡)-3-methoxy¡benzyl)(met¡l)am¡no)-5-fluoropyrimid¡n-4yl)amino)met¡l)-3-h¡drox¡p¡peridin-1-¡l)acetaminophen, 2-(4-(((6-((4-chlorobenc¡l)(¡sopropyl)amino)-5-fluorop¡rimidin-4-yl)am¡no)met¡l)-3hydroxypiperidin-1 -yl)acetamide,2-(4-(((5-fluoro-6-((2-methoxyethyl)(4-(trifluoroornethyl)benzyl)arnino)p¡rimidin-4¡l)amno)methyl)-3-h¡drox¡p¡per¡dyn-1-yl)acetate, 2-(4-(((6-((2,4-d¡chlorobenzyl)(¡subut¡l)am¡no)-5-fluoro¡r¡m¡n-4-¡l)am¡no)met¡l)-3hydroxypiperidin-1-yl)acetamide, 389 re / -2-((3R,4R)-4-(((6-(cyclobutyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyr¡mid¡n-4¡l)am¡no)methyl)-3-hydroxyp¡per¡din-1-yl)acetate, re / -2-((3R,4R)-4-(((6-(cycloprop¡l((2-(tr¡fluoromet¡l)pyrimidine-5-¡l)iTiet¡l )amino)-5fluoropyrimidine-4-l)am¡no)methl)-3-hydrox¡p¡per¡din-1-¡l)acetate, re / -2-((3R,4R)-4-(((5-fluoro-6-(¡soprop¡l(4-(tr¡fluoromet¡l)benc¡l)am¡no)pyr¡m¡d¡n-4yl)am¡no)met¡l)-3-h¡droxypiperidine-1-acetamida) re / -2-((3R,4R)-4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)benzyl)amino)pyr¡midine-4¡l)am¡no)methyl)-3-hydrox¡p¡per¡dyn-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((6-(et¡l(4-(trifluorometh¡l)benc¡l)amino)-5-fluorop¡r¡m¡din-4¡l)amino)methyl)-3-h¡drox¡piper¡din-1-yl)acetam,(3R-2 / (R-2)4R)-4-(((6-(cyclopropyl(2-fluoro-4-(tr¡fluoromet¡l)benzyl)amino)-5fluoropyrimidine-4-¡l)amno)methyl)-3-hydrox¡p¡peridin-1-yl)acetam¡da, re / -2-((3R,4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benc¡l)am¡no)-5-fluoiOpyr¡m¡d¡n-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5fluorop¡rimid¡n-4-¡l)am¡no)meth¡l)-3-h¡drox¡p¡peridin-1-a). re / -2-((3R,4R)-4-(((6-(cyclopropyl((6-(1,1 -difluoroethyl)pyridin-3-yl)methyl)amino)-5fluoropyrim¡d¡n-4-¡l)amino)methyl)-3-h¡drox¡p¡didin-1-1-a) rac-2-((3R,4R)-4-((((5-fluoro-6-(((1R,3S)-3-fluorocyclobutyl)(4(tr¡fluoromethyl)benzyl)am¡no)pyr¡midine-4-¡l)am¡no)methyl)-3-hydroxypiper-d-1, rac-2-((3R,4R)-4-(((5-fluoro-6-(((1S,3R)-3-fluorocyclobutyl)(4(tr¡fluoromet¡ l)benc¡l)am¡no)prim¡d¡n-4-¡l)am¡no)meth¡l)-3-hydrox¡p¡per¡d¡n-1-¡l)acetam¡da, 2-(4-(((6-(c¡cloprop¡l(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡r¡mid¡n-4¡l)am¡no)met¡l)piper¡n-1-yl)acetam¡da,rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroet¡l)benc¡l)amino)-5-fluorop¡r¡ni¡din-4yl)am¡no)methyl)-3-hydroxypiper¡din-1-yl)acetamida, rac-2-((3R,4R)-4-((((5-fluoro-6-((1-methylcyclopropyl)(4(tr¡fluoromethyl)benc¡l)am¡no)p¡r¡midin-4-yl)am¡no)rnet¡l)-3-hydroxyp¡n-acetate, rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(d¡fluoromethoxy)-2-fluoiObenc¡l)amino)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3-h¡drox¡p¡p¡dino-1-ace) rac-2-((3R,4R)-4-(((6-(c¡cloprop¡l(4-(d¡fluoromethoxy¡)benc¡l)amino)-5-fluoropyr¡m¡d¡n-4yl)am¡no)methyl)-3-h¡droxypiper¡din-1-yltamida,) 1-(2-am¡no-2-oxoet¡l)-4-(((6-(cyclopropyl(4-(tr¡fluorometh¡l)benzyl)am¡no)-5-fluoropyrimidine4-¡l)amino)met¡l)piper¡d¡n-4-carboxamide, 2-(4-(((6-(c¡cloprop¡l((6-(trifluoromethyl)pyrid¡n-3-yl)methyl)amino)-5-fluoropyrimidine-4¡l)am¡no)met¡l)-4-(h¡drox¡met¡l)piperid¡n-1-acetate, ινΐΛ / a / zuzz / uu phoxi 390 2-(4-cyano-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)piperidine-1-¡l)acetam¡da,2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorophr¡rmid¡n-4-yl)am¡no)met¡l)-4(h¡droxymethyl)piper¡d¡n-1-acetamide), 2-(4-(((6-(c¡cloprop¡l((5-(tnfluoromet¡l)pyridine-2-¡l)met¡l)am¡no)-5-flu orop¡r¡mid¡n-4yl)am¡no)methl)-4-(hydroxymethl)piper¡din-1-¡l)acetane, re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hidiOX¡piOpan-2¡l)b enc¡l)am¡no)-5-fluorop¡rim¡m¡dine-4-¡l)amino)meth¡l)-3-hydrox¡piper¡din-1-¡l)acetate, re / -2-((3R,4R)-4-(((6-(c¡¡cloprop¡l(4-(tr¡fluoromethyl)benc¡l)amino)-5-fluoropyrimid¡n-4¡l)am¡no)methyl)-3-hydroxypiper¡din-1-yl-2-propanamide) rac-2-((3R,4R)-4-(((6-(cycloprop¡l(3-(tr¡fluoromethoxy¡)benc¡l)am¡no)-5-fluorop¡r¡m¡n-4yl)amino)meth¡l)-3-h¡droxypiperdine-1, re / -2-((3R,4R)-4-(((6-(ethyl(4-(tr¡fluoromethyl)benzyl)am¡no)-5-fluoiOpyri¡midin-4yl)am¡no)methyl)-3-hydroxypiper¡din-1-yl)-2-methylpropanamide, rac-(3R,2-(3R,2)4R)-4-(((6-(cyclopropyl(3-methoxy¡-4-(trifluoromethyl)benzyl)amino)-5fluorop¡rimid¡n-4-¡l)am¡no)met¡l)-3-h¡drox¡p¡peridin-1-¡l)acetam rac-2-((3R,4R)-4-(((5-fluoro-6-((met¡l-d3)(4-(trifluorometh¡l)benzyl)am¡no)pyrim¡n-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1-acetate, rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fluorop¡r¡r¡m¡d¡n-4¡l)am¡no)methyl)-3-hydroxyp¡perdyne-1-hydrox-3-panamide) re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluorometh¡l)benzyl)amino)-5-fluoropyr¡m¡dyn-4¡l)am¡no)meth¡l)-3-hydroxy¡p¡per¡dyn-1-l)-3-h re / -(R)-2-((3S,4S)-4-(((6-(et¡l(4-(tnfluoromet¡l)benc¡l)am¡no)-5-fluorop irim¡d¡n-4¡l)am¡no)met¡l)-3-hydroxypiper¡din-1-¡l)-3-hydrox¡propanam¡da, re / -2-((3R,4R)4-(((6-(ethyl(4-(tnfluoromet¡l)benzyl)amino)-5-fluoropyr¡midin-4yl)am¡no)methyl)-3-h¡droxypiperidin-1-yl)-4-h¡droxybutanam¡da, 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromethyl)benzyl)am¡no)-5-fluoropyrimid¡n-4-l)amino)methyl)-4h¡drox¡piperidin-1-yl)-3-hydroxypropanamide, re-(3,2-R4R)-4-(((6-(cycloprop¡l(4-(tr¡fluorometh¡l)benc¡l)amino)-5-fluorop¡r¡m¡d¡n-4i I )am i no)methyl )-3-hyd roxi piperidine-1 -yl)acetamide-2,2-c / 2,2 2-(4-(((6-(c¡cloprop¡l(4-(tnfluoromet¡l)benzyl)am¡no)-5-fluorophrimidin-4-¡l)am¡no)met¡l)-4(hydroxymethyl)p¡per¡d¡n-1-yl)-3-hydroxyproxide, rac-2-((3R,4R)-4-(((6-(ethyl(4-(1-methyl-1H-pyrazol-4-yl)benzyl)amino)-5-fluoiOpyrimidine-4¡l)amino)methyl)-3-hydroxy¡p¡per¡din-1-yl)acetamin¡, rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(1-meth¡l-1 / - / -pyrazol-4-¡l)benzyl)amino)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3-h¡drox¡p¡p-ad¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡-l) ινΐΛ / a / zuzz / uu and ουι 391 rac-2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benc¡l)am¡no)-5fluorop¡r¡midin-4-yl)am¡no)met¡l)-3-hydroxypid-acetamida) rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4-(1H-pyrazol-1-¡l)benc¡l)amino)-5-fluoro pyrim¡d¡n-4-yl)am¡no)meth¡l)-3-hydroxyp¡d¡n-1-amino-acetate) 2-(4-(((6-(C¡clopropyl(4-(tnfluoromet¡l)benzyl)am¡no)-5-fluoropyrim¡n-4-¡l)am¡no)meth¡l)-4(1 / 7-1,2,4-triazole-3-¡l)piperid¡n-1 -yl)acetamide, 2-(4-(((6-(Cycloprop¡l(4-(trifluorometh¡l)benc¡l)amino)-5-fluoropyrim¡n-4-yl)amno)methyl)-4(1,2,4-oxadiazol-3-¡l)p¡perid¡n-1-tamida,) 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluorop¡r¡m¡n-4-yl)amino)methyl)-4(1,3,4-oxadiazol-2-yl)p¡n-1-ace) 2-(4-(((6-(C¡clopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluorophrimid¡n-4-yl)am¡no)meth¡l)-4(1 / 7-1,2,3-tr¡azol-5-yl)p¡n-1-acetamyl) rac-2-((3R,4R)-4-(((6-((4-(1H-p¡razol-1-yl)benzyl)(cycloprop¡l)amino)-5-fluoropyr¡m¡din-4yl)amino)methyl)-3-hydroxypiper¡din-1-yl)acetamide, re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidine-4yl)am¡no)met¡l)-3-h¡droxy-3-methylpiper¡d¡n-1-¡l)acetamidal, re / -2-((3R,4S)-4-(((6-(cyclopropyl(4-(trifluoromethyl)beiic¡l)am¡no)-5-fluorop¡rim¡m¡n-4¡l)am¡no)met¡l)-3-h¡drox¡-3-methylpiperid-ace-da)2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorophr¡mid¡n-4-yl)am¡no)meth¡l)-3hydroxy¡-4-methylp¡perid¡n-1-yl)acetamidamida, 2-(4-(((6-(c¡cloprop¡l(4-(tnfluoromethyl)benc¡l)amino)-5-fluoropyr¡mid¡n-4-¡l)amino)methyl)-3h¡drox¡-4-(h¡drox¡meth¡l)p¡d¡n-1-ace, re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)am¡no)-5-fluorop¡r¡mid¡n-4¡l)am¡no)met¡l)-3,4-d¡h¡droxypiperidin-1-acetamidal,) re / -2-((3R,4S)-4-(((6-(ethyl(4-(tnfluoromet¡l)benzyl)am¡no)-5-fluoropyr¡midin-4yl)am¡no)methyl)-3,4-dihydroxypiperidine-1-¡l)acetamide, re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluorometh¡l)benzyl)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)-3,4-d¡h¡drox¡p¡peridin-1-yl)acetamide, re / -2-((3R4S)-4-(((6-(c¡cloprop¡l(4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fl uorOp¡rim¡d¡n-4¡l)am¡no)met¡l)-3,4-d¡h¡droxyp¡perid¡n-1-¡l)acetamide, re / -2-((3R,4R)-4-(((6-(et¡l(2-fluoro-4-(trifluoromet¡l)benc¡l)amino)-5-fluorop¡r¡m¡d¡n-4yl)am¡no)methyl)-3,4-d¡hydroxypyridine-1-acetamide) re / -2-((3R,4S)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benc¡l)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)-3,4-d¡h¡drox¡p¡per¡din-1-yl)acetamide, re / -2-((3R,4R)-4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benc¡l )am¡no)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3,4-d¡h¡drox¡p¡perid¡n-1-yl)acetam¡da, ινΐΛ / a / zuzz / uu / ου and 392 re / -2-((3R,4R)-4-(((6-(cyclopropyl(2-fluoro-4-(1 -methyl-1 / - / -pyrazole-4-yl)benzyl)amino)-5fluorop¡rmidine-4-yl)am¡no)meth¡l)-3,4-dihydrox¡p¡per¡d¡n-1-yl)acetamide, re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropane-2¡l)ben c¡l)amino)-5-fluoropyrim¡dine-4-¡l)am¡no)methyl)-3,4-dihydrox¡p¡perdine-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(1H-p¡razol-1-¡l)benc¡l)am¡no)-5fluoropyrimid¡n-4-¡l)amino)methyl)-3,4-d¡h¡h¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡n-amino)methyl)-3,4-d¡h¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡n-amino)methyl)-amino) rac-2-((3R,4R)-4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy¡)benzyl)amino)pyrimidine-4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetam¡da., 56. The compound, stereoisomer or salt thereof according to claim 54, selected from the group comprising: 2-(4-(((6-(C¡clopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyr¡mid¡n-4-yl)am¡no)met¡l)-3h¡droxypiperid¡n-1-¡l)acetamide, 2-(4-(((6-(cyclopropyl((5-(trifluoromethyl)pyridin-2-yl)methyl)amino)-5-fluoropyrimidine-4¡l)am¡no)met¡l)-3,3-d¡fluoroph¡per¡d¡n-1-¡l)acetamin 2-(4-(((6-(cyclopropyl((5-(triflLioromethyl)pyrid¡n-2-yl)methyl)amino)-5-fluoropyrimidine-4yl)amino)meth¡l)-3-fluoropiper¡d¡n-1-¡l)acetam¡da, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrimid¡n-4-yl)amino)methyl)-3fluoropiperidine-1-¡l)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromet¡l)benzyl)amino)-5-fluorop¡rmid¡n-4-¡l)am¡no)met¡l)3,3-d¡fluoro¡per¡n-1-acetamidal, 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyr¡midin-4-yl)amino)methyl)-3(tr¡fluoromet¡l)p¡perid¡n-1-¡l)acetam¡da,1-(2-ameno-2-oxoethyl)-4-(((6-(clopropyl(4-(trfluoromethyl)bencel)amino)-5-fluoropyrimidine-4-amino)methyl)piperdin-4-carboxymethyl, 2-(4-(((6-(clopropyl((5-(trfluoromethyl)peridin-2-il)methyl)ameno)-5-fluoropyrimidine-4-amino)methyl)-4-hydroxpiperidin-1-yl)acetamoda, 2-(4-(((6-(ciclopropil(4-(tr¡fluoromet¡l)bencil)am¡no)-5-fluorop¡r¡midin-4-¡l)am¡no)met¡l)-4h¡droxipiperidin-1-il)acetamida, 2-(4-(((6-(c¡cloprop¡l((5-(trifluorometil)piridin-2-il)metil)amino)-5-fluoropirimidin-4¡l)amino)met¡l)-3-h¡drox¡p¡per¡din-1-¡l)acetam¡da, 2-(4-(((6-(c¡clobutil(4-(d¡fluorometox¡)-2-fluorobenc¡l)am¡no)-5-fluoropir¡m¡d¡n-4¡l)amino)metil)-3-h¡drox¡piperidin-1-¡l)acetam¡da, 2-(4-(((6-(ciclobutil(4-(trifluorometil)bencil)amino)-5-fluoropirimidin-4-il)amino)metil)-3hidroxipiperidin-1 -il)acetamida, 2-(4-(((6-(clopropyl((2-(trifluoromethyl)premedin-5-il)metyl)ameno)-5-fluoropyrimedin-4l)amino)metyl)-3-hydroxperidine-1-l)acetamada,393 2-(4-(((5-fluoro-6-(isopropyl(4-(trifluoromethyl)bencyl)amino)pyrimidine-4-il)amino)methyl)-3-hydroxypiperidin-1-il)acetamida, 2-(4-(((5-fluoro-6-(methyl(4-(trifluoromethyl)bencyl)amino)pyrimidine-4-il)amino)methyl)-3-hydroxypiperidin-1-il)acetamida, 2-(4-(((6-(ethyl(4-(trifluoromethyl)bencyl)amino)-5-pyrimidine-4-il)amino)methyl)-3-hydroxypiperidin-1-il)acetamida, 2-(4-(((6-(clopropyl(2-fluoro-4-(trifluoromethyl)bencel)amino)-5-fluoropyrimeden-4-il)amino)methyl)-3-hydroxipereden-1-il)acetamida, 2-(4-(((6-(etyl(2-fluoro-4-(trifluoromethyl)bencel)amino)-5-fluoropyrimeden-4-il)amino)methyl)3-hydroxipereden-1-il)acetamida, 2-(4-(((6-(c¡cloprop¡l((6-(tnfluorometil)piridin-3-il)metil)amino)-5-fluoropirimidin-4il)am¡no)metil)-3-h¡droxipiper¡din-1-¡l)acetam¡da, 2-(4-(((6-(ciclopropil((6-(1,1) -difluoroetil)piridin-3-il)metil)amino)-5-fluoropirimidin-4¡l)am¡no)met¡l)-3-hidrox¡p¡per¡din-1-¡l)acetam¡da,2-(4-(((5-fluoro-6-(3-fluorooc¡clobutyl)(4-(trifluoromethyl)benzyl)amino)p¡rimidin-4yl)am¡no)methyl)-3-h¡droxypiper¡din-1-¡l)acetam¡da, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrimid¡n-4¡l)am¡no)met¡l)p¡per¡d¡n-1-yl)acetamide, 2-(4-(((6-(cyclopropyl(4-(1,1-d¡fluoroet¡l)benc¡l)amino)-5-fluorop¡r¡m¡din-4-¡l)am¡no)met¡l)3-hydroxyp¡per¡d¡n-1-acetamide,) 2-(4-(((5-fluoro-6-((1-met¡lc¡clopropyl)(4-(tr¡fluoromet¡l)benzyl)amino)pyrim¡din-4¡l)am¡no)methyl)-3-h¡drox¡p¡per¡dyn-1-acetate, 2-(4-(((6-(c¡cloprop¡l(4-(difluoromethoxy)-2-fluorobenzyl)arnino)-5-fluoropyrirnidine-4¡l)am¡no)methyl)-3-h¡drox¡piper¡din-1-¡l)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(difluoromethoxy¡)benc¡l)amino)-5-fluorop¡rim¡din-4-yl)am¡no)met¡l)3-hydroxypiper¡dyn-1-yl)acetam¡da, 1-(2-amino-2-oxoet¡l)-4-(((6-(cyclopropyl(4-(tr¡fluoromethyl)benzyl)am¡no)-5-fluoropyrimidine4-¡l)amino)met¡l)piper¡d¡n-4-carboxamide,2-(4-(((6-(c¡cloprop¡l((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-5-fluoropyrimidine-4¡l)am¡no)met¡l)-4-(h¡drox¡met¡l)piper¡n-1-acetate, 2-(4-c¡ano-4-(((6-(cycloprop¡l(4-(tnfluoromethl)benc¡l)amno)-5-fluorop¡rmid¡n-4¡l)am¡no)met¡l)p¡per¡dyn-1-yl)acetam 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimid¡n-4-yl)amino)methyl)-4(h¡drox¡methyl)piperidin-1-yl)acetamide, 2-(4-(((6-(c¡cloprop¡l((5-(trifluoromethyl)pyrid¡n-2-yl)methyl)amino)-5-fluoropyrimidine-4¡l)am¡no)met¡l)-4-(h¡drox¡met¡l)pipend¡n-1-tam¡l), ινΐΛ / a / zuzz / uu ι ουι 394 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy¡propane-2-¡l)benc¡l)am¡no)-5fluoro¡r¡midin-4-yl)amino)met¡l)-3-hydroxypyrl(1,1,3,3,3) 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoro¡rmid¡n-4-yl)am¡no)meth¡l)-3hydroxypiperidin-1 -yl)-2-methylpropanamide, 2-(4-(((6-(c¡cloprop¡l(3-(tnfluoromethoxy¡)benc¡l)am¡no)-5-fluoropyrim¡din-4-l)amino)methyl)3-hydroxypiperid¡n-1-¡l)acetannide,2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)am¡no)-5-fluorop¡rmidin-4-yl)amino)met¡l)-3hydroxypiperidin-1-yl)-2-methylpropanamide, 2-(4-(((6-(c¡cloprop¡l(3-methoxy-4-(tr¡fluoromet¡l)benzyl)am¡no)-5-fluoropyriiTiidin-4¡l)am¡no)methyl)-3-hydroxyp¡p¡per¡din-1-yl)acetamin, 2-(4-(((5-fluoro-6-((met¡l-d3)(4-(tr¡fluoromethl)benc¡l)am¡no)p¡rmidin-4-yl)am¡no)meth¡l)-3hydroxypiperidin-1 -yl)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rirnid¡n-4-yl)am¡no)rnethyl)-3hydroxypiperidin-1-yl)-3-hydroxypropanamd, 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)am¡no)-5-fluoropyrimidine-4-yl)am¡no)methyl)-3hydroxypiperidin-1-yl)-3-hydroxypropanam, 2-(4-(((6-(et¡l(4-(trifluoromethyl)benc¡l)amno)-5-fluorop¡r¡m¡n-4-yl)am¡no)methl)-3hydroxypiperidin-1-yl)-4-hydroxybutanam¡da, 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromet¡l)benzyl)amino)-5-fluorophr¡mid¡n-4-¡l)am¡no)met¡l)-4hydroxypiperidin-1 -yl)-3-hydroxypropanamda,2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromethyl)benc¡l)amno)-5-fluoropyr¡mid¡n-4-¡l)amino)methyl)-3hydroxypiperidin-1 -yl)acetamide-2,2-d2, 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromet¡l)benzyl)amino)-5-fluorophr¡rmid¡n-4-¡l)am¡no)met¡l)-4(hydroxymet¡l)piper¡n-1-hydroxy-3-h, 2-(4-(((6-(et¡l(4-(1-methyl-1 / - / -p¡razol-4-¡l)benc¡l)am¡no)-5-fluoropyrimidine-4-¡l)am¡no)methyl)3-hydroxypiper¡d¡n-1-l)acetaminophen, 2-(4-(((6-(c¡cloprop¡l(4-(1-met¡l-1 / - / -p¡razol-4-¡l)benc¡l)am¡no)-5-fluoropyrimid¡n-4¡l)am¡no)methyl)-3-h¡drox¡p¡p¡p¡p¡acetamium, 2-(4-(((6-(c¡cloprop¡l(2-fluoro-4-(1-met¡l-1 / 7-p¡razol-4-¡l)benc¡l)am¡n o)-5-fluorop¡rmid¡n-4¡l)am¡no)meth¡l)-3-hydroxyperdine-1-l)acetamide, 2-(4-(((6-(Cyclopropyl(2-fluoro-4-(1 / - / -p¡razol-1-¡l)benc¡l)am¡no)-5-fluorop¡r¡m¡n-4¡l)am¡no)methl)-3-h¡drox¡l)am¡no)methyl) 2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoro¡rimid¡n-4-yl)am¡no)methyl)-4(1 / - / -1,2,4-triazol-3-yl)piperidin-1 -acetamide)2-(4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluorop¡r¡m¡n-4-yl)amino)meth¡l)-4(1,2,4-oxadiazol-3-¡l)pd¡l) iviA / a / zuzz / uu and ουι 395 2-(4-(((6-(Cycloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyrim¡n-4-yl)amino)methyl)-4(1,3,4-oxadiazol-2-yl)piperid¡n-1-yl)acetamide, 2-(4-(((6-(C¡cloprop¡l(4-(trifluorometh¡l)benc¡l)amino)-5-fluoro¡rimid¡n-4-yl)am¡no)met¡l)-4(1 / - / -1,2,3-triazol-5-yl)p¡n-1-acetamida) 2-(4-(((6-((4-(1 / 7-pyrazol-1-¡l)benc¡l)(cyclopropyl)am¡no)-5-fluorop¡rim¡m¡n-4yl)am¡no)met¡l)-3-h¡droxypiper¡din-1-yl)acetamida, 2-(4-(((6-(cycloprop¡l(4-(trifluoromethyl)benzyl)annino)-5-fluoropyrimid¡n-4-yl)am¡no)methyl)-3h¡drox¡-3-methylpiper¡d¡n-1 -yl)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluorophr¡rmid¡n-4-yl)amino)met¡l)-3hydrox¡-4-met¡lp¡per¡n-1-acetate, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorophr¡mid¡n-4-yl)am¡no)met¡l)-3hydroxy-4-(h¡drox¡met¡l)piper¡¡l)2-(4-(((6-(et¡l(4-(trifluoromethyl)benc¡l)amno)-5-fluorop¡r¡m¡din-4-yl)amino)met¡l)-3,4dihydroxypiperidin-1-yl)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benc¡l)amino)-5-fluoropyrimidin-4-yl)amino)methyl)3,4-d¡h¡drox¡piper¡d¡n-1-yl)acetamide, 2-(4-(((6-(et¡l(2-fluoro-4-(trifluoromethl)benc¡l)amino)-5-fluoropyrim¡n-4-yl)ani¡no)methyl)3,4-d¡hydroxy¡piper¡d¡n-1-l)acetamidal, 2-(4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropane-2-¡l)benzyl)amino)-5fluorop¡rimidin-4-¡l)am¡no)met¡l)-3,4-dih¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡Amida-amida-amida-amida-1,¡l) 2-(4-(((6-(c¡cloprop¡l(2-fluoro-4-(1-methyl-1 / - / -p¡razol-4-yl)benzyl)am¡no) -5-fluoropyrimidine-4¡l)am¡no)meth¡l)-3,4-d¡h¡drox¡p¡perdin-1-¡l)acetamin, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy¡propan-2-¡l)benzyl)a m¡no)-5fluoropyrim¡n-4-¡l)am¡no)methyl)-3,4-dih¡drox¡p¡perid¡n-1-¡l)acetamin, 2-(4-(((6-(c¡cloprop¡l(2-fluoro-4-(1H-p¡razol-1-yl)benc¡l)amino)-5-fluoropyrim¡d¡n-4iI)amino)methyl)-3,4-dihydroxypiperidin-1-yl)acetamide and 2-(4-(((5-fluoro-6-(methyl(3-(trifluoromethoxy)benzyl)amino)pyrimidin-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide., 57. The compound, stereoisomer or salt thereof according to claim 55, selected from the group comprising: re / -2-((3R,4R)-4-(((6-(C¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluorop¡r¡m¡n-4¡l)am¡no)meth¡l)-3-hydroxypiperdine-1, re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(trifluoromethyl)benc¡l)amino)-5-fluoro¡rimid¡n-4¡l)amino)methyl)-3-fluoro¡per¡d¡n-1-yl)acetam¡, re / -(R)-2-(4-(((6-(c¡chlopropyl(4-(tr¡fluoromethyl)benzyl)am¡no)-5-fluorop¡rmidin-4¡l)am¡no)methyl)-3,3-d¡fluorop¡peridin-1-¡l)acetate, ινΐΛ / a / zuzz / uu ioy ί 396 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimid¡n-4-yl)amino)methyl)-4hydroxypiperidin-1 -yl thamide,) re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡r¡midine-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(tr¡fluorometh¡l)benzyl)amino)-5fluoropyrimide¡n-4-yl)amino)methyl)-3-h¡drox¡p¡peridin-1-yl)(R,2-a) / (R-2)4R)-4-(((6-(ethyl(2-fluoro-4-(trifluoromethyl)benc¡l)am¡no)-5-fluoiOpyrimid¡n-4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-1-¡l)acetamide, rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1-difluoroethyl)benc¡l)am¡no)-5-fluoropyrimid¡n-4¡l)amino)methyl)-3-h¡drox¡piper¡din-1-yl)acetamin, rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(d¡fluoromethoxy¡)benc¡l)am¡no)-5-fluorop¡r¡m¡d¡n-4yl)amino)meth¡l)-3-h¡droxypiperdino-acetate, 2-(4-c¡ano-4-(((6-(cycloprop¡l(4-(tr¡fluoromet¡l)benzyl)am¡no)-5-fluoropyrim¡n-4yl)am¡no)methyl)piperidin-1-yl)acetamin, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benc¡l)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-4(hydroxymeth¡l)p¡perid¡n-1-yl)acetamide, re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoiO-2-hydroxypropan-2¡l)be ncil)arn¡no)-5-fluoropyr¡mdin-4-l)am¡no)methyl)-3-hydroxyp¡perid¡n-1-yl)acetam¡da, re / -2-((3R,4R)-4-(((6-(cycloprop¡l(4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fluoropyr¡m¡m¡d¡n-4¡l)am¡no)methyl)-3-hydroxyp¡per¡din-1-methyl-propanamida,¡) rac-2-((3R,4R)-4-(((6-(cyclopropyl(3-(trifluoromethoxy)benzyl)amino)-5-fluoropyrimidine-4¡l)amino)met¡l)-3-h¡drox¡p¡per¡din-1-¡l)acetam¡da, re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)am¡no)-5-fluorop¡r¡mid¡n-4¡l)am¡no)methyl)-3-h¡drox¡piper¡din-1-¡l)-l2-propanamide rac-2-((3R,4R)-4-(((6-(cycloprop¡l(4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fluoroph¡r¡m¡d¡n-4yl)am¡no)methyl)-3-h¡droxypiper¡dyne-3-hydroxy-prohl) re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrimidine-4¡l)amino)methyl)-3-h¡drox¡p¡per¡din-1 -yl)acetamide-2,2-c / 2 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorophr¡rmid¡n-4-yl)am¡rium)met¡l)-4(hydroxymethyl)p¡per¡d¡n-1-yl)-3-hp, rac-2-((3R,4R)-4-(((6-(c¡clopprop¡l(4-(1-methyl-1H-pyrazol-4-¡l)benzyl)am¡no)-5fluoropyrimidine-4-¡l)amino)methyl)-3-hydroxy¡p¡peridin-1-pyridine-(a)(a)4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benc¡l)am¡no)-5fluorop¡r¡m¡din-4-yl)amino)met¡l)-3-hydroxypiper¡n-1-acetamide) rac-2-((3R,4R)-4-(((6-(Cyclopropyl(2-fluoro-4-(1H-pyrazol-1-¡l)benc¡l)amino)-5fluoropyrimid¡n-4-¡l)am¡no)methyl)-3-h¡drox¡p¡p¡p¡p¡l-1-l) ινΐΛ / a / zuzz / uu and ουι 397 2-(4-(((6-(Cycloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyrim¡n-4-yl)amino)methyl)-4(1,2,4-oxadiazol-34l)piperid¡n-14l)acetamide, 2-(4-(((6-(C¡cloprop¡l(4-(trifluorometh¡l)benc¡l)amino)-5-fluoro¡rimid¡n-4-yl)am¡no)methl)-4(1,3,4-oxadiazol-2-yl)p¡n-1-acetal) 2-(4-(((6-(C¡clopropyl(4-(tnfluoromet¡l)benzyl)am¡no)-5-fluoropyrimid¡n-4-¡l)am¡no)meth¡l)-4(1H-1,2,3-triazole-5-¡l)piperid¡n-acetate, rac-2-((3R,4R)-4-(((6-((4-(1H-p¡razol-14l)benzyl)(cyclopropyl)amino)-5-fluorop¡r¡midin-4¡l)amino)met¡l)-3-hydroxy¡p¡per¡din-14l-(3R,4R)-(3R,2)(3)4R)-4-(((6-(c¡chlopropyl(4-(tr¡fluoromethyl)benzyl)amino)-5-fluorop¡rimid¡n-4¡l)amno)methyl)-3-h¡drox¡-3-methylpiper¡din-1-¡l)acetaminophen re / -2-((3R,4S)-4-(((6-(c¡cloprop¡l(4-(tr¡fluoromethyl)benc¡l)amino)-5-fluorop¡r¡m¡d¡n-4yl)am¡no)meth¡l)-3-h¡droxy-3-methylpid-amylol-14,1) 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrim¡n-4-¡l)am¡no)methyl)-3hydrox¡-4-methylpiperidin-1-yl)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benc¡l)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3hydroxy-4-(h¡drox¡met¡l)piper¡d¡n-1-l)acetaminophen, re / -2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)amino)-5-fluorop¡rmidine-4¡l)am¡no)met¡l)-3,4-d¡h¡droxip¡peridin-1-¡l)tamidal, re / -2-((3R,4S)-4-(((6-(ethyl(4-(tnfluoromet¡l)benzyl)amino)-5-fluoroOpyri¡midin-4¡l)am¡no)methyl)-3,4-dih¡drox¡p¡peridin-1-yl)acetamide, re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrimidine-4¡l)am¡no)meth¡l)-3,4-d¡h¡drox¡p¡per¡din-1-l¡¡l-(3R,¡l)(3),4S)-4-(((6-(c¡cloprop¡l(4-(tr¡fluoromet¡l)benc¡l)amino)-5-fluorop¡r¡m¡d¡n-4¡l)am¡no)met¡l)-3,4-dihydroxypiperidin-1-¡l)acetamida, re / -2-((3R,4R)-4-(((6-(etyl(2-fluoro-4-(tr¡fluorometil)benc¡l)amino)-5-fluorop¡r¡m¡d¡n-4¡il)am¡no)met¡l)-3,4-dihydroxypiperidin-1-¡l)acetamida, re / -2-((3R,4S)-4-(((6-(etyl(2-fluoro-4-(trifluorometyl)bencil)amino)-5-fluoropirimidin-4l)amino)metyl)-3,4-dihydroxiperidin-1-il)acetamide, re / -2-((3R,4R)-4-(((6-(etyl(4-(1,1,1,3,3,3-hexafluoro-2-hidroxiperidin-2-il)bencil)amino)-5fluoropirimidin-4l)amino)metyl)-3,4-dihydroxiperidin-1-il)acetamide, re / -2-((3R,4R)-4-(((6-(ciclopropyl(2-fluoro-4-(1-metl-1 / - / -prazol-4-il)bencl)amino)-5-fluoropirimidin-4-l)amino)metil)-3,4-dhydroxypiperidin-1-il)acetamida, re / -2-((3R,4R)-4-(((6-(ciclopropyl(4-(1,1,1,3,3,34iexafluoro-2-hidiOXpiOpan-2l)bencl)amino)-5-fluoropirimidin-44l)amino)metil)-3,4-dhydroxypiperidin-1-il)acetamida, re / -2-((3R,4R)-4-(((6-(cycloprop¡l(2-fluoro-4-(1 / - / -p¡razol-1-¡l)bencil)am¡no)-5fluoropirimid¡n-4-¡l)am¡no)metil)-3,4-d¡h¡drox¡p¡perid¡n-1-yl)acetam¡da y ινΐΛ / a / zuzz / uu / ου i 398 rac-2-((3R,4R)-4-(((5-fluoro-6-(metil(3-(trifluorometoxi)bencil)amino)pirimidin-4¡l)amino)metil)-3-hidrox¡p¡per¡din-1-yl)acetam¡da., 58. The compound, stereoisomer or salt thereof according to claim 56, selected from the group comprising: 2-(4-(((6-(C¡clopropyl(4-(tr¡fluoromet¡l)benzyl)am¡no)-5-fluorop¡r¡rnidin-4-¡l)arn¡no)met¡l)-3hydroxypiper¡n-1-ace), 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimid¡n-4-yl)am¡no)methyl)-3fluoropiperidin-1 -yl)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluorop¡rmid¡n-4-yl)amino)met¡l)3,3-d¡fluoropiperid¡n-1-¡l)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorophr¡rmid¡n-4-yl)am¡no)meth¡l)-4h¡drox¡piperid¡n-1-¡l)acetaminophen 2-(4-(((6-(et¡l(4-(trifluoromethyl)benc¡l)amno)-5-fluorop¡r¡mdin-4-yl)amino)methyl)-3hydroxypiper¡n-1-l)acetamide, 2-(4-(((6-(c¡cloprop¡l(2-fluoro-4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrimidine-4yl)amino)met¡l)-3-h¡droxypiper¡din-1-¡l)acetam¡da,2-(4-(((6-(et¡l(2-fluoro-4-(trifluorometh)benc¡l)amino)-5-fluoropyrim¡n-4-yl)amno)methyl)3-hydroxypiperid¡n-1-¡l)acetamide, 2-(4-(((6-(cyclopropyl(4-(1,1-d¡fluoroet¡l)benc¡l)amino)-5-fluorop¡r¡m¡m¡dine-4-¡l)am¡no)met¡l)3-hydroxypiper¡d¡n-1-l)acetate, 2-(4-(((6-(c¡cloppro¡l(4-(difluoromethoxy)benc¡l)amno)-5-fluorop¡rim¡n-4-¡l)amino)met¡l)3-hydroxy¡p¡perid¡n-1-l)acetaminophen, 2-(4-c¡ano-4-(((6-(cycloprop¡l(4-(tr¡fluoromethl)benc¡l)amno)-5-fluoropyr¡mid¡n-4¡l)am¡no)meth¡l)p¡per¡dyn-1-ylda)acetam 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluoro¡rmid¡n-4-yl)amno)methl)-4(h¡droximethl)piper¡d¡n-1-acetate, 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)bench¡l)amino)-5fluorophr¡rmidin-4-yl)amino)met¡l)-3-hydroxyp¡per¡d-acetate, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorophr¡mid¡n-4-yl)am¡no)methl)-3h¡drox¡piper¡d¡n-1-l)-2-methylpropanamide,2-(4-(((6-(c¡cloprop¡l(3-(tnfluoromethoxy¡)benc¡l)am¡no)-5-fluoropyrimidine-4-¡l)am¡no)methyl)3-hydroxyp¡perid¡n-1-¡l)acetamide, 2-(4-(((6-(et¡l(4-(trifluoromethl)benc¡l)amno)-5-fluorop¡r¡m¡n-4-yl)amino)methl)-3h¡drox¡piperidin-1-yl)-2-methylpropanamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoro¡r¡mid¡n-4-yl)amino)met¡l)-3hydrox¡piperid¡n-1-¡l)-3-hdrox¡piperid¡n-1-¡l)-3-h¡¡¡piperid¡n-1-¡l)-3-h¡¡¡¡piperid¡n-1-¡l)-3-h¡¡¡¡piperid¡n-1-¡l)-3-h¡¡¡piperid¡n-1-¡l)-3-h¡¡¡¡¡¡¡¡¡ / A / A / A / A / A / ου i 399 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimid¡n-4-yl)amino)methyl)-3hydroxypiperidin-1-yl)acetamide-2,2-02, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorophr¡mid¡n-4-yl)am¡no)met¡l)-4(h¡droxymethyl)p¡per¡d¡n-1-¡l¡droxymethyl)p¡per¡d¡n-1-¡l-droxy-prop, 2-(4-(((6-(c¡cloppro¡l(4-(1-meth¡l-1 / - / -p¡razol-4-¡l)benc¡l)amno)-5-fluoropyr¡m¡n-4¡l)am¡no)methyl)-3-h¡droxdine-a-pice, 2-(4-(((6-(c¡cloprop¡l(2-fluoro-4-(1-methyl-1 / 7-p¡razol-4-¡l)benzyl)amino)-5-fluoropyrimidine-4¡l)amino)met¡l)-3-hydroxy¡p¡perdin-1-acetate,2-(4-(((6-(C¡cloprop¡l(2-fluoro-4-(1 / - / -pyrazol-1-¡l)benzyl)amno)-5-fluoropyr¡midin-4¡l)am¡no)methyl)-3-hydroxyp¡p¡per¡din-1-ylda), 2-(4-(((6-(C¡clopropyl(4-(trifluoromet¡l)benzyl)amino)-5-fluorophrimidine-4-yl)am¡no)met¡l)-4(1,2,4-oxadiazol-3-l)p¡peridn-1-acetamida,) 2-(4-(((6-(Cycloprop¡l(4-(trifluorometh¡l)benc¡l)amino)-5-fluoropyrirnid¡n-4-yl)amino)methyl)-4(1,3,4-oxadiazol-2-yl)piperidin-1-yl)acetamide, 2-(4-(((6-(Cycloprop¡l(4-(trifluoromet¡l)benc¡l)amino)-5-fluoropyrimid¡n-4-yl)amino)methyl)-4(1 / 7-1,2,3-triazol-5-yl)piperidin-1 -yl)acetamide, 2-(4-(((6-((4-(1 / 7-pyrazol-1-yl)benc¡l)(cyclopropyl)amino)-5-fluoropyrim¡din-4¡l)am¡no)methyl)-3-h¡drox¡piper¡din-1-¡l)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromet¡l)benzyl)amino)-5-fluorop¡rmid¡n-4-yl)am¡no)meth¡l)-3h¡drox¡-3-methylpiperid¡n-1-acetate, 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromethyl)benc¡l)amno)-5-fluoropyr¡mid¡n-4-¡l)amino)methyl)-3h¡droxy-4-met¡lp¡per¡n-1-acetate,2-(4-(((6-(c¡cloprop¡l(4-(tnfluorometh¡l)benzyl)amino)-5-fluorormidine-4-¡l)am¡no)meth¡l)-3hydroxy-4-(h¡drox¡meth¡l)piper dino-1-ace, 2-(4-(((6-(et¡l(4-(trifluoromet¡l)benc¡l)amno)-5-fluorop¡nm¡n-4-yl)amino)methl)-3,4dihydroxypiperidin-1 -yl)acetamide, 2-(4-(((6-(c¡cloprop¡l(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrinidine-4-yl)amino)rnethyl)3,4-d¡h¡droxypiperidin-1-¡l)acetamide, 2-(4-(((6-(et¡l(2-fluoro-4-(trifluoromethl)benc¡l)amino)-5-fluorop¡r¡m¡n-4-yl)am¡no)met¡l)3,4-d¡hydroxy¡p¡per¡din-1-acetamida,) 2-(4-(((6-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy¡propane-2-¡l)benzyl)am¡no )-5fluoropyrim¡n-4-¡l)am¡no)methyl)-3,4-d¡h¡drox¡p¡perid¡n-1-¡l)acetam¡da, 2-(4-(((6-(c¡cloprop¡l(2-fluoro-4-(1-methyl-1 / 7-p¡razol-4-yl)benzyl)amino)-5-fluoropyrimidine-4¡l)am¡no)methyl)-3,4-d¡h¡drox¡p¡dine-perda-a-tami,) 2-(4-(((6-(cyclopropyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropane-2-¡l)benzyl)a m¡no)-5fluoropyrimid¡n-4-¡l)am¡no)meth¡l)-3,4-d¡hydroxy¡p¡perid¡n-1-yl)acetam¡da,iviA / a / zuzz / uu / ου i 400 2-(4-(((6-(cyclopropyl(2-fluoro-4-(1 H-pyrazol-1 -yl)benzyl)amino)-5-fluoropyrimidin-4¡I)amino)methyl)-3,4-dihydroxyp¡peridin-1 -yl)acetamide and iviA / a / zuzz / uu i ουι 2-(4-(((5-fluoro-6-(methyl(3-(trifluoromethox)benzyl)amino)p¡rmidin-4-l)amino)methyl)-3hydroxypiperidin-1-l)acetamide., 59. The compound, stereoisomer or salt according to claim 1, having a structure selected from the group consisting of: 401 ινΐΛ / a / zuzz / uu ι 402 403 ινΐΛ / a / zuzz / uu ι 404 ινΐΛ / a / zuzz / uu ι ουι ινΐΛ / a / zuzz / uu ι ινΐΛ / a / zuzz / uu ι ουι a structure selected from the group consisting of: ινΐΛ / a / zuzz / uu ι 412 ινΐΛ / a / zuzz / uu ι ουι 413 414 ινΐΛ / a / zuzz / uu ι ινΐΛ / a / zuzz / uu ι ουι ινΐΛ / a / zuzz / uu ι ουι ινΐΛ / a / zuzz / uu / ου ι structure of 62. The compound, stereoisomer or salt of claim 60, having a structure of 63. The compound, stereoisomer or salt of claim 60, having a structure of 64. The compound, stereoisomer, or salt of claim 60, having a structure of 65. The compound, stereoisomer or salt of claim 60, having a 420 structure 66. The compound, stereoisomer, or salt of claim 60, having a structure of 68. The compound, stereoisomer or salt of claim 60, having a 421 structure 69. The compound, stereoisomer, or salt of claim 60, having a structure of 70. The compound, stereoisomer, or salt of claim 60, having a structure of 71. The compound, stereoisomer, or salt of claim 60, having a structure of 72. The compound, stereoisomer, or salt of claim 60, having a structure of 73. The compound, stereoisomer, or salt of claim 60, having a structure of 74. The compound, stereoisomer, or salt of claim 60, having a structure of 75. The compound, stereoisomer, or salt of claim 60, having a structure of has has has a a a 423 76. The compound, stereoisomer, or salt of claim 60, having a structure of 77. The compound, stereoisomer, or salt of claim 60, having a structure of 78. The compound, stereoisomer or salt of claim 60, having a 424 structure 79. The compound, stereoisomer, or salt of claim 60, having a structure of 80. The compound, stereoisomer, or salt of claim 60, having a structure of 81. The compound, stereoisomer, or salt of claim 60, having a structure of 82. The compound, stereoisomer, or salt of claim 60, having a 425 structure.

83. The compound, stereoisomer, or salt of claim 60, having a CE structure.

84. The compound, stereoisomer, or salt of claim 60, having a structure of 85. The compound, stereoisomer, or salt of claim 60, having a structure of 87. The compound, stereoisomer, or salt of claim 60, having a 427 structure 88. The compound, stereoisomer or salt of claim 60, having a cf3 structure 89. The compound, stereoisomer, or salt of claim 60, having a structure of 90. The compound, stereoisomer, or salt of claim 60, having a 428 structure 91. The compound, stereoisomer, or salt of claim 60, having a structure of 92. The compound, stereoisomer, or salt of claim 60, having a structure of 93. The compound, stereoisomer, or salt of claim 60, having a structure of 94. The compound, stereoisomer, or salt of claim 60, having a structure of 95. The compound, stereoisomer, or salt of claim 60, having a structure of H?N The compound, stereoisomer, or salt of claim 60, having a CFa 97. The compound, stereoisomer or salt according to any of claims 1-40, wherein Roa is selected from the group consisting of CN, substituted or unsubstituted heteroalicyl and substituted or unsubstituted heteroaryl; and Rob is hydrogen or Cm alkyl.

98. The compound, stereoisomer or salt according to claim 97, wherein Roa is substituted or unsubstituted heteroaryl.

99. The compound, stereoisomer or salt according to claim 98, wherein Roa is substituted or unsubstituted pyridinyl.

100. The compound, stereoisomer or salt according to claim 97 or 98, wherein Rob is hydrogen.

101. The compound, stereoisomer or salt according to claim 1, having a structure of Formula (IV): where: Roa is substituted or unsubstituted pyridinyl; Rob is hydrogen; Ría is hydroxyl; Ru is hydrogen; R2 is hydrogen or hydroxyl; Ro is ethyl or cyclopropyl; Re is CF3 and Y3 is CRs, where Rs is hydrogen or fluoro.

102. The compound, stereoisomer or salt according to claim 1, wherein: Roa is selected from the group consisting of CN, pyridinyl and tetrahydropyranyl; Rob is hydrogen; Ría is hydroxyl; Ru is hydrogen; R2 is hydrogen or hydroxyl; R is hydrogen; R3 is ethyl or cyclopropyl; R4 is hydrogen; Rs is hydrogen; Re is CF3; R7 is hydrogen and Y1, Y2 and Y3 are each CH.

103. The compound, stereoisomer, or salt according to claim 1, wherein: Roa is pyridinyl; Roe is hydrogen; Ría is hydroxyl; Rib is hydrogen; R2 is hydrogen or hydroxyl; R is hydrogen; R3 is ethyl or cyclopropyl; R4 is hydrogen; R5 is hydrogen; Re is CF3; R7 is hydrogen; and Y1, Y2, and Y3 are each CH. 431 104. The compound, stereoisomer or salt thereof according to claim 1, selected from the group comprising: rac-2-c¡ano-2-((3R,4R)-4-(((6-(et¡l(4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fluoropyr¡mid¡n-4¡l)amino)meth¡l)-3-h¡drox¡pd¡p¡n-1, rac-2-((3R,4R)-4-(((6-(et¡l(4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fluorop¡r¡m¡n-4¡l)amino)met¡l)-3-h¡drox¡piper¡din-1 -yl)-2-(pyridin-4-yl)acetamide, rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluorometh¡l)benzyl)amino)-5-fluoropyrimidin-4yl)am¡no)meth¡l)-3-hydroxyp-pyridine¡p-1 -yl)-2-(pyridin-4-yl)acetamide, rac-2-((3R,4R)-4-(((6-(c¡cloprop¡l(4-(tr¡fluorometh¡l)benc¡l)am¡no)-5-fluoropyrimidine n-4¡l)am¡no)methyl)-3-h¡drox¡piper¡din-1-yl)-2-(tetrah¡dro-2 / - / -pyran-4-¡l)acetam¡da, re / -2-((3R,4R)4-(((6-(ethyl(4-(trifluoromethyl)benzyl)am¡no)-5-fluoro¡r¡midine-4yl)amino)methyl)-3,4-dihydroxypiperidin-1 -yl)-2-(pyridin-4-yl)acetamide, re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(tnfluoromethyl)benzyl)am¡no)-5-fluoropyrimid¡n-4yl)amino)methyl)-3,4-dihydroxypiperidin-1 -yl)-2-(pyridin-4-yl)acetamida, re / -(R)-2-((3S,4S)-4-(((6-(ethyl(4-(trifluoromethyl)benyl)amino)-5-fluoropyrimidin-4yl)am¡no)methyl)-3,4-dihydrox¡p¡peridine-1 -yl)-2-(pyridin-4-yl)acetamida y re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(trifluoromethyl)selfish)am¡no)-5-fluorop¡ri midin-4¡l)am¡no)met¡l)-3,4-d¡h¡droxip¡perid¡n-1-¡l)-2-(p¡ridin-4-yl)acetam¡da., 105. The compound, stereoisomer or salt thereof according to claim 1, selected from the group comprising: 2-c¡ano-2-(4-(((6-(et¡l(4-(tr¡fluoromethyl)benc¡l)amno)-5-fluoropyr¡m¡n-4-¡l)amino)methyl)-3h¡drox¡piper¡din-1-l)acetate, 2-(4-(((6-(et¡l(4-(trifluorometh¡l)benc¡l)amno)-5-fluoro¡r¡m¡n-4-yl)amino)rnet¡l)-3hydroxypiperidin-1 -yl)-2-(pyridin-4-yl)acetate, 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromet¡l)benzyl)amino)-5-fluorophr¡mid¡n-4-¡l)am¡no)met¡l)-3hydroxypiperidine-1-¡l)-2-(pyridine-4-tamyl), 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluoromet¡l)benzyl)amno)-5-fluorop¡rmid¡n-4-¡l )am¡no)met¡l)-3hydroxypiperidin-1-yl)-2-(tetrahydro-2 / - / -pyran-4-¡l)acetamide, 2-(4-(((6-(et¡l(4-(tr¡fluoromethyl)benc¡l)am¡no)-5-fluoro¡r¡m¡n-4-¡l)amino)met¡l)-3,4dihydroxypiperidin-1 -yl)-2-(pyridin-4-damice) 2-(4-(((6-(c¡cloprop¡l(4-(tr¡fluorometh¡l)benzyl)am¡no)-5-fluorop¡rimid¡n-4-¡l)am¡no)met¡l)3,4-dihydroxypiperidin-1-yl)-2-(pyridin-4-yl damida).

106. The compound, stereoisomer, or salt according to claim 105, wherein the compound is 2-cyane-2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-1)amino)methyl)-3-hydroxypyrimidin-1-yl)acetamide. 432 107. The compound, stereoisomer or salt according to claim 105, wherein the compound is 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidine-4-yl)amino)methyl)3-hydroxypiperidin-1-yl)-2-(pyrimidine-4-yl)acetamide.

108. The compound, stereoisomer or salt according to claim 105, wherein the compound is 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidine-4-yl)amino)methyl)-3-hydroxypiperidin-1-yl)-2-(pyridin-4-yl)acetamide.

109. The compound, stereoisomer or salt according to claim 105, wherein the compound is 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidine-4-1)amino)methyl)-3-hydroxypyridine-1-yl)-2-(tetrahydro-2-pyran-4-1)acetamide.

110. The compound, stereoisomer or salt according to claim 105, wherein the compound is 2-(4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidine-4-yl)amino)methyl)3,4-dihydroxypiperidin-1-yl)-2-(pyridin-4-yl)acetamide.

111. The compound, stereoisomer or salt according to claim 105, wherein the compound is 2-(4-(((6-(cyclopropyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrimidin-4-yl)amino)methyl)-3,4-dihydroxypiperidin-1-yl)-2-(pyridin-4-yl)acetamide.

112. The compound, stereoisomer or salt according to claim 105, selected from the group consisting of: rac-2-((3R,4R)-4-(((6-(ethyl(4-(tr¡fluoromethyl)benzyl)am¡no)-5-fluoropyr¡m id¡n-4¡l)am¡no)meth¡l)-3-hydrox¡piper¡din-1-yl)-2-(p¡d¡n-4-yl)acetam¡da, rac-2-((3R,4R)-4-(((6-(cyclopropyl(4-(tr¡fluorometh¡l)benzyl)am¡no)-5-fluoropyrimidin-4yl)amino)methyl)-3-hydroxyp¡per¡din-1 -yl)-2-(pyridin-4-acetamide,) re / -2-((3R4R)4-(((6-(et¡l(4-(trifluoromethyl)benzyl)amino)-5-fluorop¡r¡m¡di n-4¡l)am¡no)meth¡l)-3,4-d¡h¡droxyp¡per¡d¡n-1-¡l)-2-(p¡rdin-4-¡l)acetamide, re / -(R)-2-((3R,4R)-4-(((6-(ethyl(4-(trifluoromethyl)benzyl)amino)-5-fluoropyrim idin-4¡l)am¡no)meth¡l)-3,4-d¡h¡droxyp¡perid¡n-1-¡l)-2-(p¡r¡d¡n-4-l)acetamide, re / -(R)-2-((3S,4S)-4-(((6-(ethyl(4-(trifluoromet¡l)benzyl)amino)-5-fluoropyrimidine-4yl)am¡no)meth¡l)-3,4-dihydrox¡p¡pend¡n-1-yl)-2-(pyridin-4-yl damice) re / -2-((3R,4R)-4-(((6-(cyclopropyl(4-(tr¡fluoromethyl)benzyl)am¡no)-5-fluoropyrimidine-4¡l)am¡no)methyl)-3,4-d¡hydroxy¡p¡peridin-1-yl)-2-(pyridin-4-yl)acetamide., 113. A pharmaceutical composition comprising a compound, stereoisomer or salt according to any of claims 1-112 and at least one pharmaceutically acceptable excipient.

114. A compound, stereoisomer or salt according to any of claims 1-112 or a pharmaceutical composition according to claim 113, for use as a medicament.

115. A compound, stereoisomer or salt according to any of claims 1-112 or a pharmaceutical composition according to claim 113, 433 for use in the treatment and / or prevention of an inflammatory, metabolic, oncological or autoimmune disease.

116. A method for treating an inflammatory, metabolic, oncological or autoimmune disease in a subject suffering from it, the method comprising: administering to the subject a compound, stereoisomer or salt according to any of claims 1-112 or a pharmaceutical composition according to claim 113.

117. The compound, stereoisomer, salt, or pharmaceutical composition for use according to claim 115 or the method of claim 116, wherein the disease is selected from the group consisting of asthma, acne, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, Helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, celiac disease and food allergy, atopic dermatitis, cystic fibrosis, lung allograft rejection, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ichthyosis, bullous diseases, lichen planus, hidradenitis suppurativa, steatosis, steatohepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lupus erythematosus, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune eye disease,ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, myasthenia gravis, Guillain-Barré syndrome, Graves' disease, scleritis, obesity, obesity-induced insulin resistance, type II diabetes, and cancer.

118. The compound, stereoisomers or salt or pharmaceutical composition for use according to claim 115 or the method of claim 116, wherein the disease is selected from the group consisting of acne, atopic dermatitis, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ichthyosis, bullous diseases, lichen planus, hidradenitis suppurativa, ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (IBD), and lupus erythematosus.

119. A combination product comprising (i) at least one compound, stereoisomer, or salt according to any one of claims 1-112 and (ii) one or more active ingredients selected from the group consisting of: (a) Corticosteroids such as prednisone, methylprednisolone, or betamethasone; (b) Immunosuppressants such as cyclosporine, tacrolimus methotrexate, hydroxyurea, mycophenolate mofetil, mycophenolic acid, sulfasalazine, 6-thioguanine, or azathioprine; (c) Fumaric acid esters such as dimethyl fumarate; (d) Dihydroorotate dehydrogenase (DHODH) inhibitors such as leflunomide; (e) Retinoids such as acitretin or isotretinoin; f) Anti-inflammatory drugs such as apremilast, crisaborol, celecoxib, diclofenac, aceclofenac, aspirin or naproxen; g) JAK inhibitors such as tofacitinib, baricitinib, upadacitinib, ruxolitinib or delgocitinib; h) Antibiotics such as gentamicin;i) Anticancer agents such as lenalidomide, pomalidomide, pembrolizumab, nivolumab, daratumumab, bortezomib, carfilzomib, ixazomib, bendamustine or ventoclast; j) T cell blockers such as alefacept or efalizumab; k) Tumor necrosis factor alpha (TNF-alpha) blockers such as etanercept, adalimumab, infliximab, golimumab, certolizumab pegol; I) Interleukin 12 / 23 blockers such as ustekinumab; m) IL-23 blockers such as tristenkizumab, guselkumab or tildrakizumab; n) Anti-IL4 / IL13 antagonist such as dupilumab, lebrikizumab or tralokinumab; o) IL-1β blockers such as canakinumab; p) IL-alpha blockers such as bermekimab; q) CD6 blockers such as itolizumab; r) IL-36R blockers such as BI-655130 or bimekizumab; s) IL-6 antagonist such as tocilizumab; t) Calcineurin inhibitors such as pimecrolimus, tacrolimus or cyclosporine;u) Phototherapy agents commonly used in phototherapy such as psoralen, methoxypsoralen or 5-methoxypsoralen + UVA (PUVA) or UVB treatment (with or without tar); v) Fixed combinations of corticosteroids and vitamin D derivatives; w) Fixed combinations of corticosteroids and retinoids;(x) Corticosteroid tapes ey) one or more agents selected from the group consisting of BMS986165, PF06700841, PF-06826647, piclidenosone, tepilamide fumarate, LYC-30937, LEO-32731, Bl730357, PRCL-02, 1993; LNP-1955, GSK-2982772, CBP-307, KD-025, MP-1032, Petesicatib, JTE451, Hemay-005, SM-04755, EDP-1815, BI-730460, SFA-002 ER, JNJ-3534, SAR-441169, BOS-172767, SCD-044, ABBV-157, BAY-1834845, AUR-101, R-835, PBF-1650, RTA-1701, AZD-0284, mirikizumab, CD20 antagonist, salicylic acid, hulla tar, Mical-1, DUR928, AM-001, BMX-010, TA-102, SNA-125, brepocitinib tosylate, pegcantratinib, ESR-114, ινΐΛ / a / zuzz / uu / ου i 435 NP-000888, SM-04755, BOS-475, SB-414, LEO-134310, CBS-3595, PF-06763809, XCUR-17 and BTX-1308.; 120. A compound according to Formula (V): a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein: R3 is selected from the group consisting of Cm alkyl, C2-4 alkenyl, Cm haloalkyl, Cm hydroxyalkyl, C1-6 hydroxyhaloalkyl, (C1-4 alkylene)-(Cm alkoxy), substituted or unsubstituted C3.7 cycloalkyl and substituted or unsubstituted C3.7 cycloalkenyl; R4 and Rs are each independently hydrogen or Cm alkyl, or R4 and Rs are considered together with the carbon atom to which they are attached to form a C3 cycloalkyl.4; R7 is selected from the group consisting of hydrogen, hydroxyl, CN, halogen, Cm alkyl, Cm haloalkyl, Cm hydroxyalkyl, Cm alkoxy, Cm haloalkoxy, and substituted or unsubstituted heteroaryl; and when substituted, a heteroaryl shall be substituted with 1 to 3 substituents selected independently from the group consisting of Cm alkyl, Cm hydroxyalkyl, C2m alkenyl, C2-4 alkynyl, hydroxy, Cm alkoxy, cyano, halogen, Cm haloalkyl, Ci4 haloalkoxy, and Cm hydroxyhaloalkyl; and when substituted, a cycloalkyl or cycloalkenyl shall be substituted with 1 to 3 substituents selected independently from the group consisting of Cm alkyl and halogen; provided that, when each of R4, Rs and R7 is hydrogen, then R3 will not be cyclopropyl and, when R7 is hydrogen and R4 and Rs, together with the carbon to which they are attached, form a cyclopropyl, then R3 will not be methyl.

121. The compound, stereoisomer or salt of claim 120, wherein R3 is alkyl Cm.

122. The compound, stereoisomer or salt of claim 121, wherein R3 is ethyl.

123. The compound, stereoisomer or salt of any of claims 120-122, wherein at least one of R4 and Rs is hydrogen.

124. The compound, stereoisomer, or salt of claim 123, wherein each of R4 and Rs is hydrogen. 436 125. The compound, stereoisomer or salt of any of claims 120-124, where R is hydrogen.

126. The compound, stereoisomer, or salt of any of claims 120-124, wherein R is fluoro.

127. The compound, stereoisomer, or salt of claim 120, having the structure: F CF· 128. or a compound according to Formula (VI): V'R ] KN HO NH2 (V|), a pharmaceutically acceptable salt thereof, wherein: Rncs is alkyl Cu, haloalkyl C« or (alkylene Ci.4)-phenyl optionally substituted with hydroxyl, CN, halogen, alkyl Cm, haloalkyl Cm, alkoxy Cm, haloalkoxy Cm or NO2.

129. The compound or salt of claim 128, wherein Rues f-butyl.

130. The compound or salt of claim 128, wherein Rnes (alkylene Cm)-phenyl.

131. The compound or salt of claim 130, wherein Rn is CH2-phenyl.

132. The compound or salt of claim 131, wherein the phenyl is not substituted.

133. The compound or salt of claim 128, having the structure: Boc NH2 .

134. The compound or salt of claim 128, having the structure:

135. A compound according to Formula (Vil): 437 a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereoisomer, wherein: Rpg is H, CO2RN or (alkylen CM)-phenyl optionally substituted with hydroxyl, CN, halogen, Cm alkyl, Cm haloalkyl, C1.4 alkoxy, Cm haloalkoxy or NO2; Rn is C1 alkyl.4, Cm haloalkyl or (CM alkyl)-phenyl optionally substituted with hydroxyl, CN, halogen, C1-4 alkyl, Cm haloalkyl, C⁴ alkoxy, C1-4 haloalkoxy or NO2; R1 and Rw are independently selected from the group consisting of hydrogen, hydroxyl, halogen, amino, Cm alkyl, Cm hydroxyalkyl and C1-4 haloalkyl; R2 is selected from the group consisting of hydrogen, hydroxyl, amino, cyano, halogen, Cm alkyl, C1-4 haloalkyl, Cm hydroxyalkyl, C(=O)OH, C(=O)NH2, C(=O)O-(Cm alkyl) and substituted or unsubstituted heteroaryl; or R1 and R2 together form a double bond and Rw is hydrogen; R3 is selected from the group consisting of Cm alkyl, C2-4 alkenyl, C1 haloalkyl.4, Cm hydroxyalkyl, C1-6 hydroxyhaloalkyl, (C1-4 alkylene)-(C1-6 alkoxy), substituted or unsubstituted C3-7 cycloalkyl and substituted or unsubstituted C3-7 cycloalkenyl; R4 and Rs are each independently hydrogen or Cm alkyl, or R4 and Re are considered together with the carbon atom to which they are attached to form a C3 cycloalkyl.4; R7 is selected from the group consisting of hydrogen, hydroxyl, CN, halogen, Cm alkyl, Ch haloalkyl, Cm hydroxyalkyl, Cm alkoxy, Cm haloalkoxy and substituted or unsubstituted heteroaryl; and when substituted, a heteroaryl shall be substituted with 1 to 3 substituents selected independently from the group consisting of Cm alkyl, Cm hydroxyalkyl, C2-4 alkenyl, C2-4 alkynyl, hydroxy, Cm alkoxy, cyano, halogen, Cm haloalkyl, Ci4 haloalkoxy and Ci-e hydroxyhaloalkyl; and when substituted, a cycloalkyl or cycloalkenyl shall be substituted with 1 to 3 substituents selected independently from the group consisting of Cm alkyl and halogen.

136. The compound, stereoisomer, or salt of claim 135, wherein at least one of Riay Rw is hydrogen. 438 137. The compound, stereoisomer or salt of claim 135 or 136, wherein at least one of Riay R-ib is hydroxyl.

138. The compound, stereoisomer or salt of any of claims 135-137, wherein one of Riay R-ib is hydrogen and the other is hydroxyl.

139. The compound, stereoisomer or salt of any of claims 135-138, wherein R2 is hydroxyl.

140. The compound, stereoisomer or salt of any of claims 135-139, wherein R3 is Cu alkyl.

141. The compound, stereoisomer or salt of claim 140, wherein Rses is ethyl.

142. The compound, stereoisomer or salt of any of claims 135-141, wherein at least one of R4 and R5 is hydrogen.

143. The compound, stereoisomer or salt of claim 142, wherein R4 and R5 are both hydrogen.

144. The compound, stereoisomer or salt of any of claims 135-143, where Re is haloalkyl Cu.

145. The compound, stereoisomer or salt of any of claims 135-144, wherein R7 is hydrogen.

146. The compound, stereoisomer or salt of any of claims 135-144, wherein R7 is a halogen.

147. The compound, stereoisomer or salt of claim 146, wherein R7 is fluoro.

148. The compound, stereoisomer or salt of any of the indications 135 and 145-147, which has the structure of Formula (Vlla):

149. The compound, stereoisomer or salt of claim 148, wherein R7 is hydrogen.

150. The compound, stereoisomer or salt of claim 148, wherein R7 is a halogen.

151. The compound, stereoisomer or salt of claim 150, wherein R7 is fluoro.

152. The compound, stereoisomer or salt of claim 135, having the structure of Formula (VIIb): 439 IVIA / a / 4U44 / UU / ou 1 153. The compound, stereoisomer or salt of claim 152, wherein R7 is hydrogen.

154. The compound, stereoisomer or salt of claim 152, wherein R is a halogen.

155. The compound, stereoisomer or salt of claim 154, wherein R7 is fluoro.

156. The compound, stereoisomer or salt of any of claims 135155, where Rpg is hydrogen.

157. The compound, stereoisomer or salt of any of claims 135155, where Rpg is CO2RN.

158. The compound, stereoisomer or salt of claim 157, wherein Rpg is CO2(C1.4 alkyl).

159. The compound, stereoisomer or salt of claim 158, wherein Rpg is CO2t-butyl.

160. The compound, stereoisomer or salt of any of claims 135155, where Rpg is (alkylene Ci-4)phenyl.

161. The compound, stereoisomer or salt of claim 160, wherein Rpg is benzyl.

162. The compound, stereoisomer or salt of claim 135, having the structure: